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Abstract
Transforming growth factor beta (TGF-P) regulates many diverse biologieal processes 
including proliferation, m otility , differentiation and survival. Aberrant TGF-P 
signalling is also involved in tumour development. TGF-P signals predominantly 
through a reeeptor complex, comprising o f  AEK.5 and TpR II, to activate the R-Smads. 
Smad2 and Smad3. These activated R-Smads form complexes w ith  Smad4 to regulate 
the transcription o f TGF-p inducible genes, which results in a huge array o f biological 
responses. This has raised the question o f the mechanism by which signalling 
specificity and diversity is generated.
To address this question. I have used a model tumour cell system developed in 
Hartmut Beug's laboratory. The parental cell line. TpH4. is a non-tumorigenic. mouse 
mammary epithelial cell line that undergoes growth inh ib ition and apoptosis in 
response to TGF-p. However. EpH4 cells that have been transformed by stable 
expression o f oncogenic Ras (EpRas cells) undergo an Epithelial-to-Mesenchymal 
Transition (EM T) in response to TGF-p and form rapidly growing tumours in mice.
In itia lly . I established the TAP-tagging purification system to identity new 
Smad-interacting partners in EpH4 and EpRas cells. Unfortunately, despite great 
efforts, no novel Smad partners were found using this method. I then went on to 
characterise the components o f the TGF-p pathway in this model tumour system. This 
work revealed that Smad3 is downregulated in EpRas cells compared w ith  EpI 14 cells 
and also that Smad3 expression is cell cycle regulated. Both transcriptional regulation 
and stability play a role in determining Smad3 expression. Tow Smad3 levels in EpRas 
cells may account for their inability to growth arrest in response to TGF-p.
I have also observed C-terminal phosphorylation o f Smad 1/5 as a result o f 
autocrine Bone Morphogenetic Protein (BM P) signalling and also upon TGF-P 
stimulation. Again, this is regulated at the cell cycle level. The Smad complexs formed 
as a result o f Smadl phosphorylation by TGF-p are distinct from those formed by 
Smadl activ ated by BMP. Molecular analysis o f  these signalling pathways has led to a 
model whereby TGF-P induced Smadl acts in concert w ith Smad2 and Smad3 to 
induce transcription o f a unique set o f  genes, which adds a level o f  complexity and 
specificity to the TGF-P signalling pathway.
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Chapter 1 Introduction
1 Introduction
1.1 Signal transduction
Cellular communication is a critical process for all m ulticellu lar organisms, whereby 
transmission o f signals between cells is required for proper embryonic development 
and adult physiology. Cell interactions w ith  the extracellular matrix and surrounding 
cells allows them to sense their environment and respond to signals that regulate most 
aspects o f cell behaviour, including survival, proliferation, and differentiation. For 
coordinated biological processes, messengers usually take the form o f proteins or 
peptides and bind to receptors on the surface o f neighbouring cells. Ligand binding can 
induce many cellular activities including cytoskeletal remodelling, adhesion, m otility  
and apoptosis. In addition, many receptors invoke gene expression responses, a subset 
o f  which has been shown to be independent o f  new proteins synthesis (Gomperts. B.
D. et al.. 2003). This revealed the existence o f transcytoplasmic signalling pathways 
that regulate the activity o f transcription factors which ultimately affects gene 
expression. In order to activate or repress transcription, transcription factors must be 
located in the nucleus, bind to DNA and interact w ith  the basal transcription apparatus. 
An emerging theme is that extracellular signals, which regulate transcription factor 
activity, can affect one or more o f these processes. Furthermore, a central principle in 
the regulation o f transcription factors is the key role o f phosphorylation, which can 
alter the activity o f  enzymes through the combined action o f a protein kinase and a 
protein phosphatase. To date, phosphorylation by protein kinases is the most 
widespread mechanism o f regulation in eukaryotic cells and forms the basis o f many 
cell signalling networks (Karin, M. et al.. 1995).
One o f the simplest mechanisms o f nuclear signalling is mediated downstream 
o f the largest receptor family, the G protein-coupled receptors. In response to 
hormonal stimulation, these seven transmembrane receptors activate heteromeric G 
proteins via GTP exchange, which then directly interact w ith and activate enzymes 
such as adenyl or guanylyl cyclase leading to the accumulation o f second messengers, 
namely cAM P and cGMP (Gomperts. B. D. et al., 2003). Downstream events leading 
to the in itia tion o f transcription was first identified for the PKA/CREB system (Karin,
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M. et al.. 1995). In this case, elevated cAM P activates the tetrameric protein kinase A  
(PKA ) by binding to the regulatory subunits, thus liberating the catalytic subunit which 
then translocates to the nucleus. Therefore, the signalling cascade downstream o f G- 
protein-coupled receptors leads to the activation o f a kinase by virtue o f its 
translocation from the cytoplasm to the nucleus. The nuclear targets for PKA are the 
CRTB transcription factors, which bind to D N A sequences known as cAMP-response 
elements (CRHs). Once in the nucleus, the PKA catalytic subunit phosphorylates 
CRTB on a serine residue, thereby stimulating its ab ility  to activate transcription 
(Karin, M. et al.. 1995). In addition to the cyclic nucleotides cGMP and cAMP, 
molecules other than proteins can act as second messengers. Phosphatidylinositol 3- 
Kinase (PI3 Kinase), which is recruited to the membrane by various stimuli, 
phosphorylates membrane-bound inositol phospholipids to produce PI(4.5)P2 or 
PI(3.4,5)P3. which are potent second messengers (Gomperts, B. D. et al.. 2003). These 
phospholipids then recruit signalling proteins via PIP3-binding plectrin homology 
(PH) domains to the membrane where they are activated. In addition, phospholipase 
action on PI(4.5)P2 by phospholipase C (PLC) generates a series o f potent, 
phospholipid-derived second messengers, including diacylglycerol (DAG ), IP3, 
PI(3,4.5)P3, IP4 and IP5. DAG is required for the activity o f protein kinase C (PKC), 
whereas IP3 acts to release Ca‘ ~ from intracellular stores, thus triggering a program o f 
Ca~ -activated events. These include a Ca“ sensing protein, called Calmodulin, which 
then targets a fam ily o f  CV7calm odulin activated protein kinases (Cam Kinases) 
(Gomperts, B. D. et al.. 2003). In essence, the ultimate role o f second messengers is to 
activate kinases such as PKA. PKB. PKC and Cam Kinase, which can then 
phosphorylate downstream targets to initiate transcription.
A  more complex mechanism involving the activation o f protein kinase 
cascades is used to transmit growth-factor signals from via receptor tyrosine kinases 
(RTKs) to the nucleus (Waskiewicz, A. J. et al.. 1995). This cascade, however, results 
in the translocation o f an active kinase to the nucleus. Receptor tyrosine kinases 
(RTKs) are single pass transmembrane receptors w ith  intrinsic kinase activity that is 
activated upon ligand binding. Consequently, the receptor phosphorylates tyrosine 
residues on the cytoplasmic domains o f the receptors themselves, which creates 
recruitment centres for effector proteins at the membrane (Schlessinger, J., 2000). 
Once recruited and activated, effector proteins initiate a mitogen activated protein
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kinase (M A P K ) cascade, which involves three serine/threonine protein kinases, named 
M AP kinase kinase kinase (M A P K K K ). M AP kinase kinase (M A P K K ) and M AP 
kinase (M A PK). These protein kinases are activated in series, such that the M A P K K K  
phosphorylates the M A P K K  at serines in its activation loop, which is thereby activated 
and phosphorylates the M APK at a threonine and tyrosine in its activation loop, 
leading to its activation. The terminal M APK, once activated, can migrate into the 
nucleus, and there phosphorylate and activate transcription factors (Waskiewicz, A. J. 
et al., 1995). A  well characterised M A P K  cascade is mediated downstream o f the 
proto-oncogene Ras. consisting o f Raf. M E K  (M A P K  and extracellular signal- 
regulated kinase (ERK) kinase) and E R K /M A P K  proteins, which w ill be discussed in 
Section 1.6.1.3.
Another fundamental principle that has emerged in signal transduction 
pathways is the translocation o f latent cytoplasmic transcription factors into the 
nucleus upon receptor stimulation. In some instances, a transcription factor can be 
sequestered in the cytoplasm through the binding o f  an inhib itory protein. An example 
o f such a transcription factor is N F-k B. In this case, N F-k B is held in the cytoplasm 
through the binding to an inh ib itor protein. Ik B, which masks the nuclear localisation 
signal in the N F-k B heterodimer. Activating stim uli induce phosphorylation o f I k B, at 
specific sites, which targets it for degradation, thus releasing active N F-k B to migrate 
into the nucleus (Gomperts, B. D. et al., 2003). A  second fam ily o f transcription 
factors whose activ ity is regulated by their compartmentalisation are the STATs. In 
response to a variety o f  interferons and cytokines, members o f the Janus kinase (JAK) 
fam ily, which are associated w ith cytokine receptors, are activated. This results in 
tyrosine phosphorylation o f receptor subunits and specific STAT transcription factors, 
which leads to the dimerisation o f STATs. which then migrate to the nucleus and 
activate transcription (Gomperts. B. D. et al., 2003). This type o f regulation allows for 
rapid information transfer from the cell surface to the nucleus. A third fam ily o f  
transcription factors whose subcellular localisation is regulated by extracellular signals 
is the Smads, which is the subject o f this thesis. Activation o f the TGF-(3 receptors by 
ligand binding induces the phosphorylation o f the downstream transcription factors, 
the Smads. which leads to their complex formation. Monomeric Smads are 
continuously shuttling in and out o f  the nucleus, however complex formation allows 
accumulation in the nucleus, which results in the in itia tion o f transcription (ten D ijke.
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P. et al., 2006). The regulation o f Smad activation w ill be discussed in much greater 
detail in the Section 1.5
Stabilisation o f transcription factors is another mechanism by which growth 
factors, such as Wnt e lic it their respsones. (3-catenin is a component o f adherens 
junctions at the cell membrane where it is associated w ith  the cytoplasmic domains o f 
cadherins. Under normal conditions, the cytoplasmic (3-catenin levels are tightly 
regulated by association p f (3-catenin w ith  the adenomatous polyposis coli (APC) 
complex. The APC complex which also includes the scaffold proteins axin or 
conductin/axin2, casein kinase I (C K I) and glycogen synthase kinase3(3 (GSK-3(3), 
facilitates the sequential phosphorylation o f (3-catenin by CKI and GSK-3(3. leading to 
its degradation through the ubiquitin-proteasome pathway (Peifer, M. et al.. 2000). 
Upon Wnt binding to its receptors, the cytoplasmic phosphoprotein. Dishevelled, is 
activated at the plasma membrane, which then interferes w ith  the degradation o f the 
cytoplasmic protein (3-catenin. Stabilization o f (3-catenin. allows it to enter the nucleus 
and form complexes w ith  high m o tility  group box transcription factors o f the TTF 
(lym phoid enhancer factor)/TCF (T-cell factor) fam ily to initiate transcription o f Wnt 
target genes (Peifer. \1. et al.. 2000).
A  novel mode o f signalling was demonstrated by the Notch fam ily o f receptors, 
which utilises the principle o f  ligand-induced proteolytic cleavage (Louvi, A. et al.. 
2006). Upon ligand binding. Notch undergoes a series o f proteolytic events which 
results in cleavage o f the Notch intracellular domain o f the receptor. (N ICD), which 
carries nuclear localization signals and can therefore translocate into the nucleus. Once 
in the nucleus. N IC D  interacts w ith the D N A-binding protein CSL, resulting in 
transcriptional activation o f Notch target genes (Louvi. A. et al., 2006).
f  inally, some ligands override the need for surface receptors such as the lip id- 
soluble retinoic acid, estrogen and other homones. These hormones traverse the plasma 
membrane and bind to these so-called nuclear receptors. These complexes then move 
into the nucleus and induce cellular responses by binding to and activating members o f 
a fam ily o f zinc finger transcription factors (Gomperts. B. D. et al., 2003).
Chapter 1 Introduction
1.2 An overview  of the TGF-p pathw ay
The transforming growth factor beta (TGF-(3) superfamily is a large fam ily o f secreted 
cytokines involved in the regulation o f  diverse biological processes including 
proliferation, m otility , differentiation and survival. Members o f the TGF-(3 superfamily 
are present in vertebrates and metazoans including the fru it fly  Drosophila 
melanogaster (Padgett, R. W. et al., 1987) as well as the nematode Caenorhahditis 
elgans (C.elegans) (Estevez, M. et al., 1993). The founding member o f the fam ily. 
TGF-(3, was orig inally named as a factor produced by virus-transformed cells which 
could promote anchorage-independent growth o f fibroblasts in culture (Roberts. A. B. 
et al.. 1981). Since its discover}’, however, subsequent studies have revealed a wide 
range o f cellular responses elicited by TGF-p. including its role as a potent growth 
inh ib itor (Polyak. K.. 1996).
The basic mechanism o f signal transduction by the TGF-(3 superfamily is conserved 
from C.elegans. Drosophila and Xenopus to higher vertebrate organisms (Miyazono. 
K. et al.. 2001). Ligands in all o f  these species signal via a complex o f type I and type 
II serine/threonine kinase receptors. As depicted in Figure 1.1. signalling is initiated by 
ligand binding at the cell surface and this allows the assembly o f the type I and type II 
receptors into heteromeric complexes. The type II receptor is constitutively active and 
the ligand-induced receptor complex formation, permits the type II receptor to 
phosphorylate the juxtamembrane region o f the type I receptor, which is rich in 
glycine and serine residues (Massague. J.. 1998). This phosphorylation event results in 
the activation o f the type I receptor, which can then signal downstream to the 
intracellular mediators o f the TGF-|3 superfamily, the Smad protein fam ily. The Smads 
are divided into three distinct subfamilies, which include the receptor regulated Smads 
(R-Smads). Smad4. a common partner for R-Smads and the inhib itory Smads (I- 
Smads). Interestingly, phosphorylation o f the type I receptor creates a binding site for 
the R-Smads, which is essential and sufficient for TGF-(3 signalling. Access o f the R 
Smads to this binding site on the type I receptors is facilitated by auxiliary proteins, such 
as Smad anchor fo r receptor activation (SARA) (Tsukazaki, T. et al., 1998) The type I 
receptor then phosphorylates the R-Smads at their conserved C-terminal SSXS m otif, 
which results in dissociation from the receptor and heteromeric complex formation
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with Smad4 (Shi, Y. et al., 2003). The Smad complexes then accumulate in the 
nucleus, where they assemble w ith  specific DN A-binding transcription factors, co­
activators and co-repressors to fina lly  activate or repress transcription. Termination o f 
the signal is regulated by the I-Smads, which are upregulated in response to T G F -fl I- 
Smads act as competitive inhibitors o f the R-Smads by binding to the type 1 receptor 
and in addition, they recruit H3 ubiquitin ligases to the receptor complex which targets 
them for degradation (Shi, Y. et al.. 2003). In addition to the critical role played by the 
Smads. multiple other pathways have been demonstrated to act downstream o f the 
TG F-p superfamily, including M APK. Rho-GTPases and PI3 Kinase (Derynck, R. et 
al., 2003). This relatively simple Smad signalling cascade becomes highly complex i f  
all the potential regulator)' elements and integration o f other signalling pathways are 
considered. In the fo llow ing sections I w ill discuss the regulation o f TGF-(3 
superfamily signalling, w ith particular emphasis on the role o f the Smads in this 
pathway, which is the focus o f my thesis.
1.3 TGF-p superfam ily ligands
The TGF-P superfamily consists o f over th irty members o f structurally related 
polypeptide growth factors. The superfamily can be divided into three distinct 
subfamilies: The TGF-|3s. the Activins/Nodals and the bone morphogenetic proteins 
(BMPs), which also includes growth/differentation factors (GDFs) and M ullerian 
inh ib iting substance (M IS ) (de Caestecker, M ., 2004). TGF-P fam ily members are 
expressed in highly complex temporal and tissue-specific patterns and regulate a wide 
array o f cellular processes including cell proliferation, lineage determination, 
differentiation, m otility , adhesion and death.
Three mammalian TGF-p isoforms have been identified, named T G F -p l, TGF- 
P2 and TGF-P3 and are each encoded by different genes, located on different 
chromosomes and share approximately 80% identity. A lthough all three isoforms 
exhibit sim ilar activities in vitro, they display distinct biological functions in vivo, as 
demonstrated by considerable phenotypic differences upon targeted deletion o f each 
isoform (Goumans, M. J. et al., 2000). Interestingly, two additional isoforms exist in
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both chicken and Xcnopus. Whereas TGF-P 1 was named for its transforming activities 
in in vitro assays, bone morphogenetic proteins (BMPs) were orig ina lly named for 
their ab ility  to induce ectopic bone formation (Wozney. J. M. et al.. 1988). To date, the 
BMP fam ily represent the largest TGF-p subfamily, w ith  over 20 members identified, 
o f which can be classified into m ultiple groups o f highly related proteins (Mehler. M.
F. et al.. 1997). Drosophila melanogaster Dpp, a homologue o f BMP2 and BMP4. 
together w ith the vertebrate proteins BMP2 and BMP4 form one BMP subgroup, the 
DPP/BMP group. The functional conservation o f these ligands w ith in  this subgroup 
was demonstrated by the ability o f Dpp to induce endochondral bone formation in 
mammals (Sampath. T. K. et al.. 1993). The third TGF-|3 subfamily includes Activins. 
Inhibins. Nodals. Le fty /A n tiv in  and Derriere. A ctiv in  was first discovered as a local 
regulator o f  pituitary fo llic le-stim ulating hormone (FSH) release, whereas Inhibin was 
found to attenuate A ctiv in  effects at the pitu itary (Gaddy-Kurten. D. et al.. 1995). It 
was subsequently discovered that Inhib in. which is structurally related to Activ in , acts 
as an endogenous antagonist o f  A c tiv in  signalling, by acting as a competitive inhib itor 
o f  the receptor complex (Lebrun. J. J. et al., 1997). In addition. Lefty, a divergent 
member o f this subfamily, has been shown to antagonise Nodal signalling, and the 
balance between Lefty and Nodal activity underlies the proper execution o f many 
developmental processes (Solnica-Krezel, L.. 2003).
The high number o f ligands in this superfamily is presumably due to the need 
for finely tuned developmental patterns o f receptor activation. This is achieved in part 
by differentia l regulation o f ligand expression and activation from latent complexes. 
TGF-p superfamily members are synthesized as large inactive precursor molecules that 
undergo proteolytic cleavage, releasing the prodomain from the active, receptor 
binding, carboxy-teminal region o f the molecules. These cleavage events are regulated 
in the Golgi apparatus by endoproteases o f the convertase fam ily including 
SPG 1/Furin and SPC4/PACH4 (Dubois. C. M. et al., 1995). For members o f the 
superfamily such as TGF-p, GDI-8 and possibly others, the N-term inal cleavage 
product, also known as latency associated peptide (LAP), binds non-covalently to the 
mature ligands, preventing binding to their respective receptors (de Caestecker. M., 
2004). A  variety o f molecules release the mature ligand from its latent state, which 
includes a number o f proteases such as plasmin. and the metalloproteases M MP-2 and 
M M P-9. and also thrombospondin. integrins and even reactive oxygen species
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(Annes, J. P. et al., 2003). Activation o f mature lignad is achieved by either proteolytic 
cleavage o f LAP or through disruption o f non-covalent interactions between LAP and 
TGF-P (Crawford, S. E. et al., 1998; Lyons, R. M. et al., 1988).
Table 1.1 Members of the TGF- p superfamily of ligands
Ligand Alternative names Subgroup
TGF-p
TGF-p 1 
TGF-P2 
TGF-P3
TGF-P s
Activin! Nodal
Activin A Activin PA-PA sub-units Activins
Activin B Pb-Pb
Activin AB Pa-Pb
Inhibin A Inhibin a-Activin pA subunits Inhibins
Inhibin B ci-P b
Nodal Ndr Nodal
Lefty 1 Lefty A/EBAF Lefty
Lefty2 Lefty B
BMPIGDF
BMP2 BMP2A BMP2/4
BMP4 BMP2B
BMP5 BMP5/6/7
BMP6 Vgrl/DVR6
BMP7 OP1
BMP8A OP2
BMP8B OP3/PC8
GDF1 GDF1
GDF3 Vgr2
GDF5 CDMP1 GDF5/6/7
GDF6 CDMP2/BMP13
GDF7 BMP12
BMP9
BMP10
GDF2 BMP9/10
BMP3 Osteogenin BMP3
BMP3b G D F10/S umitomo- BIP
GDF9 GDF9
GDF9b BMP15
GDF15 MIC 1 /PLAB/PTGFB/PDF
GFD8 Myostatin GDF8
GDF11 BMP11
MIS MIF/AMH MIS
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The active domains o f the TGF-(3 ligands have six intra-strand disulfide bonds that 
form a characteristic “ cystine knot" fo lding m o tif (Shi, Y. et al., 2003). Each protein 
then dimerises, in an anti-parallel fashion, to form the active ligand, which is stabilised 
by hydrophobic interactions. W ith the exception o f GDF3 and GDF9, all TGF-[3 
superfamily members have an additional conserved cysteine residue that is required to 
form an intersubunit disulfide bridge, which further stabilises the homodimers (M ittl. 
P. R. et al., 1996). Although homodimers represent the predominant form o f these 
ligands, heterodimers, such as that between BMP7 and GDF7. have been generated in 
vitro and these proteins display greater biological activity than their corresponding 
homodimers. In vivo. heterodimers m ight also function as competitive inhibitors o f the 
homodimers, and thereby act to modulate signalling during development (ten D ijke, P. 
et al.. 2003). Upon dimerisation. the TGF-[3 superfamily ligands are secreted from the 
cell into the interstitial m ilieu where they in itiate autocrine or paracrine signalling.
1.4 TGF-p receptors
The cellular effects o f the TGF-(3 superfamily members are mediated by a complex o f 
transmembrane receptors w ith  cytoplasmic serine-threonine kinase activity (Massague. 
J.. 1998). In itia l investigations using a ffin ity  labelling o f TGF-[3 identified two types o f 
receptors found to be indispensable for signal transduction (Taiho, M. et al.. 1990; 
W'rana. J. L. et al.. 1992b). This led to the rapid identification o f many other members 
o f this receptor fam ily. To date, the receptor serine/threonine kinase fam ily in the 
human genome comprises o f 12 members, all o f  which are TGF-(3 receptors (Manning.
G. et al.. 2002). Based on structural and functional properties, the serine-threonine 
kinase receptors fall into two families called the type I and type II receptors. Type I 
receptors have a higher level o f sequence sim ilarity than type II receptors and also 
contain a highly conserved region rich in glycine and serine residues called the GS 
domain (or type I box) located just N-term inal to the kinase domain. The nomenclature 
for the types I and II receptors is somewhat confusing. For sim plicity, I have referred 
to the type I receptors by a common nomenclature, the Activin-receptor like kinases
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Figure 1.2. Dendrogram of the type I receptors
The dendrogram indicates the relative level of amino acid sequence similarity of the type I receptors. The 
tree was produced by using the ClustalX alignment package (bootstrapping method) and was viewed in 
Tree View. ALKs 1-7 are mammalian (blck type) and Saxophone (Sax), Baboon (Babo) and Thickveins 
(Tkv) are Drosophila (red type).
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(A LK s) (ten Dijke. P. et al.. 1993; ten D ijke, P. et al.. 1994a), and the type II receptors 
according to their dominant ligand interactions (de Caestecker, M.. 2004).
Type I receptors are classified according to sequence sim ilarities into three 
main groups; the ALKS group which includes the TGF-(3 type I receptor ALKS, the 
A c tiv in  receptor A L K 4  and the Nodal receptor A LK 7; the A LK 3  group comprising the 
BMP typel receptors A LK 3 and A LK 6  (Chen, Y. G. et al., 1998); and the ALK1 group 
containing ALK1 and A LK 2  which interact w ith a range o f ligands (Chen, Y. G. et al..
1999) (Figure 1.2). Interestingly, one o f each o f the three Drosophila type I receptors, 
Thickveins (Tkv). Baboon (Babo) and Saxophone (Sax), falls into each o f the three 
subfamilies (Brummel. T. J. et al.. 1994).
Type II receptors include the TGF-(3 type II receptor. TpR II. the A ctiv in  and 
BMP/GDF type II receptors. ActR II and ActRJIB. the BMP/GDP type II receptors. 
BM PRII and BM PR IIB  and the M ullerian inhib itory substance (M IS ) type II receptor. 
M ISR II. W hile ActR II and A c tR lIB  are encoded by different genes. BM PRII (long) 
and BM PR IIB  (short) are two isoforms encoded by the same gene. Punt, the 
Drosophila type II receptor for Dpp and other ligands, acts as a receptor to both 
Drosophila A ctiv in  and Dpp, the homologue o f BMP2/4.
1.4.1 Ligand binding specificity and receptor assembly
It is strik ing ly apparent that there are much fewer receptor fam ily members than TGF- 
P superfamily ligands, suggesting m ultiple ligands share a given receptor. In addition 
to overlapping receptor usage, different combinations o f type I and type II receptors 
pair w ith different ligands (Feng, X. H. et al.. 2005) (Figure 1.3). The BMP ligands 
exhibit the greatest potential in receptor combinations, which is due in part to their 
ability to bind not only the "classical" BM PR II but also w ith A ctR II/A ctR IIB  (Macias- 
Silva. M. et al.. 1998; Nishitoh, H. et al., 1996) (Figure 1.3). However, subgroups o f 
the BMP ligands form specific receptor configurations. For example, the closely 
related BMP2 and BMP4 can both bind either A LK 3  or A LK 6, in concert w ith 
BM PRII, ActR II or A ctR IIB  (Macias-Silva. M. et al., 1998; ten Dijke, P. et al., 
1994b). In addition. BMP6/7 can also form complexes w ith A LK 2  together w ith  the 
type II receptors (Macias-Silva. M. et al., 1998). A L K 2  has been implicated as a dual 
receptor, demonstrated by its ab ility  to also bind activin as well as BMP6/7, in concert
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Figure 1.3. Heteromeric combinations of TGF-P superfamily receptors.
TGF-p ligands bind to specific combinations of RII-RI heterotetramers at the cell surface. Ligands, 
type I and type II receptors are colorcoded for each pathway. (Adapted from Feng and Derynck, 2005)
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w ith  activin type II receptors (Attisano. L. et al., 1993; ten Dijke, P. et al., 1994a). 
TGF-p. itse lf has the capacity to interact w ith  and activate three type I receptors, the 
canonical ALK.5. and additionally ALK1 and A LK 2 . in the presence o f TpR II 
(Goumans, M. J. et al.. 2002; Lux, A. et al., 1999; M iettinen. P. J. et al.. 1994). GDF5 
and GDF6 interact w ith ActR II, A ctR IIB  and BM PRII w ith A L K 6  (Lrlacher. L. et al.. 
1998; Nishitoh, H. et al., 1996), while GDF9B only interacts w ith  BM PRII. ActR II 
and ALK.6 (Moore, R. K. et al.. 2003). Combinatorial use o f receptors also occur in 
Drosophila where type I receptors Tkv and Sax interact w ith the type II receptor Punt 
to bind one o f three ligands: Dpp, Gbb. and Screw (Raftery, L. A. et al., 1999). Also, 
in C.elegans, a common type II receptor Daf-4. binds to one o f two type I receptors, 
Sma-6 or daf-1 to bind to ligands. DBL-1, or daf-7. respectively (Patterson. G. I. et al.. 
2000). Although all o f these combinations o f type I and type II receptors have been 
demonstrated, it is unlikely that they all function in vivo as ligand-binding signalling 
complexes. Many o f the studies performed used overexpressed receptors, in 
combination w ith protein crosslinking thus possibly forcing interactions that would not 
normally form under physiological conditions (ten Dijke. P. et al.. 1994a). 
Consequently, the functional significance o f some o f the receptor-ligand combinations 
remain an enigma. For example Activ in  was shown to bind A LK 2  and A L K 4  in 
concert w ith its respective type II receptors. ActR II and ActR IIB . however, a 
functional response to A ctiv in  via A LK 2  has not yet been demonstrated (Attisano, L. 
et al.. 1993; Macias-Silva. M. et al.. 1998). Indeed, it has been confirmed by another 
group that A LK 2  does not function as a type I receptor for A ctiv in  in Xenopus 
embryos (Armes. N. A. et al.. 1997). Moreover, the natural ligand for A LK 2  has not 
been conclusively defined and is as such an orphan receptor.
To date, the molecular basis o f  the selectivity o f the type I-type II receptor 
interaction is largely unknown. In spite o f  this, the complexity o f this combinatorial 
system is like ly to explain the diversity o f  downstream responses generated by a given 
ligand. The downstream response o f any ligand is therefore dependent on the 
repertoire o f  receptors expressed at the cell surface. This is exemplified by binding 
experiments o f BMP-7 carried out in various cell types. D ifferent profiles o f BMP-7 
receptors complexes were observed in different cells types examined. In some cases, 
BMP-7 formed complexes w ith  either A LK 2 , 3 or 6. and combinations o f all three, 
each w ith  different affin ities (Yamashita. H. et al., 1995). Consistent w ith  this idea, the
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signalling response by individual ligands would depend on the nature o f the activated 
receptor complex. Indeed, differential signalling responses were observed by the BMP 
type I receptors in specification o f mesenchymal precursor cells, whereby A LK 3 is 
able to promote adipogenic differentiation, and A L K 6  may be more potent in 
osteoblast differentiation (Chen, D. et al., 1998). In addition, endothelial cell m igration 
and proliferation is attributed to TGF-(3 signalling via A LK 1 , whereas growth 
inh ib ition and differentiation activities functions through ALKS during angiogenesis 
(Goumans, M. J. et al., 2003b; Goumans, M. J. et al., 2002) (see Section 1.6.2). In 
conclusion, the association o f different type I and type II receptors generates a diverse 
repertoire o f receptor complexes possessing distinct signalling potentials.
1.4.2 Structural features
Type I and Type II receptors are glycoproteins o f approximately 55 kDa and 70 kDa. 
respectively. Both types o f the receptor serine/threonine kinases consist o f about 500 
amino acids, w ith an N-term inal extracellular ligand binding domain, a transmembrane 
region, and a C-terminal serine/threonine kinase domain. The extracellular domain is 
relatively short (approximately 150 amino acids), and contains either one or two N- 
glycosylation sites in type I and tvpe II receptors, respectively (Franzen, P. et al.. 
1993). A  characteristic structural feature o f all TGF-{3 receptors is the three-finger 
toxin fold in the ligand binding domain, which has a common pattern o f eight 
cysteines form ing four disulfide bonds (Greenwald, J. et al.. l999)(Figure l . 4). A 
number o f snake venom neurotoxins also share this structural fold, however, sequence 
identities between the TGF-(3 receptors and the toxins are low and no functional 
sim ilarities between the two groups are known (Kirsch, T. et al.. 2000). A highly 
conserved region o f approximately th irty amino acids, known as the GS region is 
found only in the type I receptor fam ily and is named for the l8>ITSGSGSG|y2 
sequence at its core. It is essential for the ligand-induced activation o f the type I 
receptor, whereby at least three, and perhaps four to five o f the serines and threonines 
in the GS region, must be phosphorylated to fu lly  activate the type I receptor (Wieser, 
R. et al.. 1995; W illis . S. A. et al., 1996). In addition to the GS region, the intracellular 
region o f the type I and type II receptors contains the canonical serine/threonine kinase
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Figure 1.4. Structure of the TGF-p family receptors
A) Schematic diagram of the structural features of the Type I and Type II receptors.The P represents the 
consitutive serine/threonine phosphorylations of the type II receptor. The GS region is rich in glycine and 
serine residues and contains the characteristic TTSGSGSG sequence at its core.
B) Stereo ribbon diagram of the extracellular ligand binding domain of the type II Activin receptor 
(ActRII). The strands are numbered in the order that they occur in the sequence. The structure resembles 
the so-called three-finger toxin fold. (Taken from Greenwald, et al., 1999)
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domain (Figure 1.4). C-terminal to the kinase domain, the type II receptors typically 
contain a very short C-terminal extension, w ith  the exception o f an alternative form o f 
human BM PRII, BM PRIIB . which as a long C-terminal extension o f unknown 
function. In contrast, type I receptors have essentially no C-terminal extension 
(Massague, J.. 1998).
Some members o f the TGF-(3 receptor fam ily exist in alternative forms. An 
alternatively spliced variant o f  TpR II results in an insertion o f 26 amino acids at the N- 
terminus o f the mature receptor (Rotzer, D. et al., 2001). This receptor is implicated in 
TGF-(32 isoform specific signalling, as it can bind to TGF-(32 in the absence o f the co­
receptor . betaglycan (Rotzer. D. et al., 2001). Additional isoforms o f ActR IIB  also 
exist, w ith two small inserts into either the extracellular or intracellular juxtamembrane 
regions o f A ctR IIB  (Attisano. L. et al.. 1992). The presence o f the extracellular insert 
confers a high a ffin ity  binding to A c tiv in  (Attisano. L. et al.. 1992). A  splice variant o f 
BM PRII, BM PRIIB , that was previously mentioned, contains a long C-terminal 
extension in BM PRII. This receptor displays sim ilar binding profiles as BM PR IIB  
(Macias-Silva. M. et al.. 1998). A lternative splicing also results in a 61-amino acid 
insert in A M H R -II in the same position as TpR II. two alternative N-term inal regions in 
Tkv and two alternative extracellular juxtamembrane regions in baboon (Massague. J.. 
1998). The functional significance o f these latter receptor variants is unknown. 
However, certain ligands bind preferentially to either type I or type II receptor subunits 
(See Section 1.4.4) and interestingly, insertions at the N-terminus o f the receptors are 
seen only in these high a ffin ity  ligand binding subunits (TpR II. A M H R II. Tkv). This 
suggests that the N-terminus o f the ligand binding receptor subunit is important for 
high a ffin ity  ligand binding and specificity.
1.4.3 Receptor Complex formation
The basic paradigm by which TGF-P fam ily ligands interact w ith their receptors has 
been largely established from studies o f TGF-P (Wrana, J. L. et al.. 1992b). The in itia l 
observation that stable expression o f the type II receptor in mutant m ink lung (M v lL u )  
cells which lacked functional type II receptors, restored the interaction o f the type I 
receptor w ith TGF-p. prompted investigation into the possibility o f  a ligand induced
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complex formation (Wrana, J. L. et al., 1992a). Subsequently it was shown that the 
type I and type II receptors physically associate to form a stable complex (Franzen, P. 
et al., 1993; Moustakas, A. et al., 1993; Wrana, J. L. et al., 1992a) and furthermore, 
chimeric receptor systems established that this complex is required for signalling (Luo. 
K. et al., 1996; Vivien, D. et al., 1995). Kinase dead mutants o f the type II receptor 
still restored ligand binding to type I receptor, suggesting that the kinase domain is not 
required for heteromeric complex formation (Wrana, J. L. et al., 1992a). In addition, 
truncated versions o f the receptors, which lacked their entire intracellular domain, 
were still found to crosslink to ligand, indicating that the cytoplasmic domains o f the 
receptors are not required for complex assembly (Greenwald, J. et al.. 2003).
The exact stoichiometry o f  the active receptor complex has slowly been 
unravelled. Type 1 and type II receptors were shown to form homodimers in the 
absence o f ligand (Gilboa. L. et al.. 1998; Henis. Y. I. et al.. 1994). These homomeric 
complexes are not sufficient to propagate TGF-(3 responses but are proposed to be 
functionally important for regulating receptor kinase activity (Luo, K. et al.. 1996; 
Luo, K. et al., 1997). In addition, complementation studies between kinase-defective 
A LK 5  and activation-defective A LK 5  indicated a cooperative interaction between 
m ultiple A LK 5 molecules that is essential for signal transduction (Weis-Garcia, F. et 
al., 1996). These studies raised the possibility that the active receptor signalling 
complex could be a large multimeric complex consisting o f a m inimum o f two copies 
o f each receptor. Indeed, early studies indicated that a single dimeric ligand interacts 
w ith  two type I and two type II receptors to form  a hetero-tetrameric signalling 
complex, based on either velocity centrifugation or electrophorectic m obility o f 
receptor complexes crosslinked to [ 12:4]TGF-(3 (Wells, R. G. et al., 1999; Yamashita, 
11. et al., 1994). To date, structural data confirms the proposed model o f the four- 
receptor signalling complex (Greenwald, J. et al., 2003). The elucidation o f the 
cocrystal structure o f ActR II ectodomain (LC ) w ith  BMP7 indicated that the complex 
consists o f the BMP-7 dimer and two A ctR II receptor LCs, and its structure exhibits a 
perfect twofold axis o f symmetry (Greenwald, J. et al., 2003). When crystal structure 
o f the A LK 3 LC in complex BMP2 complex, is superimposed on the ActR II-BM P2 
structure, a symmetrical complex w ith four receptors bound to the BMP-7 dimer was 
formed (Greenwald. J. et al.. 2003; Kirsch. T. et al.. 2000). Taken together, this
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evidence strongly suggests the existence o f active hetero-tetrameric signalling 
complexes, however, this does not rule out the possibility for higher order structures.
In addition, the receptors have been shown to have an intrinsic a ffin ity  for each 
other. As demonstrated by co-immunopreciptitation and antibody-mediated copatching 
experiments, a small, but detectable proportion o f A LK 5  and TpR II heteromeric 
receptor complexes exists already in unstimulated cells (Chen, R. M. et al., 1995; 
V ivien. D. et al.. 1995; Wells, R. G. et al., 1999). The dramatic induction o f complex 
formation upon ligand binding, however, suggests that the majority o f the receptors are 
unoccupied at the cell surface. This is further substantiated by the ability  o f  type I and 
type II receptors to bind in different combinations, depending on the ligand present (de 
Caestecker. M.. 2004; Wrana. J. L. et al.. 1994).
1.4.4 Ligand Binding
Surprisingly, individual members o f the TGF-P superfamilv bind to their respective 
receptors in a distinct fashion, despite sharing sim ilar patterns o f downstream 
signalling events. In general, there are two modes by which TGF-p ligands recognise 
their receptors, either by high a ffin ity  binding to the type I or the type II receptor (Shi. 
Y. et al., 2003). T G F -p i, TGF-P3 and Activ ins initiate receptor assembly by binding 
w ith high a ffin ity  to the type II receptor. The type I receptor is subsequently recruited 
by the type Il-ligand complex to stablilise the type Il-type I receptor complex (Boesen. 
C. C. et al., 2002; Hart. P. J. et al., 2002). This binding mode is characterised in the 
TGF-(3 system, whereby the type I receptor has the ability  to recognise TpRII-bound 
TGF-p but is unable to bind TGF-P free in solution (Laiho, M. et al.. 1990; Wrana, J. 
F. et al., 1992a). The elucidation o f the structure o f the TpR II ectodomain-TGF-p3- 
complex has revealed insights into the mechanism o f receptor binding. The TpR II 
ectodomain (HC) interacts w ith the homodimeric, antiparallel TGF-P3, by binding 
identical regions at opposite ends o f the ligand, called the 'fingertips ' (Hart, P. J. et al., 
2002) (Figure l . 5). Each receptor binds to one monomer o f the dimeric TGF-P3. The 
receptor assembly model predicts that A L K 5  binds TpR II-TG F-p adjacent to TpR II on 
the concave surface o f the ligand, which stabilises the complex (Hart, P. J. et al., 2002)
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Figure 1.5. Ligand-Receptor Interactions
(A) Side view of the human TpRII extracellular (ec) domain -TGF-P3 complex, with two ecTpRII 
molecules (green) and the two TGF-P3 monomers (blue and red). The TGF-p3 interchain disulfide bond 
is shown in black.The predicted positioning of ALK.5 in the complex is shown by a black circle. 
(Adapted from Hart et al., 2002)
(B) TTie structure of the BMP2-ALK3ec complex. The BMP monomers are coloured gold and blue, the 
two ALKJec molecules are green. Secondary structure elements, chain termini and receptor loops 1 and 
3 are labeled. The ‘wrist’ and the putative ‘knuckle’ epitopes on BMP-2 are highlighted and the position­
ing of the type II receptor at the knuckle epitope is represented by a black circle. (Adapted from Kirsch 
et al., 2000)
(C) The heterohexameric complex of BMP7-ALK3-ActRIl consisting of one ligand dimer bound to four 
receptor extracellular (ec) domains. The components are shown in blue and yellow (BMP7), green (ecs 
of ALK3) and red (ecs of ActRII). The ALK3 ecs were docked to the BMP7-ActRII complex by super­
position with the BMP2-ALK3 complex. (Taken from Sebald and Mueller, 2003)
39
Chapter 1 Introduction
(Figure 1.5). In contrast to TG F-p l and -3. TGF-(32 isoform has a low a ffin ity  to 
TpR II and requires an additional co-receptor, betaglycan, for efficient signal 
transduction (Lopez-Casillas, F. et al.. 1993) (Refer to section 1.4.7.1). The structure 
o f the TpR II ectodomain-TGF-p3-complex revealed nine interfacial residues, all o f 
which are conserved in T G F -p i. In TGF-(32. three o f these residues are substituted 
relative to TGF-P3, which may account for the diminished a ffin ity  o f  TGF-P2 toward 
binding TpR II (Hart, P. J. et al.. 2002). In particular, the presence o f  a lysine residue at 
position 94. compared w ith an arginine at the equivalent position in both TGF-P 1 and 
TGF-p3 isoforms, is the main determinant o f  the low a ffin ity  observed.
The mode o f ligand-receptor interaction exhibited by the BMP ligands is 
different to that o f the TGF-P ligands. BMPs bind specifically to their type I receptors, 
demonstrating only weak binding to their type II receptors alone (L iu . F. et al.. 1995). 
Thus, the intermediate BMP-type I receptor complex then recruits the low a ffin ity  type 
II receptor into the receptor complex, an order which is the reverse from most other 
TGF-p fam ily members. The crystal structure o f human dimeric BMP2 in complex 
w ith two high a ffin ity  A LK 3 extracellular domains (BRIAec) has revealed insights 
into the binding o f BMP ligands w ith  their cognate receptors (Keller. S. et al.. 2004; 
Kirsch, T. et al., 2000). As seen in Figure 1.5B. the complex consists o f  a BMP2 
homodimer, which adopts an extended fold, and two copies o f the type I receptors, 
bound at the far ends o f the elongated ligand, known as the 'w ris t epitope' (K irsch. T. 
et al.. 2000). Furthermore, a potential binding epitope for the type II receptor was 
proposed, designated the 'knuckle epitope' and located at the far end o f the central p- 
sheet o f  the dimer, opposite to but in close proxim ity to the type I receptor (Kirsch, T. 
et al.. 2000). Subsequently, the elucidated structure o f A ctiv in  and A ctR IIB  complex 
revealed that A ctiv in  type II receptor shares a sim ilar binding site to the BMP type II 
receptor on its respective ligand (Thompson, T. B. et al.. 2003). A ctiv in  A binds 
ActR IIB  along the 'knuckle ' region o f the monomer structure, sim ilarly to the 
proposed binding epitope o f BMP2 (Thompson, I . B. et al.. 2003). This binding mode 
is significantly different from TGF-p3 binding to TpR II, where TGF-p binds TpR II at 
the tips o f the monomer fingers (Hart, P. J. et al., 2002). These structural data reveal 
that the binding epitopes o f the type II receptors differs greatly between the TGF-p 
ligands compared w ith  those o f A c tiv in  and BM P ligands (Compare Figure 1.6A and
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B), supporting the idea that the type II receptors play a dominant role in determining 
the specificity o f ligand. Also, these different binding modes may have consequences 
in downstream signalling, through differential or cooperative recruitment o f type I and 
type II receptors in the holo complex.
As previously mentioned, BMP ligands have a higher a ffin ity  for their type I 
receptors than their type II receptors, however, BMP-7 differs in this respect in that it 
retains the TGF-(3/Activin-like preference for its type II receptor. As a result, the 
structure o f BMP7 type II receptor complex was elucidated, which revealed additional 
insights into the assembly o f the TGF-(3 receptor complex. Because o f the high 
sequence homology o f BMP2 and BMP7, the model o f the BM P7-ActR II structure 
could be confidently combined w ith  the BM P2-ALK3ec complex to assemble a six- 
chain complex. The most striking observation o f the predicted model was the lack o f  a 
direct physical interaction between any o f  the receptor extracellular domains, which 
were connected only through ligand (Greenwald. J. et al., 2003). This is in contrast to 
the current paradigm in which the type II receptor recruits the type I receptors. Yet the 
two receptors cooperatively bind to the BMP7 ligand, whereby the high a ffin ity  
interaction o f the type II receptor w ith  the ligand, allows the cooperative recruitment o f 
the low  a ffin ity  type I receptor. Thus, this represents a new mode o f cooperative 
ligand-mediated receptor assembly without receptor-receptor contacts (Sebald, W. et 
al., 2003). Furthermore, it has been proposed that cooperativity is achieved by 
im m obilisation o f the ligand at the membrane surface by the in itia l binding o f the high 
a ffin ity  binding (ActR II in the case o f BMP7). thus enhancing the a ffin ity  for the 
second receptor (Greenwald, J. et al., 2004).
1.4.5 Receptor activation
The basic mechanism o f receptor activation was first established w ith TGF-(3 receptors 
(Chen, F. et al., 1995; Wrana, J. T. et al., 1994) and subsequently sim ilar mechanisms 
were also revealed for the activin receptors (Attisano, L. et al., 1996) (Figure l . 6). The 
notion that ALKS acts downstream o f T|3R-II was supported by the inability o f the 
type II receptors to signal in the absence o f type I receptors, in spite o f  their ab ility  
bind TGF-(3 (Boyd, F. T. et al., 1989; Laiho, M. et al., 1990; Wrana, J. L. et al.,
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1992a). This was further substantiated by studies showing that a mutation in T(3R-II 
which inactivates its ability to recognize A LK 5  as a substrate does not signal 
(Carcamo, J. et al., 1994), and that a constitutively active A LK 5  mutant (threonine 
residue at 204 replaced by an aspartic acid residue) can signal in the absence o f ligand 
and T(3R-II (Wieser, R. et al., 1995). The TGF-P type II receptor is constitutively 
active. Autophosphorylation occurs on four residues and ligand occupancy causes no 
appreciable change in this activity (Wrana. J. L. et al., 1994). The regulation o f this 
remains elusive, however autophosphorylation o f three o f these residues, S213, S409 
and S416, were shown to positively and negatively affect receptor function (Luo, K. et 
al.. 1997). Upon ligand binding, formation o f the heteromeric complex between the 
type I and type II receptors rapidly leads to phosphorylation o f the type I receptor 
(Wrana. J. L. et al., 1994). Phosphorylation occurs on one threonine and three serines 
in the GS domain, adjacent to the N-terminus o f the kinase domain in all type I 
receptors (Weis-Garcia, F. et al.. 1996). This phosphorvlaion is catalysed by the type II 
receptor, as shown by coexpression o f w ild-type and kinase-defective mutants o f type I 
and II receptors in various combinations (Wrana. J. L. et al., 1994). These m ultiple 
phosphorylation events activate the type I receptor kinase, which transduces the signal 
by phosphorylating and activating downstream mediators o f the pathway, the Smads 
(Figure 1.6). To date, members o f the Smad fam ily o f  transcription factors are the only 
direct substrates o f the type I receptors (See Section 1.5). Phosphorylation in the GS 
domain is essential for signal propagation since mutations in two or more o f the serine 
residues impairs signalling (Franzen, P. et al.. 1995). In an additional study, Pluse et 
al.. used an elegant chemical ligation method to produce a homogenous, tetra- 
phosphorylated GS region in ALK5. By use o f this semisynthetic protein, it was shown 
that the primary effect o f GS phosphorylation is the creation o f a binding site for one 
o f A L K 5 's  downstream target, Smad2. and that the unphosphorylated GS region is 
inhibitory only through binding o f the im inunophilin  FKBP12 (Huse, M. et al., 2001) 
(Figure 1.6). Thus the receptor activation is not due to an increase o f the actual kinase 
activity, but rather is based on the creation o f a substrate binding site. In line w ith this 
idea, constitutively active (ca) type I receptors, mentioned earlier, function by 
maintaining this open conformation, to which the Smads can bind and are activated 
(Wieser. R. et al., 1995).
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Figure 1.6. Receptor Activation
In the absence of ligand (basal state), the type I receptor is stabilised in an inactive conformation by the presence of FKBP12, which organises the 
flexible GS loop into an inhibitory wedge generating a ‘locked’ conformation. This prevents spurious receptor complex formation and subsequent 
signalling. Upon ligand binding, the type II receptor recruits the type I receptor into a hetermeric receptor complex. The close proximity of the recep­
tors allows the constitutively active type II receptor to phosphorylate the GS domain of the type I receptor. Phosphorylation of the GS domain elimi­
nates a binding site FKBP12 and simultaneously creates a binding site for the Smad substrate. The GS domain in conjunction with the L45 loop of the 
type I receptor mediates the interaction with the L3 loop of an R-Smad, resulting in phosphorylation of its C-terminal SSXS motif. The green circles 
represent the putative phosphorylation sites of the type I receptor and the R-Smads. (Taken from Shi and Massague, 2003).
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The specificity o f  the interaction is determined by a nine amino acid sequence in the 
type I receptor, known as the L45 loop and a complementary region in the Smad C- 
terminal domain, the L3 loop (Chen, Y. G. et al., 1998; Chen, Y. G. et al., 1999)(See 
Seeion 1.5.4.2). Once the Smad-receptor interaction is established, the kinase domain 
o f the type 1 receptor phosphorylates and activates the Smads. The phosphorylation o f 
the C-terminal SSXS m o tif o f  the Smad triggers a conformational change which then 
results in the dissociation o f the activated Smad from the receptor and subsequent 
heteromerisation w ith Smad4 (Shi, Y. et al., 2003).
In addition, other studies investigated whether other residues o f the type I 
receptor were involved in receptor activation. Indeed, it was observed that mutations in 
either G l\ 261 or Gly322 in the kinase domain, rendered the type I receptor unable to 
be transphosphorylated by the type II receptors, however they still maintained kinase 
activity (Weis-Garcia. F. et al., 1996). Also the N A N D O R  box. which refers to 
residues 482-491 in the kinase domain have been implicated in the regulation o f GS 
domain phosphorylation (Garamszegi. N. et al.. 2001). Furthermore, residues in the 
cytoplasmic juxtamembrane domain o f the type I receptor are required for transduction 
o f the TGF-(3 signal. Phosphorylation o f S I65 in the juxtamembrane domain o f type I 
is observed upon TGF-(3 induction and has been implicated in modulation o f the TGF- 
[3 response (Souchelnytskyi. S. et al., 1996). Furthermore, mutagenesis o f the serine 
and threonine residues in the cytoplasmic juxtamembrane domain, revealed that these 
residues are dispensable for binding to TGF-(3 on the cell surface, form ing a complex 
w ith  T(3R-II and production o f PAI-1. However, these mutants could not restore the 
antiproliferative response to TGF-(3 in cells lacking endogenous type I receptor 
(Saitoh. M. et al., 1996). The mechanism by which these residues contribute to signal 
propagation remains unclear.
1.4.6 Termination of Receptor Activity
Sustained signalling in response to a stimulus is generally undesirable, and therefore 
mechanisms for signal termination are required. The inhib itory Smads (I-Smads) play 
a p iv ito l role in this regard. In itia l evidence indicated that they could act as competitor 
inhibitors o f  the receptor regulated Smads (R-Smads), by binding directly to the type I
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receptors and thereby blocking access to the receptor (Izzi, L. et al., 2004) (See section
1.5.2.3). More importantly, it has been shown that ubiquitination o f the TGF-(3 
receptor family, leading to the proteasomal degradation, is a major route for turning o ff  
the signal mediated by TGF-P superfamily ligands (ten D ijke, P. et al.. 2006). The I- 
Smads are key players in this process, whereby both Smad6 and Smad7 initiate 
degradation o f the receptors by recruitment o f E3 ubiquitin ligases (Sm urf 1 and 
Smurf2) to the activated receptors (See section 1.5.2.3) (ten D ijke. P. et al.. 2004). The 
expression o f I-Smads is quickly induced upon stimulation by members o f the TGF-p 
fam ily, thereby creating a negative feedback loop to regulate the duration o f 
downstream signalling. In addition, an emerging theme in the regulation o f the TGF-P 
signal is the action o f phosphatases for terminating the activity o f  the receptors. It was 
recently reported that the TGF-P-induced Smad7 can interact w ith  the growth arrest 
and DN A damage protein 34 (G ADD34). which acts a regulatory subunit o f  the 
serine/threonine protein phosphatase, PP1. The Smad7- GADD34 complex was shown 
to recruit the PP1 catalytic subunit (PP lc) to ALK 5, and thereby dephosphorvlate and 
inactivate it (Shi. W. et al., 2004).
Recent work has revealed that the tra ffick ing o f the TGF-p receptor fam ily is 
also tightly regulated (ten Dijke, P. et al.. 2004). This work has been demonstrated for 
TGF-p receptors but sim ilar mechanisms are inferred for the other fam ily members. 
TGF-P receptors can be internalised via two distinct routes, a clathrin- and a lip id  
raft/caveolar-dependent pathway, each o f which has a distinct outcome (ten D ijke, P. 
et al., 2004). Receptors that are internalised via the clathrin pathway enter early 
endosomes where SARA is also enriched and thus promote Smad signalling (D i 
Guglielmo. G. M. et al., 2003). These receptors can recycle back to the plasma 
membrane, where once again binding o f TGF-p is initiated (ten D ijke, P. et al., 2004). 
Termination o f receptor activity in this case is like ly to be via dephosphorylation o f the 
receptors. In contrast, internalisation o f the receptor complex via caveolin-positive 
lip id-ra ft domains results in association w ith  the Smad7/Smurf2 complex. This 
ultimately leads to accelerated degradation o f the receptors via the ubiquitin- 
proteasome pathway (D i Guglielmo, G. M. et al., 2003). The mechanism underlying 
the segregation o f the receptors between these two routes is unclear, however the 
internalisation pathway has dramatic im plications for the specificity o f  the TGF-p
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response, in terms o f receptor availability and signal duration (ten Dijke, P. et al.,
2004).
1.4.7 Regulation of Ligand-Receptor Interaction
The regulation o f ligand-receptor binding is highly complex, and this is underscored 
by additional requirements for other cell surface proteins. In itia l experiments using 
a ffin ity  labelled TGF-P to search for cell surface receptors isolated three complexes 
(Cheifetz. S. et al., 1987), which corresponded to receptors type I, II and III. Receptor 
types I and II have been discussed in detail (Section l . 4). The type III  receptor, which 
has been identified as betaglycan. is now classified as a TGF-p co-receptor. Other co­
receptors for different fam ily members have been identified and the significance o f  
these regulatory interactions w ill be discussed next.
1.4.7.1 Betaglycan
Betaglycan. orig inally identified as a type III receptor, is a highly glycosylated trans­
membrane protein w ith a large extracellular domain and short cytoplasmic tail that 
lacks kinase activ ity (Lopez-Casillas. F. et al., 1991; Wang, X. F. et al.. 1991). In 
addition to independently binding all three TGF-P isoforms (Cheifetz, S. et al., 1990). 
betaglycan acts to faciliate TGF-P binding to its type II receptor (Topez-Casillas. F. et 
al., 1993; Wang. X. F. et al.. 1991). leading to the formation o f a ternary complex 
containing TGF-p, TpR II and betaglycan (Lopez-Casillas. F. et al.. 1993; Moustakas. 
A. et al.. 1993). The TG I;p2 isoform differs from TGF-Ps 1 and 3. in that it binds 
TPRII w ith a much lower a ffin ity  (1000-fold weaker) than TGF-ps 1 and 3 (Cheifetz, 
S. et al., 1990; De Crescenzo, G. et al., 2006). However, betaglycan has been shown to 
enhance TGF-P2 binding to TpR II (Lopez-Casillas, F. et al., 1993). In addition, 
betaglycan seems to increase TGF-P2 signalling, leaving unaffected the TGF-p 1 
response in myoblasts (Letamendia, A. et al., 1998b; Lopez-Casillas, F. et al., 1993). 
Moreover, betaglycan null cells exhibited significantly reduced sensitivity to TGF-P2 
in terms o f Smad2 nuclear accumulation and transcriptional responses, effects not
46
Chapter 1 Introduction
observed w ith  other isoforms (Stenvers. K. L. et a l,  2003). In light o f these findings, a 
model has been proposed in which betaglycan acts to present TGF-|3 to its type II 
receptors, ultimately leading to an increase in signalling (Lopez-Casillas, F. et al., 
1993). The physiological relevance o f betaglycan in TGF-(32 mediated signalling was 
elegantly demonstrated in the chick heart. TGF-(32 is essential for endocardial 
epithelial-to-mesenchymal transition (EM T) during development o f the heart valves 
(Camenisch, T. D. et al., 2002)(Section 1.6.3.2). Incubation o f chick heart explant w ith 
neutralising antibodies against betaglycan, which blocked its ab ility  to bind TGF-p2, 
disrupted TGF-(32-induced endocardial EM T (Brown, C. B. et al.. 1999). In 
conclusion, these studies establish betaglycan as a high a ffin ity  receptor for TGF-(3. 
especially for TGF-|32. and indicate a requirement for betaglycan in mediating some o f 
TGF-f3 responses.
Additional roles for betaglycan in modulation o f TGF-P signalling have 
recently been proposed (Gray. P. C. et al.. 2002). It was also demonstrated that 
betaglycan can act as a co-receptor for inhibin, increasing the a ffin ity  o f inhib in for 
type II receptors, prim arily the activin type II receptors, ActR II and ActR IIB , and the 
BMP type II receptor BM PRII (Lewis. K. A. et al., 2000; Wiater, E. et al., 2003). 
Inhib in binding to betaglycan promotes interactions vvtih the type II receptors, thereby 
sequestering them, which leads to a competitive blockade in BMP and A c tiv in  
signalling (Lewis, K. A. et al., 2000; Wiater, E. et al., 2003). Betaglycan appears to 
behave sim ilarly w ith respect to both TGF-p and inhibin, enhancing binding o f these 
ligands to type II receptors. However, whereas betaglycan acts to increase TGF-p 
signalling, it appears to enhance the ability  o f inh ib in  to antagonise A ctiv in  and BMP 
signalling. Hence, betaglycan provides a regulatory network that has the capacity to 
m odify diverse TGF-p signalling pathways.
1.4.7.2 Endoglin
Endoglin is a 180-kDa homodimeric transmembrane glycoprotein that is 
predominantly expressed in vascular endothelial cells (Gougos, A. et al., 1988). Other 
sites o f expression include syncytiotrophoblasts o f  fu ll-term  placenta, stromal cell and 
certain haemopoietic cells (Gougos, A. et al., 1992; Lastres, P. et al., 1992). The first
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indication that endoglin was involved in TGF-(3 signalling was revealed upon the 
molecular cloning o f betaglycan (Gougos, A. et al., 1990). The high sequence 
sim ilarity between these two proteins, in particular in the cytoplasmic tail where these 
two proteins are 71% identical, indicated they could have sim ilar functions (Cheifetz, 
S. et al.. 1992). Subsequently, endoglin was found to act as an accessory receptor for 
TGF-P (Cheifetz, S. et al., 1992). In sharp contrast to betaglycan, endoglin only binds 
ligand while in association w ith the TGF-p type II receptor (TpR II) and can bind TGF- 
(31 and TGF-(33 efficiently but not TGF-(32 (Barbara, N. P. et al., 1999; Letamendia. A. 
et al.. 1998a). In addition, endoglin has been shown to bind other members o f the 
TGF-(3 superfamily, including activin and BMPs, and in that case interacts w ith  activin 
type II receptors (Barbara. N. P. et al.. 1999). However, the physiological role o f  
endoglin in signalling by activin and BMP is unclear. Futhennore, endoglin can bind 
to type I and II receptors even in the absence o f  ligand (Guerrero-Esteo, M. et al., 
2002; Lux. A. et al., 1999). M u ltip le  sites o f interaction in both the extracellular and 
intracellular domains o f endoglin interact w ith A LK 5 and TpR II (Guerrero-Esteo, M. 
et al.. 2002).
Endoglin has been shown to modulate TGF-p signalling (Goumans, M. J. et al., 
2003a). Ectopic expression o f endoglin has been shown to inh ib it TGF-p induced 
growth inhib ition and PAI-1 expression (Letamendia, A. et al., 1998b). Depletion o f 
endoglin by use o f antisense oligonucleotides enhances the ab ility  o f TGF-P to 
suppress growth and migration in endothelial cells (L i, C. et al., 2000). These data 
suggest a roie for endoglin in negatively regulating TGF-p signalling. In a recent 
study, light was shed on the molecular mechanism by which endoglin inhibits TGF-P 
responses (Lebrin. F. et al., 2004). This study presents data to suggest that endoglin 
acts predominantly to promote ALK1 signalling in response to TGF-p, which in turn 
antagonises the canonical ALK.5 signalling. In addition, endoglin is upregulated in 
response to A LK 1, suggesting the existence o f a positive feedback loop (Ota, T. et al.. 
2002). Furthermore, mutations o f the Endoglin and ALK1 genes are linked to the 
vascular disorder hereditary hemorrhagic telangiectasia (HUT), which firm ly  places 
these two proteins in a common pathway (Johnson, D. W. et al., 1996; M cAllister, K. 
A. et al., 1994). The highly sim ilar T G F -p i, TpR II, A LK 1, A LK 5 , Smad5 and 
Endoglin knockout phenotypes provide additional evidence for a role o f  Endoglin in
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modulating TGF-p signalling and indicate that these different components o f the TGF- 
p pathway work together during blood formation in vivo (Goumans, M. J. et al.. 2000).
Furthermore, another study has suggested that a sequential mechanism o f 
serine and threonine phosphorylation by TpR II and A LK 1 , respectively, is involved in 
the regulation o f endoglin activity (Koleva, R. I. et al., 2006). Taken together, this 
evidence suggests that the expression, activity and the protein-protein interactions o f 
endoglin are under tight regulation, which suggest important physiological roles for 
endoglin in TGF-p signalling. The contribution o f endoglin to the process o f 
angiogenesis w ill be discussed in more detail in latter sections (Section 1.6.2).
1.4.7.3 BAMBI
B A M B I (BMP and A ctiv in  membrane-bound inhib itor) is the Xenopus and Zebrqfish 
orthologue o f the mammalian gene N M A , which was first identified from differential 
m RNA screen in melanoma cell lines (Degen, W. G. et al., 1996). B A M B I/N M A  is 
structurally related to type I serine/threonine kinase receptors in the extracellular 
domain, but it lacks the intracellular serine/threonine kinase domain (Onichtchouk, D. 
et al., 1999). Functional and biochemical evidence suggest that these proteins act as 
pseudoreceptors and antagonize the effects o f TGF-p, Activ in , and BMPs. B A M B I 
interacts w ith  all o f  the type I receptors except for A LK 2 , as well as TpR II and ActR II. 
thus preventing the formation o f active receptor complexes (Onichtchouk, D. et al., 
1999; Tsang. M. et al.. 2000). Expression o f B A M B I appears to be regulated by both 
BMP and TGF-P signalling, indicating mechanisms for negative feedback 
(Onichtchouk, D. et al., 1999; Sekiya, T. et al., 2004b). Also, a recent study 
demonstrated an elevated level o f  B A M B I in colorectal and hepatocellular carcinomas 
and which may act to interfere w ith the growth inhib itory response to TGF-p (Sekiya, 
T. et al., 2004a). T his suggests that the use o f  this decoy receptor may be employed by 
tumours to actively inhib it signalling by TG F-p fam ily members.
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1.4.7.4 EGC-CFC family
The membrane-bound EGF-CFC fam ily are defined by four founding members: 
mammalian Cripto and Criptic (Dono. R. et al., 1993), zebrafish one-eyed pinhead 
(Oep) (Zhang, J. et al., 1998) and Xenopus FRL1 (FGF-Related Ligand) (Kinoshita, K. 
et al., 1995). To date, there are three known fam ily members in Xenopus, FRL1 (now 
called XCR1) and XCR2 and XCR3. A ll fam ily members contain an N-term inal signal 
peptide, a modified EGF-like region, a conserved cysteine-rich domain named CFC 
(Cripto. FRL-1. Criptic) m o tif and a short hydrophobic C-terminus bearing a 
glycosylphosphatidylinositol (GPI)-anchor signal (M inchiotti, G. et al., 2000). Genetic 
studies in zebrafish and mouse have defined an essential role for the EGF-CFC fam ily 
in Nodal signalling. Mutations in oep result in cyclopia, impaired gastrulation, loss o f 
anterioposterior positioning and defects in le ft-righ t asymmetry, processes in which 
Nodal signalling has been implicated (Gritsman, K. et al.. 1999; Zhang, J. et al., 1998). 
In mouse, cripto, like nodal. is necessary for establishing the anterioposterior axis 
(Whitman. M., 2001) and targeted disruption o f cryptic results in defects in le ft-right 
asymmetry (Yan, Y. T. et al.. 1999). More recent biochemical studies in Xenopus have 
revealed that members o f the EGF-CFC are required for Nodal-related ligands to 
signal during early Xenopus development. This is demonstrated by the inhib ition o f 
nodal-dependent developmental processes, gastrulation and mesendoderm formation, 
upon knockdown o f  XCR1 and XCR3 (Dorey, K. et al., 2006).
Biochemical data indicates a direct interaction between mouse Critpo and 
A L K 4  in Xenopus oocytes and this interaction is necessary for Nodal to bind to the 
A LK 4 /A ctR IIB  receptor complex (Bianco, C. et al., 2002; Yeo, C. et al.. 2001). In 
addition to functioning as a co receptor to Nodal. Cripto and other members o f the 
EGF-CFC fam ily mediate the binding o f A ctiv in , Xenopus V g l and GDF1 to Activ in  
receptors (Cheng, S. K. et al., 2003). These results establish that multiple TGF-p 
signals converge on A ctiv in  receptor/EGF-CFC complexes and suggest a widespread 
requirement for Cripto in TGF-p signalling, f  urthermore, Cripto is overexpressed in 
several cancers and its overexpression is associated w ith  the development o f mammary 
tumours in mice (Strizzi, L. et al., 2005).
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Table 1.2 Requirements of Co-receptors in TGF-p signalling
Ligand Type I Receptor Type 11 Receptor Co-receptor Required
TGF-02 ALK5 TPRII Betaglycan
TGF-p 1,3 ALK1 TPRII Endoglin
Nodal, Vgl, 
GDF1,Activin
ALK4/7 ActRJI/B Cripto
The TGF-p signalling pathways are subjected to delicate regulation at multiple levels. 
This is exemplified by the extracellular regulation of a subset of ligands, which require 
the co-expresssion of additional partners for signal propagation. Table 1.2 summarises 
these ligands and their absolute requirement of a co-receptor for efficient signal 
transduction. The biological relevance of two of these receptors, Betaglycan and 
Endoglin, will be discussed in more detail in the following sections (1.6.2 and 1.6.3.2).
1.4.7.5 FKBP12
In addition to the co-receptors involved in TGF-p signalling, other intracellular 
proteins also act to regulate downstream signalling events. The immunophilin, 
FKBP12, which is known to play a crucial role in mediating the effects of the 
immunosuppressant drugs FK506 and rapamycin (Schreiber, S. L., 1991), also 
functions in TGF-P signal regulation. FKBP12 has been shown to interact strongly 
with the cytoplasmic regions of several different type I receptors (Okadome, T. et al., 
1996; Wang, T. et al., 1994). In addition, FKBP12 binding has been shown to inhibit 
TGF-p receptor-mediated signalling (Chen, Y. G. et al., 1997; Stockwell, B. R. et al., 
1998; Wang, T. et al., 1996), and it has been proposed that FKBP12 serves to 
eliminate spurious signalling caused by receptor oligomerisation in the absence of 
ligand by occluding the type II receptor phosphorylation sites in the GS region (Chen, 
Y. G. et al., 1997). The structure of FKBP12 with a cytoplasmic fragment of TpRl 
supports these arguments. The 3-D structure reveals that FKBP12 binds to the GS 
region of the receptor, so that it is positioned to impede the approach of a TpRII kinase 
domain (Huse, M. et al., 1999). Further molecular investigation using a homogenously 
tetra-phosphorylated GS form of TpRI, revealed that FKBP12 stabilises the inactive
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conformation o f the T(3RI and also organises the flexib le GS loop into an inhib itory 
wedge generating a 'locked' conformation. Phosphorylation o f the GS domain 
eliminates a binding site FKBP12 and simultaneously creates a binding site for the 
Smad substrate (Huse, M. et al., 2001) (Figure 1.6). FKBP12 null mice exhibit no 
apparent defects in TGF-p signalling (Shou, W. et al., 1998), however, numerous 
studies have shown that FKBP12 dissociation, while not sufficient, is required for 
I'PRI activation (Chen, Y. G. et al., 1997; Stockwell, B. R. et al., 1998; Wang, T. et 
al., 1996). In light o f this. FKBP12 appears to act as a buffer, rather than an antagonist 
o f  the TGF-|3 system, stabilising and prolonging the life tim e o f downregulated TpRI.
1.4.8 Evolution of TGF-p receptors: A comparison with Receptor 
Tyrosine Kinases
Many o f the cell surface receptors that bind to and are activated by polypeptide ligands 
possess intrinsic protein kinase activity in their cytoplasmic domains. The largest 
fam ily o f this type is the receptor tyrosine kinases (RTKs), single pass transmembrane 
receptors whose cytoplasmic residues catalyze phosphorylation o f tyrosine residues in 
the receptors themselves and in downstream signalling proteins (Schlessinger, J.,
2000). In contrast, the TGF-P receptor fam ily mediate phosphoryl transfer on serine 
and threonine (Ser/Thr) residues. Sequence comparisons have shown that while the 
catalytic domains o f the TGF-(3 receptor kinases contain sequence m otifs that are 
characteristic o f Ser/Thr kinases, this fam ily clusters close to the tyrosine kinases in 
terms o f overall sequence sim ilarity (Hanks, S. K. et al., 1995). This raises the 
possibility that the TGF-p receptor fam ily represents a link in the evolution o f tyrosine 
kinases. Indeed, sequence sim ilarities as well as conserved mechanisms between the 
two families support this theory. Interestingly, the protein kinase o f known structure 
most closely related to A LK 5 in terms o f overall sequence identity is the tyrosine 
kinase IRK, which shares 30% identity w ith  A LK 5 , over -250  aligned residues (Huse, 
M. et al., 1999). The sequence identity between A LK 5 and Ser/Thr kinases is lower 
(e.g.. -22%  versus PKA, ERK2, and Cdk2). Also, structural analysis reveals that the 
location o f the catalytic segment o f  TGF-P receptor and, by implication, the bound
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nucleotide, resembles that seen in tyrosine kinases rather than serine/threonine kinases. 
Also, the active site configuration o f A LK 5  appears to be consistent w ith  binding both 
tyrosine as well as the smaller serine and threonine side chains, as suggested by 
previous biochemical analyses for the related type II receptor (Lawler, S. et al.. 1997). 
These sim ilarities between TGF-(3 fam ily receptors and tyrosine kinases, suggest that 
an ancestor o f the former may represent a branch point in the evolution o f tyrosine 
kinases from cytoplasmic serine/threonine kinases (Manning, G. et al., 2002).
Naturally, stark differences also exist between the two families o f 
transmembance kinases. Many receptor tyrosine kinases are activated by 
phosphorylation o f the activation loop or segment, a central structural element w ith in  
the kinase domain (Johnson, L. N. et al., 1996). The mechanism o f activation by 
multiple phosphory lations upstream o f the catalytic domain, in the GS region o f the 
type I receptor, is unique to the TGF-(3 receptor fam ily. The downstream signalling 
events also vary in that the signalling events o f the tyrosine kinase receptors are 
largely dictated by cytoplasmic sequences outside kinase domains, including Src 
Homology (SFI) domains, which are not present in the TGF-(3 receptors. In contrast, 
the type I receptors specify their signalling largely through a nine amino acid 
sequence, the L45 loop, located w ith in the kinase domain, as previously mentioned.
1.5 The Sm ads
1.5.1 Discovery of the Smads as downstream mediators of the 
TGF-p pathway
While work was underway to uncover mechanisms governing TGF-[3 receptor 
regulation, the downstream mediators o f  the signal transduction pathway were as yet 
unknown. In 1995, a genetic approach was used to identify genes involved in dpp 
signalling in Drosophila melanogaster. The screen was designed to identify dominant 
mutations which could enhance a weak dpp mutant phenotype (Raftery, L. A. et al., 
1995). These efforts resulted in the genetic identification o f mutations in Mothers 
against dpp (Mad) and Medea. Mutations in both genes resulted in embryonic
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lethality, and implicated these gene products as integral components o f the dpp 
signalling pathway (Sekelsky, J. J. et al., 1995). Furthermore, homozygous Mad 
mutant Hies exhibited phenotypes reminiscent o f  dpp mutants. Three Mad homologues 
were identified in C. elegans and called sma-2,-3, and -4 because their mutant 
phenotype results in reduced body size (Savage, C. et al., 1996). These mutants are 
phenotypically sim iliar to daf-4 mutants in C.elegans, where daf-4 encodes a 
serine/threonine kinase receptor (Savage, C. et al., 1996). Follow ing the identification 
o f these proteins in Drosophila and C. elegans, several vertebrate homologues were 
cloned in Xenopus, mouse and humans and all were shown to function as principal 
effectors downstream o f the TGF-p fam ily o f serine/threonine kinase receptors 
(Eppert, K. et al.. 1996; Graff, J. M. et al.. 1996; Hoodless, P. A. et al., 1996; L iu , F. et 
al.. 1996). A  sim plified nomenclature has been adopted for the vertebrate genes and 
their products to avoid confusion, by referring to them as Smad, a merge o f the sma- 
and Mad gene names (Derynck, R. et al., 1996). The human genome encodes eight 
Smad family members (Mad-homologues (M ADH )), and related proteins are now known 
in the rat, mouse, Xenopus, zebrafish, the helminth Schistosoma mansoni, Drosophila 
and C. elegans (Manning, G. et al., 2002)(Figure 1.7).
1.5.2 Smad Subfamilies
Smads are now well documented as integral components in the TGF-P superfamily 
signalling pathways. Based on structure and function, the Smads are classified into 
three subfamilies, as illustrated in the phylogenetic tree (Figure l . 7). The receptor- 
regulated Smads (R-Smads) are the direct substrates o f  the type I receptors, whereas 
the second group, common-partner Smads (Co-Smads), function by form ing 
complexes w ith the R-Smads which then accumulate in the nucleus. The third group, 
the inhibitory Smads (I-Smads), function to antagonise the signalling mediated by the 
R-Smads and Co-Smads. Each group w ill be discussed below.
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Figure 1.7 Phylogenetic analysis of the Smad family
This tree shows the relationship of Smads from the following species; Ciona intestinalis 
(Ciona);Drosophila Melanogaster (DM ); Halocynthia (H); Homosapiens (H); Mus musculus (M M ); 
Rattus norvegicus (RN); Schistosoma mansoni (Schisto); Sus scrofa (Sscrof);Xenopus laevis (X); Zebraf­
ish (ZB).
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1.5.2.1 R-Smads
To date, the R-Smads are the only known substrates for type I receptor kinases known 
to have a signalling function. These include the vertebrate Smad l, Smad2, Smad3, Smad5 
and Smad8 and their invertebrate homologues. Drosophila Mad and dSmad2 and 
C.elegans Sma-2, Sma-3, daJS and dafl4  (ten Dijke, P. et al., 2006). An indication that 
R-Smads could mimic TGF-(3 superfamily signals came from overexpression studies in 
Xenopus. Indeed, expression o f either o f Smad2, mimics the dorsal mesoderm induction 
and axis formation by Activin (Baker, J. C. et al., 1996; Graff. J. M. et al.. 1996), 
whereas Smadl or Smad5 overexpression mimic the ability o f BMP4 to ventralise 
mesoderm (Graff. J. M. et al.. 1996; Suzuki. A. et al.. 1997). These observations not 
only firm ly  placed the Smads as downstream components o f pathway, but also 
suggested that different Smads m ight transduce distinct TGF-(3 superfamilv signals. 
Concomitant observations that BM P4 stimulates Smadl phosphorylation and nuclear 
accumulation (Hoodless, P. A. et al.. 1996; Liu, F. et al., 1996), whereas activin or 
TGF-(3 induces Smad2 activation (Baker. J. C. et al., 1996; Eppert, K. et al., 1996; 
G raff, J. M. et al.. 1996) confirmed that these Smads participate in distinct TGF-(3 
superfamily signalling pathways. This evidence has led to a model whereby TGF-|3 
superfamily ligands signal via two distinct Smad pathways; the TGF-(3/Activin R- 
Smads. or the BMP R-Smads (ten Dijke, P. et al.. 2006). In vertebrates, BMP 
signalling is mediated by Smadl, and its close homologues SmadS and Smad8, 
whereas in Drosophila the sole BMP-specific Smad is Mad. In addition, C.elegans 
Sma-2 and Sma-3 have been demonstrated to function downstream o f BM P-like 
signals. In contrast. Smad2 and Smad3 propagate signals from  TGF-(3 and A ctiv in - 
like ligands as they act as specific substrates for the receptor kinases o f these ligands 
(ten Dijke. P. et al.. 2006). The molecular mechanisms underlying this specificity are 
explained in Section 1.5.4.2. For the most part this model holds true, however this 
proposed view o f two distinct and segregated pathways appears to be oversimplified 
and increasing evidence suggests that a certain degree o f overlap exists (Goumans, M. 
J. et al.. 2003b; Goumans, M. J. et al., 2002). This w ill be discussed in much more 
detail in Section 1.6.2 and Chapter 6.
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1.5.2.2 Co-Smads
Smad4, which was orig inally isolated as the product o f  the tumour suppressor gene 
DPC4 (Hahn, S. A. et al.. 1996), serves as the co-Smad in mammals. Additional co- 
Smads include Xenopus XSmad4a and XSmad4p (Howell, M. et al.. 1999), 
Drosophila Medea and C.elegans Sma-4 and daf-3(ten Dijke, P. et al., 2006). Unlike 
the R-Smads, the Co-Smads are not phosphorylated in response to TGF-p fam ily 
members, but engage in signalling by form ing complexes w ith  R-Smads which then 
accumulate in the nucleus to activate transcription. Co-Smads are shared among 
m ultip le signalling pathways, whereby BMP stimulation leads to complex formation o f 
Smad4 w ith Smadl, 5 and/or 8, and TG F-p/A ctiv in  signalling recruits Co-Smads to 
partner Smad2 or Smad3 (Whitman. M .. 1998). The importance o f Co-Smads in TGF- 
(3 fam ily signalling is highlighted by the fact that human Smad4 is mutated or deleted 
in about 50% o f pancreatic and in about 15% o f colorectal cancers, which results in the 
loss o f growth inhib itory responses to TGF-p (Levy, L. et al., 2006). Still, the absolute 
requirement for Smad4 in TGF-(3 fam ily signalling pathway is under much debate 
(Deckers. M. et al., 2006; Levy. L. et al., 2005). Indeed, cells w ith little  or no Smad4 
can still respond to TGF-P fam ily ligands and mediate downstream responses (Levy, 
L. et al.. 2005) (See Chapter 6).
1.5.2.3 I-Smads
Vertebrate Smad6 and Smad7 and Drosophila Dad represent members o f the I-Smad 
subfamily, whose function to inhib it TGF-P fam ily signalling (Feng, X. H. et al.,
2005). The I-Smads lack the C-terminal phosphorylation m o tif and have a highly 
divergent M i l l  domain (Whitman, M., 1998). Whereas Smad7 acts as an inhib itor o f 
TGF-p family signalling, Smad6 preferentially blocks BMP signalling (Hata, A. et al., 
1998). Lctopic expression o f dad, the Drosophilal-Smad in the Drosphila wing disc 
inhibits signalling by Dpp and can also block BMP signalling when expressed in 
Xenopus embryos.Whether Dad is a selective inh ib ito r o f  BMP signalling or m ight 
also inh ib it activin/TGF-P has not been examined (Whitman, M., 1998).
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Several mechanisms have been proposed for the action by which the I-Smads 
elic it their antagonistic effects. Firstly, it has been demonstrated that the I-Smads 
interact stably w ith the type I receptor, suggesting that they act as competitive 
inhibitors o f  receptor-mediated activation o f R-Smads (Nakao. A. et al., 1997). In 
addition. Smad6 has been shown to compete w ith Smad4 for complex formation w ith  
the phosphorylated Smadl, thus sequestering Smadl in inactive complexes which 
inhibits BMP signalling (Hata, A. et al., 1998). Another mechanism by which I-Smads 
inh ib it Smad signalling is via receptor degradation. Smad7 constitutively interacts w ith 
w ith  E3 ubiquitin ligases, Sm urfl and Smurf2 (Ebisawa, T. et al., 2001). Upon 
recruitment o f  the Smad7/Smurf complex to the activated receptor, Sm urfl or Smurf2 
induces receptor degradation via proteosomal and lysosomal pathways. In the basal 
state, I-Smads reside in the nucleus, and upon ligand stimulation, they translocate to 
the plasma membrane, whereupon they mediate inhib ition. Since Smad7 does not 
contain a known nuclear export signal (NES), it has been proposed that it interacts 
w ith Sm urfl/2  in the nucleus (Suzuki, C. et al., 2002; Tajima, Y. et al.. 2003). Using 
their N-terminal C2 domain. Sm urfl and Smuf2 target the Smurf-Smad7 complex to 
the plasma membrane, where they target the receptors for degradation (Tajima. Y. et 
al.. 2003). Finally. I-Smad expression is potently induced by TGF-(3 fam ily members 
and thus these proteins participate in a negative feedback loop to control the intensity 
and duration o f TGF-|3 signalling (Nakao. A. et al., 1997). It is important to note that 
much o f the data on both the function and mechanism o f I-Smads have come from 
overe.xpression studies, due to the poor availability o f  antibodies. Thus, studies on 
endogenous proteins w ill yie ld insight into the regulatory mechanisms governing the I- 
Smads and determine the extent o f  specificity o f inhib ition o f different TGF-(3 fam ily 
members.
1.5.3 Structure of the Smads
The primary sequence o f all Smads revealed extensive sequence homology among 
Smads in two distinct regions: an amino-terminal domain designated Mad homology l 
(M H l)  and a carboxy-terminal domain termed M H2 domain. The region between the 
M H l and MFI2 domains is referred to as the linker region and is less well conserved
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among Smads. The M H l domain o f Smad4 and most R-Smads (except the fu ll length 
form o f Smad2) is responsible for sequence specific D N A  binding. The structure o f the 
M H l domain, as exemplified by Smad3, adopts a globular fold, w ith  two small (3- 
sheets and one protruding (3-hairpin that mediates the D N A binding through direct 
contact w ith  residues o f Smad binding element (SBE) (Shi, Y. et al., 1997) (See 
section 1.5.6.1). This (3-hairpin is located next to a positively charged H2 helix, which 
contains a nuclear localisation sequence. The M H l domain has also been reported to 
inh ib it the activity o f the MH2 domain (Baker, J. C. et al., 1996; Hata, A. et al., 1997; 
L iu, F. et al., 1996), however upon receptor mediated phosphorylation o f the C- 
terminal serine residues, this inhib itory effect is relieved (Kretzschmar. M. et al., 1997; 
Macias-Silva. M. et al.. 1996). The amino-terminus o f the I-Smads is highly divergent 
from the M H l domain, as exhibited by their inability to bind DNA.
In contrast the MH2 domain is highly conserved among all Smads. It has been 
termed the 'effector' domain as it mediates m ultiple interactions required for the 
function o f the Smads. including binding w ith transcription factors, coactivators and 
corepressors (Massague. J. et al.. 2005). The MH2 domain is also responsible for 
interactions w ith  the receptor. SARA, formation o f homomeric as well as heteromeric 
Smad complexes, and directly contacting the nuclear pore complex for 
nucleocytoplasmic shuttling (Lo, R. S. et al.. 1998; Randall, R. A. et al.. 2002; 
Tsukazaki. T. et al.. 1998; Xu, L. et al., 2003; Xu, L. et al.. 2002). The M H2 domain o f 
the R-Smads, but not the Co-Smads nor I-Smads. contain a characteristic SSXS m o tif 
at their extreme C-termini(Hoodless, P. A. et al., 1996; Macias-Silva. M. et al.. 1996). 
The two C-terminal serine residues in the m o tif are phosphorylated by the type I 
receptor during signalling. Interestingly, the linker region contains m ultiple 
phosphorylation sites, which have been shown be phosphorylated by M APK, calcium- 
dependent kinases and cyclin dependent kinases (Kretzschmar, M. et al., 1997; 
Kretzschmar, M. et al., 1999; Matsuura. I. et al., 2004) (See Sections 1.5.7. and
1.6.1.4) Thus, the linker region allows specific crosstalk w ith  a spectrum o f other 
signalling pathways. In addition, the linker region contains a PY m otif, which mediates 
specific interaction w ith the Smad ubiquitination regulatory factors (Smurfs). Sm urfl 
and Smurf2 are HECT-domain-containing E3 ubiquitin ligases that target the Smads as 
well as the TGF-(3 receptors for degradation by the proteasome.
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Figure 1.8. Structure of the Smads
Diagrammatic representation o f the structure o f the Smads, indicating Mad Homology 
Domains (M H l and MH2), structural motifs and C-terminal phosphorylation sites. 
D N A binding domain (DBM ), Nuclear Export Signal (NES), Nuclear Localisation 
signal (NLS).
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1.5.4 Specificity and complexity in Smad Activation
1.5.4.1 Regulation of Smad /Access to the Receptors
The phosphorylation o f the R-Smads by the type 1 receptor is a central event in the 
signalling pathway o f the TGF-P family. As a result, the activation o f the R-Smads is a 
highly regulated process, which is achieved through a complex series o f  competitiv e 
interactions. Firstly, the recognition o f R-Smads by the receptors is facilitated by 
auxiliary proteins. One example is SARA (Smad anchor for receptor activation), which 
functions to recruit the Smads to the type I receptor by restricting the subcelluar 
localisation o f the Smads. SARA, a FYVE domain-containing protein, specifically 
interacts w ith the MH2 domain o f non-activated Smad2 and Smad3 but not w ith  the 
BMP R-Smads. Smadl. 5 and 8 despite the high sequence identity in this domain 
(Tsukazaki. T. et al.. 1998). By interacting w ith both Smad2/Smad3 and the receptor 
complex. SARA forms a bridge, which assists in the specific phosphorylation o f 
Smad2/Smad3 by the type I receptor (Tsukazaki, T. et al.. 1998). The crystal structure 
o f the Smad2 MH2 domain in complex w ith the Smad-binding domain (SBD) o f 
SARA has been elucidated. This has revealed that the SBD. which comprises a rig id  
coil, an a-he lix  and a p strand, interacts w ith an extended hydrophobic surface area on 
Smad2/Smad3 (Wu. G. et al., 2000). Interestingly the rig id coil domain o f the SARA 
SBD is sim ilar to a Smad interaction m o tif (S IM ) found in transcription factor partners 
o f the Smads, the M ixer and FoxH l fam ily members. Mutagenesis studies combined 
w ith molecular modelling, revealed that the rig id coil o f  the SARA SBD binds to the 
M l 12 domains o f Smad2 and Smad3 in the same way that M ixer and FoxH l proteins 
bind to these domains through the SIM (Randall, R. A. et al.. 2002). Structural analysis 
also reveals that SARA promotes R-Smad-kinase recognition by precisely positioning 
the phosphorylation site o f the R-Smad in the kinase catalytic centre (Qin, B. Y. et al., 
2002). Upon phosphorylation o f Smad2/Smad3 by the type I receptor, SARA can no 
longer bind the R-Smads efficiently, which results in activated Smad being released 
from SARA and the type I receptor. Furthermore, the interaction o f SARA w ith A LK 5  
has been proposed to trigger internalisation o f the SARA-receptor complexes via
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clathrin-coated pits, resulting in the formation o f endosomes where Smad2 and SmadB 
can be activated (D i Guglielmo, G. M. et al., 2003) (See Section 1.4.6).
A  second FYVE-containing protein. Hgs (Hrs) was also found to cooperate 
w ith SARA to facilitate Smad2 signalling (M iura, S. et al., 2000). Other adaptor 
proteins, including disabled 2 (Dab2), 14-3-3e, the negative regulator o f  Wnt 
signalling A x in  and the ELF (3-spectrin have been reported to facilitate TGF-(3 
signalling by linking Smad2/Smad3 to the receptor complex (Moustakas. A. et al..
2001). However, the molecular mechanisms behind these observations remain unclear. 
More recently, another modulator o f  the pathway was identified as a receptor 
associated protein, TLP (TR A P -1-like protein) (Felici, A. et al.. 2003). The data 
reveals that TLP binds to Smad4 upon TGF-p signalling and appears to influence the 
balance o f activated Smad2 versus Smad3. which may be important for generating 
distinct TGF-P responses in different cell types.
1.5.4.2 Smad-Receptor Interactions
A crucial determinant o f specificity in TGF-P superfamily signalling is the differentia l 
recruitment and subsequent activation o f Smad fam ily members by the type I receptors 
(Huse, M. et al., 2001; Shi. Y. et al., 2003). As previously mentioned, receptors for the 
TGF-p and A ctiv in  ligands recruit and activate Smad2 and Smad3. whereas those for 
the BMPs phosphorylate Smadl, 5 and 8 (Shi, Y. et al., 2003). On the one hand, there 
is a high level o f structural sim ilarity between the receptors o f these ligands, and on 
the other hand there is high sequence homology between the corresponding R-Smads. 
This led to an intense interest in elucidating the basis for this specificity. As the C- 
terminal phosphorylation m o tif is almost identical for all R-Smads, it was unlikely that 
this sequence could determine the specificity o f  the activated Smad. Interestingly, 
removal o f the C-tail actually increases the interaction between the type I receptor and 
R-Smad, suggesting that this region does not contribute to the Smad-receptor 
interaction, but may be inhibitory particularly when these sites are phosphorylated (Lo, 
R. S. et al., 1998). Instead, biochemical and structural studies have revealed that the 
specificity o f the R-Smad activation arises from two discrete structural elements: the 
L45 loop in the kinase domain o f the type I receptor, and a corresponding region in the
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L3 loop o f the MH2 domain o f the R-Smads (Chen, Y. G. et al., 1998; Lo, R. S. et al., 
1998; Wu, G. et al., 2000).
The L45 loop is a nine-amino acid sequence, which connects the (3 strands 4 
and 5 in the kinase domain o f the type I receptor, but is not part o f  the catalytic centre 
(Feng. X. H. et al., 1997; Huse, M. et al., 1999). Sequence analysis reveals that 
receptors w ith  different signalling specificities have distinct L45 sequences, whereas 
sim ilar signalling receptors share highly conserved L45 loops. The L45 sequences o f 
A L K 4  and A LK 5, which activate Smad2 and Smad3, are identical, whereas they d iffe r 
in four amino acids from the L45 sequences in A LK 3  and ATK6, whose substrates 
consist o f Smadl. 5. and 8 (Chen, Y. G. et al., 1998)(Figure 1.9). The third group o f 
type I receptors, which include A LK 1 , A LK 2  and Drosophila Saxaphone exhibits a 
more divergent L45 loop, which differs in seven residues from the L45 o f  the 
ALK3/ALK.6 group, yet they both activate Smadl. 5 and 8 (Chen, Y. G. et al.. 1999) 
(Figure 1.9). The replacement o f  all but the L45 loop in the kinase domain o f A L K 5  
w ith the corresponding regions from A LK 2, yielded a construct that still mediated 
TGF-(3 responses, which first signified the importance o f this element in dictating 
specific responses (Feng, X. H. et al., 1997). S im ilarly, the L45 loop o f A L K 6  
substituted w ith  that o f ATK5, caused a switch in the specificity to induce a TGF- 
|S/Acti\ in-like response, including phosphorylation o f Smad2/3, transcription from 
TGF-(3/Activin-responsive elements, and induction o f dorsal mesoderm in Xenopus 
embryo explants (Chen, Y. G. et al., 1998). Consistent w ith  this, A LK 5  w ith  an A L K 6  
L45 loop, also demonstrated a clear switch in substrate specificity, however this was 
incomplete w ith respect to induction o f ventral mesoderm, which is defin itive o f a 
TG F-p/Activ in  response (Chen, Y. G. et al., 1998).
The T45 loop interacts directly w ith  the L3 loop in the M H2 domain o f an R- 
Smad (Chen, Y. G. et al., 1998; Lo, R. S. et al.. 1998). As inferred from the crystal 
structure o f the Smad4 MH2 domain, the L3 loop protrudes from the (3-sandwich core 
structure o f the MH2 domain, and that it is exposed to solvent in the trimeric Smad 
complexes (Shi, Y. et al., 2003). Analogous to the L45 loop, only a few amino acids in 
the L3 loop define receptor binding specificity. The sequence o f the L3 loop is 
invariant among TGF-(3 Smads R-Smads and BMP R-Smads, but differs at two 
positions between these two groups (Lo, R. S. et al., 1998). Consequently. Smadl w ith  
an L3 loop o f Smad2 interacts w ith  and is phosphorylated by A LK 5, while Smad2
63
A
Smad-binding domain of type I receptors
Ectodomain a a  GS Kinase domain
L45 Loop
TGF-p receptor group A
Babo, Alk4, ALK4, ALK7
D N K D N G T w
BMP receptor group A
Tkv-1, ALK3, ALK6
D I K 4 G S w
ALK1 receptor group s D M T S R N S s
Sax Alk1, ALK2 H
B
MH1 domain
Receptor-binding domain of R-Smad proteins 
MH2 domainLinker
L3 Loop
Smad2/3 V K G W G A E Y  
Sm ad1/5/8 V K G W G A E Y
Binds to:
R 0 T V T S T P C  A L K 4 ,5 ,7  
R C M D V T S T P C  ALK1, 2, 3, 6
Figure 1.9 Specificity of Smad-Receptor Interactions
The specificity of the Smad-Receptor interaction is determined by the sequence of the L45 loop on the 
receptor kinase domain and the sequence of the L3 loop in the Smad MH2 domain.
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with the L3 loop o f Smadl no longer interacts w ith  TGF-(3 receptors and is not 
phosphorylated by A LK 5  (Lo, R. S. et al., 1998). In addition, complimentary 
mutagenesis o f the L45 loop and the L3 on the Smads has shown that this contact is 
the critical determinant that dictates specificity between Smads and receptor 
interactions (Chen, Y. G. et al., 1998). However, the L3 loop is not sufficient for 
Smadl to bind the third group o f receptors and requires an additional structural 
element, the a-helix 1, which is not essential for Smadl interaction w ith  the A LK 3 
group. This element is exposed on the surface o f the M H2 domain in the v ic in ity  o f  the 
L3 loop, and together these two surface structures mediate Smadl binding to the 
divergent L45 loop o f the ALK1 group o f type I receptors (Chen. Y. G. et al., 1999).
Furthermore, adjacent sequences are thought to stabilise the interaction o f the 
L3 and L45 loops (Huse. M. et al., 2001). Structural analysis o f the surface features o f  
the Smad2 and Smad4 MH2 domains revealed a positively charged groove next to the 
L3 loop on Smad2, but not on Smad4. This basic surface termed the Toop-strand' 
pocket contains residues that are conserved in all R-Smads but not in Smad4, 
suggesting an important role in receptor-Smad interactions (Wu, G. et al.. 2000). It has 
been proposed that this patch forms at least part o f the binding site for the 
phosphorylated GS region (Wu, G. et al., 2000), The L45 loop, is located immediately 
adjacent to the flexible GS region, which is phosphorylated upon ligand binding and 
becomes very acidic. Thus the phosphorylated GS region on the type I receptors might 
interact w ith  the *loop-strand' pocket on R-Smads to provide binding a ffin ity , whereas 
the L45 loop on the type I receptors recognise the L3 loop o f specific R-Smads to 
provide specificity (Wu, G. et al.. 2000). This is consistent w ith  the current structural 
model for activation o f the Smads, whereby phosphorylation o f the GS region creates a 
binding site that permits Smad docking and subsequent activation (Fluse, M. et al.,
2001). In conclusion, these data provide evidence for a complex interface between the 
type I receptors and their substrates, the R-Smads, that includes the phosphorylated GS 
region and the L45 loop o f the receptor and the basic loop-strand' pocket and L3 loop 
o f the R-Smads and possibly other components in the kinase (ten Dijke, P. et al., 
2006). The precise details o f the receptor/Smad interaction, however, await structural 
analysis o f  a receptor/Smad2 interaction.
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1.5.4.3 Smad Activation and Complex formation
Upon R-Smad binding to the type I receptor, the second and third serine residues o f an 
SSXS m otif, located at the extreme C-terminus o f the R-Smad is phosphorylated (Shi, 
V. et al., 2003) (Figure 1.7). Receptor mediated phosphorylation is proposed to relieve 
the M H l and MH2 domains from a mutually inhib itory interaction (Hata, A. et al.,
1997). thus allowing complex formation and nuclear accumulation. Phosphorylation o f 
R-Smads results in their dissociation from both SARA and the type I receptor, which is 
like ly to occur via a series o f competitive interactions (ten D ijke. P. et al.. 2004). As 
previously mentioned, the loop-strand pocket in the L3 loop region o f the Smad M H2 
domain is required for R-Smad interaction w ith  the phosphorylated GS domain o f the 
type I receptor. Interestingly, the loop-strand pocket coincides w ith  the surface that 
interacts w ith the C-terminal phosphoserines in the homotrimer (Shi, Y. et al.. 1998). 
Therefore, upon phosphorylation o f the R-Smads, the phosphorylated serine residues 
at the C-terminus o f an R-Smad compete w ith the phosphorylated GS domain for the 
loop-strand pocket, thus facilitating dissociation from the receptor (Wu, J. W. et al., 
2001b). In addition, as the type I receptors are proposed to form heterodimers , and are 
like ly to bind two Smad molecules simultaneously, the phosphorylated R-Smad 
molecules might assist each other in their release from the receptor (Qin, B. Y. et al.. 
2001; Wu. J. W. et al.. 2001b).
Upon dissociation from the receptor, Smad proteins form  complexes w ith  other 
Smads. The stoichiometry (and composition) o f  these complexes has been a subject o f 
much debate. Studies o f Smad complexes in solution have revealed that in the 
uninduced state Smad2 exists as a monomer (Jayaraman, L. et al., 2000; Kawabata, M. 
et al.. 1998; Wu, J. W. et al.. 2001a; Wu, J. W. et al., 2001b), whereas sim ilar 
biochemical analysis indicates that Smad3 can exist in m ultiple oligomeric states 
(Jayaraman, T. et al., 2000). S im ilarly Smad4 can exist as monomers, dimers or 
trimers (Jayaraman, L. et al., 2000; Kawabata, M. et al., 1998; Shi, Y. et al., 1997). 
Following ligand stimulation size exclusion chromatography analysis o f endogenous 
Smad2/Smad4 from TGF-(3-induced cells or biochemical analysis o f  purified Smad2 
and Smad4 suggested that these complexes were heterodimers (Jayaraman. L. et al., 
2000; Kawabata, M. et al., 1998; Shi, Y. et al., 1997). However, studies o f purified 
phosphorylated Smad2 and Smad3 have demonstrated that activated Smad2 and
66
Chapter 1 Introduction
Smad3 preferentially form heterotrimers (Wu. J. W. et al., 2001b). Recently, the 
crystal structure o f the complexes consisting o f the M H2 domains o f phosphorylated- 
Smad2-Smad4 and phosphorylated Smad3-Smad4 revealed that both complexes are 
heterotimers, comprising two phosphorylated R-Smad subunits and one Smad4 
(Chacko, B. M. et al., 2004). X-ray crystallography analysis o f  trimeric Smad 
complexes has revealed that these trimers are stabilised by interactions w ith in  an 
extensive protein-protein interface between MH2 domains as well as the binding o f the 
pS-X-pS m otif into the the loop-strand pocket in the L3 loop region o f the Smad MH2 
domain (Wu. J. W. et al., 2001b). From a structural standpoint, it is feasible that the 
heterotrimeric Smad complex could include two different R-Smad molecules, as the 
trimer interface among the R-Smads is highly conserved. Such combinatorial 
mechanism could greatly increase the number o f distinct signalling species, each w ith  
a different Smad constitution. Indeed, Smad2/3 mixed oligomers have also been 
observed in cell on TGF-(3 stimulation (Chacko, B. M. et al., 2004; Wu, J. W. et al., 
2001b) (see also Chapter 6).
Studies on endogenous Smads in vivo have suggested a more complex 
scenario. Analysis o f nuclear extracts o f cells transiently cotransfected w ith  
d ifferentia lly tagged Smads suggested that the DNA-bound Smad3/Smad4 complex 
was a heterodimer. In this case, Smad3 and Smad4 bind as a heterodimer in 
association w ith as yet unknown cofactors to the c-jun promoter to initiate 
transcription (Inman, G. J. et al., 2002a). In addition, this study supported the 
formation o f heterotrimeric complex o f Smad2 and Smad4, which is recruited to D N A 
by the FoxFll transciption factor (Inman, G. J. et al., 2002a). These data suggest that 
both heterodimers and heterotrimers may be formed depending on the target gene and 
the other factors present. In view o f the stability o f  the trimeric complex, it is unclear 
how these heterodimeric complexes form in vivo. However, one possibility is that 
Smad cofactors, upon binding the R-Smad/Smad4 complex can disrupt the core 
heterotrimer in such a way that one o f the R-Smad subunits is replaced by a cofactor, 
resulting in a Smad heterodimer. Interestingly, IRF-3, a member o f the interferon 
regulatory factor (IRF) fam ily o f transcription factors aswell as the forkhead- 
associated (FF1A) domain, found in many signalling proteins including the forkhead 
transcription factors, exhibit marked structural sim ilarity to the M H2 domain o f the 
Smad protein fam ily (Qin, B. Y. et al., 2003).
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1.5.5 Nucleocytoplasmic shuttling of Smad proteins
Once the Smad complexes are formed, they accumulate in the nucleus where they 
modulate gene transcription. This dual role o f the Smads in transmitting the signal 
from the nucleus and the regulating transcription demands strict regulation o f the 
subcellular localisation o f the Smads. Early studies on Smad regulation established 
that in the basal state, R-Smads are predominantly cytoplasmic, whereas Smad4 is 
distributed throughout the cytoplasm and nucleus. Upon ligand stimulation, Smad 
complexes rapidly accumulate in the nucleus, where they appear to remain for several 
hours (Baker. J. C. et al., 1996; Hoodless. P. A. et al., 1996; L iu, F. et al., 1996). 
However, it has now become clear that the Smads are not stationary but are constantly 
shuttling between both compartments in the uninduced and induced state and that this 
activity is highly regulated (Inman. G. J. et al.. 2002c). This was first observed through 
transport studies o f Smad4. Treatment o f  cells w ith  leptomycin B (LM B ), a specific 
inhib itor o f the prototvpic export receptor CRM l or exportin 1 led to a rapid 
accumulation o f Smad4 in the nucleus (Pierreux, C. E. et al., 2000; Watanabe, M. et 
al.. 2000). This demonstrated that Smad4 must be rapidly shuttling between both 
compartments in the absence o f signal and that CRM1 activity is required for nuclear 
export (Pierreux, C. E. et al., 2000; Watanabe, M. et al., 2000). Subsequently, it has 
been shown that the R-Smads also engage in nucleocytoplasmic shuttling in the 
absence and presence o f TGF-|3 (ten Dijke, P. et al., 2004).
The detailed molecular mechanisms governing Smad nucleocytoplasmic 
shuttling remain lim ited. Smad4 has been shown to contain a basic bipartite nuclear 
localisation signal (NLS) m o tif in its M H l domain, which is generally conserved in R- 
Smads and in addition it contains a nuclear export signal (NES) in the linker region. 
The NLS o f Smad4 binds im portin-a, which can then bind to im p o rtin g  to mediate 
import (Xiao, Z. et al., 2003b). As previously mentioned, the NES, mediates CRM1- 
dependent export o f Smad4. Smadl, the BMP-regulated R-Smad, also has a NLS in its 
M H l domain and, like Smad4 also possesses an NES although this is located in its C- 
terminal domain (Xiao, Z. et al., 2003a; Xiao. Z. et al., 2001). It has been 
demonstrated that Smadl also accumulates in the nucleus upon treatment w ith LM B, 
suggesting that it is also shuttling via CRM 1-dependent export, however the import 
mechanism is not yet clear (Xiao, Z. et al., 2001). The transport mechanism for Smad2
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and Smad3 is less evident, although, a nuclear localisation signal has been identified in 
the M H l domain o f Smad3, which is thought to bind directly to importin-|3 (Kurisaki. 
A. et al., 2001). An NLS is also present in Smad2 but in the fu ll length protein, its 
function appears to be masked by a 20-amino acid insert encoded by exon3 (Kurisaki, 
A. et al., 2001). It has been proposed that the Smads (Smad2, 3 and 4) bind directly to 
components o f the nuclear pore and it is through this interaction that nuclear transport 
is driven (Xu, L. et al., 2003; Xu, L. et al., 2002). It may be the case that shuttling o f 
Smads between compartments is controlled by the NLS and NES motifs as well as by 
non-classical pathways involving interactions between the M H2 domain and the 
nuclear pore complex. The mechanism remains to be clarified.
Another question which arises from this work is what mediates the strong 
nuclear accumulation o f Smad4 upon induction o f TGF-P signalling? (Inman. G. J. et 
al.. 2002c). A  variety o f mechanisms have been proposed to explain the switch in the 
balance o f cytoplasmic to nuclear Smad that accounts for nuclear accumulation o f 
Smad complexes in response to TGF-|3. One such mechanism involves the existence o f 
cytoplasmic and nuclear anchoring proteins (Xu, L. et al.. 2002). SARA was suggested 
as a candidate for a cytoplasmic retention protein as overexpression o f SARA 
sequestered Smad2 in clusters in the cytoplasm (Tsukazaki, T. et al., 1998; Xu. L. et 
al., 2000). A  candidate nuclear retention factor was the Smad2 transcription partner, 
F oxH l. Consistent w ith this, expression o f FoxH l trapped Smad2 in the nucleus even 
in the absence o f ligand (Xu, L. et al., 2002). This model was supported by the fact 
that both proteins interact w ith a common binding pocket in Smad2, and that 
phosphorylation dependent disruption o f Smad2-SARA interaction allowed Smad2 to 
move into the nucleus where it could be retained by interaction w ith  FoxH l or related 
proteins (Xu. L. et al., 2002). However, a Smad2 mutant (W 368) which cannot interact 
with several transcription factors, including F oxH l, accumulates in the nucleus in 
response to TGF-[3 as efficiently as w ild  type Smad2 (Schmierer, B. et al., 2005). Thus 
it is unlikely that transcription factor complexes play a role in nuclear retention. 
Nonetheless, kinetic analysis o f  Smad2 and Smad4 reveal that decreased nuclear 
m obility  in the presence o f TGF-(3 stimulation supports a role for trapping o f active 
Smad complexes in the nucleus (Schmierer, B. et al., 2005). In addition, this study 
revealed that TGF-|3-induced nuclear accumulation o f Smad2 is a reflection o f  its 
decreased nuclear export rate, associated w ith  this observed decrease in nuclear
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m obility (Schmierer, B. et al., 2005). These data suggest that the import rate does not 
play an important role in nuclear accumulation o f Smads, but more importantly, the 
decreased rate o f export results in a shift in the localisation o f the active Smad pool. 
Therefore, it has been proposed that mechanisms are in place to selectively trap active 
Smad complexes in the nucleus, possibly by masking binding sites for the export 
machinery, as has already been shown for Smad4 (Chen, H. B. et al., 2005).
Nucleocytoplasmic shuttling has been proposed to function as a mechanism 
whereby Smads can monitor receptor activity in response to ligand (Inman, G. J. et al., 
2002c). It has been shown that continuous activity o f  the receptors is required to 
maintain active Smads in the nucleus and that a rtific ia l abrogation o f receptor activity 
by use o f the ALK5 kinase inhib itor SB-431542, caused redistribution o f the Smads 
into the cytoplasm (Inman, G. J. et al., 2002c). In addition, the shuttling o f Smads in 
the presence o f TGF-(3 appears to require cycles o f Smad phosphorylation and 
dephosphorylation (Inman, G. J. et al.. 2002c; Xu, L. et al., 2002). Dephosphorylation 
o f R-Smads results in their dissociation from Smad4 and recycling back to the 
cytoplasm, which allows active receptors to rephosphorylate the R-Smads (Inman, G. 
J. et al., 2002c). Duration o f signalling is a critical determinant in TGF-|3 signalling 
(Nicolas, F. J. et al., 2003a). To this end, the Smads employ a rapid mechanism to 
actively 'sense' when the receptors have been turned on or off, through the process o f 
nucleocytoplasmic shuttling (ten Dijke, P. et al.. 2004).
Termination o f activated Smad signalling is also a highly regulated process. As 
previously mentioned, the activity o f the receptors is terminated by either 
dephosphorylation or ubiquitin-mediated degradation (Shi. Y. et al., 2003). However, 
elucidation o f the mechanims by which the TGF-P signal is terminated at the level o f 
the R-Smads is only just emerging. It was in itia lly  suggested that the nuclear R-Smads 
are ubiquitinated and subsequently degraded by the proteosome, thus terminating 
TGF-p superfamily signalling (Lo, R. S. et al., 1999). However, in light o f the 
nucleoplasmic shuttling o f Smads, a more favoured model for the termination o f Smad 
signalling is the dephosphorylation o f the R-Smads (ten Dijke, P. et al., 2004). Indeed, 
the identification o f these phosphatases has proved a d ifficu lt task, perhaps due to the 
redundancy o f catalytic subunits o f  these enzymes. Several studies have been reported 
which identify phosphatases capable o f dephosphorylating BMP/dpp R-Smads have 
been proposed, including a small C-terminal domain phosphatase (SCP) (Knockaert,
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M. et al., 2006) and pyruvate dehydrogenase phosphatase (PDP) (Chen, H. B. et al., 
2006). In addition, PPM1A has been proposed as the phosphatase that regulates 
termination o f Smad2/3 signalling through dephosphorylation (L in , X. et al., 2006). 
These data suggest that specific phosphatases target the BMP R-Smads and the TGF-p 
R-Smads. However, future work is required to investigate the role o f these 
phosphatases and the mechanisms that govern them.
1.5.6 The Smads as Transcriptional Regulators
1.5.6.1 DNA binding ability
The Smad proteins direct transcriptional responses through both activation and 
repression o f genes. SmadT and all R-Smads (except the fu ll length Smad2) have an 
intrinsic, site specific DN A-binding activity. This was first demonstrated for the M H l 
domain o f Mad. which binds a site in a Dpp-responsive element in the gene vestigal 
(vg) in vitro (K im . J. et al.. 1997). The DN A binding specificity o f  the Smads has been 
determined through a site selection strategy as a S’ -GTCT-ST or its compliment 5’ - 
A G AC -5 ' and has been termed the Smad binding element (SBE) (Y ing ling, J. M. et 
al., 1997; Zawel. L. et al., 1998). Many Smad-responsive promoter regions contain one 
or more SBEs, and in many cases it contains an extra base, as 5"-C AG AC -3‘ hence 
termed the CAG A m otif. By crystal structure analysis o f  Smad3, it was revealed that a 
conserved 11-residue p-hairpin m o tif in the M H l domain mediates D N A  binding, 
through specific contact w ith three o f the four bases o f the SBE (Shi, Y. et al., 1998). 
The p-hairpin element is conserved in all Smads regardless o f whether they function in 
the BMP, TGF-p or activin pathways Therefore, the Smad-DNA interaction is unlikely 
to provide selectivity in the gene targets o f individual Smads (Shi, Y. et al., 1998).
Individual Smad2 and Smad3 genes are thought to result from a gene 
duplication in chordates o f the single Smad2/3 gene found in flies and worm (Newfeld, 
S. J. et al., 1999) and this duplication event has resulted in a difference in the DN A 
binding ability o f these R-Smads (Yagi, K. et al., 1999). Exon 3 o f Smad2, a 30 amino 
acid insert, is not found in Smad3 and precludes the DNA-binding o f Smad2.
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However, a naturally occurring Smad2 splice variant/form o f Smad2 lacking exon 3 
can bind interchangeably w ith Smad3 to the SBE in D N A (Yagi, K. et al., 1999).
In addition to the SBE, Smads have also been reported to bind to G/C rich 
sequences. Mad (Drosophila Smadl) was shown to interact w ith  a 5 -GCCGNCGC 
m o tif in the promoters o f Vestigal (K im , J. et al., 1997) and Tinman (Xu. X. et al.,
1998). Similar Smadl consensus sequences have also been found in Drosophila 
Ultrabithorax (Ubx) (Szuts, D. et al., 1998), Smad6 (Ishida, W. et al., 2000) and 
Smad7 (Benchabane, H. et al.. 2003). In addition, the Bcl-2 promoter region contains 
three overlapping copies o f a GC-rich repeat, which is identical to the Drosophila Mad 
binding element, GCCGnCGc, and has been shown to bind Smad3 in vivo (Yang. Y. 
A. et al.. 2006). This suggests that both TGF-p and BMP R-Smads can bind GC-rich 
elements although it is possible that Smad3 may be bound to the Bcl-2 promoter by 
association w ith Smadl (See Chapter 7). Furthermore, a second D N A  binding 
consensus site has been proposed for Smad 1/4 complexes which recruit the 
transcription factor Schnurri (Yao. L. C. et al.. 2006). This site includes a Mad/Smadl 
binding GC-rich m o tif and a canonical Smad4 SBE m otif, which is separated by 5 bp 
and is found in many BMP responsive genes such as the Id  I,  Vent 2 and Drosophila 
brinker. bag o f marbles (bam) and gooseberry (gsb) (see below) (Yao, L. C. et al., 
2006). These data suggest that Smadl and Drosophila Mad preferentially bind to GC 
rich sequences however, it cannot be ruled that Smadl can also bind an SBE. 
Cooperation o f SBE and GC rich motifs is also required for binding o f Smad3-Smad4 
complexes to promoter elements, such as the Id l  promoter (Kang, Y. et al., 2003; 
Korchynskyi, O. et al., 2002). The Id l promoter contains both BMP and TGF-P 
responsive elements, where binding o f Smad3-Smad4 complexes to the Id l promoter 
results in transcriptional repression and the binding o f  Smad 1/4 complexes results in 
the transcriptional activation promoter (Kang. Y. et al., 2003; Korchynskyi, O. et al.,
2002). However, it is not clear in the case o f Smad3-Smad4 complexes, which Smad 
binds the individual motifs and whether the spacing o f these sites are critical for 
binding o f the cooperating transcription factor. ATF3 (Kang, Y. et al., 2003). As no 
crystal structure for Smad binding to a GC-rich m o tif has been reported, it is not clear 
how the Smads bind to this GC-rich m otif, but it has been proposed that the region o f 
the M H l domain that binds to GC-rich sequences may be distinct from the (3-hairpin 
loop which binds to the SBE (Shi, Y. et al., 2003).
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Smads bind to these low complexity sites w ith  weak a ffin ity  and thus it is 
generally assumed that the Smad-DNA interactions are enhanced by interactions w ith  
other transcription partners that are also crucial for promoter selectivity. The role o f 
these factors is discussed below.
1.5.6.2 Transcription Factors
To date, at least 60 regulatory transcription factors, corepressors and coactivators have 
been reported to physically and/or functionally interact w ith the Smads (Massague, J. 
et al.. 2005). These include factors from  almost every structural fam ily  and a wide 
range of functional classes and these interactions allow  the Smads to mediate 
transcriptional activation or repression in response to TGF-|3 superfamily ligands. This 
may reflect the functional diversity o f the Smads themselves but it is important to note 
that the majority o f these reports have relied on data derived from studies carried out in 
vitro or by protein overexpression. Indeed many o f the interaction motifs have not 
been characterised. Many o f these interactions await confirm ation by 
immunoprecipitation o f endogenous proteins, chromatin immunoprecipitation (ChIP) 
and siRNA depletion to verify a functional role in TGF-|3 signalling (Massague, J. et 
al., 2005). For the purpose o f this thesis, I w ill focus on some o f the Smad-interaction 
factor interactions that have been extensively characterised.
The first identified Smad transcription partner was Xenopus forkhead A c tiv in  
signal transducer (FAST-1, now renamed X F oxH la ), which directly binds Smad2. 
FoxH l contains an N-term inal forkhead/winged helix D N A  binding domain and forms 
a transcriptionally competent complex w ith  activated Smad2 and Smad4 in response to 
Activ in, when bound to the Activ in  response element (ARE) in the Mix. 2 promoter 
(Chen, X. et al., 1996; Chen, X. et al., 1997). The TGF-|3 R-Smads, Smad2 and 
Smad3, also interact w ith the paired-like homeodomain proteins. M ixer and M ilk  
(Germain, S. et al., 2000). Sequence analysis o f  the M ixer and FoxFIl fam ily o f 
transcription factors revealed that these transcription factors bind active Smad 
complexes through a common, proline rich, 25 amino acid Smad interaction m o tif 
(S IM ), characterised by a core PPNK sequence, present in their C-terminal regions 
(Germain, S. et al., 2000). The S IM  is necessary and sufficient to interact w ith  both
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monomeric Smad2 and Smad3, and activated Smad complexes, which can then 
subsequently recruit these complexes to D N A  (Germain, S. et al., 2000). In addition, 
FoxH l fam ily members have a second conserved interaction m o tif named the FoxH l 
m o tif (FM) (Randall, R. A. et al., 2004). Unlike the SIM, the FM only interacts w ith  
activated complexes o f Smad2 and Smad4, and homomeric Smad2 complexes. The 
binding sites for the SIM and FM m otifs in Smad2 have been investigated by site 
directed mutagenesis in combination w ith  structural modelling. The binding sites o f 
these two motifs partially overlap on a target Smad2, and thus it has been suggested 
that a FoxH l monomer can interact w ith  both subunits o f Smad2 in a Smad2-Smad4 
heterotrimer (Randall. R. A. et al., 2004) (Figure 1.10). The interaction between the 
FM m otif and Smad2 discriminates Smad2 w ith Smad3, thus conferring on FoxH l 
specificity for Smad2 binding. A lthough there were some report that FoxH l can bind 
Smad3, this was using overexpressed protein (Randall, R. A. et al., 2002; Randall, R. 
A. et al.. 2004).
Much less is known about the Smad interacting transcripton factors which 
determine the specificity o f  gene targets in response to BMP. However, recently 
progress has been made in revealing a crucial component o f  the nuclear Smad/Mad 
complex in dpp/BMP signalling. Drosophila Schnurri (Shn) is a large DN A-binding 
transcription factor w ith  multiple, widely separated zinc finger domains, and was one 
o f  the first partners identified for BMP-specific R-Smads (Dai, H. et al.. 2000; 
Udagawa, Y. et al.. 2000). Genetic studies in Drosophila revealed that Shn plays an 
important role in Dpp signalling, downstream o f the receptors and is essential for Dpp 
signalling at many developmental stages. Interestingly, the early function o f dpp, 
which is to pattern the developing embryo, is not affected in shn mutants, suggesting 
that Shn is not an essential component o f  dpp signalling but it m ight act as a tissue- 
specific cofactor (A ffo lte r, M. et al.. 2001). It was subsequently uncovered that 
Schnurri can interact directly w ith Mad, the Smadl homologue, to engage in 
transcriptional activation, but more often repression (A ffo lte r, M. et al., 2001). A  
major target o f Shn is the transcriptional repressor brinker, and inhib ition mediated by 
Shn, relieves repression o f a plethora o f  Dpp target genes. Shn represses brinker via 
the formation o f a Shn/Mad/Med complex on defined elements in the brinker promoter 
(M uller, B. et al., 2003; Pyrowolakis, G. et al., 2004). In addition to the founding 
member in Drosophila, Schnurri homologues exist in other phyla, namely Sma-9 in C.
74
B Dros. Shn  
Vert. Shn1
brk, bam, gsb
GTCTG
5 bp
Dros. Shn 
Vert. Shn1
Vent2, Id3
GTCTG
5 bp
Figure 1.10 Transcription Factor Interactions
(A) FoxH 1 binds to each monomer of a Smad2 subunit in a heterotrimeric complex through a Smad- 
interacting (SIM) motfi and an FoxHl motif (FM). This interaction recruits Smad2-Smad4 complexes to 
site specific DNA sequences and stabilises the complex on DNA. Based on model from Randall, et. al., 
2004.
(B) Schnurri as a scaffolding platform for Smadl-Smad4 complexes. Smad 1/Mad and Smad4/Med bind 
to GRCKNC and GTCT sites, probably as a heterotrimeric complex (not represented in this figure). 
Shn/Shn 1 interacts with the MH2 domains of Smads and acts to stabilise the complex and provide docking 
sites for cell specific co-repressors and coactivators. (Taken from Yao, 2006).
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elegans and three vertebrate homologs Shnl, Shn2 and Shn3, which exibit high 
sequence sim ilarity to the fly  protein. In a recent study, Yao et al., revealed that the 
closest vertebrate Shn homologue, Shnl, can also mediate BMP responsiveness 
through a mechanism similar to Drosophila Shn, i.e. through interaction w ith  Smads 
on sim ilar regulatory elements (Yao, L. C. et al., 2006).
Genetic and biochemical analysis has revealed that elements in the promoters 
o f dpp/BMP responsive genes contain consensus sites, w ith a GC-rich binding site for 
Mad/Smadl and an SBE, GTCTG site for Medea/Smad4 separated by a spacer o f  5 bp. 
This precise spacing is required for Shn to dock to Smad complexes on the D N A  and 
mediate its effects on transcription (Pyrowolakis, G. et al.. 2004; Yao, L. C. et al., 
2006) (Figure 1.10). Drosophila Shn and its vertebrate homologues can mediate either 
repression or activation o f gene expression. This switch in transcriptional output is 
mediated through identical consensus elements, depending on the cellular context, thus 
suggesting that Shn proteins can recruit co-activators or co-repressors in a cell-type 
specific fashion (Yao. L. C. et al., 2006).
Previous investigations have implicated OAZ, a Smad-interacting factor as a 
transcription partner for Smad 1/4 complexes, critical for Xvent2 transcription (Hata, 
A. et al., 2000). However, the OAZ binding site on Xvent2 overlaps w ith  the highly 
conserved Smadl binding m o tif and mutation o f this O AZ site did not affect BMP 
responsiveness, suggesting that OAZ may not have a crucial role in Xvent2 
transcription. These results also question the role o f O AZ as transcriptional partner to 
Smad 1/4 (Yao, L. C. et al., 2006).
1.5.7 Crosstalk with other Signalling Pathways
The response elicited by cells upon TGF-(3 superfamily ligand stimulation is not an 
isolated event. The cell type and context specific response is a net result o f 
contributing environmental cues, which is dictated by the signalling pathways that are 
activated in the cell (Massague, J., 2000). Thus, TGF-|3 superfamily signalling is a 
constituent o f an integrated network, by which the activation o f other pathways often 
defines cellular responses o f TGF-|3 fam ily  members. Communication can be achieved 
at different levels o f the TGF-(3 superfamily pathway, either through direct activation
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o f signalling components or through integration by targeting the activity o f  the Smads 
(Massague, J., 2000).
1.5.7.1 Smad-independent Signalling
Although the Smads represent the major and most direct route o f communication o f 
the TGF-(3 ligands, alternative signalling cascades may also be activated by TGF-(3 
family members (Derynck, R. et al., 2003). These include a diverse array o f signalling 
pathways involved in many aspects o f cellular regulation. For example, TGF-[3 can 
activate the ERK. JNK and p38 M A P K  kinase pathways. Activation w ith  slow kinetics 
in some cases may result from Smad-dependent transcriptional respsonses, but the 
rapid activation (5-15 min) in other cases suggests independence from transcription 
(Javelaud, D. et al., 2005). Studies using mutated A LK 5 receptors, defective in Smad 
activation demonstrated that activation o f p38 in mouse mammary epithelial cells did 
not require activation o f the Smads (Yu, L. et al., 2002). The mechanism o f receptor 
coupling however is poorly understood. It is likely that TGF-|3 can activate upstream 
regulators o f these kinases, such as M A P K K  or M A P K K K . Indeed, both TGF-[3 and 
BMP4 can activate TGF-f3-activated kinase 1 (TAK1), a M A P K K K  fam ily member 
(Lutz. M. et al., 2002), which in turn can trigger p38 and JNK pathways. Because 
TAK1 can phosphorylate and activate Ik B kinase, thus stimulating N F-k B signalling, 
TAK1 represents a point o f convergence w ith  TGF-[3/BMP signalling and other 
signalling pathways (Lutz, M. et al.. 2002).
In addition, rapid activation o f small Rho-like GTPases, including RhoA, Rac 
and Cdc42 has also been demonstrated upon stimulation o f TGF-f3 in a subset o f  cell 
lines (Bakin, A. V. et al., 2002; Bhowmick, N. A. et al., 2001). A  delayed activation o f 
RhoA and Cdc42 has also been observed, which is dependent on protein synthesis. The 
activity o f these Rho-like GTPases have been implicated in TGF-|3-induced 
cytoskeletal reorganisation, such as membrane ru ffling , stress fibre formation and 
epithelial-to-mesenchymal transition (EM T) (Bakin. A. V. et al., 2002; Bhowmick, N. 
A. et al., 2001). Furthemore, Ras activation in response to TGF-|3 may also contribute 
to the induction o f Rho-like GTPase activ ity (Yue, J. et al., 2000). In addition, a recent 
study also revealed that a member o f the p21-activated kinases (PAKs), PAK2, was
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activated by TGF-p specifically in fibroblasts but not in epithelial cells (W ilkes, M. C. 
et al., 2003). PAK2 activation was found to be Smad-independent but required Racl 
and Cdc42 GTPase activity, to mediate cell proliferation and morphological 
transformation (W ilkes, M. C. et al., 2003).
TGF-|3 has also been shown to activate the phosphatidylinositol-3-kinase 
(P I3K) pathway, as indicated by phosphorylation o f its effector A k t (Bakin, A. V. et 
al., 2000; Vinals. F. et al., 2001). This activation can be direct, w ith  possible 
involvement o f RhoA (Bakin, A. V. et al., 2000), but can also be mediated through a 
Smad-dependent pathway, whereby induction o f TG F-a expression leads to Epidermal 
Growth Factor (EGF) receptor activation (Vinals, F. et al., 2001). The role o f P I3K 
activity in promoting EM T is under debate due to conflicting results (Bakin, A. V. et 
al.. 2000; Piek, E. et al., 1999), but accumulating evidence has implicated a role in 
modulating TGF-p-induced apoptosis (Bakin, A. V. et al., 2000; Janda, E. et al., 2002; 
Piek. E. et al., 1999). Two recent studies investigated the molecular mechanism into 
how the P I3K /Akt pathway can regulate Smad (Conery, A. R. et al.. 2004; Remy, I. et 
al.. 2004). They propose that in some epithelial and hematopietic cell lines, A k t can 
physically interact w ith  Smad3 and sequester it at the plasma membrane, thus 
preventing nuclear accumulation and transcriptional activity and ultimately, protection 
from TGF-p induced apoptosis (Conery, A. R. et al., 2004; Remy. I. et al., 2004). 
Therefore a balance between A kt activity and Smad3 level w ill determine the 
sensitivity o f  a cell to TGF-P-induced apoptosis.
Also, an additional substrate for the TGF-p type II receptor has been 
uncovered. PAR6, a component o f junction complexes in epithelial cells is 
phosphorylated in response to TGF-P signalling and contributes to loss o f epithelial 
polarity (Ozdamar, B. et al., 2005). This w ill be discussed in more detail in Section
1.6.3.1.
1.5.7.2 Signal Integration with signalling pathways
In addition to the Smad independent signalling responses, the Smads can also act as 
nodes for signal integration. Many signalling pathways have been shown to affect 
Smad activity through a number o f mechanisms including nuclear accumulation and
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transcriptional activity. One o f the first pathways to be implicated in modulating Smad 
activity was the Ras/Raf/ERK M A P K  pathway (Kretzschmar, M. et al., 1997; 
Kretzschmar, M. et al., 1999). The linker region o f the R-Smads contains m ultiple Ser- 
Pro and Thr-Pro residues that are phosphorylated by ERK1/2, downstream targets o f 
the Ras M APK pathway. ERK phosphorylation o f the linker sites o f Smadl, 2 and 3 
has been proposed to inhib it nuclear accumulation o f R-Smads and thus dampen down 
the transcriptional response (Kretzschmar, M. et al., 1997; Kretzschmar, M. et al.,
1999). It has also been shown that Smad2 signalling is abrogated in mid-gastrula 
Xenopus explants due to increased Ras/ERK activity, whereby phosphorylation o f 
Smad2 sites by ERK 1/2 was shown to prevent Smad2 accumulation in the nucleus 
(Grimm, O. H. et al., 2002). In addition, activation o f Ras/MAPK that is required for 
neuralization in dissociated Xenopus embryonic ectodermal cells, which acts to inh ib it 
BMP signaling by phosphorylation o f Smadl in the linker (Kuroda, H. et al., 2005).
However, extensive variab ility  has been observed on the activity o f ERK on 
Smad responses in different cell types and moreover, contradictory results have also 
been reported. Inducible activation o f ERK 1/2 in canine kidney epithelial cells 
(M D C K  cells) w ith  a constitutively active form o f Raf did not significantly influence 
the function o f Smad2 or Smad3 at the level o f nuclear accumulation, D N A  binding or 
transcriptional activation (Lehmann, K. et al., 2000). In another study, the activity o f 
H-Ras in squamous carcinoma cells was shown to promote the transcriptional activity 
o f  Smad2 and Smad3, which resulted in a synergistic TGF-P response (O ft, M. et al.,
2002). In addition. Smad2-dependent formation o f mesoderm in the blastula stage o f  
Xenopus embryos appears to occur in regions o f peak M A P K  activation (Schohl, A. et 
al.. 2002). The paradox that Ras/MAPK and Smad signalling may cooperate in some 
instances (Lehmann, K. et al., 2000; Oft, M. et al., 2002) while acting in opposition in 
others (Kretzschmar, M. et al., 1997; Kretzschmar, M. et al., 1999) requires further 
investigation. Uncovering the mechanism by which phosphorylation o f the Smad 
linker region exerts its effects w ill hopefully gain insight into the contradictory results 
obtained.
In addition, the JAK/STAT pathways activated by cytokines and growth factors 
also mediate crosstalk w ith  both BM P and TG F-p Smad pathways. Cooperation 
between STAT3 and Smadl has been reported to mediate BMP-2 and Leukamia 
inhib itory factor (LIF)-induced differentiation o f primary fetal neural progenitor cells
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to astrocytes (Nakashima, K. et al., 1999). The formation o f a complex between 
STAT3 and Smadl, bridged by p300, is required for the synergistic activation o f 
astrocyte-specific gene encoding the glial fib rilla ry  acidic protein (GFAP). The 
JAK/STAT pathway has also been implicated in modulation o f  the TGF-P signallling. 
Interferon-y (INFy) signalling via the JAK/STAT pathway has been shown to 
indirectly regulate Smad3 activity through upregulation o f the inhib itory Smad7 
(Ulloa, L .e t al., 1999).
Notch signalling has also proven to be a key player in the regulation o f both 
TGF-(3 and BMP signalling. Here both synergistic and antagonistic effects on Smad 
signalling have been observed (Kluppel, M. et al., 2005). Furthermore, the TGF-p 
signalling cascade is also influenced by cross-talk w ith  other pathways such as N F-kB  
and p-catenin/LEF signalling. A  more in depth discussion on the integration o f  these 
signalling pathways w ith TGF-P signalling during EM T can be found in Section
1.6.3.1.
1.6 Biological Functions of TGF-p superfam ily m em bers in 
developm ent and in adult hom eostasis
The biological actions o f TGF-p superfamily members are diverse and sometimes 
opposing effects can be observed dependent on cell type and environmental cues. In 
this section many o f the m ultifunctional actions o f TGF-P and related factors w ill be 
discussed.
1.6.1 Cell Cycle Control during G1
TGF-P has been shown to be a potent inducer o f  growth inhib ition in many cell types. 
To appreciate the molecular mechanisms by which TGF-p affects cell proliferation, a 
b rie f outline o f the regulation o f the cell cycle is given below'.
1.6.1.1 The Cell cycle
A ll vertebrate embryos begin their existence as a single cell entity, which then divides 
over time by a process o f D N A  duplication and cell division to form the entire
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organism. The development o f the cell cycle is clearly illustrated in Xenopus embryos. 
These early divisions in the embryo occur rapidly, w ith  continuous cycles o f D N A 
replication and nuclear division, which are completed in approximately th irty  minutes. 
However, as the embryo reaches gastrulation, environmental cues need to be 
interpreted to direct the fate o f the cells. Hence, the cell cycle adapts by incorporation 
o f two distinct gaps whereby these signals can influence progression o f the cell cycle 
and the fide lity o f D N A  replication can be checked (Blagosklonny, M. V. et al., 2002). 
The first, called G1 phase occurs between nuclear division (M  phase) and D N A  
synthesis (S-phase), and a second gap called G2 phase between S and M  phases 
(Massague, J., 2004) (Figure 1.11). During the G1 phase, growth factors play a 
prominent role in the in itiation and maintenance o f the transition through G1 phase 
leading to S-phase. Cell cycle progression requires growth factor stimulation up to a 
stage late in G1 phase known as the restriction point, at which point commitment 
occurs. Once past this point, cells are refractory to both mitogenic and anti-m itogenic 
signals until the next G1 phase. A fte r a successful completion o f D N A  synthesis, cells 
enter G2 phase in preparation for mitosis. During the G2 phase, the accuracy o f D N A  
replication is scrutinised, whereby replication errors are corrected and the integrity o f  
the microtubule function is assessed, to ensure efficient chromosome segregation. 
Most mammalian cells are diploid and therefore after D N A  duplication, a cell must 
divide (Blagosklonny, M. V. et al., 2002). As cells exit mitosis, the cell cycle is reset, 
allow ing the whole cycle to start again.
A t the molecular level, cell cycle progression through G1 is driven by the 
activities o f cyclin-dependent kinases (CDKs), in association their regulatory subunits, 
cyclins (Sherr, C. J. et al., 1999). The D-type cyclins (cyclin  D l,  D2, D3) bind to and 
activate CDK4, as well as the homologous CDK.6, at early to mid G l. As the cells 
progress to late G l, cyclins E l and E2 form  active complexes w ith CDK2. For 
complete activation o f the CDKs a critical threonine is phosphorylated by C A K  (CDK- 
activating kinase) and an inhibitory phosphorylation is removed by the phosphatase 
CDC25 (Massague, J., 2004). A fter m itogenic stim uli active cyclin-CD K complexes 
accumulate and assemble in the nucleus wTiere they phosphorylate a set o f substrates to 
initiate cell cycle progression. In addition, the activity o f these kinases is also 
constrained by two classes o f CD K inhibitors, (CDIs), which function to suppress 
inappropriate cell cycle progression (Sherr, C. J. et al., 1999).
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Figure 1.11 Regulation of the cell cycle by CDKs
(A) CDK activity regulates G l entry and cell cycle progression.The activation o f 
cyclinD-CDK4/6 and cycllinE-CDK2 in turn promotes hyperphosphorylation o f Rb, 
leading to the release o f histone deacytyases (HDAC) and activation o f E2F allowing 
E2F-dependent transcription. Along w ith  cyclin E, the E2Fs activate transcription o f a 
large set o f  components that support D N A replication (ORCs, MCMs, D N A poly­
merase ) and subsequent events (cyclin B, C dkl and various DN A quality-control 
components).
(B) Effects o f CDK Inhibitors. p21, p27, and p57 can either activate or inactivate 
CDK4/6. In addition, phosphorylation o f  p27 by CDK2 targets it for degradation. The 
IN K  fam ily o f CDKIs target cyclinD-dependent kinases only.(Adapted from Blago- 
slonny and Pardee, 2002).
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A major target o f CDKs is the tumour suppressor, retinoblastoma protein, a member o f 
the fam ily o f pocket proteins, which also include the related proteins p i30 and p i07 
(Cobrinik, D., 2005). In the hypophosphorylated state, pRb blocks Gl/S-phase 
transition by binding to members o f the E2F fam ily, thereby repressing transcription o f 
responsive genes, whose products are essential for nucleotide metabolism and D N A 
synthesis (Stevaux, O. et al., 2002)(Figure 1.11). Upon mitogenic stimulus, active 
cyclinD-cdk4/6 complexes phosphorylate Rb, which disrupts this interaction thereby 
liberating E2F transcription factors, and in itiating transcription o f genes including 
cyclin E. This results in activation o f CDK2 and subsequent phosphorylation o f Rb on 
additional sites by cvclinE-cdk2 complexes further potentiates the inactivation o f Rb 
and sustains the phosphorylated state o f Rb beyond G l (Mittnacht. S.. 1998) (Figure 
1.11). E2F accumulation bypasses a G l arrest and drives the transcription o f genes 
required for S-phase entry, such as cyclin A, thymidine kinase and dihyrofolate 
reductase. Growth factor dependency ends w ith  the phosphorylation o f Rb, which is 
initiated by cyclinD -CDK4/6 activity, but is completed by cyclinE-CDK2 
accumulation (Blagosklonny, M. V. et al., 2002). This transition from mitogen- 
dependent cyclinD /C DK complexes to mitogen-independent cyclinE/CDK2 
complexes accounts in part for the loss o f dependency on growth factors and the 
ability o f cells to pass through the restriction point and commit to completing the 
remaining phases o f the cell cycle (Blagosklonny, M. V. et al., 2002). The activity o f 
cyclinE/CDK2 complex peaks at the G l /S-phase transition, after which, cyclin E is 
degraded and replaced by cyclin A. Accumulation o f cyc linA  occurs prior to S-phase 
entry and cyclinA  associated kinase activity is required for completion o f S-phase and 
entry into M-phase.
Many studies have supported the general scheme outlined above, however, it 
would be a gross oversimplification to suggest that a linear scheme o f activation o f 
CDKs occur. Positive and negative feedback loops exist throughout the G l phase and 
act to attenuate or perpetuate the signals (Massague, J., 2004). In addition, the 
knockout mouse studies have revealed that not all o f  the components are absolutely 
essential for cell proliferation. Cyclin E, Cyclin D, CDK4 and CDK6 deletions suggest 
that these components are only required in certain tissues, whereas most organogenesis 
and development are unaffected. Furthermore, it is generally viewed that the activity o f  
CDK2 is the engine that drives progression through the G l/S  transition, yet strikingly,
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mice lacking CDK2 are viable. This adds to the growing suspicion that different 
mammalian CDKs are redundant, either in the absence o f  a fam ily member or in 
certain abnormal circumstances (Massague, J., 2004).
1.6.1.2 CDK inhibitors (CKIs)
The activities o f cyclin-CDK complexes are also modulated by CD K inhibitors 
(CKIs). These inhibitory proteins are major targets for regulation by many growth 
factors including TGF-(3. CDKIs can be divided into two families based on their 
structures and CDK targets; the IN K 4  fam ily and the fam ily o f C IP/KIP proteins. The 
INK4 proteins (inhibitors o f CDK4) specifically inh ib it the catalytic subunits o f  CDK4 
and CDK6 through direct 1:1 interactions with, and sequesteration of, CDKs. In 
contrast, members o f the C ip/KIP inhib itor fam ily (C D K interacting protein/kinase 
inhib itor protein). p21Cipl,VkAF1, p27Kipl and p57Kip2, bind to CDKs and disrupt their 
catalytic centre. These proteins share a homologous CDK binding region in their 
amino terminus and act as inhibitors for CDK2 compelxes in vivo but they have been 
found to bind and inhibit all cvc lin /C D K  complexes in vitro (Sherr, C. J. et al., 1999). 
A t high levels. p21 and p27 function as integral brakes o f the cell cycle, in that they 
silence cyclin-CDK2 activity resulting in growth arrest. M itogenic stim uli release 
CDK2 from inhib ition by suppressing the transcription, translation, stability or nuclear 
localisation o f either p21 or p27. Once CDK2 is activated, it bites back by 
phosphorylating p27 on a C-terminal threonine, thus targeting it for degradation 
(Sheaff, R. J. et al., 1997). In addition to their inhib itory role, the C ip/K IP  proteins can 
positively affect cyclinD-dependent kinases (Sherr, C. J. et al., 1999). A t low levels, 
p21 and p27 actually promote the assembly, stability and nuclear retention o f cyclin D- 
CDK4 and cyclinD-CDK6 complexes. In proliferating cells, p27 is predominantly 
bound to cyclinD-CDK4 w ithout inhib iting this kinase, and allow ing the assembly o f 
cyclinD /CDK4 complexes (Soos, T. J. et al., 1996). Also, a non catalytic function o f 
the cyclinD -CDK4 complexes is to sequester p21 and p27 from CDK2, relieving its 
inhib ition and promoting cell cycle progression (Sherr, C. J. et al., 1995). M itogen 
withdrawal results in rapid cyclinD  degradation and the previously sequestered
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C ip/K ip  proteins are released, inhib iting cyclinE/CD K2 activity and thus leading to 
cell cycle arrest (Reynisdottir, I. et al.. 1997).
The members o f the IN K4 proteins, p i6, p i 5, p i 8 and p i 9 contain m ultiple 
ankyrin repeats, allowing them to specifically inhib it the kinase activ ity o f  the cyclin D 
associated CDKs, CDK4 and CDK6. The signals which lead to the synthesis o f  IN K 4 
proteins are poorly understood, but it is clear that p l5 INK4b is induced by TGF-|3 which 
participates in G l arrest (Reynisdottir, I. et al., 1997). In general, the IN K 4 proteins act 
as competitive inhibitors o f D-type cyclins for binding to their CDKs, preventing 
formation o f the active cyclin-CD K complex (Pruitt, K. et al., 2001). It has also been 
demonstrated that INK4 activity is dependent on the displacment o f  C ip /K ip  proteins 
from complexes containing cyclinD -C DK4, releasing free C ip /K ip  proteins that then 
bind to and inactivate cyclinE-CDK2 complexes, resulting in growth arrest 
(Reynisdottir. I. et al., 1997). In conclusion, it is clear that the relative levels o f  cyclin, 
CDK and CDKI proteins determine the activity o f Rb and the proliferative state o f  the 
cell. The effects o f growth factors on the relative levels o f  these components and the 
progression through the G l phase are discussed below.
1.6.1.3 Cell cycle control by Ras
In contrast to TGF-|3, many growth factor signalling pathways contribute to the 
progression o f the cell cycle through the G l/S  phase transition. O f these, the Ras 
pathway has been implicated as a major player in this respect (Coleman, M. L. et al., 
2004). As the two pathways are integrated on many levels, it is important to 
understand the opposing actions o f Ras in the control o f  the cell cycle and a b rie f 
outline o f the role o f Ras signalling is discussed below'. Diverse extracellular stim uli 
signal through many different receptor tyrosine kinases (RTKs), which transduce their 
signal by activation o f Ras proteins. Once activated, Ras in turn interacts w ith  a 
diverse spectrum o f effectors and initiates a m ultitiude o f cytoplasmic signalling 
cascades (Schlessinger, J., 2000). Hence Ras proteins act as a nodal point, whereby 
multiple signals converge to e lic it their responses. The importance o f Ras signalling in 
cell cycle progression is underscored by the fact that the prototypical Ras proteins, H- 
Ras, N-Ras and K-Ras wrere first identified as the products o f active oncogenes in
85
Chapter 1 Introduction
human tumours. Aberrant cell cycle regulation due to inappropriate activation o f Ras 
proteins leads to uncontrolled proliferation and cancer, however these GTPases also 
contribute to cell-cycle regulation in normal, non-transformed cells. The Ras GTPase 
proteins are positioned at the inner face o f the plasma membrane, where they serve to 
transmit signals via receptor tyrosine kinases to the cytoplasm (Malumbres, M. et al.,
1998). The RTKs initiate signalling by creating docking sites that are recognised by 
adaptor proteins such as Grb2 and Sos, which subsequently recruit effectors (Figure 
1.12A). Upon recruitment, Ras proteins are activated by GTP-GDP exchange, 
catalysed by GTP exchange factors (GEFs), to form an active GTP-bound state, which 
can then engage a complex network o f effectors. Among these, the Ras-M EK-ERK 
kinase cascade and the PI3Kinase pathways have key roles in promoting cell cycle 
progression.
Early studies established a central role for Ras in G l/S  progression as 
demonstrated by blocking the entry o f  cells into S-phase upon m icroin jection o f Ras- 
neutralising antibodies or use o f a dominant negative RasN17 (Mulcahy, L. S. et al., 
1985; Stacey. D. W. et al., 1991). It was later revealed that the principal function o f 
Ras in Gl/'S-phase progression is to increase levels o f cyclin D and ultimately 
inactivate Rb (Mittnacht, S. et al., 1997). In the absence o f mitogenic growth factors, 
levels o f cyclin D remain low, due to its highly labile state. Flowever, accumulation o f 
cyclin D is essential for mitogen-dependent progression through the G l phase. Upon 
mitogen activation, the Ras/Raf/ERK pathway induces cyclin D1 transcription, which 
leads to the inactivation o f  Rb (Coleman, M. L. et al., 2004). Ectopic expression o f 
cyclin D1 was shown to rescue cell cycle inh ib ition by dominant negative ras (Peeper, 
D. S. et al., 1997) and also cells derived from p i6 null mice, were found to be less 
sensitive to the inhib itory effects o f the anti-Ras antibody (M ittnacht, S. et al., 1997). 
This establishes that the function o f D-type cyclins is to link  extracellular signals to the 
cell cycle machinery, and thereby act as growth factor sensors. The regulation o f 
Cyclin D stability is also modulated by downstream effectors o f Ras, the PI3 kinase 
pathway (Massague, J., 2004) (Figure 1.12A). Cyclin D turnover is governed by 
ubiquitination and proteasomal degradation, which are stimulated by cyclin D1 
phosphorylation on threonine 286 by glycogen synthase kinase-3(3 (Diehl, J. A. et al., 
1998; Diehl, J. A. et al., 1997). PI3 kinase signalling to Akt/protein kinase B (PKB) 
results in inh ib ition o f GSK-3|3, thereby enhancing cyc linD l stability (Massague, J.,
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Figure 1.12. Regulation of the Cell Cycle by Ras and TGF-p pathways
(A)Ras signalling in cell cycle control. Activation of Ras initiates a cascade of events leading to cell 
cycle progression. These include increased expression and stabilisation of Cyclin D, downregulation 
of p27 and induction of p21.
(B) Cell cycle control by TGF-P through transcriptional regulation. TGF-p signalling leads to the 
inhibition of CDK4/6 and CDK2 activities by downregulating expression of c-Myc, Id, CDC25A and 
upregulation of pi 5 and p21 .(Adapted from Liu and Matsuura, 2005).
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2004). In addition to the regulation o f cyclinD  levels, assembly o f newly synthesized 
cyclin D1 w ith  CDK4 or CDK6 is also dependent on Ras signalling (Coleman, M. L. 
et al.. 2004).
Ras mediated activation o f the R af-M EK-ER K pathway has also been shown to 
promote cell-cvcle progression by reducing p27 C D KI levels, resulting in increased 
CDK activity. P27 levels m RNA levels are unaffected, but p27 protein levels are 
regulated by translational control and enhanced ubiquitin-mediated proteolysis (Pruitt, 
K. et al., 2001)(Figure 1.12A). Counter-intuitively, activation o f Ras via the Raf- 
M EK-ER K pathway acts to induce expression o f p21. The upregulation o f p21 by Ras 
might be explained by the role o f p21 in cell cycle progression at lower expression 
levels. As previously mentioned, p21 can facilitate c y c lin -D l-C D K  assembly. In 
addition, it can function to promote nuclear accumulation and stability o f  these 
complexes and therefore Ras upregulation o f moderate levels o f  p21 is like ly to aid 
progression o f the cell cycle (Coleman, M. L. et al., 2004).
A  large body o f work points to a negative role for Ras in cell cycle progression 
(L loyd. A. C., 1998). It has been shown that expression o f oncogenic Ras in primary 
fibroblasts leads to cell cycle arrest through the induction o f p53 or activation o f the 
C D K inhib itor p i6 (Benanti, J. A. et al., 2004). Furthermore, p i6 null MEFs and P53 
null MEFs no longer undergo growth arrest in response to Ras (Serrano, M. et al., 
1997). Although p i6 is upregulated by Ras. there is no conclusive evidence as to 
which pathway is involved in this expression. Increased p i6 levels lead to growth 
arrest and senescence depending on the cell type and may provide an important 
mechanism for preventing clonal expansion o f cells w ith  an activated ras oncogene 
(Serrano. M. et al., 1997). In conclusion, the outcome o f Ras activation appears to 
depend on the cell type and the biological context o f  the cell (See also Chapter 7).
1.6.1.4 TGF-/3-induced gro wth inhibition
In most systems TGF-|3 is a potent physiological inh ib itor o f cell growth (Polyak, K., 
1996). The majority o f nontransformed mammalian cell types are growth inhibited by 
TGF-|3, but its growth inhib itory effect is most pronounced on epithelial, endothelial, 
lymphohematopoietic cells, and some cells o f  neuroectodermal origin, where TGF-|3
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treatment leads to complete growth arrest (Polyak, K., 1996). TGF-p exerts its potent 
growth-inhibitory effects through inhib ition o f CD K activity. This is achieved by 
several mechanisms, the most characterised o f which, is the transcriptional regulation 
o f key targets by the Smads (Massague, J. et al., 2006).
The primary mediators o f the cytostatic transcriptional programme in response 
to TGF-P are Smad3 and Smad4. The key role o f Smad3 in the antiproliferative effects 
o f TGF-P was revealed from studies in knockout mice. Smad3 deficient mice show' 
increased re-epithelialization due to impaired TGF-P growth inh ib ition (Ashcroft, G. 
S. et al., 1999), and a variety o f primary cells from Smad3 null mice, such as 
fibroblasts, keratinocytes, astrocytes and T cells are largely resistant to the TGF-P 
cytostatic response (ten D ijke, P. et al., 2006). It has also been convincingly 
demonstrated by two independent groups that Smad4 is essential for the 
antiproliferative effects o f  TGF-p. Knockdown o f Smad4 in either transformed human 
keratinocyte cells or mouse mammary epithelial cells, completely abolished TGF-p- 
induced cell cycle arrest and responses were restored upon re-expression o f Smad4 
levels into these cell lines (Deckers, M. et al., 2006; Levy, L. et al., 2005). The role o f 
Smad2 in TGF-p induced growth arrest is less well defined. Interestingly, it was 
shown that the depletion o f Smad2 by siRNA markedly enhanced the TGF-p cytostatic 
response (K im , S. G. et al., 2005). Moreover, depletion o f Smad2, in cancer cell lines, 
which exhibit resistance to the antiproliferative effects o f TGF-P, was sufficient to 
restore TGF-p-induced G l cell cycle arrest (K im , S. G. et al., 2005). These 
observations have led to a model w?hereby the intensity o f  the TGF-P cytostatic signal 
depends on the endogenous ratio o f Smad3 to the ratio o f  Smad3 to Smad2 (K im , S. G. 
et al., 2005). These data are not conclusive for a negative role for Smad2 in TGF-p 
induced growth inhibition, in particular regarding its role as a tumour suppressor. Thus 
the role o f Smad2 in TGF-p induced growth inh ib ition requires further investigation.
M olecular basis o f  G l arrest by TGF-P
The antiproliferative effect o f TGF-p generally results from growth arrest at the G l 
phase o f the cell cycle. It has been shown that a critical set o f  TGF-p cytostatic gene 
responses result in the inhib ition o f G l Cdk activities and the subsequent accumulation
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o f hypo-phosphorylated retinoblastoma protein (pRB) (Massague, J. et al., 2000a). 
These gene responses by TGF-p cooperatively mediate cell cycle arrest at the G l phase 
(Figure 1.12B). A  major target o f the cytostatic programme is the protooncogene, c- 
myc, whereby TGF-P causes a rapid inh ib ition of c-myc transcription (Massague, J. et 
al., 2000a). Conversely overexpression o f c-Myc abrogates the growth inh ib ition o f 
keratinocytes by TGF-P (Claassen, G. F. et al., 2000). c-Myc plays a major role as a 
transcriptional activator o f growth and proliferation, and additionally acts as a direct 
transcriptional repressor o f p 15 and p21 C ip l/W a fl (Claassen, G. F. et al., 2000; Feng, 
X. H. et al., 2002). Therefore, targeting c-Myc for downregulation by TGF-p, renders 
p21 and p i5 competent for activation. Repression o f c-Myc occurs in cooperation w ith  
E2F4/5 and the Rb fam ily member p i 07 (Chen, C. R. et al., 2002). TGF-p induces a 
repressor complex containing Smad3. Smad4, together w ith E2F4/5 and p i 07 which 
binds to the TGF-P inhib itory element (TIE) o f the c-Myc promoter and repress its 
transcription (Chen, C. R. et al., 2002; Yagi, K. et al., 2002).
Furthermore, TGF-p has been found to directly alter components o f the cell 
cycle, whereby TGF-p upregulates expression o f the CDIs, p i 5 and p21. c-M yc 
expression plays a key role in coordinating the expression levels o f p i 5 and p21 
(Massague, J. et al., 2006) (Figure 1.12B). Firstly, c-myc actively represses the 
transcription o f p i 5 and p21 in complex w ith Miz-1 (Myc-interacting zinc finger 1), 
which binds to p !5  in itiator and the proximal region o f p21 (L iu , F. et al.. 2005). 
Repression mediated by c-myc inhibits the transcriptional activation o f these genes by 
TGF-p. p53 and other signals. In addition, high levels o f  c-myc persistant in the in itia l 
hours o f TGF-p treatment also inhib it TGF-P induction o f p !5  and p21 by directly 
binding to Smad3 and Smad4 and suppressing their function (L iu , F. et al., 2005). 
Once Myc repression is relieved upon downregulation o f myc levels by TGF-p, p i 5 
and p2I  are rendered competent for activation by the Smads. Smad-mediated induction 
o f p 2 I(,pl "u11 occurs in cooperation with FoxO, p53 and possibly other factors whereas 
induction o f p l5 ,SK4B has been reported to occur in cooperation w ith Spl (Massague, J. 
et al., 2006). It was demonstrated that accumulation o f p i 5 in the cytoplasm prevents 
p27 from binding to Cdk4/6-Cyclin D complexes, and is therefore released from these 
complexes and redistributes to bind to and inactivate Cdk2-Cyclin E complexes
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(Reynisdottir, I. et al., 1997; Reynisdottir, I. et al., 1995). p21 also acts to inhib it cyclin 
F-CDK2 activity (ten Dijke, P. et al., 2006).
In addition, TGF-P targets the inhib itor o f  differentiation (Id) proteins for 
repression. The Id proteins (Id 1, Id2, and Id3) are H elix-Loop-H elix  (H LH ) proteins 
that promote cell cycle progression by releasing E2F from the effects o f Rb as well as 
by inhib iting differentiation (Perk, J. et al., 2005). For downregulation o f Id 1, Smad3 
activates ATF3, a transcriptional repressor, and together w ith Smad4 repress the 
transcription o f the Id l promoter (Kang, Y. et al., 2003). Downregulation o f CDC25A 
is also important for the growth-inhibitory response o f TGF-p. CDC25A promotes cell 
cycle progression from G l to S phase by dephosphorylating and activating CDK2 and 
CDK2/4. Downregulation o f CDC25A can be achieved by m ultiple mechanisms 
including transcriptional repression, inhib ition o f enzymatic activity or enhanced 
ubiquitin-mediated degradation (ten D ijke, P. et al., 2006). Along with induction o f 
CKIs, downregulation o f all the cell cycle promoting factors by TGF-P contributes to 
its negative effect on G l progression (Figure 1.12B).
Interestingly, in addition to the effect o f TGF-p on components o f the cell 
cycle, recent evidence suggests that this regulation is bidirectional. A  recent study has 
implicated Smad3 as a target for CDK2 and CDK4 activity (Matsuura, I. et al., 2004). 
Phosphorylation o f Smad3 at three sites including two serine/proline rich sites in the 
linker region, decreases the transcriptional activity o f  Smad3 (Matsuura, I. et al.,
2004). Mutation o f these sites increases the transcriptional activity o f  Smad3, leading 
to an increase in p i 5 expression and decreased c-M yc levels. Furthermore, mutation o f 
the CDK phosphorylation sites increases Smad3 ab ility  to inh ib it cell cycle 
progression from G l to S phase (Matsuura, I. et al., 2004). Taken together, these data 
suggest that negative feedback control o f  Smad3 by C D K is achieved by inhib ition o f 
its transcriptional activity and antiproliferative function (Figure 1.12B).
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1.6.2 Angiogenesis
Another function o f TGF-P signalling is the critical role it plays in normal vascular 
development and physiology. The vasculature is the first functional organ system to 
develop in vertebrate embryos, and is v ita l for the distribution o f  nutrients and oxygen 
as well as the removal o f waste products (Bohnsack, B. L. et al., 2004). Two processes 
are responsible for the formation o f new blood vessels, both o f  which result in the 
formation o f endothelial-lined tubes (Figure 1.13). The first, vasculogenesis, is the 
primary in situ differentiation o f endothelial cell precursors (angioblasts) which then 
form the primary capillary plexus (Figure 1.13). This non-functional plexus is 
subsequently remodelled to form  a mature vascular network consisting o f  large 
vitelline vessels and capillary networks during angiogenesis (Pepper, M. S., 1997). 
Angiogenesis, which involves the differential growth and sprouting o f  endothelial 
tubes, is a multistep process that can be divided into two phases (Table 1.3). In the 
activation phase, endothelial cells degrade the perivascular basement membrane, 
migrate into the extracellular space, proliferate, and form capillary sprouts and tubular 
structures. In the resolution phase, endothelial cells cease m igration and proliferation, 
reconstitute a basement membrane and recruit smooth muscle cells perm itting the 
maintenance o f vessel wall integrity. A  key regulatory step during this process is the 
control o f  endothelial cell proliferation. To this end, both mitogenic and anti­
proliferative signals are required for appropriate vessel formation and remodelling.
Table 1.3 Phases of angiogenesis
Activation: initiation and progression
Increased vascular permeability and extravascular fibrin deposition
Basement membrane degradation
Cell migration/matrix invasion
Cell division
Lumen Formation
Resolution: termination and maturation
Cessation of migration 
Inhibition of cell division 
Basement membrane reconstitution 
Junctional complex maturation
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Figure 1.13. Vasculogenesis and Angiogenesis
A) Capillary blood vessels are formed by two processes. Endothelial precursors (angioblasts) in the 
embryo assemble in a primitive network during the process of vasculogenesis. Angiogenesis is the 
formation of new capillaries by a process of sprouting from pre-existing networks, such as the primary 
vascular plexus in the yolk sac or the vasculature in injured tissues during wound healing. (Taken from 
Pepper, 1997)
B) Schematic representation of the angiogenic process. Endothelial cell activation is triggered by an 
angiogenic stimulus (A), which results in the degradation of the basement membrane by matrix metal lo- 
proteinases (B), which allows the extension of thin cytoplasmic processes in the direction of the stimulus 
(C). This is followed by cell migration into the surrounding matrix and the formation of a capillary 
sprout. The maturation phase occurs by reconstitution of the basement membrane and recruitment of 
pericytes and smooth muscle cells (SMCs), which protect the bare endothelial cells and function to 
inhibit proliferation and migration of the endothelial cells (D). (Adapted from Pepper, 1997 and 
Goumans et al., 2003).
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The importance o f TGF-P in vascular morphogenesis was revealed by the generation 
o f genetically altered mice w ith targeted mutations in components o f the TGF-P 
signalling pathway (Goumans, M. J. et al., 2000). S im ilar vascular defects were 
observed in TGF-fll, TfiRIL ALK5 and Smad5 knockout mice, demonstrating clear 
roles in vasculogenesis, angiogenesis, haematopoiesis as w e ll as smooth muscle cell 
differentiation. This evidence implicated a requirement fo r the components o f the 
TGF-p pathway in coordinated signalling during formation o f  the circulatory system in 
vivo. Interestingly, highly sim ilar phenotypes were also observed in ALK1 and 
Endoglin null mice (Arthur, H. M. et al., 2000; L i. D. Y. et al., 1999; Oh, S. P. et al., 
2000). In line w ith these observations, the regulation o f TGF-P signalling in 
endothelial cells was investigated and revealed additional mechanisms not observed in 
other cell types. In addition to the prototypical TGF-p type I receptor (A L K 5 ), 
endothelial cells also express a second type I receptor, A LK 1. The expression o f 
ALK1 is tightly restricted, w ith highest levels found in endothelial cells (Roelen, B. A. 
et al., 1997). It has been demonstrated that ALK1 can bind TG F-p i in transfected COS 
cells (Attisano, L. et al., 1993; ten D ijke, P. et al., 1994a), and also in nontransfected 
endothelial cells (Oh, S. P. et al.. 2000). In contrast to A LK 5 which signals via Smad2 
and Smad3, ALK1 signalling results in phosphorylation o f Smadl and 5, the 
specificity o f which is determined by the L45 Loop sequence in the kinase domain 
(Figure 1.9) (Chen. Y. G. et al., 1999). Therefore, TG F-p stimulation induces 
phosphorylation o f both Smads 2 and 3 and Smads 1 and 5 in these cells, whereas its 
targets are lim ited to Smads 2 and 3 in cells that lack expression o f ALK1 (Chen, Y. 
G. et al., 1999; Goumans, M. J. et al., 2002; Oh, S. P. et al., 2000).
Further investigation into the mechanism by which ALK1 mediates TGF-p 
signalling revealed that ALK1-induced phosphorylation o f Smadl and -5 is inhibited 
in mouse embryonic endothelial cells deficient in A L K 5  (Goumans, M. J. et al., 
2003b). Moreover, biochemical studies demonstrated that A L K 5  is required to recruit 
ALK1 into the TGF-p receptor complex in a TGF-P dependent manner (Goumans, M. 
J. et al., 2003b), presumably due to its higher a ffin ity  for TGF-P ligand than ALK1 
(ten Dijke, P. et al., 1994a). In addition, the kinase activity o f  both A LK 5  and TPRII is 
required for optimal TG F-p /A LK l-induced  responses (Goumans, M. J. et al., 2003b).
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The mechanism by which TGF-p signalling regulates angiogenesis has not 
been clearly defined. However, these biochemical studies prompted investigations as 
to how the individual type I receptors contribute to TGFp signalling during 
angiogenesis. Both ALK1 and A LK 5, are clearly required for embryonic angiogenesis, 
as demonstrated by the defect in vessel formation in mouse embryos lacking either one 
o f them (Larsson, J. et al., 2001; Oh, S. P. et al., 2000; Urness, L. D. et al., 2000). To 
determine the individual roles o f each receptor, investigators used constitutively active 
(ca) forms o f ALK1 and A LK 5, thereby circumventing dual receptor activation by 
stimulation w ith TGF-p. In embryonic endothelial cells, A L K 5  induced transcription 
o f the Smad3/4-dependent reporter construct, (C A G A )i2 -luciferase, however, it was 
unable to activate the Smad5/4-dependent BRE-luciferase reporter (Goumans, M. J. et 
al., 2003b; Goumans, M. J. et al., 2002). In contrast, ALK 1 specifically induced 
transcription o f  the BRE-luciferase reporter and not the (C A G A )i2 -luciferase reporter. 
Both receptors stimulated the (SBE)4 -luciferase, which is responsive to all TGF-P 
fam ily members (Jonk, L. J. et al., 1998). In agreement w ith  this data, microarray 
analysis o f ALK1 and A LK 5  activity, revealed remarkable differences in their 
transcriptional gene targets (Ota, T. et al., 2002). Thus, ALK 1 and A LK 5  mediate 
TGF-P signalling through distinct transcriptional regulation o f target genes, thereby 
increasing the diversity o f responses.
The two phases o f angiogenesis clearly require opposing actions (Table 1.3). In 
light o f  this and other accumulating evidence, a hypothesis has been proposed whereby 
TGF-P exerts differential responses via the individual type I receptors (Goumans, M . J. 
et al., 2003b; Goumans, M. J. et al., 2002; Lamouille, S. et al., 2002; Ota, T. et al., 
2002). Plasminogen activator inhib itor type I (PAI-1) and fibronectin are induced 
specifically by A LK 5  (Goumans, M. J. et al., 2002; Ota, T. et al., 2002), resulting in 
increased ECM deposition. PAI-1 is a potent inh ib iter o f  EC m igration in vitro and 
angiogenesis in vivo indicating that A LK 5  may be involved in the antiangiogenic 
properties o f TGF-p (Goumans, M. J. et al., 2003a). In addition, A LK 5 specifically 
induced SM22a and other smooth muscle-related genes in HUVECs (Ota, T. et al., 
2002), suggesting that TGF-p stimulates the differentiation o f periendothelial cells. 
These data implicate a role for A L K 5  in the resolution phase in angiogenesis. In 
contrast, ALK.1 induced expression o f Inh ib ito r o f  D N A  binding 1 ( Id l)  and Id2
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proteins (Goumans, M. J. et al., 2002; Ota, T. et al., 2002). Id proteins, helix-loop- 
helix proteins, act dominantly to inh ib it other transcription factors such as Ets fam ily 
members from promoting cell-cycle exit into a differentiated fate (Perk, J. et al., 2005). 
Interleukin 1 receptor like 1 (IL1RL1), which plays a role in cell growth, was also 
identified as a specific target for ALK1.These target genes suggest that ALK1 has a 
mitogenic effect on endothelial cells. In agreement w ith  a role for A LK 5 in the 
maturation stage, caALK5 activity has been shown to inh ib it endothelial cell 
proliferation (Goumans, M. J. et al., 2002; Ota, T. et al., 2002) and m igration 
(Goumans, M. J. et al., 2002). Conversely, ALK1 stimulates EC proliferation and 
m igration in mouse embryonic endothelial cells. Ota and colleagues also showed that 
caALK5 clearly inhibits the formation o f a tube-like network o f HUVECs in 3-D 
collagen gels (Ota, T. et al., 2002), whereas caA LK l shad no significant effect.
The emerging scheme whereby ALK1 and A LK 5 elic it distinct transcriptional 
programmes, and therefore biological actions helps to explain the multitude o f TGF-p- 
induced effects during angiogenesis. However, in this model the regulation o f the 
individual receptor activities is a critical factor for normal angiogenesis. Interestingly, 
it was shown that ALK1 not only induced biological responses distinct from  those o f 
A LK 5. but also antagonised ALK 5 transcriptional responses (Goumans, M. J. et al., 
2003b). The mechanism by which this antagonism is achieved has not yet been 
elucidated but it is thought to act downstream o f the receptors (Byfie ld , S. D. et al., 
2004; Goumans, M. J. et al., 2003a) (Figure 1.14). In addition to the requirement for 
A LK 5 in efficient ALK1 activation, the antagonistic effect o f  ALK 1 on A LK 5  activity 
provides an endothelial cell w ith a regulated TGF-(3-controlled switch, which would 
then determine the fate o f the cell, whether it is quiescence or active migration and 
proliferation. In addition, it has been revealed that endoglin, an accessory receptor o f 
TGF-fT acts as a modulator o f the balance between T G F -p /A L K l and TG F-p/ALK5 
signalling pathways (Lebrin, F. et al., 2004). Previous investigations have shown that 
mutations o f the Endoglin and ALK1 genes are linked to the autosomal dominant 
disorder human hereditary hemorrhagic telangiectasia (H H T) type I and type II, 
respectively (Johnson, D. W. et al., 1996; M cA llis ter, K. A. et al., 1994), a 
heterogenous disease which is characterised by bleeding through haemorrhage from  
vascular malformations (van den Driesche, S. et al., 2003). These data suggest that 
endoglin and ALK1 may act in the same pathway in vivo. Indeed, inhib ition o f
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Figure 1.14. A model of the regulation of TGF-p signalling during Angiogenesis
TGF-p can stimulate two distinct type I receptor/Smad signalling pathwasy with opposite effects in endo­
thelial cells. The TGF-p/ALK5 pathway induces transciption of PAI-1 and fibronectin which ultimately 
leads to inhibition of cell proliferation and migration, whereas, the TGF-p/ALKl pathway induces Idl 
expression and thus promotes enothelial cell proliferation and migration. Endoglin, an accessory TGF-P 
receptor, is essential for ALK1 signalling. In the absence of endoglin, the TGF-p/ALK5 signalling is 
predominant and maintains quiscence resulting in the resolution phase of angiogenesis. High endoglin 
expression stimulates the ALK1 pathway and indirectly inhibits ALK5 signalling, thus promoting the 
activation state of angiogenesis. Smad complexes downstream of ALK.1/ALK5 receptor complexes are 
thought to mediate the antagonism of ALK5 activity by ALK1. (Adapted from Byfield and Roberts, 2004 
and Goumans et al., 2003b).
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endoglin translation in human um bilical vein endothelial cells (HUVECs), enhances 
the ability  o f TGF-(3 to suppress growth and m igration in these cells (L i, C. et al.,
2000). implicating endoglin as a negative regulator o f  A L K 5  signalling. Moreover, it 
was demonstrated that endoglin, which is highly expressed in endothelial cells, is 
absolutely required for ALK1 signalling in response to TGF-(3, and that knockdown o f 
endoglin using siRNA completely abolished ALK1-induced phosphorylation o f 
Smadl/5 (Lebrin, F. et al., 2004). From these observations it has been proposed that 
endoglin promotes signalling through ALK1 and by this means, both endoglin and 
ALK1 act in concert to negatively regulate A LK 5 mediated signalling (Lebrin, F. et 
al., 2004) (Figure 1.14).
However, although this is a highly attractive model to explain the dual effects o f  TGF- 
(3 during angiogenesis, this m ight not be the whole story. By using caA LK  to override 
dual activation o f receptor, this system is not like ly  to recapitulate events in vivo, 
whereby ALK1 and A LK 5 actually work together. This is highlighted by the 
observation o f mixed complexes in these cells, which could not be reproduced either 
by expression o f caALK 1 or caALKS alone. Indeed, there has been evidence against 
the model from two independent studies which suggest that ALK1 activity may be 
involved in the resolution phase (Lamouille, S. et al., 2002; Oh, S. P. et al., 2000). 
Targeted deletion o f ALK1 in mice, resulted in hyperplasis o f  the blood vessels and 
increased expression o f angiogenic factors, therefore it has also been proposed that 
ALK1 acts to dampen the proliferative effects o f A LK 5 (Oh, S. P. et al., 2000).
Taken together, these results suggest that the balance between the ALK1 and 
A LK 5 signaling pathways in endothelial cells plays a crucial role in determining 
vascular endothelial properties during angiogenesis. The specific expression o f  two 
TGF-(3 type I receptors on the surface o f endothelial cells, allows the formation o f two 
distinct receptor complexes, which signal via different Smad complexes to e lic it 
opposing effects (Figure 1.14). The selective use o f  each complex by TGF-(3 is 
regulated on several levels, such as the requirement for a co-receptor, endoglin, and the 
antagonistic activity elicited by ALK1 signalling. These mechanisms are in place to 
ensure the correct signal is received during the highly complex process o f 
angiogenesis.
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1.6.3 Epithelial-Mesenchymal Transition (EMT)
Epithelium is the earliest tissue formed during embryogenesis by compaction o f 
loosely adherent cells at the blastula stage or by cellularisation o f the syncytial 
blastoderm. Epithelial cells form layers o f cells that are closely adjoined by specialised 
membrane structures w ith  distinct apical-basal polarity. This polarity manifests itse lf 
through the localised distribution o f adhesion molecules and cell-cell junctions and the 
presence o f a basement membrane or basal lamina (Schock, F. et al., 2002). The 
structures which mediate cell-cell and cell-matrix contact in epithelia include adherens 
junctions, tight junctions, desmosomes and gap junctions. The adherens junction is 
generally a circumferential junction located just basal to the apical-basolateral 
boundary (Figure 1.15). Adherens junctions are mediated by homotypic interactions o f 
the extracellular domains o f E-cadherin (cad for calcium dependent). Its major 
function is to link the actin cytoskeleton o f neighbouring cells, which is mediated 
through interactions via a - and p-catenin. Tight junctions are located in the most 
apical lateral regions and seal the space between adjacent cells to prevent transport o f 
molecules through the intercellular space. A t a molecular level, tight junctions are 
mediated by transmembrane claudins, occludins and scaffold proteins such as Z O l 
(TJP1), which associate w ith the intracellular actin cytoskeleton and various signalling 
systems. Epithelial cells under tension develop very strong adherenes junctions called 
desmosomes. Desmosomes support the integrity o f the epithelial unit and ce ll-ce ll 
adhesions through cadherin molecules (desmoglein and desmocollin) and link  the cell­
cell adhesion molecules w ith cytoskeletal keratin fibers by desmosomal plaque 
proteins such as desmoplakin and plakoglobin (Getsios, S. et al., 2004).
Epithelial cells are motile and can move away from neighbouring cells, while 
remaining w ith in the epithelial layer. Epithelia migrate either as a sheet, as during 
would closure, or as a tube. However, cells do not detach and move away from the 
epithelial layer under normal conditions. Most epithelia are single-layered, but a few 
adult epithelia are multilayered such as the stratified skin o f mammals. Epithelial cell 
plasticity has been conserved in all metazoans. Epithelial sheets can undergo 
remodelling by various processes, including cell intercalation (the basis o f body-plan 
formation in many species), invagination, evagination, branching and m ultilayering
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Figure 1.15. The structure of Epithelial and Mesechymal Cells
A) Organisation of epithelium. Most epithelium form a compact, single cell layer, however different 
packing arrangements of cells are also found, such as the multilayered skin of mammals.
B) Epithelial cells have apical-basal polarity. The apical (free) side may have microvilli. The basal 
actin cortex attaches the cytoskeleton to the underlysing basal lamina that contains collagen and 
laminin. They often secret glandular products from the apical surface and some also secrete ECM from 
the basal surface. Epithelial cells form tight contact with neighboring cells through numerous 
structures, including tight junctions, adherens junctions, desmosomes and gap junctions. (Adapted 
from Hay, 2005).
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(Schock, F. et al., 2002). In addition, in most metazoans, epithelial sheets can be 
reversibly or irreversibly converted into mesenchymal cells by a process known as 
epithelial-to-mesenchymal transition (EM T) (Hay, E. D., 2005). The term EM T 
describes a series o f events during which epithelial cells lose many o f their epithelial 
characteristics and take on properties that are typical o f mesenchymal cells. Epithelial 
and mesenchymal cells d iffer in various functions and phenotypic characteristics. 
Mesenchymal cells do not form an organised layer, nor do they have the same apical- 
basolateral organisation and polarisation o f the cell-surface molecules and the actin 
cytoskeleton as epithelial cells. They contact neighbouring cells only focally, and are 
not typically associated w ith a basal lamina. In culture, mesenchymal cells have a 
spindle shaped, fibroblast-like morphology, whereas epithelial cells grow as clusters o f 
cells that maintain complete cell-cell adhesion w ith their neighbours.
1.6.3.1 Mechanisms of EMT: Pathways and Regulation
Definition o f EMT
EMT was in itia lly  defined as a process during which epithelial cells: first, acquire a 
fibroblastoid, invasive phenotype; second downregulate epithelial-specific proteins 
(fo r example, tight- and adherens-junction proteins) and induce various mesenchymal 
proteins (for example, vimentin); and third, digest and migrate through the 
extracellular matrix (ECM) (Grunert, S. et al., 2003). These criteria for EM T processes 
have been ascribed to three major physiological and pathophysiologcal contexts, 
including embryonic development and morphogenesis, cancer progression and 
metastasis, and chronic degenerative, fibrotic disorders o f mature organs. Early 
embryonic events such as mesoderm formation during gastrulation, palate fusion and 
emigration o f neural-crest cells from the neural tube involve EMT, including 
transcriptional loss o f epithelial markers (E-cadherin) and induction o f vimentin (See 
section 1.6.3.2). Significantly, a sim ilar variety o f  epithelial-plasticity changes occur 
during pathological processes. It is increasingly appreciated that inflammatory 
mediators that are produced in response to in jury o f  epithelial cells, can trigger EMT, 
which can lead to fibrosis. For example, EM T is a major contributor to the 
pathogenesis o f renal fibrosis, as it leads to a substantial increase in the number o f
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myofibroblasts, leading to tubular atropy (Zeisberg, M. et al., 2003a). In addition, 
EMT can also contribute to lung fibrosis, chronic obstructive pulmonary disease and 
chronic asthma. The phenotypic changes observed in EM T events, are also reminiscent 
o f a progressive metastatic carcinomas, such as conversion from  a sessile to a 
migratory phenotype and proteolytic degradation o f the basement membrane (Thiery, 
J. P., 2002). Over the past ten years, EM T has gained recognition as a central 
mechanism for carcinoma progression and metastasis (See section 1.6.3.4).
Molecular mechanisms o f EMT
Early work on the regulation o f EM T focused on embryonic development. However, 
the observation that a polarised epithelial line, Madin-Darby canine kidney (M D C K ) 
cells, could be induced to scatter into individual, m igratory cells by incubation w ith  
conditioned medium from cultured fibroblasts, opened up new avenues for in vitro 
experimental investigations (Stoker, M. et al., 1985). The factor involved in this 
transition was designated scatter factor (SF) and was later identified as hepatocyte 
growth factor (HGF) (Nakamura, T. et al., 1989; Naldini, L. et al., 1991). Over the last 
twenty years, EM T has received much attention and many in vitro and in vivo model 
systems have been established to investigate the signalling mechanisms involved in its 
regulation. Accumulating evidence from these studies show that a common set o f 
molecular events occurs during the process o f EMT. Prim arily, the delocalisation and 
downregulation o f adherens junction proteins, such E-cadherin has become a 
widespread marker for the progression o f EM T and is associated w ith  the loss o f a 
polarised phenotype. Dramatic remodelling o f the actin cytoskeleton and upregulation 
o f mesenchymal proteins such as vimentin are also frequent events during EMT, which 
allows epithelial cells to become more migratory (Thiery, J. P., 2002). In addition, 
these systems have provided many insights into the molecular mechanisms governing 
EMT in both development and cancer progression and it has become clear that many 
parallels are being found between these two processes. In each model system, inducers 
o f  EM T signal via a specific set o f downstream effectors to e lic it the transition o f 
polarised epithelial cells to a mesenchymal phenotype (Figure 1.16). Many signalling 
proteins, including TGF-(3 fam ily members, receptor tyrosine kinases (RTKs), small 
GTPases, M AP kinases, integrins as w e ll as matrix-metalloproteinases and 
extracellular matrix components have been implicated in the regulation o f EM T
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(Thiery, J. P. et al., 2006). These studies also show that extensive crosstalk exists 
between the signalling pathways that activate and repress EM T, and that EM T- 
inducing signalling pathways have many common endpoints, including 
downregulation o f E-cadherin and expression o f EMT-associated genes. In contrast, 
however, developmental EM T events are regulated by a particular subset o f EM T 
activators and repressors. This is highlighted by the discrim inatory ability  o f  specific 
isoforms o f TGF-J3 to elicit developmental EM T in vivo. For example, TGF-|32 
regulates EM T in the atrioventricular canal, whereas TGF-|33 regulates EM T during 
palatal fusion (See section 1.6.3.2).
Epithelial plasticity is triggered by an interplay o f extracellular signals, 
including components o f the extracellular matrix (ECM), such as collagen and 
hyaluronic acid, as well as soluble growth factors such as members o f the TGF-(3 and 
fibroblast growth factor (FGF) families, epidermal growth factor (EGF) and SF/HGF 
(Thiery, J. P. et al., 2006) (Figure 1.16). Studies using in vitro models o f  EM T have 
revealed that these growth factors can induce alterations in epithelial plasticity termed 
* scattering’ or else a complete EM T, depending on the specific cell system analysed 
(Grunert, S. et al., 2003). The common denominator o f these processes is a 
morphological change to a spindle-like phenotype. Scattering occurs by exposure o f 
cells to growth factors or inducible oncogenes for 48 hours or less, which induces a 
fibroblastoid, migratory phenotype concomitant w ith  a loss o f epithelial polarity, 
characterised by a downregulation o f epithelial markers (M iettinen, P. J. et al., 1994; 
Piek, E. et al., 1999). However, these cells fa il to turn on mesechymal gene- 
expression programmes (Janda, E. et al., 2002). In contrast to scattering, fu ll EM T is 
completed only after 4-6 days o f exposure to several signals and occurs only in certain 
cell types. One critical difference is the persistence o f a mesenchymal phenotype, even 
after removal o f the inducing agent, which can be achieved through the induction o f an 
autocrine loop (Oft, M. et al., 1996). The differences observed in vitro can be 
explained by the observation that different signals can cause qualitatively different 
alterations o f epithelial plasticity in the same cell type (Janda, E. et al., 2002). 
Therefore, the precise spectrum o f changes that occur during EM T is probably 
determined by the integration o f extracellular signals the cell receives. Another critical 
parameter for inducing scattering or E M T  appears to be acute versus chronic signal 
exposure (Grunert, S. et al., 2003). Due to these differences observed, it has been
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Figure 1.16. Overview of the signalling networks that regulate E M T events
A) Schematic diagram of the cycle of events duing EMT. The different stages during which epithelial cells 
are transformed into mesenchymal cells is shown. For a complete EM T process to occur epithelial junction 
proteins are delocalised and donwregulated, resulting in a loss of epithelial polarity. In addition, mesenchy­
mal proteins are upregulated. A number of markers have been identified that are characteristic of either 
epithelial cells or mesenchymal cells, which are listed here.
B) Overview of the signalling pathways that are involved in the regualtion of EMT. ETaR, endothelin-A 
receptor; FAK, focal adhesion kinase; GSK3fJ, glycogen-synthase kinase-3fi; H/E(Spl), hairy/enhancer of 
split; ILK, integrin-linked kinase; MAPK, mitogen-activated protein kinase; NF-kB, nuclear factor-KB; 
PAR6, partitioning-defective protein-6; PI3K, phosphatidylinositol 3-kinase; PKB, protein kinase-B; ROS, 
reactive oxygen species; TAK1, TGF-ji-activated kinase-1; TGF|3R, TGF-0 receptor; WntR, Wnt receptor. 
(Adaptated from Thiery and Sleeman 2006).
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important to establish parameters to define a complete EM T. Several groups have 
established essential criteria for EM T, based on the molecular differences between 
mesenchymal cells and epithelial cells and molecular markers are now routinely used 
to characterise the epithelial plasticity observed in a given system (Janda, E. et al., 
2002) (Figure 1.16).
TGF-f$-induced EMT and Cooperation with other Signalling Pathways
TGF-p has been identified as an important molecular player o f  EM T both in vitro and 
in vivo. Tissue-culture studies have been instrumental in defin ing the molecular 
regulation o f TGF-(3-induced EM T and by this means, it was discovered that a central 
feature o f TGF-(3-induced EM T is the cooperation o f TGF-p fam ily  members w ith  
receptor tyrosine kinase (RTK)-driven signalling pathways. As previously discussed, 
TGF-P stimulation o f epithelial cells results in growth inhib ition. By employing R TK  
signalling pathways, cells overcome the growth inhibitory7 responses to TGF-P and the 
net result is the induction o f EMT.
In some cell systems, a synergistic cooperation between FI-Ras activation and 
TGF-P is required for induction o f a complete EM T (Gotzmann, J. et al., 2002; Janda, 
E. et al., 2002; Oft, M. et al., 1996). This mechanism has been explored in EpFI4 
mammary epithelial cells, which are non-tumourigenic and undergo growth inhib ition 
and apoptosis in response to TGF-p. Ras-transformed EpH4 (EpRas) cells s till exhibit 
an epithelial phenotype in the absence o f TGF-P, however, in contrast to EpFI4 cells, 
EpRas cells undergo EM T and invasive growth in 3-D collagen gels in the presence o f 
TGF-P (Oft, M. et al., 1996). These cells then continue to maintain a mesenchymal 
phenotype by producing TGF-P in an autocrine manner, characteristic o f  a complete 
EMT (Oft, M. et al., 1996). The participation o f  each specific signalling pathway 
activated by TGF-p and/or H-Ras to induce EM T has also been elucidated (Janda, E. et 
al., 2002). In this study, Beug and colleagues implicate the requirement o f M A P K  
activity for TGF-P-induced EMT, tumourigenesis and metastasis, whereas they show 
that Ras-induced PI3K activity promotes cell scattering and rescues cells from TGF-p- 
induced cell-cycle arrest and apoptosis (Janda, E. et al., 2002). S im ilarly, the 
cooperation between Ras and TG F-p signalling pathways are involved in
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hepatocarcinogenesis, where PI3K signalling is important in maintaining the 
fibroblastoid phenotype o f hepatocytes (Gotzmann, J. et al., 2002).
The synergism between Ras and TGF-P signalling has also been observed in 
models o f tumour progression. Tumour cell lines derived from  sequential stages o f 
mouse skin carcinogenesis, show elevated TGF-P signalling and an increase in 
mutated FI-Ras during progression to the metastatic phenotype, from squamous 
carcinoma cells to spindle-cell carcinomas (Buchmann, A. et al., 1991; Oft, M. et al., 
2002). In an elegant study by O ft and colleagues using this model, they showed that 
squamous carcinoma cells cannot undergo EM T by TGF-P alone, but require a 
cooperation between TGF-P signalling and FI-Ras, which m im ics the in vivo 
progression towards the spindle-cell carcinoma stage (Oft, M. et al., 2002). Activated 
Smad2 or Smad3, co-expressed w ith  H-ras induce upregulation o f mesenchymal 
markers such as vimentin and a-smooth muscle actin, whereas expression o f either 
Smad or FI-Ras alone, cannot induce a fu ll EMT. Here, it has been claimed that H-Ras 
induces nuclear accumulation o f  P-Smad2 and consequent upregulation o f 
transcription, whereas Smad2 is required for maintaining the mesenchymal phenotype 
(Oft, M. et al., 2002). Furthermore, it has been proposed that a high threshold o f  H-Ras 
activity is needed for PI(3)K activation, which is required for protection against TGF- 
p-induced apoptosis, a model which is consistent w ith the EpRas model (Janda, E. et 
al., 2002; Oft, M. et al., 2002). In addition, constitutive Raf signalling in an 
immortalized dog kidney epithelial line, M DCK cells, is able to induce EM T, leading 
to the establishment o f an autocrine TGF-p loop that promotes invasive behavior o f  the 
cells in collagen gels in vitro (Lehmann, K. et al., 2000). In this model strong 
activation o f Raf, and. consequently, the ERK M AP kinases, protects the cells from  the 
growth inhibitory and apoptotic effects o f TGF-p, while enhancing the invasive 
responses (Lehmann, K. et al., 2000). It is now essential to further analyse at which 
levels these two pathways cooperate to abrogate the classical functions o f TGF-P in 
growth arrest and induction o f apoptosis (See Chapter 5 and Chapter 6).
NF-k B, a transcriptional regulator o f  inflammatory and innate immune 
responses, has also been implicated in the progression o f EM T (Huber, M. A. et al., 
2004b). A  recent study using the EpRas EM T model, revealed the N F-k B signalling 
pathway as a modulator o f TGF-P-induced EM T (Huber, M. A. et al., 2004a). TGF-P
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stimulation leads to induction o f a functionally active N F-k B in EpRas cells, which is 
required in combination w ith oncogenic Ras fo r effic ient protection o f EpRas cells 
from TGF-|3 induced apoptosis (Huber, M. A. et al., 2004a). Interestingly, activation o f 
NF-k B activity by a constitutively active (ca) IK K -2 /p  mutant promoted EM T and 
induced a partial EMT-phenotype even in the absence o f TGF-p (Huber, M. A. et al., 
2004a). This observation suggests that N F-k B can partly substitute for the essential 
role o f  TGF-P in the collaboration w ith  Ras, leading to EMT. Also, inhib ition o f NF- 
k B activity reverses the TGF-P-induced EM T in mesenchymal cells, which suggests 
that N F-k B is essential for both induction and maintenance o f  EM T (Huber, M. A. et 
al., 2004b). TGF-p activates TGF-P-activated kinase 1(TAK1), which has been shown 
to induce NF-k B activation by phosphorylation o f the IK K  complex in response to 
TGF-p, thus providing a potential mechanism o f crosstalk between the two signalling 
pathways (Arsura, M. et al., 2003) (Figure 1.16). In addition, the Ras-activated PI3K- 
Akt/PKB pathway has also been implicated in NF-k B activation, suggesting the 
possibility o f crosstalk between all three pathways (Huber, M . A. et al., 2004b). 
Downstream targets o f N F-k B activation may include the transcription factors tw ist 
and snail, which are induced by N F-k B and act to repress E-cadherin expression 
(Bachelder, R. E. et al., 2005; Sosic, D. et al., 2003).
Accumulating evidence also implicates cooperative signalling between p- 
catenin/LEF and TGF-p during EM T (Eger, A. et al., 2004; Eger, A. et al., 2000; 
Liebner. S. et al., 2004; Nawshad, A. et al., 2003). p-catenin is an integral component 
o f E-cadherin-type adherens junctions in epithelial cells (Eger, A. et al., 2000). It also 
functions as a downstream effector o f the wnt/wingless signalling cascade and 
interacts w ith transcription factors o f the LEF/TCF fam ily , regulating gene expression 
and cell-fate decisions during embryonic development (Peifer, M. et al., 2000). 
Aberrant nuclear expression o f p-catenin is a frequent event during tumour 
progression, occurring through loss o f E-cadherin or mutations in p-catenin or APC 
(Bienz, M. et al., 2000). It was previously shown that long-term stimulation o f an 
inducible c-fos estrogen receptor (c-FosER) in mouse mammary epithelial cells 
induces EMT (Reichmann, E. et al., 1992), and this process was accompanied by a 
dramatic reduction in E-cadherin expression, resulting in p-catenin nuclear 
translocation and upregulation o f P-catenin/lymphoid enhancer binding factor-1
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(LEF1) transcriptional activity (Eger, A. et al., 2000). Further investigation revealed 
that autocrine production o f TGF-(3 is induced at late stages o f  EM T, which cooperates 
w ith  P-catenin to maintain an undifferentiated mesenchymal phenotype (Eger, A. et 
al., 2004). This cooperation was convincingly demonstrated by simultaneous inh ib ition 
o f both pathways, which reverted mesechymal FosER cells to a polarized epithelial 
phenotype, whereas inhibition o f a single pathway caused only partial rescue o f 
epithelial features (Eger, A. et al., 2004). In addition, TGF-P2 induction o f E M T o f 
endocardial cells in the developing heart is accompanied by activation o f  p-catenin 
activity in vivo (Liebner, S. et al., 2004). Indeed, targeted deletion o f P-catenin in 
endothelial cells severely impaired formation o f the heart cushion and A V  explants 
from p-catenin deficient mice failed to undergo TGF-p2-induced EM T in vitro 
(Liebner, S. et al., 2004). Insights into the molecular mechanism for the cooperation o f 
the P-catenin/LEF and TGF-P pathways were uncovered w ith  the demonstration that 
the Smad2, 3 and 4 can physically interact w ith members o f the LEF/TCF fam ily  o f 
HMG-box proteins to activate transcription o f LEF/TCF target genes (Labbe, E. et al., 
2000; Nishita, M. et al., 2000). Flowever, it has also been shown that TGF-p can 
activate LEF1/TCF target genes in the absence o f P-catenin. During palatogenesis, 
TGF-P stimulates Smad2/4-dependent induction o f  LEF1, a downstream target o f 
Wnt/p-catenin signalling independently o f P-catenin (Nawshad, A. et al., 2003). It was 
also demonstrated that while LEF1 and Smad4 were required for TGF-P-induced 
palatal EM T, P-catenin was not (Nawshad, A. et al., 2003).
Role o f the Smads
The role o f Smad3 and Smad4 in TGF-P-induced E M T was in itia lly  established in the 
mouse mammary epithelial line, N M uM G  cells (Piek, E. et al., 1999). Cells, infected 
with retroviruses expressing a combination o f  Smad3 and Smad4, together w ith a low 
dose o f caALK5, resulted in a d ifferentiation o f  these cells to a mesenchymal 
phenotype. The transdifferentiation was less w e ll pronounced when Smad3 was 
replaced w ith Smad2, suggesting a more prominent role for Smad3 in TGF-P-mediated 
EMT. Further investigations in this model system, eliminated a role for Smads o f the 
BMP branch in e liciting EM T, and implicated only the (Valcourt, U. et al., 2005). In 
addition to these in vitro studies, Smad3 null mice were employed in numerous studies
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to ascertain the role o f Smad3 in EM T and fibrosis in vivo (Saika, S. et al., 2004b; 
Saika, S. et al., 2004c; Sato, M. et al., 2003). In a model o f  renal fibrosis, in jury was 
induced by unilateral uretal obstruction (UUO), which led to the progression o f EM T 
w ild  type renal tubular cells, resulting in fibrosis o f  the kidney, which was absent in 
Smad3 null mice (Sato, M. et al., 2003). In this model, Smad3 induced upregulation o f  
Snail and a -S M A  and autocrine signalling o f TGF-(3, however these EM T associated 
events were abrogated in Smad3 null mice, indicating that the transition o f renal 
tubular epithelial cells to myofibroblasts is mediated by a Smad3-specific mechansim 
(Sato, M. et al., 2003). Similar results for the requirement o f  Smad3 were 
demonstrated in models o f EM T induced injury in the eye, including a lens in jury 
model and partial detachment o f  the retina to model proliferative vitreoretinopathy 
(PVR) (Saika, S. et al., 2004b; Saika, S. et al., 2004c).Consistent w ith  these 
observations, TGF-|3 fails to induce EM T in primary tubular epithelial cells derived 
form kidneys o f Smad3 knockout mice (Zavadil, J. et al., 2004).
In addition, hepatocytes isolated from liver-specific Smad3 knockout mice 
failed to undergo EM T, whereas the Smad2 knockout hepatocytes spontaneously 
transition to a mesenchymal phenotype in the absence o f TGF-P (Ju, W. et al., 2006). 
This suggests that Smad2 may function to maintain an epithelial phenotype, whereas 
Smad3 is required for induction o f EMT. However, although Smad3 appears to play a 
more prominent role in EM T than Smad2, this is not always the case. In squamous 
carcinoma cells, where TGF-p signalling in concert w ith  H-Ras activation, is required 
for a fu ll EMT, expression o f an activated form o f either Smad2 or Smad3 w ith  H-Ras 
was sufficient to induce a fu ll EM T (Oft, M. et al., 2002). A lso, Smad2 activity was 
convincingly shown to act downstream o f TGF-p, to enhance the invasive and 
metastatic properties o f spindle tumour cells (O ft, M. et al., 2002). In addition, Smad2 
mediates TGF-P induced EM T during palatal fusion (Cui, X. M. et al., 2003; 
Nawshad, A. et al., 2003). Formation o f  the secondary palate (palatogenesis) in Smad3 
null mice is unimpaired (Yang, X. et al., 1999), further supporting the role for Smad2 
in EM T during palatal fusion (Nawshad, A . et al., 2005).
Although Smad3 is often an essential component o f  the signalling pathway 
during EMT, a recent study revealed that the level o f  Smad3 is gradually 
downregulated during EM T in M D C K  cells (Nicolas, F. J. et al., 2003b). In this study, 
the Smad3 levels were decreased to low  levels but they never completely disappeared.
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The activation o f the Raf/ERK M A P K  pathway in these cells induces autocrine TGF-p 
production, which then synergises w ith  ER K/M A PK to induce EMT. By this means, 
M D C K cells are protected from the growth inhib itory and apoptotic effects o f  TGF-p 
(Lehmann, K. et al., 2000). Strong evidence supports an essential role for Smad3 in 
TGF-P-induced growth arrest, and it was demonstrated that the gradual loss o f  Smad3 
during EM T is sufficient for these cells to lose their ab ility  to undergo growth arrest in 
respone to TGF-p (Nicolas, F. J. et al., 2003b). Ectopic expression o f Smad3 restores 
the growth inhib itory response to TGF-p, however the cells do not revert to an 
epithelial phenotype. The loss o f Smad3 during EM T provides a mechanism by which 
cells overcome the growth inh ib itory responses to TGF-p, whereas the low  Smad3 
level is still sufficient to transduce the invasive effects o f TGF-p.
Critical roles for the inh ib itory Smads, Smad6 and Smad7 in EM T processes 
have also been suggested. Several studies have implicated Smad6 as a negative 
regulator o f EM T in the atrioventricular (A V ) cushion o f the developing heart 
(Desgrosellier, J. S. et al., 2005; Galvin, K. M. et al., 2000; Yamada, M. et al., 1999) 
(Figure 1.21). In support o f this, Smad6 mRNA exhibits a highly restrictive pattern, 
w ith  high levels expressed during endocardial EM T in both mouse and chick (Galvin, 
K. M. et al., 2000; Yamada, M. et al., 1999). Hyperplasia o f the cardiac valves in 
Smad6 null mice, due to excess mesenchymal cells, further supports an inh ib itory role 
for Smad6 in EM T in the developing heart (Galvin, K. M. et al., 2000). The type I 
receptor, A LK 2, is sufficient to induce EM T in the chick heart and it has been 
suggested that Smad6 may act to inhib it A LK 2 signalling, since Smad6 is a selective 
antagonist o f BMP signalling (Desgrosellier, J. S. et al., 2005; Hata, A. et al., 1998) 
(See section 1.6.3.2 and Figure 1.21). Indeed, overexpression o f Smad6 in A V  cushion 
chick explants resulted in decreased EMT, supporting a role for Smad6 as a negative 
regulator o f EM T (Desgrosellier, J. S. et al., 2005). In contrast, Smad7 acts specifically 
in Smad3 mediated EMT, as its overexpression consistently inhibits Smad3-dependent 
EM T progression (Zavadil, J. et al., 2005). For example, adenoviral infection o f 
NM uM G  cells w ith Smad7, abrogated the robust TGF-P-induced EM T in vitro 
(Valcourt, U. et al., 2005). In addition, injury-induced EM T o f lens epithelial cells 
(Saika, S. et al., 2004a) and UUO  model o f  EM T (Lan, H. Y. et al., 2003) were 
blocked in vivo by ectopic expression o f  Smad7, providing strong evidence for the 
inhibitory role o f Smad7 in Smad3-dependent EMT.
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The role o f Smad4 has been more d ifficu lt to define. Conflicting data suggest 
either a requirement for Smad4 or Smad4 independency during TGF-|3 mediated EM T 
in NM uM G  cells or Colo-357 cells, respectively (Deckers, M. et al., 2006; Levy, L. et 
al.. 2005). This contradiction may be explained by differences in cell type, w ith  
particular reference to the contributing signalling pathways fo r TGF-(3 induction o f 
EMT. In Colo-357 cells, TGF-p cooperates w ith K-Ras to e lic it a transition from an 
epithelial cell to a fibroblastoid phenotype, whereas N M uM G  cells signals through 
Smad-dependent and independent pathways, including PI3 kinase and p38-M APK, to 
achieve a mesenchymal state (Bakin, A. V. et al., 2002; Bakin, A. V. et al., 2000). 
These differences may underlie the controversial data obtained. In addition, it is 
important to note that the use o f N M uM G  cells as a model system for EM T is 
somewhat controversial. These cells exhibit an epithelial polarity but also express the 
mesenchymal marker vimentin. Furthermore, EMT is achieved w ith in  a short time 
frame o f approximately 36 hrs and after this time, the cells cease to proliferate but 
grow in size. Thus, requirement o f  EM T effectors in this system m ight d iffe r 
dramatically from other systems and as a result, observations in these cells should be 
confirmed elsewhere.
Smad Independent Signalling During EMT Pathways
Tight junctions help establish polarity in mammalian epithelia by form ing a physical 
barrier that separates apical and basolateral membranes. During EM T, tight junctions 
dissolve and their essential components are downregulated. A  recent study by Wrana 
and colleagues revealed a direct link between the components o f tight junctions and 
the TGF-p receptors. In N M uM G  cells, a major component o f  tight junctions, 
occludin, was found to bind directly to A LK 5 and promote its recruitment (Ozdamar, 
B. et al., 2005). In addition, a component o f  an epithelial polarity complex, Par6 was 
also identified as an interacting protein o f A L K 5 . Upon stimulation w ith TGF-p, Par6 
located in the occuldin-ALK5 complex, is phosphorylated on Ser345 by TpR II. This 
protein interaction is direct and independent o f  Smad proteins (Ozdamar, B. et al.,
2005). Interestingly, expression o f a Par6 mutant, which cannot be phosphorylated by 
the type II receptor, completely abrogated downregulation o f Zona-Occludins 1 (Z0-1), 
w ithout affecting Smad activation. This resulted in a partial progression o f TGF-p- 
induced EMT. Phosphorylation o f Par6 allows it to recruit Sm urf 1, which in turn
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mediates ubiquitination o f RhoA, a small GTPase fam ily  member involved in 
cytoskeletal reorganisation. This leads to local disassembly o f the actin cytoskeleton 
and dissolution o f tight junctions (Ozdamar, B. et al., 2005). Depletion o f  Sm urfl or 
use o f RhoA mutants lacking ubiquitination sites, inhibited the dovvnregulation o f  tight 
junction components. This work revealed not only a Smad-independent pathway, but 
also the first example o f a non-TGF-(3 receptor substrate for the type II receptor, which 
acts to alter a cell surface protein complex structure, independently o f  transcription.
Transcriptional Programmes o f  TGF-p in EMT
Expression pro filing  by microarray analysis has identified genes specifically regulated 
during TGF-P-induced EM T, including genes w ith  defined roles in cell proliferation, 
epithelial polarity, cell-matrix interaction, cell m otility  and survival (Jechlinger, M. et 
al., 2003; Xie, L. et al., 2003; Zavadil, J. et al., 2001). In addition, p ro filing  o f 
polysome-bound m RNA revealed that a substantial number o f these genes were 
regulated at the translational level including ILE I and Tenascin C (Jechlinger, M . et 
al., 2003; Waerner, T. et al., 2006). A  phlethora o f transcriptional regulators have also 
been identified as downstream targets o f TGF-P at the onset o f  EM T (Zavadil, J. et al.,
2005). Interestingly, it has been revealed that a major target o f  these transcription 
factors is the transcriptional repression o f the E-cadherin gene, which leads to a 
dovvnregulation o f  E-cadherin expression, a hallmark o f EM T (Thiery, J. P. et al.,
2006). This discovery has prompted extensive studies to define the role o f  these 
transcriptional repressors in EM T during embryonic development and during the 
acquisition o f invasive properties in epithelial cells.
E-cadherin, a homophilic Ca2+'dependent transmembrane adhesion protein, and 
and its associated catenins are among the major constituents o f  the epithelial cell 
junction system (Schock, F. et al., 2002). Epithelial-specific expression o f E-cadherin 
is governed by regulatory elements in the E-cadherin promoter, namely two E2 boxes 
(CACCTG) (Peinado, H. et al., 2004). Subsequently, it has been revealed that 
transcriptional repressors can downregulate E-cadherin by binding to proximal E- 
boxes, particularly in the E-pal element in the mouse promoter (Cano, A. et al., 2000). 
The first transcriptional repressor o f  E-cadherin to be identified was the zinc finger 
protein, Snail 1, whereby its stable expression led to the loss o f E-cadherin expression 
and induction o f EM T (Batlle, E. et al., 2000; Cano, A. et al., 2000). Snail repression
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o f E-cadherin was also observed during mesoderm formation in early embryonic 
development and in neural crest cells which undergo EM T (Carver, E. A. et al., 2001). 
In vertebrates, three members o f the Snail fam ily o f  zinc-finger transcription factors 
have been identified, Snail 1 (Snail), Snail2 (also known as Slug) and the most recent 
fam ily member, Snail3 (Barrallo-Gimeno, A. et al., 2005). Snail2 is also a strong 
repressor o f E-cadherin, however it binds w ith  a lower a ffin ity  than Snail 1 to the 
proximal E-boxes (Bolos, V. et al., 2003). Ectopic expression o f Snail2 results in 
repression o f E-cadherin and is sufficient to induce complete EM T in M D C K  cells 
(Bolos, V. et al., 2003; Hajra, K. M. et al., 2002). The central role o f  Snail 1 in EM T 
was highlighted by the complex regulation o f Snail 1 stability, subcellular localisation 
and function by the activity o f glycogen-synthase kinase-313 (GSK-3|3) (Zhou, B. P. et 
al., 2004). It was recently discovered that Snail is highly unstable, which is governed 
by dual phosphorylation events mediated by GSK-3[3. GSK-3(3 phosphorylates two 
serine residues on Snail 1, one which targets Snail 1 for ubiquitination and degradation, 
whereas the other promotes its nuclear export (Zhou, B. P. et al., 2004). Mutations in 
Snail 1 that prevent GSK-3|3 phosphorylation result in a stabilised form  o f Snail 1 that 
localizes in the nucleus and induces EMT. Thus, GSK-3(3 activity maintains the 
integrity o f adherens junctions and o f epithelial phenotype by inh ib ition o f Snail 1 
activity. Consistent w ith a role in EMT, Snail is expressed in high-grade human breast 
carcinoma tissues and also in lymph-node-positive tumours (Blanco, M. J. et al., 
2002). Moreover, an inverse correlation has been shown between E-cadherin and Snail 
levels in breast carcinoma and oral squamous-cell carcinoma (Blanco, M. J. et al., 
2002; Yokoyama, K. et al., 2001).
TGF-p has also been shown to regulate Snail, by inducing expression o f  Snail 
in epithelial cells (Peinado, H. et al., 2003). This induction was abrogated using the 
MEK1/2 inhib itor suggesting that it requires M EK1/2 activity. However, expression o f 
a dominant negative Smad4 mutant had no effect, and it was proposed that the effects 
o f TGF-p on Snail reporter are Smad4-independent. The dominant negative Smad4 
mutant was been found to be highly unstable compared w ith  w ild  type Smad4 and as 
such, its use is not representative o f inactivating Smad4 signalling (Maurice, D. et al.,
2001). It has also been shown that TGF-P synergistically cooperates w ith  either FGF 
or H-Ras to induce Snail 1 transcription and use o f the well characterised Ras mutants, 
which selectively signal along either the M A P K  pathway, the PI3K pathway or the
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Ral-GDP pathway, revealed that both M A P K  and PI3K pathways are required for the 
H-Ras /TGF-p mediated induction o f the Snail promoter (Peinado, H. et al., 2003). 
Futhermore, TGF-P activation o f Snail 1 and Snail2 in primary mouse kidney epithelial 
cells was found to be mediated via Smad3, since Smad3 null cells are unable to induce 
transcription o f  either Snail genes (Zavadil, J. et al., 2004). This evidence strongly 
argues in favour o f Smad3 requirement for Snail induction. In addition, different 
members o f the Snail fam ily members can be regulated by different TGF-p isoforms, 
for example, TGF-P3 regulates transcription o f Snail 1 during EM T o f palate fusion 
(Martinez-Alvarez, C. et al., 2004), whereas TGF-P2 induces Snail2 expression in 
endocardial cells to initiate cushion formation during heart development (Romano, L. 
A. et al., 2000). Snail 1 and Snail2 have been shown to be key components in in itia ting 
EM T o f the neural crest cells, however the inductive signals for expression, vary for 
different species (Tucker, R. P., 2004). In chick, BMP signalling is crucial for Snail2 
expression and inhib ition o f BMP activity by implanting noggin by the neural folds in 
vivo or in vitro abolishes Snail2 expression (Selleck, M. A. et al., 1998).
Increasing investigation into the mechanisms that repress E-cadherin has 
uncovered numerous transcription factors that function sim ilarly to the Snail fam ily 
such as the prototypical vertebrate members o f the two-handed zinc 
finger/homeodomain protein fam ily, ZEB-1 (6EF1) and ZEB-2 (SIP 1) (Com ijn, J. et 
al., 2001; Eger, A. et al., 2005) (Figure 1.17). ZEB-2 was orig ina lly identified as a 
Smad interacting, binding to the MH2 domain o f Smadl and has subsequently been 
found to interact w ith Smad2, Smad3 and Smad5, although the significance o f this is 
not clear (Verschueren, K. et al., 1999). ZEB-2 can be induced by TGF-p and its stable 
expression in M D C K cells significantly downregulates E-cadherin, resulting in loss o f 
cell-cell adhesion, activation o f invasion and m igration (Com ijn, J. et al., 2001). 
Similarly, ZEB-1 has been shown to interact w ith  the E-cadherin promoter and its 
expression in mammary epithelial cells causes these cells to undergo EM T resulting in 
an invasive phenotype (Comijn, J. et al., 2001; Eger, A. et al., 2005). A  more recent 
finding has revealed that Twist, the basic Helix-Loop-FIe lix (bHLH) transcription 
factor that is important in developmental events, is also involved in the downregulation 
o f E-cadherin (Yang, J. et al., 2004). Ectopic expression o f Tw ist in M D C K  cells 
causes transcriptional repression o f E-cadherin, a -, p- and y- catenins, and expression 
o f mesenchymal markers including fibronectin, vimentin, smooth muscle actin and N-
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Figure 1.17. Mediators of TGF-P signalling during EM T
TGF-p signals via Smad-dependent and Smad-independent mechansims to elicit downstream responses which mediate.
A)TGF-P signalling via Smad2/3 complexes with Smad4 leads to activation of multiple transcription factors which function by repressing of the E-cadherin promoter. Downregula- 
tion of E-cadherin results in loss of E-cadherin-dependent intercellular epithelial junctional complexes, and E-cadherin-mediated sequestering of P-catenin in the cyoplasm is 
abolished. As a result, p-catenin localises to the nucleus and feeds into the Wnt signalling pathway by activating transcriptional regulation through LEF1/TCF4.
B) TGF-p induces the recruitment of TpRII to the preexisting ALK5-Occludin-Par6 Complex.TpRII phosphorylates Par6, which then binds to Smurfl. Smurf ubiquitinates RhoA, 
which is degraded in the proteasome. Subsequent loss of the actin network leads to the disassembly of tight junctions, possibly followed by adherens junction dissolution. However, 
adherens junction disintegration likely occurs through a Smad-dependent pathway after transcriptional repression of the E-cadherin gene. (Adapted from Thiery and Huang, 2005).
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cadherin(Yang, J. et al., 2004). This is consistent w ith  studies indicating that N F-kB, 
which can act cooperatively w ith TGF-P to induce EM T, can activate expression o f 
Twist (Sosic, D. et al., 2003)(Figure 1.17). In addition, Tw ist has been implicated in 
TGF-p3-induced EM T during palatal fusion (el Ghouzzi, V. et al., 1997).
The inhibitors o f DN A binding (Id) proteins have also been demonstrated to 
play a role in the progression o f TGF-|3-induced EMT. Id proteins function by 
inhibiting members o f the Ets proteins fam ily and retinoblastoma, which results in 
inhibition o f differentiation and proliferation (Perk, J. et al., 2005). Using microarray 
analysis in mouse mammary epithelial cells, the Id proteins were identified as a 
common target o f TGF-|3 and BMP7 pathways, w ith  opposing effects (Kowanetz, M. 
et al., 2004). Whereas BMP7 induces robust expression o f Id proteins, TGF-|3 
stimulation results in their dovvnregulation (Kowanetz, M. et al., 2004). It was 
subsequently shown that reduction o f Id2 expression is required for cells to undergo 
TGF-|3-induced EMT. Overexpression o f Id2 prevented a TGF-|3 induced EM T 
response in mammary and lens epithelial cells, and consistently, depletion o f the 
protein led to an enhanced response by TGF-p and even sensitised the cells to 
induction o f EM T by BMP7 (Kowanetz, M. et al., 2004). These data suggest that a low  
level o f Id2 expression is critical during EMT progression (Kowanetz, M. et al., 2004; 
Xie, L. et al., 2003) and upregulation o f Id2 interferes w ith  this process. As BMP-7 
stimulates the synthesis o f Id2, this may explain the antagonistic role o f BMP7 in 
TGF-p-induced EM T in a model o f renal in jury (Zeisberg, M. et al., 2003b). The 
molecular mechanism by which Id2 elicits its biological effect has been elucidated, 
and involves repression o f the E-cadherin promoter (Kondo, M. et al., 2004). The 
transcriptional mediator and Id2 interacting proteins E12/E47, have previously been 
demonstrated to repress E-cadherin (Perez-Moreno, M. A. et al., 2001) (Figure 1.17). 
Therefore a decrease in Id2 levels is required for E12/E47 bHLH transcriptional 
factors to be able to bind to the E-cadherin promoter and e lic it repression (Kondo, M. 
et al., 2004), resulting in a downregulation o f  adherens junctions and progression o f 
EMT.
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1.6.3.2 The role of TGF-/3 superfamily members in EMT throughout 
Development
KMT is a fundamental process during embryonic development. The formation o f 
mesenchymal cells from a prim itive epithelium is an essential feature o f most 
metazoans. Structural epithelial units disaggregate and during this transition, 
mesenchymal cells exhibit a morphology, which allows them to migrate in an 
extracellular environment to areas involved in organ formation. During embryonic 
development, these transitions are highly coordinated in a spatial and temporal 
manner, resulting in a synchronised process. Events such as gastrulation, neural crest 
cell formation, heart valve formation, somite differentiation, M ullerian duct regression 
and palate fusion rely upon the formation o f mesechymal cells from an epithelial sheet 
(Thiery, J. P., 2003). In the absence o f EMT, development cannot proceed past the 
blastula stage. Eventually these mesenchymal cells may regain a fu lly  differentiated 
epithelial phenotype via a mesenchyme-to-epithelium transition (M ET) and thus 
participate in the formation o f epithelial organs (Thiery, J. P., 2003). M ET occurs 
during somitogenesis, kidney development, and coelomic-cavity formation (Thiery, J. 
P. et al., 2006). Individual developmental EM T events are governed by different 
strategies and are species-dependent. Members o f  the TGF-P superfamily have been 
implicated in many developmental EM T processes such as gastrulation, heart valve 
formation, Mullerian duct regression and palate formation.
The aberrant signalling mediating EM T during tumourigenesis is in sharp 
contrast to the tightly controlled signalling mechanisms governing EM T events in 
development. A  focus o f my thesis is the role o f TGF-P in EM T during tumorigenesis. 
However, it is also important to understand the integration o f TGF-p and other 
pathways in naturally occurring EMT. This is like ly to shed light on the main players 
involved in EMT events during tumour progression. To this end, I discuss three EM T 
ev ents in development and the role o f TGF-p superfamily members in these processes.
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FA IT during Palate Fusion
I he lorm ation ot the secondary palate (palatogenesis) in mammals involves the 
orchestration o f  several processes to produce the correct separation o f  the oral and 
nasal cavities. It is a complex process, invo lv ing  fine-tuned interactions between the 
epithelial and meseneymal cells (Nawshad. A. et al.. 2004). fa ilu re  o f palatogenesis 
results in cle ft palate, one o f the most common birth defects in humans (Ferguson, M. 
\V., 1988). During mammalian development, bilateral palatal shelves arise from the 
m axillary process and grow vertically down the sides o f  the tongue. The palatal 
shelves elevate rapidly into a horizontal position above the tongue, adhere in the 
m idline, fo llowed by fusion o f  the paired shelves ( f  igure 1.18). A critica l step in 
mammalian palatal fusion is the removal o f  the tip  o f  the prefusion palatal shelves, the 
medial edge epithelial (MHH) cells, from the m id line seam and formation o f 
continuous mesenchyme ( fig u re  1.18). The cellular mechanisms underlying seam 
degeneration and the fate o f the M id i seam cells have been a major focus o f 
investigation for more than a decade, yet s till, controversies remain on this issue, 
fhree major models have been postulated to explain the m idline epithelial seam 
degeneration: epithelial-mesenchymal transdifferentation (Nawshad. A. et al.. 2004; 
Shuler. (A F. et al.. 1002); M FF cell apoptosis (Cuervo. R. et al.. 2004; Cuervo. R. et 
al.. 2002); and lateral m igration o f M id i cells (Carette. M. J. et al.. 1002). Recently. 
how e\er. a comprehensive stud) was performed to assess the contribution o f each 
mechanism to palatal fusion (Jin. J. X. et al.. 2006). To assess the fate o f  the MHF 
cells, a Cre lox labelling system was employed to genetically mark keratin-14- 
expressing palatal epithelial cells, which allowed the investigaters to fo llow  their fate 
during palatal fusion in vivo. S trik ing ly, a significant number o f mesenchymal cells 
stained positively for |S-Gal during and after palate fusion, revealing conclusive 
evidence for the occurrence o f HM T during palate fusion (Jin. J. Z. et al.. 2006). In 
addition, a non-essential role for apoptosis was demonstrated, whereby palatal fusion 
was unimpaired in vivo using Ajuifl mutant mouse embryos that cannot activate 
Caspase 3. a key effector easpase (Jin. J. /.. et al.. 2006).
l he first ev idence to rev eal an essential role o f  TGF-|3 in palatal dev elopment 
was the observ ation o f c left palate formation in TCil -(43 null mice (kaartinen, V. et al.. 
1095; Proet/el. G. et al.. 1095). Cnlike other null mutants w ith  cleft palate. TGF-|33 
null mice did not exhibit other concomitant craniofacial abnormalities. C left palate can
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Figure 1.18. Diagrams of palate development in the mouse
The development of the mammalian secondary palate involves multiple steps.The anterior palate 
(shown) o f the mouse fuses with the nasal septum (ns), but the posterior palate does not, because there 
is no nasal septum posteriorly.
(A ) Between 13 and 14 dpc, the palatal shelves grow out from the inner face of the maxillary processes 
and move across the roof of the mouth.
(B) Sloughing of the outer epithelial layer promotes adherence of the basal epithelial cells that form the 
midline palatal seam.
(C) The medial edge epithelia that form the seam then undergo EM T (arrowheads, B and C) between 
15 and 17 dpc. This results in connective tissue confluence and fusion of the palate shelves with the 
nasal septum. The dark cells (arrowheads) show diagramatically the relative contribution to 
mesenchyme made by these epithelial seams. (Taken from Hay, E., 2003).
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occur at several stages during palatal development, but the mechanism underlying this 
detect in the I Ci 1 -(>3 null mouse is a failure o f  palatal shelf fusion ( l ava. V. et al..
1 9 9 9 ) .  Indeed, addition o f exogenous TCiI;-(}3 in an in vitro organ culture system 
rescued the defective palatal fusion in TGF-p3 null mutant mice, supporting an 
essential role tor I ( i l - p 3  in palatal shelf fusion (Brunet. C\ T. et al., 1995; l ava. Y. et 
al.. 1 9 6 9 ) .  Interestingly, other isoforms o f TG F-p could not induce normal palatal 
fusion ( la v a . Y. et al.. 1999). suggesting that this process discriminates between 
isoforms o f  IC j I -(Y In addition, inh ib ition o f  normal IC i I -|33 activ ity either by 
antisense oligonucleotide or neutralising antibody, resulted in a failure o f palate fusion 
in vitro (Brunet. C\ I., et al.. 1995). The spatial and temporal expression o f TGF-p3 is 
consistent w ith  its role in mediating palatal fusion, as it is abundantly expressed in the 
tips o f  prefusion palatal shelv es, the medial edge epithelium.
I CiT-|>3 serves several functions in seam degeneration during palatal fusion, 
includ ing in itia ting  cell adhesion (Ciato. A. et al.. 2002; Sun. I), et al.. 1998). inducing 
I M I (kaartinen. V. et al.. 1997; Sun. I), et al.. 1998). and by this means promoting 
basement membrane and cell m atrix degeneration (B lavier. I., et al.. 2001 ). Although 
the rede o f ! CiT- (>3 in F M T  during palatal fusion has been w ell documented, the 
downstream events remain somewhat elusive. Investigation o f the TG F-p receptors 
involved in this process, revealed that AI.K.1. -2 and -5 are all endogenously expressed 
in the palatal epithelium  (Hildas. M. et al.. 2004). In vitro analysis further 
demonstrated that constitu tive!)- active (ea) AI.K.5 could rescue the failed induction o f 
palatal fusion o f  /(/7--/>a null palatal shelves (Oudas. M. et al.. 2004). eaAI.K.2 could 
also rescue the TGF-p3 deficient fusion although less e ffic ien tly  than A I.K 5 . but 
A l . k l .  although highly homologous to A I.K 2 . could not. In addition, incubation w ith 
the specific AI.K.5 inh ib itor. SB-4151542 (Inman, ( i. J. et al.. 2002b). prevented 
mesenchv mal confluence in the anterior palate (I)udas. M. et al.. 2006). Moreover, 
specific deletion o f AI.K.5 in the ectodermal epithelial and neural crest lineages, 
resulted in impaired palatal fusion ( Dudas. M. et al.. 2006), further supporting a role 
for A I.K 5  in 1 (>1 -p5-induced palatal KM I (Dudas, M. et al.. 2006; Hildas. M. et al.. 
2004). In contrast, however, these palatal defects observed in A I.K 5  conditional 
knockouts are not present in corresponding T pR II knockout mice, arguing against a 
role for this type II receptor and furthermore, for TG F-p in this process, as TGF-p3
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binding to alternative type 11 receptors has not. as yet. been described (Ito. V. et al.. 
2003; Xu. X. et al.. 2006). However, as AI.K.5 mutant mice have far more severe facial 
phenotypes than T|5RII. it has been proposed that another type II receptor, other than 
the conventional T|5RII may function to transduce the T G I;-|33 signal during palatal 
fusion (I)udas. M. et al.. 2006). hvidence was provided to show that A I.K 5  can 
interact w ith  A ctR II. the dual specificity type II receptor for BMP and A ctiv in . using a 
heterodimerisation model system. However, as previous data suggests that this is not 
the ease, a more detailed investigation in vivo is required to confirm  this hypothesis 
( Dudas. M. et al.. 2006).
A ctiva tion  o f A I.K 5  results in the phosphorylation o f  Smad2 and or 3. Smad2 
null cells die during or immediately after gastrulation. prev enting the use o f these mice 
in palatal studies (Nomura. M. et al.. 1998). However, palate form ation is unimpaired 
in the Smad3 null mice (I)atto. M. B. et al.. 1999; Vang. X. et al.. 1999; Zhu. V. et al.. 
1998). suggesting that the role o f Smad3 in palatogenesis. i f  any. is redundant and that 
it can be functionally compensated by Smad2. Indeed. Smad2 signalling has been 
im plicated in the process o f  T ( i l ;-|i3-induced K M T during palate fusion (Dudas. M. et 
al.. 2004; Nawshad. A. et al.. 2003). Immunohistochemical data demonstrate that in 
vivo P-Smad2 activation is abolished in T ( i l ’-|33 null palate shelves, whereas P- 
Smadl 5 8 is unaffected (Dudas. M. et al.. 2004). fu rtherm ore. Smad2 4 signalling has 
been im plicated in up-regulation o f the I.fF -1  gene during palatal KM T (Nawshad. A. 
et al.. 2003). but the fu ll details o f  this mechanism remain to be established. It is 
noteworthy that the role o f  Smad2 v ersus Smad3 is complicated by the existence o f an 
alternative splice variant o f  Smad2. Smad2Ae\on3. which has D N A  binding ab ility  
(Shi. Y. et al.. 1997) and the fact that Smad3 can functiona lly compsenate tor Smad2 
loss (Dunn. N. R. et al.. 2004).
Downstream effectors o f the pathway are being uncovered, including the 
transcriptional repressor. Snail, which is involved in triggering the MKK cells to 
undergo KM T in mouse ( M artine/.-Alvarez. ( '. el al.. 2004). It has been proposed that 
Snail 1 confers the MKK cells, resistance to cell death thus enabling them to 
differentiate. Snail 1 expression is detected at the time o f fusion in a subset o f  cells, 
which correlates w ith  low K-cadherin staining, suggesting it is involved in TCiP-|33 
mediated KM T o f M id : cells. Interestingly. Snail2 is the Snail fam ily  member 
expressed in the chick MKK. prov id ing another example o f the interchange o f  Snail 1
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and Snail2 expression between avian and mammalian embryos (M artinez-A lvarez. C. 
et al.. 2004). f in a lly . the basic H e lix-Foop-H e lix  ( b ll l .H )  transcription factor. Tw ist, 
has also been implicated in palatogenesis. M utations o f  the gene are associated w ith  an 
autosomal-dominant craniosynostosis (Saethre-Chotzen syndrome) characterised by 
c le ft palate, and may contribute to the inh ib ition  o f palatal KM T (el (ihouzzi. V. et al.. 
1007).
S eu ra l Crest Formation
In addition to the role o f TG F-p in FM T. other members o f  the superfam ily have also 
been im plicated in TM T. During the neural crest. BM P signalling is important to 
mediate this F M T  event as discussed below.
The neural crest is a unique and highly specialised population o f  cells found in 
all vertebrate embryos. The appearance o f this tissue was like ly a turning point in 
vertebrate evolution, since many o f the structures which define the vertebrates are 
derived from neural crest cells (Meulemans. D. et al.. 2004). During embryogenesis. 
the neural crest develops at the border between the neural plate and embryonic 
ectoderm and once specified the neural crest cells undergo an FM T. which confers on 
them the ab ility  to migrate (Figure 1.19). When the F M T  is complete, the neural crest 
cells delaminate from the neural folds dorsal neural tube and migrate along 
characteristic pathways to differentiate into a w ide variety o f  derivatives including 
bone, smooth muscle, peripheral neurons and glia, and melanocytes ( fucker. R. P.. 
2004).
Most o f  the studies on the signalling pathways governing neural crest induction 
and subsequent F M T  have been performed using Xenopus and avian embryological 
models. As a result, analysis o f  neural crest gene-regulatory relationships have largely 
been restricted to gain- or loss-of-lunction studies using injected m RNA. cD N A, or 
antisense oligonucleotides, llie ra rch ia l relationship o f these genes have not been lu ll)  
elucidated, however most o f  the main players in the pathway have been identified 
(Meulemans. 1). et al.. 2004). Though different species seem to use d ilterent 
combinations o f  factors, members o f the W’nt and fibroblast growth factor (FGF) 
fam ilies are frequently implicated as working together w ith  BMP to drive neural crest 
induction (Tucker. R. P.. 2004). The spatial and temporal integration o f these signals, 
which originate from the non-neural ectoderm, the neural plate and or the paraxial
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Figure!.19. Neural Crest Cell Formation
A) Schematic diagram of the developmental events during neural induction. The central nervous system 
forms during the process of neuralation, as the neural plate bends and folds into the neural tube. Presump­
tive neural crest cells are initally localised at the edges of the neural plate at its border with the non-neural 
ectoderm. During the folding process, neural crest precursors are contained within the neural folds and 
subsequently localised within the dorsal portion of the neural tube when closure is complete. Shortly there­
after, these cells undergo an EMT, delaminate from the neuroepithelium, and migrate away from the neural 
tube to various embryonic sites.
(Taken from http://www.med.umich.edU/lrc/coursepages/M l/embryology/embryo/08nervoussystem.htm)
B) Schematic summary o f signalling events at the neural plate border during neural crest induction using 
data from several organsims. (Adapted from Meulemans and Bronner-Fraser, 2004).
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mesoderm, is crucial during induction, delam ination, m igration and d ifferentiation o f 
the neural crest cells (Morales, A. V. et al.. 2005). BM P expression is tigh tly  regulated 
so that a gradient ot BMP4 activ ity is established along the dorsal neural tube by a 
reciprocal gradient o f  expression o f its inh ib ito r noggin, resulting in high levels 
expressed in the ectoderm and low BMP expression found in the neural plate itse lf 
( f ig u re  1.10). Also, both Wnt and 1 Ci 1 pathways have been proposed to act as signal 
inducers in the paraxial mesoderm (Bang. A. ( i. et al.. 1007; Monsoro-Burq. A. H. et 
al.. 2003). These inductive signals in itiate a transcriptional programme that includes 
the expression o f neural plate 'border specifiers' (Z ic. Pax3 7. Dl.\5 and N lsxl 2) 
(Meulemans. I), et al.. 2004) (fig u re  1.10). Once specified at the neural plate border, 
intermediate levels o f  BMP activate high-level expression o f  "neural crest specifiers" 
such as Snail. Slug. Ap-2. SoxO and Fo.xD3 (Morales, A. V. et al.. 2005). fxpression 
o f  this set o f  transcriptional activators, equips the neural crest cells w ith  the 
transcriptional machinery required to initiate the process o f TM T. It has been 
demonstrated in the chick that BMP expression is absolutely required for neural 
induction, however, in Xcnopus and zchrafish, BM P activ ity  is not sufficient to induce 
neural crest cells suggesting a more prom inant role for Wnt and I CiI in these 
organisms (I)elaune. f .  et al.. 2005; Linker. (A et al., 2004). These differences may lie 
in the absolute requirement for BMP2 signalling in the chick for Snail2 
expression) Meulemans. I), et al.. 2004).
O f these neural crest specifier genes, the two related transcription factors. 
Snail 1 and Snail2 are crucial components in regulating neural crest TM T. however, the 
fam ily  member which triggers this process depends on the species examined. In 
Xcnopus and mouse. Snail is expressed just before Slug in neural crest cell precursors, 
and gain and loss-of-function studies in Xcnopus show that Snail initiates a cascade ot 
expression o f many neural crest cell markers includ ing Slug (Aybar. M. .1. et al.. 2003). 
In contrast, in the chick Snail2 expression precedes Snail (Selton. M. et al.. 1008). and 
was first shown to initiate T M T  o f the chick neural crest in functional interference 
studies. Incubation o f earl\ chick blastomeres w ith  antisense oligonucleotides to 
Snail2. inhib ited neural crest delamination from  the neural tube (N ieto. M. A. et al.. 
1004). Subsequently, defects in crest m igration and lack o f  specific derivatives were 
demonstrated in the neural crest o f  Xcnopus embryos after inh ib ition  o f Snail2 
function (N ieto. M. A.. 2002). Overexpression o f  Snail2 in Xcnopus resulted in
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Figure 1.20. Overview of the Neural Crest Genetic network.
The steps represented in the Figure run from the induction of dorsal properties to the neural plate/neural 
tube up to the completion o f the EM T prior to delamination. Multiple factors signal in a coodinated 
fashion to trigger the induction of “neural crest specifiers", which leads to the acquisition of the properties 
o f the neural crest cells. Neural crest cells require an integrated network of interactions among factors 
with differential coordinated functions to achieve their specific fate. The arrows indicate the flow of the 
pathway, not the direct transcriptional regulation. The different players are shown in light green and their 
effects are shown in turquoise. (Taken from Morales et al., 2005).
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increased levels ol RhoB. concomitant w ith  an increase o f  neural crest production, 
h igh ligh ting  their role in neural cell induction and a possible mechanism to e lic it HMT 
events (del Barrio. M. ( i. et al.. 2002) ( fig u re  1.10). In addition, a tight regulation o f 
eadherin expression by Snail fam ily members is fundamental for the emigration o f the 
neural-crest cells (N ieto. M. A.. 2002). Another candidate for regulating neural crest 
HM T is the w inged-helix transcription factor I o.xI)3. since its misexpression in the 
chick leads to the ectopic appearance o f cells w ith in  the neural tube that are positive 
for the neural crest cell marker I1NK.-1 (I)o tto ri. M. et al.. 2001) ( fig u re  1.20).
More recently, the cell cycle was found to play a pivotal role in HM T o f neural 
crest cells. The HM T process involves a profound reorganization o f  the cytoskeleton 
and induction o f a transcriptional programme, which may not be compatible w ith  a 
high pro life ra tion rate. Indeed, it was recently shown that in cultured cells. Snail 1 
blocks the cell cycle, specifically the 01 S transition, by maintaining low levels o f 
cyc lin  I) and high levels o f  p21 (Vega. S. et al.. 2004). W ith respect to the neural crest, 
cell p ro life ra tion is very low in Snail-expressing cells (Snail 1 in the mouse and Snail2 
in the chick, undergoing HM T). which in turn express very low levels o f  Cyclins 1)1 
and 1)2 (Morales. A. V. et al.. 2005). However, it has also been shown that transition 
from 01 to S is necessary for the epithelia l to mesenchymal conversion o f 
prem igratory neural crest cells ( Burst) n-Cohen. I . et al.. 2002). It was demonstrated 
that trunk level avian neural crest cells synchronously emigrate in the S-phase o f  the 
cell cycle. Specific inh ib ition  w ith  O l S blockers in explants and in ovo. but not w ith  S 
or 0 2  blockers, prevents mesenchymalization o f  prem igratory neural crest cells 
( Burst) n-Oohen. I . et al.. 2002). This suggests that synchronization o f  the neural crest 
cells in O l may occur during HM T. however progression to S-phase is required for the 
fu ll acquisition o f m igrator) properties o f these cells, \ lo re o \e r, BMP signalling 
driv es the onset o f  neural crest m igration in the trunk neural tube though the control o f 
O l S transition, which is controlled upstream by Wnt signalling ( Burst) n-C'ohen. I . et 
al.. 2004).
The programme o f  HM T during neural crest form ation is a h ighly integrated, 
complex interplay o f genes in a coordinated manner. A lthough man) effectors o f HMT 
have been identified, the precise spatio-temporal expression and activ ity  o f  all o f  these 
factors and the complex pattern o f interactions and crossregulations requires further 
investigations. In addition, despite the plethora o f  growth factors and transcription
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factors identified, none o f  these genes have proven to be the master regulator o f HM T 
and important regulator) mechanisms remain to be discovered.
Regulation o f  EM T in the development o f  the heart
A classical example ot developmental!) regulated HM T occurs during the in itia l stages 
o f  cardiac morphogenesis. A t embryonic day 8.5 (H8.5). the mouse heart tube is 
composed ol an outer myocardial layer lined by a monolayer o f specialised 
endothelium, the endocardium, separated by a th ick extracellular m atrix, the cardiac 
je lly  ( fig u re  1.21). In response to regionalized myocardial signals, a subset o f  
endocardial cells that overlies the atrio-v entricular (A V ) canal and out( Azhar. M. et al..
2003)flovv tract regions undergoes H. These cells delaminate from the endocardial 
sheet and invade the cardiac je lly  to form  the endocardial cushions, which w ill 
contribute to cardiac valve development and heart septation. However adjacent 
endothelial cells in the atrium and ventricle remain epithelial (Azhar. M. et al.. 2003). 
The localised nature o f the HMT suggests a mechanism to molecularlv distinguish the 
myocardium and or endocardium o f  the A Y  canal from  the rest o f  the non-cushion- 
form ing heart. The signals that induce HM T have been investigated in chick embryos 
using a 3-1) collagen gel assay (Runyan. R. B. et al.. 1983). Data from these co-culture 
experiments show that signals from both the adjacent myocardium and from the 
extracellular m atrix o f the cardiac je ll) play a critica l role in the endocardial cell HMT 
(Hisenberg. H. M. et al.. 1995) ( fig u re  1.21). In addition, these studies revealed that 
f ( i f - |3 2  and 1 Ci 1 -|33 perform crucial and sequential functions in cushion 
morphogenesis. 1 C if-{32 is thought to mediate the activ ation o f the endocardium, while 
I ( if - |)3  functions in mesenchymal invasion o f  the cardiac je lly  (Boyer, A. S. et al., 
1 9 9 9 ;  Brown. (A B. et al.. 1 9 9 6 ;  C'amenisch. T. I), et al.. 2002). It is noteworthy that 
f ( i f - | J l  n iR N A is absent in the developing chick heart.
f  urther studies using neutralising antibodies in the chick explant model have 
suggested that the prototypical TGI j )  receptor. AI.K.5. is not involved in the cushion 
HM T. whereas inh ib ition  o f AI.K.2 prevents transdifferentiaion (Lai, V. T. et al.,
2000). Subsequently it was shown that constitu tive!) active ALK.2 is sufficient to 
stimulate HM T ( Desgrosellier. J. S. et al.. 2005). The type III TGF-|3 receptor 
(betaglean) has also been shown to play a critica l role in endocardial HM T as 
antibodies against the receptor were found to inh ib t HM T and m igration in A V  cushion
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A) Schematic representation of the atrioventricular (AV) canal during heart development. 
(Adapted from Azhar et al., 2003).
B) Summary of the signalling pathways that function in the AV canal in mouse.
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explants (Brown. C. 1C et al.. 1999). Ihe type III TGF-|3 receptor has been reported to 
present ligand to the T|3R-T|3RII signalling complex and is essential for the high 
a ffin ity  binding o f  TG F-^2 by the T|3R-T|3RII complex (Lopez-Casillas, F. et al.. 
1994; Hope/.-Casillas. F. et al.. 1993). It has been postulated that the type III IGF-|3 
receptor signals in response to I'GF-|32 and its restricted pattern o f expression in 
endocardial cells overlying the A Y  cushion and on m igrating meseehymal cells, may 
function to localise the response (Brown. C. B. et al.. 1999). The downstream 
mediators involved in chick endocardial HM T tire as yet undetermined, however Slug 
has been implicated as a putative target o f  IGF-|32 during chick endocaridal HMT 
( Romano. L. A. et al.. 2000). Also RhoA activ ity  may function downstream o f TGF-02 
and 3 in both the endocardial activation and mesenchymal invasion by altering 
cytoskeletal components (Tavares. A. L. et al.. 2006).
In mouse embry os, the requirements for induction o f  endocardial FAFF d iffe r 
from  those in chick (Camenisch. T. I), et al.. 2002). To date d ifferent TGF-p isoforms 
have been identified in the mouse and chicken heart during HMT. In chicken. TGF-|32 
and TGF-(G  m R N A are expressed in the A V  canal (Potts. J. D. et al.. 1992). whereas 
in mouse. TGF-|M and TGF-|32 are present (Akhurst, R. J. et al.. 1990; M illan. F. A. et 
al.. 1991). Data from in -v itro  studies suggest that TGF-|32 is the signal required for 
HMT. whereas inh ib iting  TG F-|G  activ ity has no effect (Camenisch. T. D. et al.. 
2002). fro m  this study, it was suggested that TGF-|32 could also carry out the 
functions assigned to TGF-|33 in chick. TGF-|32 was observed in both the my ocardium 
as well as in transformed mesenchymal cells suggesting that it may act in an autocrine 
fashion as well as its paracrine pathway (Camenisch. I . D. et al.. 2002; Dickson, M. C. 
et al.. 1993). In addition, it has been reported that Notch signalling play s a role during 
murine endocardial cushion formation. M yocardial Notch pathway mutants, which fail 
to form endocardial cushions, have a severe reduction in HCiT-(32 expression 
(Timmerman. H. A. et al.. 2004). It was concluded from this study that the primary role 
o f  Notch in endocardial HMT was to upregulate IG f-|32 . However, cardiac Snail 
expression was also dramatically affected in these mice and this may have attributed to 
the defects observed. Increasing evidence suggests that other signals are required in 
vivo to induce HM T in mammals. This is highlighted by the fact that mice
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homozygous for a null allele o f  TGF-|32 s till make cushions (Sanford. L. P. et al..
1997).
More recent data has implicated the BM P ligands in playing a critical role in 
endocardial HMT. It was shown that Bmp2 is expressed in the A V  myocardium at 9.5 
and 10.5 days (Sugi, Y. et al., 2004). Hxperiments using the collagen gel assay showed 
that BN1P2 could substitute tor myocardium to induce I 'M  I in mouse embryos (Sugi. 
,'t . et al., 2004). In accordance w ith  this hypothesis, gene inactivation studies in mice 
revealed that Bmp2 was necessary for m yocardial development (/hang . H. et al.. 
1996). Moreover, specific deletion o f Bmp2 in the A V  myocardium resulted in failure 
o f  the A Y  endothelial cells to form  cushions, im plicating BMP2 signalling in 
endothelial HM T (Ma. L. et al.. 2005).
The relationship between BMP2 and TGF-(32 signalling, and the requirements 
o f  each ligand to induce HM T has not yet been fu lly  established. It was reported that a 
tissue specific deletion o f  the BM P type I receptor A L K 3  in myocardial cells resulted 
in downregulation o f  TGF-|32 expression specifically in myocardium adjacent to the 
A Y  canal (Gaussin. V. et al.. 2002). This suggests that BMP ligands act to regulate 
myocardial TGF-|32 expression in a cell autonomous manner, which is importatant for 
later aspects o f  A Y  cushion development (Ma. H. et al.. 2005). Furthermore, BMP2 
induces TGF-|32 expression in explants cultured in collagen gel (Sugi. Y. et al., 2004). 
and TGF-|32 expression is dram atically reduced in the A Y  cushions o f  BMP2 
conditional knockout mutant embryos (Ma. L. et al.. 2005). Additional work is 
required to firm ly  establish the genetic relationship between BMP signalling and TGF- 
transcriptional regulation and its role in mouse endocardial HMT.
The type I receptors which transduce the BM P signal have also been 
investigated. Conditional inactivation o f  AHK3 in the myocardium resulted in normal 
A Y  cushions in mutant embryos (Gaussin, Y. et al., 2002). whereas targeted deletion 
o f AI.K.3 in the A Y  endocardium disrupted HM T in most mutants (Ma, H. et al., 2005). 
This indicates that endocardial A I.K 3  tranduces the BM P signal required for HMT. 
However, one third o f  conditional mutants lacking endocardial A LK 3 , s till made 
cushions. In addition, the level o f  P-Smadl 5 8 in the endothelial cells was only 
reduced by 50°o in the absence o f  A L K 3 . This evidence suggested the possibility that 
other type I receptors function in the cushion endocardium.
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A L K 2  h as also been shown to be required for endocardial KM T in the mouse as well 
as in chick embryo as discussed previously (Desgrosellier. J. S. et al.. 2005; W ang. J. 
et al., 2005). Mouse embryos deficient tor A L K 2  in cushion endocardium had a severe 
defect in A Y  cushion morphogenesis (W’ang. J. et al., 2005). A lthough ligands 
signalling via AI.K.2 in vivo are currently unknown, it is like ly  that they include the 
BMPs. ALK.2 interacts w ith  BM PR II as w e ll as LCi 1'-1i and activin type 1 receptors in 
the presence o f  their respective ligands (Attisano. I., et al., 1903; Lbner, R. et al., 1993; 
Yamashita. 11. et al.. 1995). Despite potentia lly signalling through TG L-|L activin and 
BM P ligands. ALK.2 activation has thus far only been demonstrated for BMP7 in 
conjugation w ith  the activ in type II receptors (Macias-Silva. M. et al.. 1998). 
However, there is evidence that A L K 2  signals downstream o f  ligands other than 
BMP7 since alk2 null mice die early in gastrulation (Gu. Z. et al.. 1999). while BMP7 
null mice survive until soon after birth (Dudley. A. T. et al.. 1995; Luo. G. et al.. 
1995). Furthermore. A I.K 2  has been proposed to mediate M IS-induced KM T o f 
coelom ic epithelium  during M ullerian duct regression (Zhan. Y. et al.. 2006). A L K 2  
has also been implicated in TGF-|3 mediated KM T in cultured mammary epithelial 
cells (M iettinen. P. J. et al.. 1994).
In the A Y  tract A I.K 2  signalling has also been implicated in regulating TGK-|3 
signalling. Activa tion o f  both BMP Smads and TGK-p Smads is affected in A Lk2  
mutant mice. However. KM T cannot be rescued by exogenous addition o f  TGKfJ 
(W’ang. J. et al.. 2005). suggesting that the role o f  BMP A L K 2  signalling is not solely 
the induction o f I G l -|3 expression. These data suggest that A L K 2  and A LK 3  may 
both function as BMP ty pe I receptors in regulating KM T in mouse endocardium. 
D istinct but overlapping target pathway s have been suggested for the ty pe 1 receptors 
by comparision of downstream signalling pathways in knockout mice (Ma. L. et al.. 
2005; W’ang. .1. et al.. 2005).
In accordance w ith  a crucial requirement for BMP signalling for endocardial 
KM T, Smadb has been implicated as a regulator o f  the process. A specific role for 
Smadb in endocardial KM T was first revealed by the targeted deletion o f Smad6 in 
mouse (G a h in . K. M. et al.. 2000). which revealed the presence o f  excess 
mesenchymal cells in the cardiac valves o f  Smad6 mutant mice. Since Smad6 has been 
shown to have a preferential inhibitory role in BM P signalling (Hata. A. et al.. 1998; 
Imamura. L. et al.. 1997). it is possible that Smad6 acts by lim iting  the response to the
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inductive BM P signal. Whether Smad6 functions to antagonise ALK.2 and ALK.3 
signalling, or an individual typo I receptor, has yet to be uncovered.
In conclusion, strong evidence has accumulated to demonstrate the role o f 
BM P signalling in mouse endocardial HMT. Furthermore, this process displays the 
line ly  tuned interplay o f signalling components and pathways to implement 
morphogenetic ev ents that are crucial to the dev elopment o f  an embryo.
1.6.3.3 Conclusions
The most strik ing property o f  the HM T process is the use o f a plethora o f growth 
factors and transcription factors in a coordinated and cooperative fashion to e lic it 
d istinct changes in the structural morphology o f  epithelial cells. In the TGF-p 
superfam ily, all three TGL-[3 isoforms induce various developmental HM I s. whereas 
BM P ligands function as both inductive and inh ib itory signals during HMT. In addition 
to the inh ib ito ry  roles o f BMPs during FAIT, BM P-7 has been identified as a key 
regulator during M HT in kidney ontogenesis (Dudley. A. T. et al.. 1995). f  urthermore, 
intricate requirements for receptors by the IG F -|I fam ily members in different 
developmental and cell systems have been im plied, suggesting that although a sim ilar 
endpoint is reached in many cases, specific pathways are required to e lic it these 
signals. This is true also o f  the d iscrim inator) use o f TGF-|3 isoforms throughout 
development, which is not based on the expression profiles o f  these ligands. S im ilarly, 
a wide variety o f  transcription factors are employed to mediate an HMT signal, 
however it is clear that many o f  these signalling pathways converge to e lic it 
transcriptional repression o f the H-cadherin promoter. Moreover, as the mechanisms 
underlying HMT are gradually unravelled, it is apparent that developmental and 
metastatic HMTs seem to be governed by common signalling pathways, thus raising 
the hvpothesis that tumour metastasis could be regarded as a reactivation ot at least 
some aspects o f the embryonic programme o f  HMT (Thiery, J. P.. 2002). As TGF-|3 
fam ily  members are major players in developmental HM I events, it is not surprisingly 
that they are also involved in tumourigenesis.
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1.6.3.4 EMT during Tumour Progression
Tumours associated w ith  metastasis form ation account for 90% o f  cancer deaths, and 
represent one o f the prime causes o f human m orta lity (Sporn. M. B., 1996). The 
release o f tumour cells from organised tissue structures and invasion to more distal 
sites requires phenotypic changes and alterations in gene expression profiles, common 
to TMT-associated changes (Thiery. J. P., 2003). Tor a long time, however, the 
relevance o f  T M T  during tumour progression in was questioned, due to the d iff ic u lt)  
in distinguishing an T M T  process in progressing human tumours. However, tumour 
cells that have undergone T M T  eo-express mesenchymal markers such as vim etin 
(w hich is also present in stromal fibroblasts) together w ith  epithelial cytokeratines 
(laking in stromal fibroblasts). More recently, in vivo imaging techniques have been 
developed which allow the identification o f  such dedifferentiated cells in human 
tumours (Ahmed. T. et al.. 2002).
To date, numerous observations support a central role for TM T  in tumour 
progression. Detailed immunocytochemical analysis o f  adenocarcinomas o f  the colon, 
revealed the release o f single-cells from an epithelial island. These solitary cells 
stained T-cadherin-negative and were found at the sites o f tumour invasion, 
im plica ting a mechanism o f TM T. In addition, the metastatic potential o f  carcinoma 
cells correlates w ith  the mesenchymal gene expression patterns and the loss o f 
epithelial markers such as T-cadherin (Thiery. J. P., 2002). Tor example in breast 
cancers, the loss o f T-cadherin expression has been shown to positively correlate w ith  
advanced grade, metastasis and decreased survival (Peinado. H. et al.. 2004). It has 
also been observed that Snail l promotes the recurrence o f  mammary tumours in mice 
and high levels o f  Snail l act as a marker tor poor prognosis in human cancer (M oody. 
S. T. et al.. 2005).
In addition, it is also clear that induction o f T M T  in many carcinoma cell lines 
results in the acquisition o f metastatic properties in vivo. In a microarray analysis to 
iden tit\ genes involved in metastasis. Tw ist, a transcription factor important in 
development, was found to be essential in the metastatic process (Yang. J. et al..
2004). It was subsequently shown that suppression o f  Tw ist expression in highly 
metastatic carcinoma cells reduces their ab ility  to metastasize from the mammary 
gland to lung (Yang. J. et al.. 2004). Tctopic expression o f  Tw ist, however, promotes
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HMT. expression o f  mesenchymal markers, increased m o tility  and loss o f  H-cadherin 
expression, thus, clearly establishing a mechanistic link  between HM T and metastasis.
1 he role ol I GF-|3 induced I 'M  I' in vivo also strengthens the argument for 
HM 1 in tumour cells. In vivo mouse models o f  skin carcinogenesis have shown a dual 
role o f  I GF-{3, whereby TGF-|3 inhib its form ation o f  benign papillomas, but promotes 
pro life ra tion and dedifferentiation during the squamous-cell carcinoma stages, leading 
to the lorm ation ot spindle-cell carcinoma, the most aggressive from skin cancer (C'ui. 
W. et al., 1996). These spindle cell carcinomas also upregulate TGF-|33 expression, 
which may be required in maintenance o f the aggressive phenotype. Also, the stable 
expression o f  dominant negative T|3RII in a squamous carcinoma cell line prevented 
the spontaneous progression o f these cells to a spindle cell phenotype in vivo, clearly 
demonstrating that the HM T event is mediated directly via the TGF-(3 signalling 
pathway (Portella. G. et al.. 1998). In the HpRas mammary carcinoma model, it was 
demonstrated that after in jection into mice, these polarized cells formed tumours 
consisting o f  depolarised, spindle shaped cells capable o f invasive growth. These 
tumours displayed autocrine production o f TGF-p. which is required to maintain the 
mesenchymal, spindle-like phenotype (O ft. M. et al.. 1996). Adm inistration o f TGF-(3 
in the v ic in ity  o f the injected HpRas cells dramatically accelerated the conversion o f 
these cells into a fibroblastoid phenotype, indicating a key role o f  TGF-|3 in regulating 
HM T during tumourigenesis (O ft. M. et al.. 1996). In addition, expression o f  a 
dominant negative T p R lI in HpRas cells was employed to block TGF-|3 signalling, 
which resulted in delayed tumour formation and prevention o f  FAFF and metastasis in 
vivo (O ft. M. et al.. 1998). Thus, it was proposed that autocrine TGF-|3 signalling is 
required for both induction and maintenance o f  invasiveness and metastasis during 
late-stage tumourigenesis. Furthermore. NT-kB , has been shown to be essential lo r 
TGF-|5-indueed FAFF in HpRas cells, and inh ib tion o f  NF-kB  activ ity reverses the 
1 GF-|Finduced FAFF and also abrogates the metastatic potential ot these cells in vivo 
(Huber. M. A. et al.. 2004a).
F inally, a secreted interleukin-related protein (IHHI), which is upregulated during 
TGF-|S-induced HMT in HpRas cells, has been shown to induce tumour growth. FAFF 
and lung metastasis in vivo when stably expressed in non-tumourigenic HpH4 cells
134
Chapter 1 Introduction
( \ \  aerner. I. et al., 2006). I aken together, these studies suggest a role for TGF-P 
signalling in the progression o f  tumours to late stages, associated w ith  HMT.
1.7 TG F-p  and C ancer
l GF -p was orig ina lly  discovered by its ab ility  to induce malignant behaviour o f 
normal fibroblasts in culture, a property which led to the notion that TGF-p was an 
etleetor o f  transformation, and hence named “transform ing ' growth factor (Roberts, A. 
B. et al.. 19 8 1). However, it later emerged that TG F-p has profound growth 
suppressive effects on many cells, thus uncovering the role o f  TG F-p as a tumour 
suppressor (Roberts. A. B. et al.. 2003). Over the last twenty years it has been 
demonstrated that TGF-p plays a complex, biphasic role in cancer, exhib iting opposing 
effects at either early or late states o f tumour progression. In the in itia l phases o f 
cancer, it acts as a tumour suppressor p rim arily  through its growth inh ib itor) effects on 
epithelial and lym phoid cells from which the m ajority o f  human tumours are derived. 
However, in advanced stages o f cancer TGFp appears to act as a tumour promoter. 
t\ p ically when the growth inh ib itor) response o f cells to TGF-p has been lost 
(W akefie ld . L. M. et al.. 2002).
The dual role o f  TG F-p in cancer was first demonstrated in transgenic mouse 
models. In a model o f  chemical carcinogenesis in the skin, targeted expression o f 
T G F -p l inhib ited the formation o f benign papillomas but led to an enhanced rate o f 
aggressive and highly malignant tumours which expressed high levels o f endogenous 
TGF-p3 (Cui. \V. et al.. 1996). It was also observed that T G F -p l heterozygous mice 
exhib it increased cell turnover in liver and lung ( fang, B. et al., 1998). However, 
treatment o f  these mice w ith chemical carcinogens resulted in an increase in tumor 
incidence. Moreover, these tumours retained the remaining T G F -p l allele, suggesting 
that haploid loss o f  TG F-p is insufficient lo r the tumour suppressive function o f TGF- 
p (Tang. B. et al.. 1998). In addition, introduction o f  dominant negative TpR II into 
mice enhanced tumorigenesis in the mammary gland and lung in response to a 
carcinogen (Bottinger. H. P. et al.. 1997). Furthermore, it has also been demonstrated 
that the pro-oncogenic activities o f TG F-p in the progressive stages o f cancer, is
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associated w ith  the requirement o f  many tumours for TGF-(3 activ ity to form 
metastases (Akhurst. R. J. et al.. 2001). Indeed, two independent studies revealed that 
adm inistration o f  soluble TGF-|3 antagonists selectively inhib its metastatic disease 
w ithout affecting normal physiology or tumorigenesis at the primary site in metastatic 
mammary mouse models (Muraoka. R. S. et al., 2002; Vang. V. A. et al.. 2002). 
Furthermore, using a series o f breast cancer cell lines that d iffe r in degrees o f 
malignancy, it was shown that Smad2 and Smad3 exerted tumour suppressive activ ity 
in premalignant and well-d ifferentiated tumour cells but enhanced lung metastases o f 
more aggressive carcinoma cells (Tian. F. et al.. 2003). In addition, a high percentage 
o f human tumors overexpress T G F -p l. and this excess production o f T G F -p l appears 
to be associated w ith  poor prognosis (Tsushima. H. et al.. 1096; W ikstrom. P. et al..
1998). These date clearly establish a role for TG F-p in mediating both tumour 
suppressive and tumour prom oting activities in vivo.
1.7.1 Genetic Alterations in TGF-/3 signalling components
The importance o f TG F-p signalling in the suppression o f  tumourigenesis is supported 
by the presence o f  deletions and mutations in genes encoding both TGF-p receptors 
and downstream components o f  the signalling pathway in cancer (Levy. F. et al., 
2006). Smad4 was orig inally identified as a tumour suppressor gene lost in pancreatic 
cancers, deleted in pancreatic cancer locus 4 (DPC4) (Hahn. S. A. et al.. 1996). Smad4, 
located in I8 q 2 l. fo llows the classic Knudsonian paradigm for a tumour suppressor, in 
that the second allele is disrupted by loss o f  heterozy gosity (LO H ) in about 90% o f 
pancreatic cancers (Levy. L. et al.. 2006). Indeed, Smad4 has now been shown to be 
mutated or deleted in about 50°o pancreatic cancers, 15% o f colorectal tumours and 
less frequently in a number o f other cancers including breast, prostate and cervical 
cancer. Germ line mutations in Snunl4 also occur in a subset ot patients w ith  juvenile  
poly posis (JP). an autosomal dominant gastrointestinal polyposis syndrome (Howe. J. 
R. et al.. 1998). Smad2, also located on I8 q 2 l.  is mutated at a low frequency in a small 
proportion o f  colorectal cancers (hppert. K. et al.. 1996; I'ch ida, K. et al.. 1996). Io  
date, no mutations have been identified in patients, although loss o f Smad3 expression 
o f tumour samples has been demonstrated (see below ) (Levy. L. et al.. 2006). Somatic
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inactivating mutation o f the gene encoding TpR II. occurs in tumours from patients 
w ith  hereditary non-polyposis colorectal cancer (HNPCC). a hereditary form o f colon 
cancer. Ihese patients have defects in their recombination error repair system, and 
hence mutations arise in TpR II due to mismatch repair errors resulting in a truncation 
ot the receptor (K im . S. J. et al., 2000). In addition, mutation o f A I.K 5  has been also 
been detected in human cancers, w ith  a particularly high level found in ovarian cancers 
(W’ang, I), et al., 2000). More recently, mutations in the gene encoding A I.K 3  have 
been found in a subset o f  JP patients (Howe. J. R. et al., 2001). Interestingly these 
patients are w ild type for Smad4.
1.7.2 Resistance to tum our suppressor activities o fTG F-fi
The vast m ajority o f  epithelial-deriv ed tumours (>85° o o f all human cancers) become 
resistant to the growth inh ib ito r) effects o f  TGF-p. but remain responsive to the 
tumour prom oting activ ities o f l CiI -|3 (Akhurst. R. J. et al.. 2001). A lthough some o f 
the mechanisms for the loss o f  the antipro liferative response have been defined by 
mutations in components o f  the pathway in tumours, most cancer cells retain normal 
I 'GF-p receptors and Smads. As a result, alternative mechanisms for resistance to the 
antip ro life ra tive  effects o f  TGF-p-induced have been proposed. An emerging theme is 
a dovvnregulation o f components o f the pathway, including the receptors. TpR II. 
T f ^  R11 and also Smad3 (K im . S. J. et al., 2000). The loss o f expression o f TpRII in 
association w ith  resistance to the growth inh ib ito r) effect o f'T G F -p  has been reported 
in various tvpes o f cancers, including gastric, colon, breast, and prostate (Levy. L. et 
al., 2006). Furthermore, decreased Smado expression has been reported in gastric 
cancers, which are refractory to the antipro liferative effects o f  TGF-p (Han, S. U. et 
al., 2004). The loss o f'T G F -p  growth inh ib ito r) and apoptotic effects accompanied by 
this dovvnregulation is often associated w ith  activation o f other signaling pathways 
such as Ras and P loK inase (Akhurst. R. J. et al.. 2001). By lowering the expression 
lev el o f  these TGF-p signaling components, tumour cells escape the growth inhib itory 
effects o f  TG F-p but maintain other 'TGF-p responses. In tact, it has been proposed 
that tumours which maintain TG F-p signalling correlates w ith  poor prognosis. This has
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been demonstrated in patients w ith  HNPCC. whereby individuals w ith  a complete loss 
o f  TpRII  have a better prognosis than patients w ith  sporadic colon cacner that retain 
functional TG F-p receptors (Akhurst. R. J. et al., 2001).
1.7.3 Tumour promoting role of TGF-p
Although the tumour suppressive activities o f  TG F-p have been lost in cancers, other 
TG F-p responses prevail, many o f which contribute to the spread o f metastasis. 
Tum our metastases arise as a result o f  a complex series o f events that involves cellular 
m igration, tumour vascularisation. interactions w ith  the m icroenvironment, 
intravasation into blood or lymphatic vessels, and cell survival at distant sites. TGF-p 
is involved in several o f these processes either by effects o f  TGF-P on the tumor cells 
themselves or indirectly through affecting the m icroenvironment. As previously 
mentioned. TG F-p signalling in conjunction w ith  Ras induces an epithelial-to- 
mesenchymal transition (H M T) which results in a more m igrator) and invasive 
phenotype. These events lead to the acquisition o f  metastatic properties in vivo (Cui, 
\V. et al.. 1996) (See section l . 6.3.4). In addition, many tumours have increased
production o f  TGF-p. w hich benefits the cancer cells ind irectly through production o f
extracellular matrix, suppression o f immune system function, or promotion o f 
angiogenesis (Akhurst. R. J. et al.. 2001). f  or a solid tumour to grow beyond l -2 mm 
in diameter, they require nutrients and oxygen, which is often acquired through the 
form ation o f  a new blood supple (i.e. angiogenesis). As described in Section 1.6.2. 
TG F-p plays a prominent role in stimulating angiogenesis and many studies implicate 
the angiogenic-inducing properties o f  high levels o f  TG F-p in tumour progression (de 
Jong. J. S. et al., 1998). Consistent w ith  a role in stim ulating angiogenesis. expression 
o f  endoglin on endothelial cells is dram atically increased during tumour-induced 
angiogenesis (Burrows. F. J. et al., 1995). TG F-p also induces the expression o f 
vascular endothelial growth factor ( Rertovaara, T. et al., 1994), which then directly 
promotes angiogenesis. In addition. TGF-p-induced expression o f the metalloproteases 
M.MP-2 and M M P-9 and downregulation o f  the protease inh ib ito r tissue inh ib itor o f  
metalloproteases (P IM P ) in both tumour cells and endothelial cells, promotes
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degradation o f  the HCM. By inereasing the m o tility  o f  tumour cells and endothelial 
cells in a protease rich environment. TG F-p stim ulation results in invasive tumour 
cells, which may represent one o f  the tumour prom oting activities o f TG F-p (Akhurst. 
R. J. et al., 2001). To conclude, it is increasingly evident that genes known to perform 
critica l roles during early embryogenesis, are also expressed during the development o f  
cancer. In this regard, oncogenesis may be considered as the recapitulation o f 
embryogenesis in an inappropriate temporal and spatial manner. As the role o f TGF-p 
is crucial to the developing embryo, it is not surprising that cancer cells exploit the 
activities o f  this multifaceted cy tokine for the progression and spread o f  tumours.
1.8 Aims of Thesis
The dual role o f  TGF-p in cancer has prompted a lot o f  work in this area. However, 
investigation into the molecular mechanisms regulating the paradoxical responses o f 
TG F-p signalling during tumour progression has just scraped the surface. How TG F-p 
functions as a tumour suppressor or a tumour promoter at different stages during 
tumorigenesis is still a great mystery, although current work is slow ly unravelling 
pieces o f the puzzle. The identification o f mutations in key components o f the pathway 
or their downregulation by epigenetic mechanisms have revealed ways in which 
tumour cells exploit the pro-oncogenic activities o f  TG F-p and have opened the door 
to exciting new avenues o f investigation. The importance o f the Smads in both tumour 
suppressor and pro-oncogenic activities cannot be underestimated and represent a 
primary target for modulation o f  TGF-p activities. To this end, the aim o f my study 
was to investigate the molecular mechanisms underlying the different responses o f 
cells to TG F-p w ith  a particular focus on the role o f  Smad regulation in these 
processes. Here, I present data detailing my extensive characterisation o f TGF-p 
signalling in a tumour cell model sy stem which uncovers new determinants that could 
act to modulate TG F-p activities during cancer progression.
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2 Materials and Methods
2.1 M o lecu lar Biology
2 . 1.1 Materials and Solutions
Most chemicals and solvents were obtained from either Merck. Sigm a-A ldrich. Roche 
or BioRad and are o f analytical grade. A ll buffers and solutions were made up using 
deionised water or DHPC treated water to reduce RNAse contamination. This is a list 
o f  general materials and solutions. Details o f  solutions used specifically for one 
method are described in the relevant section.
1 E hutfer
10 mM  Tris-U C l (pH 7.5). 1 mM  HDTA (pH 8.0)
>t)x TAP
2 M Tris-acetate. 50 mM  HDTA (pH 8.0)
10 x PC R buffer
500 m M  KC1. 100 m.M Tris-H C l (pH 8.3). 15 m \ l  MgCB and 0.01 % (vv v) gelatin 
l o . x d X T P s
2 m M  dATP. 2 m.M dCTP. 2 mM  dCi I P. 2 m M  dTTP (Amersham Pharmacia Biotech) 
0 x D.XA Load ing  Dye
0.25 00 (w v ) bromophenol blue. 0.25 °o (vv v ) xylene cyanol IT .  30 °o (v v ) glvcerol 
E lh id ium  llrom ide
Stock solution made to 10 mg ml in water. I 'sed at 0.5 ug ml
A m p ic i l l in
Stock solution made to 50 mg ml in water. Used at 50 ug ml
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Luria-Bertani /LB) Medium
1 °o \v  v Bacto-tryptone. 0.5 °o \v v Bacto-yeast extract, 1 % \v v NaCl, pH 7 
LB . l^>w
l .5 °o w v Bacto-agar in LB  medium
2.1.1.1 List o f Plasmids
For plasmids constructed by me tor this work see Appendix I. A ll constructs were 
sequence verified and checked by restriction digestion and where appropriate gene 
expression.
Other Plasmids
p -Z om e-l-N  was a g ift from  Justin Cross (Cancer Research I  K), which was orig ina lly  
obtained from  Cell zome (based on pBABE-puro). pcD NA3N was also provided by 
Justin Cross (Cancer Research CK).
The fo llow ing  plasmids have been previously described; pFTX5 \S m a d 2 A 3 T IR  and 
pi 1X5 HS dpc4 (How ell. M. et al.. 1997); LT:p link myc hSmad3 and EFplink FLAG - 
Smad3 (Inman. Ci. J. et al.. 2002a). The human Smad2 cD N A  (26-261). human Smad3 
cD N A  (321-626) and G APDH cD N A  (51-231) cloned into pG EM -T were as 
previously described (Nicolas. F. J. et al.. 2003b). The human y-actin cD N A (B am lll- 
H in d lll fragment) in pSP64 was previously described (Enoch. I. et al., 1986). The 
fo llow ing  reporter plasmids were as previously described; C A G A c-Lucite rase 
(I)ennler. S. et al., 1998). ARE3-I.uc (Pierreux. C. V.. et al.. 2000).) c-jun SBR„-
I.uciferase (Inman. Cl. J. et al., 2002a), BRL-luciferase ( Korchvnskyi, (). et al., 2002). 
and the 1 T -I.a c / control plasmid (Bardwell. V. J. et al.. 1994).
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2.1.2 Purification of Plasmid DNA
To prepare plasmid D N A. a single am picillin-resistant colony was picked and used to 
inoculate either 3 ml (small-scale preparation -  'm in ip rep ') or 50 ml (large-scale 
preparation 'm id ip rep ') o f  LB containing am p ic illin  (50 ug ml). The culture was 
then shaken overnight at 37°C. Lor m inipreps. the D N A was isolated using Q IAprep* 
spin m iniprep k it (Qiagen) according to the Manufacturers' instructions. Lor 
m idipreps. the D N A  was isolated using either a Plasmid M id i K it (Qiagen) or a 
NucleoBond Plasmid M id i K it (Clontech). both according to the Manufacturers' 
instructions.
2. 1.3 Estimation of Nucleic Acid Concentration
Double-stranded D N A. RNA and synthetic oligonucleotides were quantified by 
spectrophotometer using a Beckman General Purpose Spectrophotometer. A  l 400 
d ilu tion  in water o f  D N A solutions was made, and the optical density (OD) determined 
at a wavelength o f 260 nm on a Beckman General Purpose Spectrophotometer. This 
value was then used to obtain the concentration o f  the D N A or RNA in ug ml using 
the fo llow ing  equation:
O D :n! x d ilu tion factor x Lxtinction Coefficent = Concentration in //g /d
The extinction coefficients are as follows: 
dsDNA: 50 
ssRNA: 40 
ssDNA: 33
single-stranded oligo: 20
To estimate the purity o f  the sample, the OD at 280 nm was also measured. A ratio 
(()!):,„, O D ^ ii) o f>  1.8 but < 2.0 is an indication o f pure DNA.
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2.1.4 Subcloning Procedures
Restriction enzy me digestion
Restriction enzyme digestions were performed for l -2 hr in the appropriate NHB 
buffers at 37 C' unless recommended otherwise in the manufacturer’s specification 
sheet. l() pi o f  reaction m ixture and l unit o f  enzyme were used per microgram o f 
D N A. Products were analysed by agarose gel electrophoresis.
Klenon'
fo  form  blunt end D N A  fragments by f illin g -in  5' overhang, digests were treated w ith  
l unit D N A  Polymerase I Klenow fragment (NHB) per ug D N A  supplemented w ith  2 
u l 10 m M  dN I Ps (10 m M  dATP. 10 m M  dCTP. 10 m M  dGTP and 10 mM dTTP 
[Amersham Pharmacia B iotech]), and incubated for 15 minutes at room temperature 
prior to purification.
Ph osp/t at use treatment
Before phosphatase treatment, reactions were ethanol precipitated using sodium 
acetate. The pellet was resuspended in 50 pi 10 m M  T ris -IIC l pH 9.5. 1 mM 
spermidine. 0.1 mM HDTA. 1 mM MgCH. 0.1 mM XnCH and incubated at 37°C for 1 
hr w ith 1 unit o f  alkaline phosphatase (Boehringer Mannheim).
Ligation
10 pi ligation reactions were carried out at room temperature using 200 units o f  T4 
D N A ligase in 10 mM MgCH. 60 mM  T ris -IIC l pH 7.4. 6 mM DTT, 1 mM ATP and 
left for a m inim um  o f 3 hr or overnight.
Sequencing
Sequencing was used to verify  sequences using the applied Biosystems BigDye* 
term ination protocol. D N A  template (500 ng) was m ixed w ith  20 ng o f primer and 8 ul 
B igDye* Term inator v2.0 v3.1 (Applied Biosystems) in a final volume o f 20 ul. The 
sequencing reaction was then carried out in a GeneAmp* PRC System 9700 (Applied 
Biosystems). Cnincorporated dye terminators were removed from sequencing
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reactions using DyeLx™ 2.0 Spin K its (Qiagen) and the pellet was dried. Prior to 
loading on the sequencing gels, the pellet was resuspended in 3 u l M icro STOP^Red 
loading buffer (M icro /one  L im ited) and denatured at 95 °C for 5 minutes. A ll 
sequencing was performed on A B I PR ISM * 377 D N A Sequencers (Applied 
Biosystems).
2.1.5 Agarose Gel Electrophoresis
Agarose (Invitrogen) gels ( l -  2 %) were prepared in l x TAP w ith  0.5 ug ml ethidium 
bromide. The molten gel was poured into a sealed gel tray w ith  the appropriate gel 
eomb(s) and allowed to set at room temperature. A ll gels were run in l x TAP w ith  a 
Lambda DNA-TCy/l'II digest D N A  ladder (New Lngland Biolabs: NHB) at 120 volts for 
15-45 minutes. Visualisation and photography o f  gels was by u ltravio let illum ination 
using a I VP 21 V Transillum inator at 310 320nm.
2.1.6 Polymerase Chain Reaction (PCR)
Polymerase Chain Reaction (PCR) was used to am plify  cD N A for subcloning and for 
semi-quantitative Reverse Transcriptase (RT-PCR) reactions. O ligonucleotide primers 
were designed to be 20-25 mers. These were supplied by the in-house Cancer Research 
CK oligonucleotide synthesis service and laterally S igm a-A ldrich. A list o f all 
o ligonucleotides used in this thesis has been included in Appendix II.
PC'Rs contained template D N A. 100 nM o f forward and reverse primers, and 
200 uM  each o f  dA'TP. d l l P. dCiTP and dCTP ( l x dNTPs) in a final concentration o f 
10 mM  T ris -IIC l (pH 8.3). 50 mM KC l. 1.5 m M  M gC L andO.OOl ° o  (w v) gelatin ( l x 
PCR buffer), w ith 2.5 units Taq polymerase (Developmental S ignalling Laboratory. 
Cancer Research L K ). PC'Rs were carried out in a CieneAmp* PCR System 0700 
(Applied Biosystems).
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Standard conditions were as follows:
94°C 3 min
94°C 30 sec
55°C 30 sec 35 cycles
72°C 30 sec
72°C 10 min
4°C ◦0
2.1.7 RNA preparation from Cells
Total RNA was extracted from EpH4 and EpRas cells using TRIZOL® Reagent 
(Invitrogen). 15 ml of TRIZOL® was added to each 15 cm dish and pipetted up and 
down before transfer to a sterile falcon and incubation at RT for 5-10 min. For other 
dish sizes refer to the table below.
Area cm2 Volume T R IZ O L®
6 well plate 10 cm* 1 ml
6 cm dishes 20 cm* 2 ml
10 cm dishes 55 cm2 6 ml
15 cm dishes 150 cm* 15 ml
This was followed by addition of 0.2 ml of chloroform per ml of TRIZOL added 
initially. Samples were shaken vigourously for 15 sec and then incubated at RT for 5 
min. Phase separation was performed by centrifugation at 3000 rpm at 4 °C for 30 min 
(Beckman Allcgra* 6K.R centrifuge). The upper aqueous phase was then transferred to 
a fresh tube and 0.5 ml of isopropanol was added per ml of TRIZOL used for the 
initial homogenization. Samples were incubated for 10 min at room temperature before 
centrifugation at 3000 rpm for 30 min at 4 °C to precipitate the RNA. RNA was then 
washed with 75% ethanol and pelleted by centrifugation at 3000 rpm for 10 min. The 
supernatant was removed and the pellet was left to dry for 5-10 min at RT. The RNA
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was resuspended in 480 //I water. The concentration o f RNA was determined using 10 
//I o f RNA in 600 ul o f H ;0. To the remaining 470 ul, 50ul o f 3 M NaOAc and 500 ul 
o f Isopropanol were added. This RNA slurry was then stable at 80 °C.
Determination o f RSA concentration
The concentration o f RNA in this slurry is calculated using the equation below. In this 
case two d ilu tion factors must be taken into account.
O D ;f>() x d ilu tion  factor x Extinction Coefficent = Concentration in //g/'/d
D ilu tion  factor 1: 10 ul 600 ul = 60
D ilu tion  factor 2: 470 ul (470 ul + 50 ul + 500 u l) = 2.17
Extinction coefficient for dsRNA: 40
O D :m1 x (40x60 2.17) = Concentration in //g //I in the slurry
2 1 8  RT-PCR
Reverse transcription
Total RNA prepared from 1'p i 14 and HpRas cells was used for reverse transcription. 
RN A (5 fag) was reverse transcribed using Superscript™  II RNase H- Reverse 
Transcriptase (Invitrogen) Total RNA. dNTPs and Random hexamer were combined
(see table) for each RT reaction and heated to 65°C for 5min before being placed on
ice. A ll incubations were carried out in a (ieneAm pK PC'R System 9700 (Applied 
Biosvstems).
Total RN A 5 ug in 11 ul
I 50-5()0ng Random Hexamer (250 ng/ul) 1 u l
; dN I P (lO m M ) 1 u l
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4 pi of 5x Buffer and 2 pi of DTT 0.1M (supplied by Invitrogen) was added to the mix 
and incubated at 25°C for 2min. Finally lp l of Superscript™ II RNase H- Reverse 
Transcriptase was added to each tube and the following incubation programme was 
used.
25°C 10 min
42 °C 50 min
70°C 15 min
PCR reactions
PCR was carried out in the exponential phase (20 to 35 cycles) to allow a 
semiquantitative comparison of RNA levels. 3 pi of cDNA prepared by reverse 
transcription was used in each PCR reaction. Specific primers were used for analysis 
of genes, for which the sequences are given in Appendix II. Grb2 was used as a 
control. PCR products were analyzed in 1.5% agarose gels. PCR reactions were carried 
out in a GeneAmp® PCR System 9700 (Applied Biosystems). The standard PCR 
programme (Section 2.1.6) was used for analysis of the ALK genes.
2.1.9 RNAse Protection Assay
Mouse Smad2, Smad3, GAPDH and actin transcripts were analyzed by quantitative 
RNase mapping as previously described (Treisman, R., 1985) with singlestranded, 
uniformly labeled RNA probe synthesized in vitro with Sp6/T7 RNA polymerase and 
[a -32P] rUTP.
2.1.9.1 Probes
All of the probes used for RNase protection were designed against the human 
sequences but cross-reacted with the mouse sequences (See also section 2.1.1.1). 
Smad2
The Smad2 probe protects the region encoding amino acids 9-86 of the human 
sequence (Nicolas, F. J. et al., 2003b). Linearised with Spel and transcribed with T7.
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Smad3
The Smad3 probe protects the region encoding amino acids 107-208 o f the human 
sequence (Nicolas, 1; . J. et al., 2003b). Linearised w ith  Spel and transcribed w ith  17.
G A P D /t
The ( iA P I)H  probe protects the region encoding amino acids 18-77 (Nicolas, F. J. et 
al., 2003b). Linearised w ith  B a m lll and transcribed w ith  Sp6 .
y-actin
The y-actin was as previously described (Lnoch. T. et al.. 1986). Linearised with H infl 
and transcribed with Sp6 .
Linearisation o f  Plasmids fo r  Probes
10 //g o f plasmid was digested w ith the appropriate enzyme at 37 °C overnight. 
Linearised plasmid was then extracted using phenol chloroform , fo llowed by ethanol 
precipitation resuspension in 5 //I o f DEPC-treated water. The concentration o f RNA 
w as determined and adjusted to 1 pg ul.
2.1.9.2 Sp6 and T7 RNA Probe Synthesis for RNA Protection Assays
RN A probes were synthesised as previously described using the linearized reporter and 
reference templates (See section 2.1 .9 .1) (M elton. D. A. et al.. 1984). The 10 ul 
labelling reactions contained 0.5ul linearised template cD N A  (1 pg u l). 0.5 ul o f the 
appropriate RNA-polymerase (17, NEB; Sp6  Promega). 2.5 ul 'P - IH P  
(OOOCi m m ol). 0.5 id o f  each rATP (10 m M ), r ( i fP  (10 m M ). and rCTP (10 m \l) .  0.5 
id o f  RNase inh ib ito r (Amersham) and 0.25 ul I) I f  (200 m M). The reactions were 
incubated at 37 C' for 1 hr.
A fte r RNA synthesis. D N A template was digested in 95 id o f  50TE, 0.5 pi o f  
RNase inh ib itor. 1.25 pi m ixture (10 pi o f  1 M o f MgC'L. 5 p i o f  1 M C'aCL. 10 pi o f 
200 m M  I) I f ) ,  using 0.75 pi o f  DNase I at 37°C for 30 min. fo llo w in g  addition o f 4 
pi o f  0.5 M L D T A  pH 8.0 and 10 pg tR N A  as carrier, the reactions were phenol 
extracted and precipitated w ith  25 pi 4 M ammonium acetate and 0.3 ml ethanol on
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dry ice. Precipitates were spun down at 13000 rpm for 10 min, washed with 80% 
ethanol. The dried pellet was dissolved in 1 pi of water and 5 pi of formamide loading 
buffer (see below) and denatured at 95 °C for 3 min. The probes were gel-purified 
using 6% denaturing acrylamide gel (see below). The gel running was carried out in 
0.5 x TBE at 13 W for 1.5 hr. The labelled probes were excised from the gel and eluted 
in elution buffer for 2 hrs at 50 °C. After phenol extraction, the probes were ethanol 
precipitated in the presence of carrier tRNA, the pellet was dissolved in 20 pi water 
and counted in a scintillation counter by Cherencov counting.
Formamide Buffer 
0.25% xylene-cyanol 
0.25% bromophenol-blue 
20 mM EDTA  
95% v/v formamide
6% acrylamide gel
6% 40:1 acrylamide:bis acrylamide
7M urea
0.5 x TBE
Elution Buffer 
0.5 M  NH4OAc 
0.1 % SDS 
1 mM EDTA
2.1.9.3 RNA Analysis with Sp6/T7 probes
For probe hybridisation the reactions were carried out in a total volume of 30 pi 
containing 15 pg total RNA in 30 pi hybridisation buffer and 1 pi labelled probe (2 x 
105 cpm/sample). Samples were incubated at 85 °C for 5 min to denature RNA and 
they were hybridised overnight at 45 °C. Digestion of un-hybridised single stranded 
RNA was carried out by RNAase treatment in 350 pi RNase buffer with 0.4 pi
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RNaseTl ( 20 U/pl; calbiochem) at 37 °C for 30 min. The RNase was then digested by 
addition of 5 pi Proteinase K (10 mg/ml, Sigma) and 0.25% SDS at 37°C for 30 min. 
After phenol/chloroform (1:1) extraction, the double-stranded RNA was precipitated 
using 1 volume isopropanol and dissolved in 1 pi water and 5 pi formamide loading 
buffer. The reactions were electrophoresed using 6% denaturing acrylamide gel at 11 
W for approximately 1.5 hr. The gel was fixed (10% methanol, 10% acetic acid), dried 
on Whatman 3M M  paper and visualised by autoradiography.
Formamide hybridisation Buffer 
400 mM NaCl 
40 mM PIPES pH 6.4 
1 mM EDTA
80% v/v formamide (deionised)
RNAase Buffer 
10 mM Tris HC1, pH 7.5 
5 mM EDTA  
300 mM NaCl
2.2 Cell Culture
2.2.1 Materials and Solutions
All tissue culture media and solutions were supplied by the in-house Cancer Research 
UK Cell Services.
Dulbecco’s M odified Eagle M edia (D -M E M )
6.4 g NaCl, 4.5 g D-Glucose, 10 ml 3:5 Penicillin/Streptomycin solution, 110 pg 
sodium pyruvate, 3.7 g NaHCC>3 , 584 pg L-Glutamine, 2 ml 20 %  (w/v) KC1, 1 ml
26.5 % (w/v) CaCl2, 1 ml 20 % (w/v) MgS04, 1 ml 14 % (w/v) NaH2P04, 1 ml 0.01 %
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(\v \ ) Fe(N O jh . 1 ml 0.02 ° o  (w v) antim yotic. 1.5 ml 1 % (w /v) phenol red. 50 ml 
amino aeids and 8  ml vitam ins in 1 litre o f  water. The media was bubbled w ith CO: 
until pH 7 and filte r sterilised. Media was supplemented w ith  10 % ( \ \ ) lbetal bovine 
serum (Invitrogen) and stored at 4 °C. Prior to use, 10 % D -M H M  was heated in a 
water bath to 37 °C.
5 x Trypsin I ersene
2.5 g trypsin. 8  g NaCl. 1.15g NadlPO.*. 200 ug KdDlOO, 1 g \ersene (H l)T A ), 1.5 ml 
1 ° o (w v)pheno l red
2.2.7.7 Growth factors and Inhibitors
T G F - f i l  TGF-/13
TGF-|S1 TGF-03 (R & D ) was reconstituted in sterile 4 mM HC1 containing 1 mg ml 
BSA to a stock concentration o f 1 pg ml and stored at -80 °C. Stim ulation w ith  TGF-p 
was used at a final concentrations o f 2  ng ml.
S B-43 1342 (AI .K5 inh ib i tor)
SB-431542 (CiSK.) was resuspended in DM SO to make a stock concentration o f 10 
m M. Final concentrations were used at 10 iiM .
10126
The MFK.1 2 inhib itor. 10126 (Promega). was dissolved in DMSO to make a stock 
solution o f 10 m M. final concentration used at 25 uM .
( ' vcloheximide
Cyclohexim ide was made up in water to a stock concentration o f 10 mg ml. Used at 20 
ug ml final concentration.
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2.2.2 General Culture Conditions
Cell lines were all cultured on plastic dishes or flasks of tissue culture grade (Coming 
Incorporated and BD Falcon™) in an incubator (Sanyo) at 37 °C and 10 % CO2 .
2.2.2.1 Cell lines
Cells were cultured in D-MEM supplemented with foetal bovine serum (Invitrogen) 
that was warmed to 37 °C before adding to the cells. To remove cells from the flask, 
the cells were washed once with PBSA and then incubated with trypsin:versene 
solution for 1-10 minutes, depending on the cell line.
Cell Line Source Media FCS
(% )
Supplements
EpH4 Martin Oft,
Schering-Plough BioPharma
D-MEM 8% 10 mM HEPES
EpRas Ernst Reichmann,
University-Children's
Hospital,
Zurich
D-MEM 8% 10 mM HEPES
+G418
(500mg/ml)
X-tumour Ernst Reichmann, 
University-Children's 
Hospital, Zurich
D-MEM 8% 10 mM HEPES
+G418
(500mg/ml)
HaCaT Cancer Research UK D-MEM 10%
C2C12 Richard Treisman, 
Cancer Research UK
D-MEM 10%
M DA-M B-
468
ATCC D-MEM 10%
AM12 Julian Downward, 
Cancer Research UK
D-MEM 10%
GP+E Julian Downward, 
Cancer Research UK
D-M EM 10%
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2.2.2.2 EpH4 system
EpH4 mouse mammary epithelial cells and their Ras-transformed derivatives EpRas or 
X-Tumour cells were cultured in DMEM containing 8 % FBS (Invitrogen) and 10 mM 
HEPES (Invitrogen). EpRas and X-tumour cells were supplemented with G418 
(Invitrogen) 500 mg/ml. Subculturing was performed every 2 or 3 days at a ratio of 1: 
4 for epithelial cells and 1: 6 for EpRas and XT cells.
2.2.3 Transient Transfections
2.2.3.1 Lipofectamine 2000 Procedure
EpH4, EpRas and HaCaT cells were transfected at a confluency greater than 90% 
using Lipofectamine™2000 Reagent (Invitrogen) and Opti-MEM8 I Reduced Serum 
Medium (Invitrogen). The DNA, Lipofectamine™ 2000 Reagent (Invitrogen) and 
Opti-MEM8 I Reduced Serum Medium (Invitrogen) were combined (see Table), 
vortexed and allowed to incubate at room temperature for 15-30 minutes.
Culture Vessel DNA (pg) and 
dilution volume
Volume of 
Lipofectamine 2000 
and dilution volume
Volume of Plating 
Opti-M EM
12-well 1.6 pg in 100 pi 4 pi in 100 pi 200 pi
6 well 4 pg in 250 pi 10 pg in 100 pi 500 pi
6 cm 8 pg in 500 pi 20 pi in 500 pi 1 ml
The cells were washed once with Opti-MEM and the appropriate volume of 
Opti-MEM was added to each dish (see Table). The transfection mix was added and 
the cells were incubated for 3-5 hours at 37 °C and 10 %  CO 2 before washing and 
replacing with D-MEM supplemented with 8-10 % foetal bovine serum (Invitrogen). 
The cells were then incubated overnight or 48 hrs before any inductions with TGF-P 
were performed.
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2.2.3.2 Superfect Procedure
The superfect transfection procedure was used for M D A -M B 468  cells only. M D A - 
M B468 cells (in  12 well plates w ith  700pl D -M H M  supplemented w ith  10 ° o  foetal 
bovine serum) were transiently transfected when they were approximately 50-60 % 
confluent using Superfect transfection reagent (Qiagen). In a sterile eppendorf. 120 ul 
( )p ti-M H M K I Reduced Serum Medium (Invitrogen) was combined w ith  3.5 pi 
Superlect translection reagent and allowed to incubate at room temperature for 5 
minutes. This transfection m ixture was then added dropwise to 1.5 pg D N A  and left at 
room temperature for 10-15 minutes. The transfection m ixture was then added to the 
M D A -M B 468  cells and incubated for 3 hours at 37 °C and 10 % C'O: before washing 
and replacing w ith  D -M H M  supplemented w ith  10 % foetal bovine serum (Invitrogen). 
The cells were then incubated overnight before any inductions w ith  TGF-p were 
performed.
2.2.3.3 The Dharmafect Procedure
5 x 104 cells HpI14 and HpRas cells were plated out to achieve 20-30% confluence the 
fo llow ing  day. siR NA pools (a mix o f 4 different s iR N A duplexes) and individual 
s iR N A  duplexes, obtained from Dharmacon (see table below ), were resuspended in IX  
s iR N A  Buffer (Dharmacon) to a stock concentration o f  20 uM . siRNA pools or 
ind iv idual duplexes were transfected at a final concentration o f 75 nM  into HpH4 
and or HpRas cells using Dharmafect2 reagent (Dharmacon). f  o llow ing an overnight 
incubation, the transfection mix was replaced w ith  fresh media. The next day. the cells 
were plated for reporter assays or protein preparation.
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SMARTpool siRNA reagents were as follows:
S M A R Tpool siRNA Catalogue number
Smadl M-055762-00
Smad2 M-040707-00
Smad3 M-040706-00
Smad5 M-057015-00
Smad8 M-046344-00
ALK1 M-043004-00
ALK2 M-042047-00
ALK6 M -051071-00
TPRII M -040618-00
Individual siRNA duplexes were as follows:
siRNA duplexes Catalogue number
ALK3 (4) D-040598-04
ALK5 (2) D-040617-02
siRNA duplexes Catalogue number
RISC-Free siRNA D-001220-01-05
non-targeting D-001206-13-05
2.2.3.4 Luc if erase and p-Galactosidase assays
All Luciferase and p-Galactosidase assays were performed as previously described 
(Pierreux, C. E. et al., 2000). EpH4, EpRas and HaCaT cells were plated out in a 12- 
well plate and transfected with 500 ng reporter construct (either CAGAi2 -Luciferase, 
c-jun SBR6-Luciferase, ARE3-Luciferase or BRE-Luciferase), 25-75 ng transcription 
factor, and 500 ng pEF LacZ as an internal control (Bardwell, V. J. et al., 1994). Cells
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were treated ^ IGF-|3 tor 8  hours prior to lysis in 100 ul 1 x Reporter Lysis buffer 
( Promega).
2.2.4 Generation of Stable Cell lines
2.2.4.1 Retroviral Infection
Generation of HaCats expressing the ecotrophic receptor
fo  generate HaCaT cell lines stably expressing p-Zome. w ild-type cells were first 
infected w ith  an amphotropic retrovirus encoding the ecotrophic receptor (p \VZL-Neo- 
FeoR). Retrovirus stock was obtained from the medium o f  the packaging cell line. 
A M  12 cells. HaCaT cells were seeded in 10 cm plates so that they reached 40% 
confluence the fo llow ing  day. Virus supernatant from  A M  12 cells was diluted 1:10 
w ith  fresh media and supplemented w ith  8  ug m l Polybrene. A fte r sterile filte ring  w ith  
a 2.2 uM  membrane (Roche). 2.5 mis o f  the retroviral m ixture was added to the 
HaCaT cells and incubated for 3 hrs at 37°C. The next day. pools o f  cells were 
selected w ith  800 ug ml G418 for 5 -6  days. This generated a HaCaT cell line 
expressing the ecotrophic receptor required for subsequent infections (HaCaT HcoR).
Generation of HaCats expressing TAP-Smads
I AP-Smad2. TAP-Smad3. TAP-Smad4-expressing HaCaT cells were generated by 
retroviral gene transfer using retroviral vectors o f  the Smads in p-Zome (Cellzome). p- 
Zome-Smad constructs were transfected into the packaging cell line. GP+H. (grown in 
DM1-M plus 10% PC'S) which were then selected w ith  2.5 u g m l puromycin for 3-4 
days. V irus supernatants from these transfected G PM i cell lines were then used to 
infect the HaCaT LcoR cells. These cells were then selected w ith  5 ug nil puromycin 
lo r 3 4 days. Pools were made from re trov ira lly  infected and drug-selected cell 
populations. Clones were then isolated by seeding at low density, expansion for 10-14 
days and isolation o f colonies using sterile cloning rings, dipped in autoclaved silicon 
grease. The rings were placed over the selected colonies prior to trypsinisation. A fte r 
the cells had detached they were transferred to selective medium and subsequently 
cultured as normal.
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2.2.4.2 Transfection
EpH4 cells were transfected w ith  the pcD N A3N  constructs using the lipofectamine 
2000 transfection procedure (Section 2.2.3.1) and incubated overnight. The fo llow ing 
day. the cells were trysinised and replated at low density, to make clones and at higher 
density to produce a pool o f  cells. These cells were then selected w ith 5 ug ml 
purom ycin for 3 4 days. Clones were isolated as described above.
2.2.5 Cell cycle analysis
2.2.5.1 Synchronisation of cell by Contact Inhibition
f  or G1 S phase progression studies. 5 x l O' EpH4. EpRas and X-tum our cells were 
seeded into 6  cm plates, so that cells were 100% confluent after two days. The cells 
were arrested in G,i Gi by contluency for two days and E D TA  released using \ ersene 
(Gibco. 0.2 g E ED TA) for 30-45 m in at 37°C. Cells were then replated at a d ilu tion o f 
either 1:4 (EpH4 cells ) or 1:6 (EpRas and X-tum our cells). The m ajority o f  cells enter 
S-phase after 18 hr. Samples for all G l S profiles shown were collected 22 h after 
ED TA  release. The results were, however, verified extensively throughout a 16-h to 
48-h time window.
2.2.5.2 DNA Analysis using Propidium-lodide
To examine cell cycle d istribution, cells were detached from plates by incubation w ith  
trypsin, washed in PBS and fixed in 70% ice-cold ethanol for 30 min. A fte r treatment 
w ith  RNase (lO O ugm l) for 5 min at room temperature, cells were stained w ith  
50ug ml propidium -iodide (Becton D ickinson) for 5 min. Stained cells were analysed 
bv flow cytometry using 488 nm excitation, carried out by the Cancer Research UR 
Service. The data profiles were analysed by the Dean-Jett-Eox integration method.
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2.2.6 Epithelial-to-Mesenchym al Transtitions (EMT)
2.2.6.1 EMT Assay on Plastic
5 x lO4 HpRas cells were plated out in 6 -w ell plates and either grown in the presence 
or absence o f TGF-|3l (2 ng m l). The medium was changed 1 d after seeding and then 
every other day. TGF-|3 was added to the cells upon medium change. Three days after 
plating, the cells were trypsinised and re-plated at equivalent density to day 1. Cells 
were grown for a total o f  1 0  days, which required two trypsinisations. and then 
harvested 48 hrs after final TG F-p addition. Cells were processed for 
immunofluorescence using an anti-H-cadherin antibody (BD), to analyze adherens 
junctions or an anti-Zona Occludens 1 (Z0-1) antibody (Zymed). to analyze tight 
junctions. Actin  reorganization was visualized w ith  Texas red-conjugated phalloidin. 
and nuclei were visualized w ith  DAPI.
2.2.6.2 Adaptation o f EMT assay for use with siRNA oligonucleotides
5 x 104 HpRas cells were plated out in 6 -well plates and were transfected w ith siRNA 
oligonucleotides (Section 2.2.3.3). A fte r overnight incubation, cells were replated 1:2 
and grown in the presence or absence o f TGF-(3 (2 ng/ml). The medium was changed 1 
d after seeding and then every other day. TGF-|3 was added to the cells upon medium 
change. Three days after plating, the cells were trypsinised and re-plated at equivalent 
density to day 1. A second siRNA transfection was performed on day 4. One. final 
replating o f  cells was carried out on day 7. Cells were grow n for a total o f  9 days in the 
presence or absence ot' TCil'-(3 and then harvested 48 hrs after final TGF-|3 addition.
2.2.6.3 3-D Collagen gels
Serum-free 3-1) collagen gel cultures were prepared as previously described (Oft, M. et 
al., 1996) w ith  m inor modifications. Cells were suspended in standard growth medium 
to a final density o f 1500 100 ul. 500 ul o f  cells were then m ixed w ith 500 ul o f ice- 
cold rat tail collagen type I solution (BD). achieve a final concentration o f 1.5 mg/ml.
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Drops (100 pi) were placed into the wells of 17 mm 4-well plates (Nunc). After 
incubation at RT for 30 min and at 37°C for 4 h the gels were overlaid with 0.5 ml 
serum-free medium (Mammary Epithelial Basal Medium, Promocell) supplemented 
with growth factors (see below). Medium changes were performed every other day. 
For EMT assays, TGF-pl was added at day 2-3, and then every other day.
Supplements fo r  Feeding Media  
Pen/Strep 
5ng/ml TGF-a 
lOpg/ml Insulin 
lp M  Isoproterenol 
1 pM Dexamethasone
Bovine Pituatary Extract-15 (BPE-15) 1:250
2.2.7 Immunofluorescence
2.2.7.1 Indirect Immunofluorescence on Plastic
Cells were grown on glass coverslips and fixed either by Formaldehyde or Methanol 
acetone as previously described (Nicolas, F. J. et al., 2003b).
Formaldehyde fix
Coverslips were placed in a 24-well dish and washed twice with PBS. Fixing was 
performed using 3.7% Paraformaldehyde (PFA) for 10 minutes at RT. Coverslips were 
washed again with PBS and then permeabilised for 10 minutes with 0.3 % triton X-100 
in PBSA. Blocking was subsequently carried out for 30 minutes at room temperature 
with a blocking solution (see below) After blocking, coverslips were washed once with 
PBS before incubation with primary antibody (see table). Antibodies were diluted in 
blocking solution without milk and incubated for 1 hour at room temperature. The list 
of antibodies and the concentration used is below. Cells were then washed three times 
with 1-3 ml of 0.1 % triton X-100 in PBSA and subsequently incubated with 
secondary antibody diluted in blocking solution without milk for 30 min. After several 
washes with PBS including a 5 min incubation with dapi and a final wash with water,
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coverslips were mounted onto slides using Mioviol (Hoechst) and analysed by 
confocal microscopy (Section 2 .2 .13 ).
PFA f ix  Blocking Solution
0.3% avid BSA
10 % foetal calf serum (Invitrogen), 
5 % powdered milk (Marvel)
0.3 % Triton X-100 
made up in PBSA
Methanol: Acetone Fix
Coverslips were washed as above in PBS and fixed in methanol: acetone (1:1) at -  
20°C for 20 min. The fix solution was removed and coverslips were left to dry so any 
remaining fix evaporated. Coverslips were washed three times with PBS and then left 
in PBS to rehydrate. Cells were permeabilised for 10 minutes with 0.1 % triton X-100 
in PBS for 10 min at RT and then blocked in 2%  fish gelatin (Sigma) in PBS for 30 
min. Primary antibodies were diluted in fish gelatin blocking solution and added to 
cells for 1 hr at RT. After the antibody was removed, the cells were washed twice in 
0.1 %  Trition/PBS and once in PBS and subsequently incubated with secondary 
antibody also diluted in fish gelatin blocking solution for 30 mintues. Cells were 
washed, mounted on slides as described above.
Primary Antibodies:
Antibody Supplier Species Concentration Fixation Method
E-cadherin BD Mouse 1:200 Methanol/Acetone
Z0-1 Zymed Rabbit 1:400 Methanol/Acetone
Vimentin Sigma Mouse 1:200 Methanol/Acetone
Smad2/3 BD Mouse 1:200 PFA
Ki67 Sigma 1:1000 PFA
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Phalloidin is a toxin from the toadstool "Death Cap" (Amanita phalloides) that binds 
specifically to F-actin. A fluorescent analog of phalloidin (Phalloidin-AlexaFluor 594, 
Invitrogen) is used to study F-actin distribution in permeabilised cells (Wulf, E. et al., 
1979). It is used at a 1:200 dilution and using a PFA fix.
Secondary Antibodies:
Antibody Conjugate Supplier Species Concentration
Mouse IgG AlexaFluor 488 Invitrogen Goat 1:700
Rabbit IgG AlexaFluor 488 Invitrogen Goat 1:700
Mouse IgG AlexaFluor 594 Invitrogen Goat 1:700
Rabbit IgG AlexaFluor 594 Invitrogen Goat 1:700
2.2.7.2 Indirect Immunofluorescence on Collagen Gel
Collagen gels were fixed with 1% formaldehyde in 250 mM Hepes, pH 7.4, freshly 
diluted from 16% paraformaldehyde stocks stored at -20°C. After 15 min at room 
temperature, the gels were washed once each with Tris- and phosphate-buffered saline 
plus 0.2% Tween 20 (TBST and PBST, respectively) and treated for 1 h at 4°C with 
blocking solution Gels were incubated with primary antibodies plus DAPI in blocking 
solution for 1 h at 37°C in a wet chamber, washed three times in PBST for 30 min, and 
postfixed with 4% PFA in PBST for 15 min at 23°C. After 30-min washes in TBST, 
PBST, and blocking solution, the gels were incubated with appropriate secondary 
antibody mixtures made up in blocking solution for at least 1 h or overnight at 4°C. 
Gels were washed three times in PBS, once in distilled water, and mounted in Mowiol 
(Hoechst).
Collagen Gel Blocking Solution 
PBST
0.1% gelatin
10 pg/ml nonimmune bovine IgG
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2.2.7.3 Con focal Microscopy
Immunostained cells were visualised using a Zeiss 520; Zeiss confocal ESM 510 laser 
scanning confocal light microscope. Samples were excited at 543 nm and observed 
w ith  a long-pass filte r a llow ing passage o f  wavelengths o f  600 nm and above.
2.3 Protein Analysis
2.3.1 General Materials and Solutions
10 x TBE
0.9 M  Tris-borate. 10 m \ l  ED TA (pH 8.0)
Phosphate buffered saline (PBSA, Cancer Research CK central services)
8  g NaCl. 0.25 g KC1. 1.43 g NaHIPCC. 0.25 g K H 2 PO4 in 1 litre o f water. pH was 
adjusted to 7.2
Pro tease Inhi hi to rs
Complete EDTA-free tablets (Roche) were dissolved directly in 50 ml o f the buffer to 
be used.
D l l '
Stock solution made up to 1 M in water. Used at 1 m \ l  
poly d l-d ( '
Stock solution made in water to make 1 mg, ml. The solution was sonicated on ice for 
approximately 30 seconds to reduce its average si/e to below 1 kb
2.3.2 Protein Extract Preparation
2.3.2.1 Whole Cell Extract
Cells were washed twice w ith  ice-cold PBS, ensuring all PBS was removed after the 
second wash. Extracts were then made essentially as previously described (Marais. R.
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et al., 1993). The cells were scraped from the tissue culture dishes into lysis buffer 
(see below) and sonicated for 10 seconds on ice. Extracts were then centrifuged at
13,000 rpm (Biofuge fresco Heraeus centrifuge) for 5 minutes at 4 °C to remove cell 
debris and the supernatant transferred to a cold sterile eppendorf. Protein 
concentration was measured as described. 30 pg of whole cell extract was used for 
analysis of proteins by Western blotting.
DO. 4 Extraction buffer
20 mM HEPES (pH 7.5), 10 %  (v/v) glycerol, 0.4 m KC1, 0.4 %  (v/v) Triton 
X-100, 10 mM EGTA, 5 mM EDTA. 1 mM DTT.
RIPA Extraction buffer
150mM NaCl, 50mM Tris pH 8.0, 1% NP-40, 0.5 % deoxycholate, 0.1 % SDS
To each buffer the following was freshly added: 25 mM NaF, 25 mM sodium 
p-glycerophosphate , 1 mM DTT, and 1 x Complete Protease Inhibitors.
2.3.2.2 Nuclear and Cytoplasmic Extracts o f Cells
Nuclear and cytoplasmic extracts were prepared as described previously (Wong, C. et 
al., 1999) with minor modifications. Cells were washed twice with ice-cold PBS, 
ensuring all PBS was removed after the second wash. The cells were allowed to swell 
in ice-cold hypotonic buffer (1 ml for a 15 cm tissue culture dish) for a few minutes 
before they were scraped into a cold sterile tube. The nuclei were then pelleted by
TM
centrifugation at 800 rpm in a swinging-bucket centrifuge (Beckman Allegra 6KR 
centrifuge) for 15 minutes. The supernatant (cytoplasmic fraction) was transferred to a 
cold sterile eppendorf and protein concentration assayed. The nuclei were washed in 
hypotonic buffer once and then resuspended in five times the pellet volume of 
hypertonic buffer. Extracts were rotated for two hours at 4 °C and then centrifuged at
13,000 rpm (Biofuge fresco Heraeus centrifuge) for 5 minutes at 4 °C to remove cell 
debris. The supernatant (nuclear fraction) was transferred to a cold sterile eppendorf.
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Protein concentration was measured as described. Typically, 10 pg of nuclear extract 
and 30 pg of cytoplasmic extract was used for analysis of proteins by Western blotting.
Hypotonic Solution 
20 mM HEPES (pH 7.6)
20 % (v/v) glycerol
10 mM NaCl
1.5 mM MgCl2
0.2 mM EDTA
0.1 % (v/v) Triton X-100
Hypertonic Solution
As for Hypotonic buffer but containing 450 mM NaCl
To each buffer the following was freshly added: 25 mM NaF, 25 mM sodium P- 
glycerophosphate , 1 mM DTT, and 1 x Complete Protease Inhibitors.
2.3.2.3 Determination of protein concentration
Protein concentrations were determined by the Bradford method using 200 pi of 
BioRad Protein Assay solution (Biorad). A standard curve was determined using 1-8 
pi of a 1 mg/ml BSA solution (NEB). 3 pi of the sample to be determined was used in 
the assay. The absorbance at 595 nm was measured on a SpectraMax Plus 
spectrophotometer (Molecular Devices). The protein concentration of the sample was 
then determined from the BSA standard curve.
2.3.2.4 TCA preciptiation
Final eluates of the dual purification procedure were concentrated before loading on an 
analytical gel by TCA precipitation (Harlow, E. et al., 1988). One twentieth the total
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eluute volume o f  deoxyeholic acid (2m g/m l) was added to the protein sample. The 
eluates were then adjusted to 10 % TC A w ith  100% TC A and incubated on ice for 1 hr 
w ith  periodic vortexing. Hluates were then centrifuged at 13.000 rpm (Biofuge fresco 
Heraeus centrifuge) for 45 minutes at 4 °C. The supernatant was discarded and the 
pellet was washed in acetone (-20°C) containing 5 mM  MCI. A fte r 5 min 
centrifugation at 13.000 rpm, the supernatant was discarded again. The pellet was 
washed a second time in pure acetone (-20°C). The supernatant was removed and the 
pellet was dried in a speed vaccum. Pellets were resuspended in 4x SDS buffer (10 
m M  DTT).
2.3.2.5 Alkylation o f Proteins
An additional a lkylation step was performed to prevent m odification o f Cysteine 
residues in the sample protein, which interferes w ith mass spectrophometric analysis. 
The protein samples were boiled in 4x SDS sample buffer (DTT). A fte r cooling down 
to RT. a fresh solution o f iodoacetamide in water (0.25 M ) was added to give a final 
concentration o f 20 mM. Samples were incubated in the dark at RT for 20 min before 
loading.
2.3.3 Protein Analysis
2.3.3.1 SDS Polyacrylamide Gel Electrophoresis (SDS-PAGE)
The samples to be analyzed were first boiled in 4x sample buffer to denature the 
protein structure. Two glass plates (10 cm x 20 cm) were assembled w ith  silicon 
tubing to form a seal between the plates, and 0.8 mm plastic spacers. Resolving gel 
m ix (15 ml at the appropriate percentage) was then poured between the vertical plates 
and overlaid w ith 1 cm o f 75 % ethanol to ensure a level, air-free polymerisation 
interface. The gel was allowed to polymerise for approximately 20 minutes before 
removal o f  the surface w ater. The stacking gel was then poured onto the surface o f  the 
resolving gel and a 0.8 mm plastic comb was inserted between the plates to produce 
the wells.
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Once the stacking gel was polymerised, the gel plates were clamped into an 
electrophoresis apparatus (Cambridge Electrophoresis Ltd), and 1 x SDS Running 
buffer was added. The comb was removed from the gel and the wells were thoroughly 
washed out with the Running buffer. Samples were run alongside molecular weight 
markers that were prepared by Mike Howell (Developmental Signalling Laboratory) 
(see below for composition). Gels were run for 1 hour 30 minutes at 230 volts and 65 
mAmp. Gels were then either stained with Silver stain or Coomassie blue stain or 
transferred to PVDF membrane and used for Western blotting (see below).
Resolving Gel Stacking
Gel
15.0% 20.0 %
40 % (w/v) acrylamide 5.625 ml 7.5 ml 0.625 ml
2 % (w/v) bisacryamide 0.645 ml 0.495 ml 0.333 ml
1.5 M Tris-HCI (pH 
8.8)
3.75 ml 3.75 ml
1.0 M  Tris-HCI (pH 
6.8)
0.625 ml
Water 4.98 ml 3.255 ml 3.417 ml
20 % (w/v) APS 40 pi 40 pi 15 pi
TEMED 30 pi 30 pi 10 pi
4 x Sample buffer
8 %  (w/v) SDS, 320 mM Tris-HCI (pH 6.8), 40 % (v/v) glycerol, 1 % (v/v) 2- 
mercaptoethanol or lOmM DTT, bromophenol blue
1 x SDS Running buffer 
384 mM Glycine 
50 mM Tris-HCI 
0.1 % (w/v) SDS
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Protein Markers
50 pg/ml each of myosin (212 kDa), fl-galactosidase (116 kDa), phosphorylase 
(97.5 kDa), BSA (66.5 kDa), catalase (57.8 kDa), glutamate dehydrogenase 
(55.5 kDa), GAPDH, ovalbumin (42.7 kDa), carbonic anhydrase (28.9 kDa), 
SBT1 (20 kDa) and RNase A (13 kDa).
2.3.3.2 Staining o f Protein gels 
Silver Stain
Silver staining was carried out as previously described (Harlow, E. et al., 1988). 
Following electrophoresis, gels were fixed for 20 minutes in 5 % acetic acid (v/v) and 
50 %  methanol (v/v) with gentle rocking. This was followed by washing for 10 
minutes in 50 % methanol (v/v) with gentle rocking and further washing in water for 2 
hours to overnight. Gels were then sensitised for 1 minute in 0.02 %  w/v sodium 
thiosulphate with gentle rocking and subjected to two 1-minute rinses in water. This 
was followed by incubation with 0.1 %  silver nitrate (w/v) for at least 20 minutes at 4 
°C and in the dark. Gels were then rinsed for 1 minute with water and transferred to a 
fresh gel tray. Finally, development was carried out with 4 % sodium carbonate (w/v) 
and 0.04% Formalin (v/v) (added directly before use) until protein bands were of an 
appropriate intensity. The development reaction was terminated with 5 %  acetic acid 
(v/v). The gels were either stored in 1 %  acetic acid or dried in cellulose acetate sheets 
(Promega).
Coomasie Stain
Acrylamide gels were fixed first in 12% glacial acetic acid and 50% methanol for 20 
min. A staining solution with 0.125% Coomassie blue R250 was prepared freshly and 
filtered using 150mm Whatman paper to avoid precipitation. The gel was then stained 
for 1-2 hr or overnight. Gels were slowly destained in 7.5% acetic acid and 10% 
methanol for approximately 1 hour to visualise the proteins. Protein gels were then 
stored at 4°C.
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2 .3 .3 .3  Western Blotting
After electrophoresis, SDS gels were soaked in 1 x Semi-Dry Transfer buffer for 15 
minutes. Six pieces of Whatman 3 mm paper and a piece of Immobilon™-P PVDF 
0.45 \x membrane (Millipore) were cut to the size of the gel. The membrane was pre- 
wet in methanol, rinsed in water and, along with the Whatman paper, equilibrated in 
the 1 x Transfer buffer with the gel. Three pieces of Whatman paper, followed by the 
membrane, the gel and another three pieces of Whatman paper were assembled in the 
SemiPhor Transfer Unit (Hoefer) and rolled over with a pen to ensure removal of all 
air bubbles. Proteins were then transferred for 1 hour 30 minutes at 0.8 mAmps/cm2 of 
gel.
After transfer, the membrane was stained with Ponceau S solution to visualise 
the markers. The membrane was then washed briefly in PBS and incubated in 5 % 
(w/v) milk powder (Marvel)/PBST for an hour at room temperature to block non­
specific binding of antibody to filter. Next, the membrane was incubated with the 
primary antibody in 5 % (w/v) milk/PBST at 4 overnight on a rocking platform. The 
membrane was then washed 4 times for 15 minutes in 5 %  (w/v) milk/PBST prior to 
incubation with a secondary antibody conjugated to horseradish peroxidase (HRP) in 5 
%  (w/v) (w/v) milk/PBST for I hour. Finally the membrane was washed again 4 times 
for 15 minutes in 5 % (w/v) milk/PBST, and the HRP was detected with ECL™ 
Western blotting detection reagents (Amersham Pharmacia Biotech). When the HRP- 
conjugated primary antibodies (anti-HA-HRP and anti-Flag-HRP), were used, 
incubation with the secondary antibody was omitted.
JO x Semi-dry Transfer buffer
1.5 M glycine
200 mM Tris-HCI
0.1 % (w/v) SDS
The 1 x solution was made up to contain 20 %  (v/v) methanol
Ponceau S solution
2 %  (w/v) Ponceau S
30 % (v/v) trichloroacetic acid
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2.3.3A Antibodies
Primary Antibodies:
Antibody Supplier Smad Specificity Species Concentration
Smadl Zymed Smadl only Rabbit 1:1000
Smadl/5 (Madr) Upstate Smadl &  5 Rabbit 1:1000
Smad2/3 BD Smad2 &  3 Mouse 1:1000
Smad3 Zymed Smad3 only Rabbit 1:750
B8 Santa Cruz Smad4 only Mouse 1:750
P-Smad 1/5/8 Cell Signalling P-Smad 1 , 5 & 8 Rabbit 1:500
P-Smad2 Cell Signalling P-Smad2 only Rabbit 1:1000
P-Smad3 Cell Signalling P-Smad 1 & 3 Rabbit 1:1000
P-Smad3 Ed Leof (Gift) P-Smad 1 &  3 Rabbit 1:3000
P-T178 Fang Liu (Gift) Smad2 &  3 Rabbit 1:6000
P-S207 Fang Liu (Gift) Smad3 only Rabbit 1:6000
P-ERK Sigma Mouse 1:10,000
M2 Sigma Mouse 1: 1000
FLAG-HRP Sigma 1:1000
PAI-1 Santa Cruz mouse 1:500
Id2 Santa Cruz mouse 1:500
Pan-actin Sigma goat 1:1000
Grb2 BD Mouse 1:1000
Secondary Antibodies
Antibody Supplier Conjugate Species Concentration
Rabbit IgG DAKO HRP Goat 1/3000
Mouse IgG DAKO HRP Goat 1/3000
Goat IgG DAKO HRP Donkey 1/3000
169
Chapter 2 Materials and Methods
2.3.4 Protein-DNA Interactions
2.3.4.1 DNA pull-downs
Double-stranded oligonucleotide baits were prepared by annealing 0.5 pg p i1 of each 
of the appropriate single-stranded oligonucleotides in IX  buffer 2 from New England 
Biolobs. These annealing reactions were heated at 95 °C for 10 mins and allowed to 
cool slowly to room temperature over a period of 2 hours.
Probe Oligonucleotide Sequence
c-Jun SBR wild- 
type
ggaggtgcgcggagtcaggcagacagacagacacagccagccagccaggtcggca
c-Jun SBR mutant ggaggtgcgcggagtcaggcatatatatatatacagcatgcatgcatggtcggca
For each DNA pulldown (DNAP), a 10 cm dish of cells (500 pg of extract) and 25 pi 
oligo-saturated beads was used. Immobilised Neutravadin™ Biotin Binding beads 
(Perbio) were washed twice in 1 ml cold DNAP Buffer and resuspended in DNAP 
Buffer to form a 1:1 slurry. The slurry was then incubated with the desired oligo (8pg 
oligo/ 25pl beads in water) for 1 hour at 4 °C with rotation. Dishes of cells (10 cm) 
were lysed in 400 pi DNAP Buffer. Lysates were sonicated for 10 seconds on ice and 
centrifuged at 13,000 rpm (Biofuge fresco Heraeus centrifuge) for 5 minutes at 4 °C. 
The supernatant was transferred to a sterile pre-chilled eppendorf and the protein 
concentration assayed. Samples (2 x 30 pg) were retained for use as controls. The 
oligo-conjugated beads were washed three times in DNAP Buffer, resuspended to give 
a 1:1 slurry and then incubated with the cell lysates for 1 hour at 4 °C with rotation. 
After this incubation, the beads were washed three times with DNAP Buffer, 
resuspended in 4 x Sample buffer and Western blotted to visualise associated proteins.
DNAP Buffer 
150 mM NaCl 
50 mM Tris 
0.1 % Triton 
2 mM EDTA
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2.3.4.2 Band shift Assay
Whole cell extracts were prepared as previously described from cells that were 
uninduced or induced with 2 ng/ml TGF-|3 for 1 hr (Section 2.3.2.1). Extract (10 pg) 
was preincubated for 5 minutes of antibody prior to addition of 10 pi probe mix. Final 
buffer conditions were 210 mM KC1, 5.5 mM MgCl2, 10 % (v/v) glycerol and 0.5 pg 
poly dl-dC. The samples were then briefly centrifuged in a microcentrifuge and 
incubated at room temperature for 15 minutes prior to loading on a bandshift gel. 
Bandshifts were run for 3 hours and 45 minutes. For supershifts, 1 pi of anti-Smad2/3 
(BD Biosciences), 1 pi of anti-Smad4 (B8, Santa Cruz) or 1 pi of anti-Flag (m2, 
Sigma) antibodies were added to extract for 5 minutes before addition of probe.
Probe Mix
1 pi 200 mM KC1 
1 pi 110 mM MgCl2 
1 pi ARE probe (0.2 ng/pl)
1 pi poly dl-dC
4 pi 50 % (v/v) glycerol
2 pi water
2.3.4.3 Probe Synthesis
Bandshift probes were labelled with |a 32PldATP and la 32P|dCTP by PCR. Probe 
synthesis reactions contained 1 pi of each oligonucleotide (50 ng/pl), 1 pi 10 x PCR 
buffer (2.1.1), 1 pi |a 32P|dATP, 1 pi [a32PldCTP, 1 pi dGTP and dTTP mix (0.5 mM), 
1 pi dATP and dCTP mix (50 pM), 0.5 pi Taq polymerase (Developmental Signalling 
Laboratory, Cancer Research UK) and 3.5 pi water.
PCRs were carried out in a GeneAmp® PCR System 9700 (Applied 
Biosystems). Standard conditions were as follows:
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94 °C 3 minutes
94 °C 25 seconds 1
37 °C 25 seconds \ x 31 cycles
72 °C 25 seconds J
72 °C 3 minutes
10 °C 00
After synthesis the probes were gel purified on a 5 % (w/v) acrylamide gel, 
assembled with 0.4 mm spacers and comb. Gels were run for 1 hour at 150 volts and 
150 mAmps in 0.5 x TBE. The gels were then exposed on MXB Film (Kodak) for 1 
minute. The film was then used to identify the location of the probe band on the gel 
which was excised with a scalpel, immersed in 350 pi Elution buffer and incubated 
overnight at 37 °C. Following this incubation, the probe was extracted with 350 pi 
phenol, centrifuged at 13,000 rpm for 5 minutes (Biofuge pico Heraeus centrifuge) and 
the aqueous phase removed. The probe was then precipitated with 1 pg tRNA and 700 
pi 100 % ethanol at -80  °C for 30 minutes and centrifuged at 13,000 rpm for 20 
minutes at 4 °C (Biofuge fresco Heraeus centrifuge). The pelleted probe was washed 
with 350 pi 70 % ethanol and air dried at room temperature before being resuspended 
in TE and then quantitated.
Non-denaturaing acyrlamide gel 
3.125 ml 40 % (w/v) acrylamide 
2.15 ml 2 % (w/v) bisacrylamide 
1.25 ml 10 x TBE 
Up to 25 ml with deionised water
25 ml gel mix was polymerised with 60 pi 20 % (w/v) APS and 50 pi Temed
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2.3.4.4 Probe Quantitation
A ll probes used in bandshilt reactions were at 20 ng/pl. In order to calculate the 
isotope incorporation and thereby quantitate the probes, 1 pi o f  the TL-resuspended 
probe was counted in the scintilla tion counter (Beckman LS 6500 multi-purpose 
scin tilla tion counter) along w ith  1 pi o f  the orig inal pre-PCR probe mix. The probe 
was then quantitated as follows:
(°o Incorporation) x (number moles A+C in probe) x probe MW’T 
number labelled A+C in probe
This equation gives a weight in pg that is then converted into ng. The probe is 
resuspended in a suitable volume o f I H to give a stock solution o f probe at a 
concentration o f 0.2 ng pi.
ARE probe:
The 0o incorporation is established. 100 ° o  Incorporation is equivalent to 1 3 4  ng o f 
probe. The probe is resuspended in a suitable volume o f  T L  to give a stock solution o f 
probe at a concentration o f 0.2 ng pi.
2.3.5 Protein-Protein Interactions
2.3.5.1 Co-lmmunoprecipitation
Cells in 15 cm dishes were lysed in 1 ml 100 mM  Co-IP Lysis buffer. Lysates were 
sonicated lo r 10 seconds on ice and centrifuged at 13,000 rpm (B iofuge fresco Heraeus 
centrifuge) for 5 minutes at 4 °C. Protein concentration was assayed and 3 x 30 pg 
samples were retained for use as controls. The supernatant was then precleared w ith 
pre-equilibrated IgCi sepharose for 1 hr at 4 °C w ith  rotation. Lxtracts were transferred 
to new eppendorls and incubated w ith  antibody overnight. The fo llow ing day, IgG 
beads, blocked w ith  1 mg ml BSA, were added to each sample for 2 hrs at 4 °C w ith 
rotation. The beads were washed tw ice w ith  Co-IP Lysis buffer, resuspended in 4 x 
Sample buffer and Western blotted to visualise associated proteins.
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Co-IP Lysis buffer
100 mM NaCl
20 mM Tris-HCl (pH 7.4)
1 mM EDTA 
1 mM EGTA 
0.1 % (v/v) Triton X -100
5 mM NaF, 10 mM sodium p-glycerophosphate and Complete EDTA-free 
protease inhibitor tablets were added fresh
2.3.5.2 Covalent crosslinking o f anti-HA antibody to protein G-sepharose 
beads
For two-step affinity purification, the mouse monoclonal anti-HA antibody 12CA5 
was covalently conjugated to protein G beads using dimethlypimelimidate (DMPD). 
The method used is based on that described by Harlow and Lane (Harlow, E. et al., 
1988). 500 pi dry beads were washed three times and resuspended in an excess of 
hypotonic buffer containing 140 mM NaCl. Antibody was then added at a ratio of 
0.07 pg antibody per pi bead slurry and this mixture was subjected to gentle agitation 
at room temperature for 1 hour. Beads were then poured into a Bio-Spin disposable 
chromatography column (BioRad), washed with 5-7 ml of 0.1 M sodium borate (pH 
9.0) and resuspended in 0.1 M sodium borate with 20 mM DMFD. This mixture was 
subjected to gentle agitation for 30 minutes at room temperature and poured into 
another disposable column. The beads were then washed with 5-7 ml of 0.2 M 
ethanolamine, resuspended in this buffer and subjected to gentle agitation for 2 hours 
at 4 °C. This mixture was then poured into another column, washed with 5-7 ml 
PBSA and stored in PBSA with 0.1 %  sodium azide.
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2.3.5.3 Peptide Pulldowns and Peptides
Peptide pulldowns were performed as described (Randall, R. A. et al., 2002). For each 
peptide pulldown, a 10 cm dish of cells and 40 pi peptide-saturated beads was used. 
Immobilised Neutravadin™ Biotin Binding beads (Perbio) were washed twice in 1 ml 
cold Buffer Y  (Vastrik, I. et al., 1999) and resuspended in Buffer Y to form a 1:1 
slurry. The slurry was then incubated with the desired peptide (at a concentration of
1.5 mg/ml in water) for 1 hour at 4 °C with rotation.
Dishes of cells (10 cm) were lysed in 400 pi Buffer Y. Lysates were sonicated 
for 10 seconds on ice and centrifuged at 13,000 rpm (Biofuge fresco Heraeus 
centrifuge) for 5 minutes at 4 °C. The supernatant was transferred to a sterile pre­
chilled eppendorf and the protein concentration assayed. Samples (5 x 30 pg) were 
retained for use as controls. The peptide-conjugated beads were washed three times in 
Buffer Y, resuspended to give a 1:1 slurry and then incubated with the cell lysates for 
1 hour at 4 °C with rotation. After this incubation, the beads were washed three times 
with Buffer Y, resuspended in 4 x Sample buffer and Western blotted to visualise 
associated proteins.
Peptide Name Peptide Sequence
XFoxHI-1 FM W T’C LLSLDLPTSYTKSVAPNVVAPPSVLP
XFoxH 1 -Scrambled’0 YSNLLDSTPLAPLVSVPKTLSPVAVP
XFoxH-l SIM WT’d PLDLNMLRAMPPNKSVFDVLTSHPGDLV
XFoxH-3 SIM W T'e PEVKNAPKDFPPNKTVFDIPVYTGHPGFLA
All peptides were synthesised by the Cancer Research UK Peptide Synthesis Laboratory.
*A1I o f these peptides were synthesised with an N-terminal biotin group followed by 16 amino acids 
from helix 3 o f Antennapedia prior to the peptide sequence: Biotin.Aminohexanoic acid- 
RQ IKIW FQNRRM KW KK.
cThese peptides correspond to codons 400-425 of XFast-1. The scrambled peptide corresponds to 
codons 400-425 of XFast-1 but in a random order.
dThese peptides correspond to codons 467-495 o f XFast-1. The mutant peptide has amino acid 
substitutions at positions 11 (P-A), 12 (P-A) and 13 (N-A). These peptides are as described (Howell, M. 
et al., 2002).
c These peptides correspond to codons 291-320 of XFast-3. The mutant peptide has amino acid 
substitutions at positions 11 (P-A), 12 (P-A) and 13 (N-A). These peptides are as described (Howell, M. 
et al., 2002).
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Buffer Y
50 mM Tris-HCl (pH 7.5)
150 mM NaCl 
1 mM EDTA  
1 % (v/v) NP-40
1 mM DTT and 1 x Complete EDTA-free were added fresh
2.3.6 Tandem Affinity Purification (TAP)
The TAP procedure was based on the methods described (Puig, O. et al., 2001; Rigaut, 
G. et al., 1999). A brief description with modifications is given below.
TAP Purification Protocol: Conditions used in Figure 3.6.
15 x 150 cm2 plates of TAP-Smad4 HaCaTs were lysed in 1.5ml Lysis Buffer and 
sonicated for 10 seconds on ice. Lysates were then centrifuged at 10,000 rpm 
(Beckman Avnti™ J-20 centrifuge) for 30 minutes at 4 °C. Extracts were rotated for 2 
hours at 4 °C with 250 pi of IgG sepharose (Sigma), after which the beads were 
washed extensively in binding buffer. Washed beads were resuspended in TEV  
cleavage buffer and transferred to Polyprep® Chromatography Columns (Biorad). 250 
units of recombinant TEV protease (in house) was added to the capped column. After 
rotation for 2 hours at 16°C, the eluate was recovered and stored on ice at 4 °C 
overnight. The beads were resuspended in additional TEV cleavage buffer and 250 
units of recombinant TEV protease was added to the IgG column and left rotating at 
4°C overnight. Eluates were pooled and adjusted to the Calmodulin binding 
conditions: 45 mM Tris pH 8.0, 90 mM NaCl, 0.2 % NP-40, 0.7 mM MgAcetate, 0.7 
mM Imidazole, 3.5 mM CaCh, 10 mM p-ME and rotated with 250 pi of CAM beads 
(Stratagene) for 5 hours. After extensive washing, the bound proteins were eluted with 
Calmodulin Elution buffer. Ten elution fractions of 125 pi each were collected. 
Eluates were pooled and concentrated in Microcon® Centrifugal Filter Devices
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(Millipore). Concentrated eluates were loaded onto a 15% SDS-PAGE gel, which was 
silver stained. Bands were excised and proteins identified by mass spectrometry.
2.3.6.1 TAP Purification Protocol: Conditions used in Figure 3.7.
40 x 150 cm2 plates of TAP-Smad4 HaCaTs were lysed. Extracts were rotated in batch 
for 2 hours at 4°C with 600 pi of IgG sepharose. Addition of 600 units of recombinant 
TEV was used in each cleavage. An equivalent 600 pi of CAM beads were used in the 
second affinity step. Twenty elution fractions of 200 pi each were collected and were 
subsequently pooled and concentrated in centricon-20 columns and transferred to 
Microcon* Centrifugal Filter Devices (Millipore). Samples were loaded onto a 15% 
SDS-polyacrylamide gel. Proteins were detected by coomassie staining, band were 
excised and analysed by mass spectrometry.
Lysis Buffer 
10 mM Tris pH 8.0 
180 mM NaCl 
5 %  Glycerol 
0.2 %  NP-40 
2 mM EGTA,
TEV Cleavage Buffer 
10 mM Tris pH8.0 
150 mM NaCl 
0.5 mM EDTA  
0.1 %  Triton 
1 mM DTT
CAM Elution Buffer
(10 mM Tris pH 8.0, 90 mM NaCl, 0.1% NP-40, 0.7 mM MgAcetate, 0.7 mM 
Imidazole, 20 mM EGTA, 10 mM P-ME)
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2.3.7 Dual Tag Purification
C 'e ll P repara tion
Cells were synchronized and released into new media for 18-22hrs. Cells were 
stimulated w ith  IGF-|3 for 1 hr prior to harvest. Cells were then washed twice w ith  
PBS and subsequently scraped in 5 ml PBS. Cells were pelleted by centrifugation at 
1000 rpm (Beckman A llegra ' 6K.R centrifuge). Cell pellets were stored at -80 °C until 
further use. A lternative ly cells were lysed directly in lysis buffer on the day o f use.
P u rific a tio n  P rocedure: C onditions used f o r  F igures 4.11 and 4.12 
Cell pellets were lysed in High Salt Lysis Buffer (see below) and douced 3-4 times in a 
homogeniser before centrifugation at 10. 000 at 4 °C (Beckman Avnti™ J-20 
centrifuge) for 20 minutes. Supernatants were then adjusted to 150 m M  NaCl w ith  
d ilu tion  buffer and incubated in batch w ith  3 u l o f  pre-equilibrated IgG Sepharose 
beads per mg o f protein for 6-8 hr at 4 °C w ith rotation. Beads were then pelleted by 
centrifugation for 5-10 minutes at 1000 rpm (Beckman A lle g ra '' 6K.R centrifuge). 
Beads were then washed tw ice w ith  wash Buffer and then subsequently w ith  THV 
Protease Buffer and transferred to columns Poly prep® Chromatography Columns 
(Biorad). 1 ml o f THV cleavage buffer was added per 200 ul o f  beads. Beads were 
then incubated w ith 10 units o f  AcTHV protease (Invitrogen, 10 C u l) per ml o f  THV 
cleav age buffer used, for 2 hrs at 14°C. The eluate was recovered and stored on ice at 4 
°C overnight. The IgG beads were then resuspended in additional THV cleavage buffer 
and incubated w ith equal units o f THV protease and le ft rotating at 4°C ov ernight. The 
eluates were recovered from the columns and pooled. These eluates were then 
incubated in re-equilibrated beads beads conjugated w ith  an ti-LLA G  antibody for 6-8 
hrs. H lution was performed w ith  10 x 200 u l LLAG -peptide (200 ug m l) per 200 ul o f 
beads. 10 ul o f  sample were used for W estern B lo tting  analysis. Fractions that were 
positive for bait protein were pooled. TC A  precipitated treated w ith  alkylating agents 
and loaded onto a 15 % acrylamide gel.
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High Salt Lysis Buffer 
50 mM Tris pH 8.0 
400 mM NaCl 
0.1 %  Triton 
2 mM EGTA 
1 mM DTT  
Add Fresh
Dilution Buffer
As for High Salt Lysis Buffer but with 0 mM  
Wash Buffer
As for High Salt Lysis Buffer but with 150 mM NaCl
TE V  Cleavage Buffer 
10 mM Tris, pH 8 
150 mM NaCl 
0.5 mM EDTA  
0.1% Triton
To each buffer the following was freshly added: 25 mM NaF, 25 mM sodium (3- 
glycerophosphate , 1 mM DTT, and 1 x Complete Protease Inhibitors.
Purification Procedure: Conditions used fo r  Figures 4.13
The experiment was carried out as described above but with the following 
modifications. The cells were lysed at with DT Lysis buffer and douced 3-4 times 
before centrifugation at 18, 000 rpm for 30 minutes at 4°C (Beckman Avnti™ J-20 
centrifuge). This centrifugation step was repeated three times. In each case the 
supernatant was removed and transferred to a new tube. After elution with TEV, 
lysates were then incubated with fresh IgG Sepharose for 1 hr at 4°C to remove any 
excess actin. The purification then proceeded as described above.
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D T  Lysis Buffer 
50 mM Tris pH 8.0 
150 mM NaCl 
0.1 %  Triton 
2 mM EGTA 
0.2 mM EDTA
The following was freshly added: 25 mM NaF, 25 mM sodium P-glycerophosphate , 1 
mM DTT, and 1 x Complete Protease Inhibitors.
2.3.7.1 Mass Spectrometry
Mass spectrometry analysis was carried out by the Cancer Research UK Service. 
Triptic digests were performed. Pepide extracts were fractionated using an LC 
Packings Integrated nano-LC System. Fractions were analysed with an Applied 
Biosystems 4700 Proteaomics Analyzer (Foster City, CA). The peptide masses were 
searched against the National Centre for Biotechnology Information (NCBI) non- 
redundant database using the Protein Prospector MS-FIT, MS-TAG or Mascot 
programs.
The mass spectrometry analysis carried out laterally by U lf Heilman, Ludwig Institute 
for Cancer Research, Uppsala Sweden. In this case, the data were analysed by database 
searching using the ProFound search algorithm.
http.7/129.85.19.192/profound bin/WebProFound.exe?FORM=l
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3 Tandem Affinity Purification
3.1 Introduction
As outlined in Chapter l. TGF-(3 regulates many diverse biological processes including 
proliferation, m otility , differentiation and survival. The huge diversity o f  responses 
elicited by TG F-p is in sharp contrast to the simple intracellular Smad signalling 
pathway mediated by Smad2. Smad3 and Smad4. This has raised the question o f the 
mechanism by which signalling specificity and diversity is generated to mediate the 
wide array o f  cell-specific responses. The TGF-P signal transduction cascade is 
controlled at many levels. One important level o f  regulation, in terms o f specific 
activation and repression o f TGF-p target genes, is the interaction o f the Smads w ith  
various transcription factors. Previous work in our lab has shown that the specific 
transcription factors that recruit activated Smad complexes determine which specific 
genes are induced (Germain. S. et al.. 2000; Howell. M. et al., 2002). In accordance 
w ith this view, a current model o f  the pathway envisages the Smads interacting w ith  a 
set o f  partner proteins that are specific to a particular cell type in a given set o f  
conditions. These partners determine the D N A  sequences that the Smad complex w ill 
bind, the transcriptional co-activators or co-repressors it w ill recruit, the other 
transcription factors it w ill cooperate w ith, and how long the response lasts. The 
repertoire o f  Smad partners and regulators present in a given cell at the time o f TGF-p 
stimulation would thus decide the outcome o f the response and defines in molecular 
terms, the cellular context. Identify ing these partners and regulators is. therefore, 
critica l for understanding TGF-|3 action. So far, some candidates have been identified, 
as mentioned in Chapter l.  but although some o f these are genuine interactions and 
have been demonstrated to bind w ith  endogenous Smads in vivo. many o f the proteins 
discussed have been identified through overexpression o f  the partner and/or the Smads. 
As a consequence, the mechanism by which they function and their physiological 
relevance is unclear.
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M y in itia l aim was to investigate the role o f  transcription factor partners o f the 
Smads in the context o f  tumourigenesis. Hpithelial cells norm ally undergo growth 
arrest and apoptosis in response to TGF-JC whereas tumour cells are resistant to these 
growth inh ib itory effects but frequently maintain responsiveness to the pro-oncogenic 
activities o f ICib-|3 (W akefield, L. M. et al.. 2002). The main question posed here is 
whether these different biological responses are governed by the set o f  transcription 
factors to which the Smads bind? Consistent w ith  the current model for Smad 
signalling in a given cell, one could postulate that the differences in TGH-|3 responses 
during tumourigenesis may arise as a result o f  the tumour cell altering its expression 
pattern o f transcription factors and thus diverting the activities o f Smads to a different 
set o f  target genes. To test this hypothesis, my in itia l approach was to identify novel 
Smad-interacting proteins and subsequently determine their involvement in target gene 
activation and ultimately, in different biological responses.
To identity new interacting partners o f the Smads. I made use o f a recent 
innovative purification system developed in the Seraphin lab in HM BL (Rigaut. G. et 
al.. 1999). The tandem a ffin ity  purification (TAP) system is a two-step a ffin ity  
purifica tion scheme, which allows for the purifica tion o f  endogenous proteins under 
m ild  conditions. The TAP tag consists o f  two IgG binding domains o f  Staphylococcus  
aureus protein A and a calmodulin binding peptide (CBP) separated by a Tobacco 
Etch l i r u s  (THV) protease cleavage site (Rigaut. G. et al., 1999). Under native 
conditions, the fusion protein is first bound to IgG sepharose which binds the protein A  
(fig u re  3.1). The bound protein is released by cleavage w ith  THV protease and the 
supernatant is bound to calmodulin-coated beads. The protein is fina lly  eluted in 
HGTA and protein identification can then be made by mass spectrometry. Hpitope- 
tagged a ffin ity  purification has proved to be a valuable tool in purifiy ing  protein 
complexes. The use o f two a ffin ity  steps further improves its efficacy by a llow ing two 
gentle discrim inatory separations under native conditions to retrieve highly purified 
target proteins. In addition, the process is re lative ly fast in comparison to the classical 
biochemical purifica tion methods and results in a high yie ld o f  protein complexes. In 
combination w ith  mass spectrometry, this is an excellent strategy to deline interactions 
w ith bait proteins.
The application o f the TAP method has proved very successful in yeast, 
however, the transfer o f  the TAP method for use in mammalian cells had not been
Chapter 3 Tandem A ffinity Purification
fu lly  established when 1 first began this project in 2002. M y first aim was to adapt the 
TAP-tag technique to purity Smads in epithelial cells. Once the technique was 
established, I could then apply it for use in a tumour model system. In this Chapter, I 
present data on the p ilo t study o f the purifica tion o f  Smads and interacting proteins 
using the IAP-tagging system in the TGF-(3 responsive HaCat cell line. Here I show 
functional expression o f  TAP-Smad proteins in stable lines and optim isation o f  the 
purifica tion o f TAP-Smads.
3.2 Results
3.2.1 Development of the Tandem Affinity Purification System in 
Mammalian Cells
M y first aim was to make N-term inal TAP-tagged constructs o f  Smad2, Smad3, and 
Smad4 in the retroviral vector. p-Zome (CellZome) (Figure 3 .1). C-term inal tags were 
not an option in this case due to the location o f the phosphorylation sites o f Smad2 and 
Smad3 at the extreme C-terminus.
Since the I AP-tagging system was orig ina lly  developed in yeast, it was 
necessary to adapt the system to mammalian cells. The keratinocyte cell line. HaCaTs. 
was chosen as an appropriate cell line, as the TGF-(3 Smad signalling pathway is 
extremely well characterised in these cells (Nicolas. F. J. et al.. 2003a; Pierreux, C. F. 
et al.. 2000). To generate stable cell lines o f  the TAP-Smads by retroviral gene 
transfer, it was first necessary to create a HaCat cell line. HaCat-HcoR cells, that 
expressed an ecotropic receptor, as described in Chapter 2. Subsequently, TAP-Smad2. 
TAP-Smad3. I AP-Smad4 expressing HaCaT cells were generated by infection o f the 
HaCat-FcoR cells using retroviral vectors o f  the TAP-Smads. Pools and clones were 
isolated as described in Chapter 2 and clones whose expression level closely matched 
endogenous Smad level were chosen. The expression level o f  endogenous Smads in 
the clones was examined to ensure homogeneity w ith  the parental line ( f  igure 3.2). It 
is clear that TAP-Smad2 and TAP-Smad4 are expressed at a slightly higher level than 
endogenous Smad2 and Smad4 and TAP-Smad3 is closer to endogenous level.
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Figure 3.1. The Tandem A ffin ity Purification (TAP) Procedure
(A) Schematic representation of the N-terminal TAP-tagged Smad constructs. The sequence and 
structure of the N-terminal tandem tag are illustrated in detail. The TAP tag consists of two 
tandem Protein A IgG-binding domains, a spacer, a TEV cleavage sequence, and one copy of the 
Calmodulin Binding Peptide (CBP) sequence.
(B) Overview of the TAP purification strategy. A protein complex containing the TAP-tagged 
protein is purified sequentially by two independent affinity steps on IgG- and 
calmodulin-conjugated resins, respectively. The immobilized protein is specifically eluted in the 
first instance by protease cleavage (TEV) and in the second by lowering the calcium affinity of 
CBP to calmodulin using EGTA.
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Interestingly, all clones examined expressed the TAP-Smad at a level close to 
endogenous and not a single clone was obtained which overexpressed any o f the TAP- 
Smad proteins (data not shown). This may possibly be explained by a growth 
disadvantage o f cells overexpressing the Smads. which are known to function in the 
growth inh ib itor) actions o f TGF-p (Shi, Y. et al.. 2003). It is also evident from these 
results that TAP-Smad2 and TAP-Smad3 are successfully phosphorv lated after TGF-|3 
stimulation (Figure 3.2). By using cells expressing the TAP-Smad baits at endogenous 
lev els, I hoped to ensure a high ratio o f  associating proteins per tagged Smad in each 
cell. By this means I also expected to increase the like lihood o f purify ing genuine 
interacting proteins and avoid the occurrence o f false positives, which can be observ ed 
when the bait protein is overexpressed.
3.2.2 Functional Studies of TAP-tagged Smads: TAP-Smads 
behave as their endogenous counterparts.
For the purification system to be optimal, it was essential to express fu lly  functional 
TAP-Smads. I inv estigated the possibility that the addition o f  the 19 kDa TAP-tag to 
the Smads may compromise their functionality by a number o f assays, f  irstly. I 
demonstrated functional transloeation o f the TAP-Smads into the nucleus in response 
to TGF-|3 (Figure 3.2B). W estern blots o f  nuclear extracts showed that all three TAP- 
Smads translocate to the nucleus in the induced cells. However, the transloeation is not 
as complete, as that seen w ith endogenous Smads (Figure 3.2. Compare total level o f 
P-TAP-Smad2 and P-TAP-Smad3 in f  igure 3.2A w ith  nuclear level o f P-TAP-Smad2 
and P-TAP-Smad3 in Figure 3.2B). There may be a few explanations for this 
phenomenon: It is possible that the TAP-tag may be masking the nuclear localisation 
signal in some wav or preventing fu ll interaction w ith  the nuclear transport machinery 
(Reguly, I . et al.. 2003). Another possibility is that the tag stabilises the interaction o f 
a naturally occurring Smad retention factor or that a new retention factor is created as a 
result o f  the tag. reducing nuclear transloeation o f a pool o f  the TAP-Smads (Nicolas, 
F. J. et al.. 2004). In contrast, however, the phosphorylation o f  TAP-Smad2 and TAP- 
Smad3 by the TGF-(3 receptors was not compromised. As a result o f  this finding, all 
other functional studies and purifications were performed using whole cell extracts.
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Figure 3.2. TAP-Smads undergo nuclear transloeation in a TGF-p-inducible 
manner
(A ) Levels of expression of the TAP-Smads and endogenous Smads in TAP-Smad HaCaT stable cell 
lines. TAP-Smad2,TAP-Smad3 clones and the TAP-Smad4 pool were either untreated or stimulated 
with TG F-pl for 1 hr. Whole cell extracts were prepared and analysed by Western blotting using 
antibodies against Smad2/3, phosphorylated-Smad2 (P-Smad2), phosphorylated-Smad3 (P-Smad3) and 
Smad4.
(B) Nuclear extracts of the TAP-Smad HaCaT stable cell lines were prepared and proteins were 
visualized by western blotting using antibodies against Smad2/3, phosphorylated-Smad2 (P-Smad2), 
phosphorylated-Smad3 (P-Smad3) and Smad4.
* Indicates the TAP-Smad4 protein, which has been recognised by the a-rabbit secondary antibody via 
its IgG-binding domains.
# Indicates the TAP-Smad2 protein, which has been recognised in the same manner.
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The next aspect I needed to examine was whether the TAP-Smads still possessed 
transcriptional activity. Endogenous Smad3 and Smad4 bind directly, albeit, w ith  low 
a ffin ity  to Smad binding elements (SBTs) on DN A. To investigate the D N A-binding 
ab ility  o f  TAP-Smad3 and TAP-Smad4. I used the well-characterized TGF-p-inducible 
promotor element o f  c-jun to carry out D N A  pulldown assays, as described in Chapter 
2 (Wong, C. et al., 1999). 1'he oligonucleotide used was the Smad binding region 
(SBR) in the 5' I H R o f the c-jun promoter consisting o f three SBHs and adjacent 
sequences (Inman. G. J. et al.. 2002a). In a pattern identical to endogenous Smad3, 
phosphoryiated TAP-Smad3 bound to the c-jun SBR oligo and not to the control 
mutant oligo (Figure 3.3. left). TAP-Smad4 binds to the c-jun SBR oligo in the 
uninduced state and w ith  higher a ffin ity  in the induced state, as observed w ith  
endogenous Smad4. Recent data in the lab suggests that Smad4 is present on the c-jun 
SBR promoter element in the absence o f  TGF-|3 and may possess some repressive 
activ ity, which is consistent w ith  this finding. These results indicate that indeed TAP- 
Smad3 and TAP-Smad4 can bind D N A  in a TGF-(3 inducible manner.
Next, I wanted to investigate the ab ility  o f the TAP-Smads to form  complexes 
w ith known transcription factors. The prototypical Smad-Transcription factor complex 
is termed ARF1, fo r A ctiv in  Responsive Factor 1. It is composed o f Smad2, Smad4 
and X F oxH la . a winged helix/forkhead transcription factor (Chen, X. et al., 1996; 
Chen, X. et al.. 1997). It is responsible fo r mediating Activin-induced transcription via 
the Activin-responsive element (ARE) o f the Xenopus Mix.2 promoter. X F oxH la  can 
recruit the Smad2 Smad4 complex to the ARE through direct interactions between 
Smad2 and two interaction motifs in X F oxH la , the Smad Interaction m otif (S IM ) and 
the Fast. FoxH l m otif (EM) (Randall, R. A. et al., 2004). The SIM  is necessary and 
sufficient to interact w ith the M H2 domain o f either Smad2 or Smad3 and thus recruit 
active complexes to DNA. The EM differs from the SIM by interacting w ith only 
activated complexes o f Smad2 and Smad4, or homomeric complexes o f Smad2 and 
not those o f Smad3 (Randall, R. A. et al., 2004).
Using SIM and FM peptide pulldowns, as described in Chapter 2, I 
demonstrated that the SIM peptide bound both unphosphorylated and phosphoryiated 
TAP-Smad2 and the FM bound phosphoryiated TAP-Smad2 (Figure 3.4). TAP-Smad4 
was detected in SIM and FM pulldowns in the TGF-(3 induced extracts, through 
interaction w ith endogenous Smad2 and Smad3. This pattern exactly m imics the
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Figure 3.3. TAP-Smad3 and TAP-Smad4 form complexes on DNA
Whole cell extracts were made from uninduced or TGF-{5-induced TAP-Smad HaCaT cells. The cell 
extract was adjusted to 200 mM NaCl and then incubated overnight with either c-jun SBR or mutant 
c-jun SBR oligo-conjugated beads as indicated. After washing, the beads were resuspended in SDS 
sample buffer and associated proteins were analysed by Western blotting using antibodies against 
phosphorylated-Smad3, Smad3 and Smad4. Ten percent protein input is shown.
* Indicates the TAP-Smad4 protein, which has been recognised by the a-rabbit secondary antibody 
via its IgG-binding domains.
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Figure 3.4. TAP-Smad2 and TAP-Smad4 form complexes with Sniad-interacting 
motifs
Whole cell extracts were made from uninduced or TGF-p-induced TAP-Smad HaCaT cells. The cell 
extract (1 mg) was incubated for 2 h with either wild type SIM, wild type FM or scrambled FM peptide- 
conjugated beads as indicated. After washing, the beads were resuspended in SDS sample buffer and 
associated proteins analysed by Western blotting using antibodies against phosphorylated-Smad2, Smad2 
and Smad4. 30 pg input protein is also shown.
♦ Indicates the TAP-Smad4 protein which has been recognised by the a-rabbit secondary antibody via its 
IgG-binding domains.
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behaviour o f endogenous Smads. The demonstration o f these interactions indicates 
that the TAP-Smads can form  functional complexes w ith endogenous Smads and w ith 
Smad-interacting peptides. Hence, the TAP-Smads m im ic the endogenous Smads in 
their interactions w ith a partner protein.
To further establish the formation o f the TAP-Smads in complexes on D N A, I 
used bandshift assays to detect ARF1 complexes containing the TAP-Smads. The 
formation o f a stable XFoxI I la  Smad2/Smad4-DNA bound complex (ARF1) can be 
readily detected in a bandshift assay in TGF-p-induced extracts using radiolabeled 
ART probe. This complex can also be retarded on the gel by addition o f specific 
antibodies, which bind components o f  the complex and cause a supershift o f  the 
complex. The ARF1 complex containing TAP-Smad4 was detected by supershift w ith  
the anti-Smad4 antibody, seen as a second, slower m igrating band above the 
endogenous Smad complex (Figure 3.5A). W hilst endogenous complexes were formed 
in the TAP-Smad2 HaCaTs. the fraction o f TAP-Smad2 containing complexes could 
not be identified. This may be due to the inab ility  o f  the antibody to recognise the 
TAP-Smad in the DNA-com plex. or. more like ly the rather low level o f  TAP-Smad2 
compared w ith endogenous Smad2.
The expression o f the TAP-Smads from  the weak LTR (long terminal repeats) 
promoter in transient transfections was not sufficient to compete w ith endogenous 
Smads in luciferase reporter assays. However, using M D A -M B 468 cells, which are 
Smad4-null cells, I was able to analyse TAP-Smad4's transcriptional activity (Figure 
3.5B). This was not possible fo r Smad3 as the Smad3-null cells were not available at 
the time (Piek, E. et al.. 2001) . The Smad2-null cells that have been reported in the 
literature (Piek, E. et al.. 2001), have recently been shown to express a truncated form  
o f Smad2, which can form  complexes w ith Smad4 and actively engage in TGF-|3- 
induced transcription, thus elim inating their use as Smad2-null cells (Randall and H ill, 
unpublished data). To test the ab ility  o f TAP-Smad4 to induce transcription, M D A -
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Figure 3.5. TAP-Smad4 forms complexes which are transcritpionally active
(A ) TAP-Smad4 forms stable complexes with XFoxHla and activates endogenous Smad2 on the ARE 
probe. HaCaTs, TAP-Smad2 HaCaTs and TAP-Smad4 HaCats were transfected with XFoxHla and 
were either uninduced or induced with TGF-fJl for 1 hr prior to lysis. Whole cell extracts were analysed 
by bandshift assay using radioactively labelled ARE probe and in the presence or absence of 1 pi anti- 
Smad2/3 or anti-Smad4 antibody, as indicated. The Smad-containing complex, Activin Responsive 
Factor (ARF), is indicated, as is the supershifted complex. When TAP-Smad4 HaCaT cells are super- 
shifted with a-Smad4 antibody, two complexes are seen-one containing endogenous Smad4; the other 
lower mobility one containing TAP-Smad4 as indicated.
(B) Smad4-null MDA-MB468 cells were transfected with the (ARE)3-luciferase reporter gene together 
with plasmids expressing XFoxHla alone or with HA-Smad4 or increasing amounts of TAP-Smad4 as 
indicated. Cells were lysed in reporter lysis buffer and luciferase assays were performed. Luciferase 
was quantitated relative to fJ-galactosidase from the pEFLacZ internal control. The data are means and 
standard deviations of 3 independent experiments.
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MB468 cells were transiently transfected w ith the (A R E f-luc ife rase reporter. In the 
absence o f Smad4, X F oxH la  elicited a weak TGF-(3 induction via the ARE. 
Overexpression o f HA-Smad4 increased the basal activ ity and substantially increased 
the TGF-p-induced level o f transcription. Increasing amounts o f TAP-Smad4 also 
increased the basal activity and TGF-(3-induced transcription w ith increasing dose. 
These data indicate that TAP-Smad4 cells can integrate in a known promoter complex 
(ARF1 at the ARE) and initiate transcription in response to T G F -( l
Thus far, w ith the exception o f complete nuclear transloeation, all the assays 
v alidate fu ll functionality o f the TAP-Smads as mediators o f TGF-[3 signalling.
3.2.3 Purification of TAP-Smad4 associated proteins
Prelim inary experiments to optimise conditions for the TAP procedure were carried 
out using the pool o f  TAP-Smad4 HaCaT cells. By using Smad4 as bait, the possibility 
o f identify ing transcription factors involved in Smad2 and/or Smad3 transcription was 
increased. Small-scale experiments using 6 \150  cnT plates were used in in itia l 
experiments and results indicated excellent binding to the IgG beads, good TEV 
cleavage, but variable binding to the Calmodulin (C A M ) beads. Having in itia lly  
optimised the conditions, I performed the purification on a large scale. In my first 
attempt I used extract from 15 x l5 0  cirT plates o f uninduced and TGF-(3-induced cells. 
Samples were taken at each step to monitor the progress o f TAP-Smad4 throughout the 
purification procedure. Progression through each purification step was successful w ith  
a final elution peak at fraction 5 for both samples (Figure 3.6A). Analysis by Western 
blotting revealed Smad2 in association w ith  Smad4 throughout the whole purification 
procedure for the extract o f induced cells ( f  igure 3.6A), and not w ith  the extract from 
uninduced cells, as was expected (data not shown). This acted as an excellent marker 
for specific interacting proteins co-purify ing w ith  the TAP-Smad4 bait. The 
concentrated fractions o f the eluates were then analysed by silver staining (Figure 
3.6B). The pattern o f bands in both samples was remarkably sim ilar but w ith  the 
exception o f two bands. The first protein was present only in the induced sample and 
migrated on the SDS-PAGF gel at approximately 66kDa. It was suspected that this
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Figure 3.6. Purification ofTAP-Smad4 associated proteins
(A) Samples taken from TGF-p-induced TAP-Smad4 HaCaTs at each stage of the purification were 
analysed by Western blotting. The top blot is probed with an anti-Smad4 antibody. This blot was 
then reprobed with an anti-Smad2/3 antibody (lower panel). The following proportions of samples 
were loaded: Input (1/1,300), IgG flow through (1/1,300), TEV eluate (1/60), IgG beads post TEV  
cleavage (1/8), CAM beads post EGTA elution (1/8), CAM flow through (1/150) and final eluates 
(1/4).
(B) Silver-stained gel depicting proteins recovered following purification of TAP-Smad4 associated 
proteins from unstimulated and cells stimulated with TGF-fJ for 1 hr. The numbers to the left show 
the positions of molecular size markers (kDa). Proteins identified by mass spectrometry are 
indicated. Mass spectrometric anlaysis was carried out by the Cancer Research UK Service.
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was Smad2. The second band was present only in the uninduced lane and was detected 
slightly above the 42 kDa marker.
Mass spectrometry analysis obtained a positive identification for the Smad4 
bait. The only other identification made was for the 66 kDa band and a low molecular 
weight protein. Mass Spec data revealed that the 66 kDa band was not Smad2. 
However, a positive identification could not be made due to lim ited sample. From the 
single peptide that was recovered, the database revealed a number o f possible 
candidates. The most probably candidate was a protein disulfide-isomerase (Trp57). 
This protein contains th ioredoxin-like fo ld  and in recent years this fam ily o f  proteins 
has been implicated in an increasing number o f processes including wound healing and 
development (Clissold. P. M. et al.. 2003). Interestingly, in a screen for proteins 
interacting w ith  the Drosophila Smadl orthologue. Mad. a protein possessing th io l- 
disulfide exchange activity was identified (http://www.curagen.com). The third 
positive identification revealed an E-coli protein, an outer membrane protein F 
precursor, which was obviously a contaminant from the beads or the THV protease.
However, despite these three identifications, no other bands detected could be 
identified. This was in part due to the staining technique used. The metallic silver dye 
covalently binds to acidic residues which interferes w ith  mass spectrometric analysis. 
Coomassie B rillian t Blue stain has a lower sensitivity, but is fu lly  compatible w ith  
mass spectrometry o f  eluted polypeptide chains. In order to use Coomassie staining for 
detection o f bait and interacting proteins. I needed to further expand the purification 
procedure by increasing the input. To this end, I carried out a very large scale TAP 
purification using 40 x 15 c ir f  plates o f uninduced and TGF-p-induced TAP-Smad4 
HaCaT cells (Figure 3.7). A t this scale, proteins could be visualised using Coomassie 
stain. I he Western blot and Coomasse stained gel revealed that a high level ol Smad4 
bait was purified from uninduced cells. Unfortunately, very little  bait was recovered 
from induced cells. This was attributed to the considerable loss o f bait during the 
second step o f purification.
A positive identification for human Smad4 was made by mass spectrometry, 
however, all other identifications made were oi' E-coli proteins. These included Phage 
>. receptor protein. O m pf Porin (mutant R82c), Phage Lambda receptor protein and 
Ferrienterobactin receptor precursor. Once again, these proteins were obviously 
contaminants from the IgG beads, the Calm odulin beads or the TEV protease and were
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Figure 3.7. Large-scale purification of TAP-Smad4 associated proteins
(A) Samples taken at each step of the purification o f both uninduced and TGF-f3-induced 
TAP-Smad4 HaCaTs were analysed by western blotting for Smad4 in each case. The following 
proportions of samples were loaded: Input (1/2,200), IgG flow through (1/2,200), TEV eluate 
(1/170), IgG beads post TEV cleavage (1/10), CAM  beads post EGTA elution (1/15), CAM flow 
through (1/800) and final eluates (1/7).
(B) Coomassie-stained gel depicting proteins recovered following purification of TAP-Smad4. 
The final eluate fractions of the purifications were pooled and concentrated and analysed by 
SDS-PAGE. Proteins identified by mass spectrometry are indicated.
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in terfering w ith  the identification o f possible Smad interacting-proteins. To tackle this 
problem. I examined all sources o f contamination. Despite some m inor contamination 
from the Calmodulin beads, the use o f either the IgG beads or the Calmodulin beads 
did not contribute significantly to the contamination purified in the final eluates. To 
test whether the in-house source o f THV protease was clean, I used a high purity, 
commercial enzyme from invitrogen for comparison. Silver-stain analysis o f  both THV 
protease sources, clearly showed a high degree o f contaminants in the in-house 
purified enzyme compared w ith  the commercially supplied form ( f  igure 3.7). The 
THV protease was obviously the source o f  contaminants in the final eluate.
Once I had overcome the problem o f contamination, I continued to optim ise 
this TAP-tagging system. Unfortunately, s im ilar hurdles were met repeatedly, where 
the bait protein would fa il to bind to the Calm odulin beads (Figure 3.7 and data not 
shown). M u ltip le  approaches o f buffer optim isation, varying the concentration o f 
HGTA. NaCl. and detergent at each stage o f  the purifica tion did not alleviate the loss 
o f bait experienced during the final purification round. The presence o f this unreliable 
a ffin ity  step made it very d ifficu lt to compare samples o f treated and untreated cells. 
And ultimately, it was impossible w ith  this methodology to purify  a sufficient level o f  
bait, which could be used to identify novel proteins.
3.3 Discussion
O rig ina lly , protein complexes were purified using classical biochemical methods. This 
process was generally time-consuming, especially for low abundant complexes as very 
large amounts o f starting material (hundreds o f  grams o f cells or tissues) and numerous 
purification steps were needed. Yields were usually low and the procedure was so long 
that less stable complexes were not preserved. Development o f a ffin ity -purifica tion  
techniques has dramatically improved the purification o f  protein complexes. In the 
ease o f the Tandem A ff in ity  Purification procedure, this system has been used to 
isolate a w ide variety o f  bait proteins, and moreover, has been applied for use in large 
scale analysis in yeast (Gavin. A. C. et al.. 2002). G iven the previous success w ith  this 
system in yeast, my in itia l goal was to adapt this procedure to analyse components o f 
the TGF-(3 pathway in mammalian cells. Indeed, the data presented in this p ilo t study
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Figure 3.8. Comparison of TEV protease from different sources
5pl of Tobacco Etch Virus protease (TEV) from Invitrogen and from an in-house source were analysed 
by SDS-PAGE and silver stained to visualise contaminants. The invitrogen protein was very pure 
compared with the in-house version.
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shows the development o f a purifica tion system for interacting-Smad proteins in 
HaCat cells. I successfully established stable cell lines expressing exogenous tagged 
Smad protein, at levels close to endogenous. The expression o f the tagged proteins 
prov ed non-toxic to the cells. 1 hav e confirmed that the presence o f a 19kDa tag does 
not interfere w ith the ability  o f  the Smads to complex w ith  other proteins. Apart from 
the slightly compromised nuclear import, the functionality o f  the TAP-Smads is not 
hindered.
The in itia l problem encountered during this p ilo t study was the presence o f 
contaminants from the purified TEV protease. This resulted in a high level o f 
interference in the process o f identification o f Smad-interacting proteins. For example, 
a protein disulfide-isomerase (Erp57) was identified as a possible candidate for a novel 
Smad partner, but further investigation failed to confirm  this interaction (data not 
shown). Other protein identifications were more obviously classified as contamination 
due to their bacterial orig in (Figure 3.7B). However, this obstacle could be overcome 
w ith  the use o f a highly purified source o f TEV protease, as was the case w ith  repeat 
experiments (Figure 3.8 and data not shown). The major problem, however, was the 
unreproducible and unreliable two-step purification o f the bait Smad4. This is 
exem plified in f  igure 3.7B. which shows the unsuccessful purification o f the TGE-fT 
induced extract, whilst uninduced extract performed well. It was evident from Western 
blot analysis that substantial loss o f the bait protein (TAP-Smad4) occurred during the 
second step o f the purification. In the Coomassie stained gel, background bands were 
observed in both lanes but Smad4 was only detected in the uninduced lane. This is 
consistent w ith the good elution profile  o f  the uninduced sample as confirmed by 
western blotting ( f  igure 3.7A).
It was evident from this and many other subsequent experiments that the C A M  
binding step was the weak point o f  the purification technique. In some cases, none o f 
the cleaved TAP-Smad bound to the C A M  beads. It is important to note that the IA P - 
Smad protein did not fail to bind the C A M  beads because o f  stimulation w ith TGE-p. 
Repeated experiments showed no correlation between the failure o f the second step 
w ith  induction by TGF-|1 In fact, despite rigorous testing o f purification conditions, 
there seemed to be no correlation w ith  any o f  the parameters investigated. This is 
underscored in the purification o f uninduced and induced TAP-Smad4. which were run 
in parallel under identical conditions, however the efficiency o f  the bait binding to the
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C A M  beads differed drastically (Figure 3.7). Purification o f both TAP-Smad2 and 
TAP-Smad3 yielded sim ilar inconsistencies, which indicated that it was not specific to 
TAP-Smad4.
Interestingly, previous studies have demonstrated that the Smads can interact 
w ith  C A M  (Scherer, A. et al., 2000; Zimmerman, C. M. et al., 1098). Other evidence 
implicate the Smads as substrates o f Calcium calmodulin-dependent protein kinase II 
(CamK.II) and suggest that phosphorylation o f the linker domain by C'amKII prevents 
nuclear translocation o f the Smads (W icks. S. J. et al., 2000). I f  this is the case. I 
speculated that this could explain the decreased capacity o f  the TAP-Smads to 
translocate to the nucleus and the lim ited ab ility  o f  the TAP-Smads to bind to the 
C A M  beads. It was possible that perhaps the presence o f the CBP tag increased the 
amount o f  endogenous Calmodulin binding to the TAP-Smads. This Calmodulin m ight 
recruit Cam KII to phosphorylate the TAP-Smads. However, using IgG pulldown 
assays, it was clear that endogenous Calm odulin did not bind the TAP-Smads during 
the Protein A-IgG  binding step (data not shown). The presence o f HGTA in the lysis 
buffer presumably prevented binding o f endogenous Calmodulin to the CBP tag. as 
intended. Hence, the only other possibility that m ight explain the poor binding o f  the 
TAP-Smads to the C A M  beads, is that it is due to a m islblded or denatured CBP in the 
context o f  the Smad fusions. This may not happen in all cases, perhaps due to the 
presence o f a chaperone protein in variable amounts in the proteins extract. 
Furthermore, the TAP-tag was cloned directly upstream o f the Smad ATG  start site, 
w ithout the incorporation o f a linker sequnce to separate the tag from the Smads. It is 
possible that this may hav e increased the steric hindrance o f the 'Fag. in particular upon 
cleav age o f the ProteinA IgG binding domains.
To conclude, it is possible to generate Smad fusion proteins in mammalian 
cells that are functional w ith respect to their ab ility  to form  complexes w ith 
endogenous Smads, bind to DN A and in itiate transcription. In addition, the Protein A- 
IgG binding step together w ith TEV cleavage o f the TAP-Smad, provide a highly 
discrim inating separation step, which allows fo r the purification o f known and 
unknown interacting partners. Unfortunately, the C A M  binding o f the TAP- 
purification procedure proved to be unreliable as a second, final step o f purification.
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As a result, 1 investigated the use o f an alternative tag, which w ill be discussed in the 
next chapter.
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4 Chapter 4
4.1 Introduction
As introduced in Chapter 3. the in itia l aims o f my study were to gain insight into the 
molecular mechanisms governing TGF-(3 signalling through identification o f new 
components o f the pathway. The interactions between Smads and other proteins 
represent an important determinant o f  specificity w ith in  the TGF-(3 pathway (ten 
D ijke. P. et al., 2004). The Smads interact w ith  a wide array o f proteins, including 
cytoskeletal components and nuclear transport machinery which allow  access to the 
nucleus, and a range o f discrete and distinct D N A  binding cofactors, which give rise to 
high a ffin ity  binding to a specific gene set (ten D ijke. P. et al.. 2004). To shed light on 
new partners o f the Smads. I wanted to use the Smad proteins as bait to co-purify 
associated proteins. It is evident from the p ilo t study in Chapter 3 that it is feasible to 
use a two-step purification procedure to search for Smad-interacting partners. The 
conventional TAP system, however, failed to yie ld reproducible results due to the 
unre liab ility  o f the Calmodulin binding step. However, the redeeming feature o f the 
TAP system was the efficiency and reproducib ility o f  the Protein A -IgG  binding step 
combined w ith  the TEV cleavage. In this Chapter, I present data on a modified TAP 
purification scheme, which utilises the Protein A -IgG  a ffin ity  purification and TEV 
cleavage steps but w ith  a FLAG-tag as a replacement tag for Calmodulin binding 
peptide (CBP) for the second purification step.
The TAP system was in itia lly  tested in the HaCat keratinocyte cell line in order 
to establish the feasibility o f  the purification technique. The HaCat cell line served as 
an excellent tool in testing the functionality o f  the TAP-tagged Smads and also in 
demonstrating a viable multi-step purification procedure. U ltim ately though, the aim o f 
this work was to use the purification system to identify novel Smad-interacting 
transcription factors in a tumour cell model system. A well characterised system 
developed in Hartmut Beug's laboratory was chosen fo r this purpose. It is an ideal 
system to use in this study because the TGF-(3 responses in the individual cell lines 
have been investigated in detail. The parental cell line, EpH4 cells, are a non­
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transformed clonal epithelial derivative o f IM -2  mouse mammary gland epithelial cells, 
which were originally isolated from mammary tissue o f a mid-pregnant mouse 
(Reichmann, E. et al.. 1989). EpH4 cells are non-tumorigenic and undergo growth 
inh ib ition and apoptosis in response to TGF-(3 (O ft. M. et al., 1998; Oft, M. et al.. 
1996). However, EpH4 cells that have been transformed by stable expression o f 
oncogenic Ras (EpRas cells) undergo an Epithelial-to-Mesenchymal Transition (EM T) 
in response to TGF-|3 and form  rapidly growing tumours in mice (O ft, M. et al.. 1998; 
O ft. M. et al.. 1996). Cells recovered from these mouse tumours give rise to 
mesenchymal-like cells (X-tum our). These X-tum our cells are characterised by a 
spindle-like morphology and loss o f epithelial markers. The cell lines represent the 
progression o f a tumour from a normal epithelial to an invasive spindle-like cell.
W hile individual aspects o f TGF-(3 responses have been studied in detail, much 
less is known about how a cell interprets the TGF-(3 signal to e lic it d ifferent responses, 
such as growth inh ib ition or EMT. The molecular mechanisms by which TGF-(3 
induces growth arrest in cells has been well documented (Shi, V. et al.. 2003). In 
epithelial cells. TGF-(3 induces activation o f pl5lnk4b , which encodes a cyclin- 
dependent kinase (CDK.) inh ib itor and also acts to repress c-mvc. which encodes a 
potent transcriptional activator o f genes required for growth and proliferation 
(Massague. J. et al.. 2000b). The molecular requirements for EM T are more complex 
but a number o f  the signalling pathways involved in this process have been elucidated 
(Huber, M. A. et al.. 2005). In the EpH4 system, a cooperative signal via the TGF-(3 
and Ras was found to be essential for progression o f EM T (Janda. \i. et al.. 2002). 
However, the necessary molecular steps required to achieve EM T versus growth 
inh ib ition is yet to be determined. To address this question, I used this tumour model 
system as a tool to investigate how cells respond d iffe rentia lly  to TGF-[1 M y primary 
aim was to determine why EpH4 cells respond to TGF-(3 by growth inhib ition 
compared w ith the EM T response observed in EpRas cells. The ultimate goal was to 
unravel a mechanism whereby tumour cells become resistant to the growth suppressive 
effects o fT G F -p , but remain responsive to TGF-(3 as a tumour promoter.
In this chapter I present data on the use o f  a tumour model system in 
combination w ith  an advanced protein purifica tion technique. I begin w ith  results o f 
my in itia l characterisation o f the three different cell lines in the EpH4 tumour model
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system and characterisation o f the responses o f the cell system to TGF-(3. I then go on 
to demonstrate the use o f these cells in isolating Smad proteins and their interacting 
partners.
4.2 Results
4.2.1 Establishing the Tumour Model System
4.2.1.1 Phenotype of EpH4 derivatives
M y first task was to set up the EpH4 tumour model system in the lab and demonstrate 
the different responses to TG F-p o f the individual cell lines, as previously observed 
(O ft. \1. et al.. 1998: Oft. M. et al., 1996). I began w ith the morphology o f each cell 
line on plastic. From Figure 4.1 A. it is clear that both EpH4 and EpRas cells exhib it a 
clear epithelial morphology. These cells grow in clusters and form  monolayers o f cells 
in close contact, tigh tly  adherent to neighbouring cells and to the plastic substrate. In 
addition, confluent cultures o f  EpF14 cells develop hemicysts or domes, which are 
believed to be due to unidirectional flu id  secretion o f  polarized epithelial cells when 
cultured on plastic (Lever, J. E.. 1979). The X-tum our cells, on the other hand, display 
a distinct mesenchymal phenotype (Figure 4.1 A, right hand panel). This is evident 
from the elongated cells w ith  a spindle-shaped, fibroblastoid morphology and the lack 
o f contact w ith  neighbouring cells.
4.2.1.2 Characterisation of the EpH4 model system in Collagen Gels
Next, it was important to assess the responses o f each cell type to TGF-p. To 
demonstrate TGF-p-induced EM T in EpRas cells and its absence in EpM4 cells, I set 
up 3-1) collagen gels as previously described (O ft, M. et al., 1998; Oft, M. et al., 
1996). Using this technique it is possible to visualize the 3-D structures formed. 
Previous studies have indicated that both EpH4 and EpRas cells tend to form tubular, 
branched structures o f fu lly  polarized cells. EpRas cells grow faster and mainly form 
alveolar structures w ith  larger lumina, however the precise structures formed by each 
cell type can be variable (O ft, M. et al., 1998; O ft, M. et al., 1996). In collaboration 
w ith  Hartmut Beug's laboratory, experiments were conducted to observe the structures 
o f EpH4 and EpRas cells in 3-D collagen gels. Structures o f EpH4 and EpRas cells
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performed in the H ill Laboratory were more heterogenous than those carried out in the 
Beug laboratory. Therefore, experiments conducted in collaboration w ith  the Beug 
laboratory are shown in Figure 4 .IB . In the case o f the FpH4 cells, the cells form 
organ-like ducts sim ilar to those formed by primary mammary epithelial cells (Figure 
4.1, right panel). In the presence o f TGF-(3, however, the structures are absent and the 
cells progress toward apoptosis. In the absence o f TGF-(3, HpRas cells also form 
tubular structures but, after TGF-|3 stimulation, these cells form elongated, invasive 
cords ( f  igure 4 .IB . m iddle panels). This fibroblastoid phenotype was also observed in 
the X-tum our cells (Figure 4 .IB . left panel).
To understand the nature o f the structures. I employed immunostaining to 
identity cell-cell contacts. In this experiment, individual structures o f EpRas cells in 
collagen gels prepared in the F lill laboratory were examined. This revealed that the 
structures were formed by communication between many cells as seen by dapi staining 
(Figure 4.1C). Individual cells retained their cell-cell junctions w ith in  the structures as 
observed by the H-cadhering staining. In the presence o f TGF-(3, EpRas cords were 
formed by a single cell chain w ith  slightly reduced E-cadherin staining at cell-cell 
junctions.
To conclude, it is clear that the EpH4 tumour model cell system behaves as 
previously described by the Beug laboratory (O ft, M. et al., 1998; Oft. M. et al.. 1996). 
HpRas cells undergo an EM T in response to TGF-(3 in 3-D collagen gels, and the 
progression to invasive spindle-like cords m im ics the phenotype o f the X-tumour cells.
4.2.1.3 Effects of TGF-/3 on the Cell cycle in EpH4 derivatives
Next. I went on to investigate the effect o f  TGF-(3 on the growth arrest. EpH4 cells 
only respond to TGF-|3 by growth inh ib ition at specific points in the cell cycle 
(Fetritseh. C. et al.. 2000), which does not appear to be the case for other cell lines 
such as HaCats (Nicolas, F. J. et al., 2003a). Possible explanations for this w ill be 
discussed later (Chapter 5 and 7). For an effective response to TGF-(3, the cells require 
synchronisation by contact inh ib ition (Petritsch, C. et al., 2000) and subsequent release 
into fresh media in the presence or absence o f TGF-(3. The effect o f  TGF-(3 can be 
assayed by the ab ility  o f  the cells to enter S-phase. Using this technique, FACS 
analysis revealed that all three lines o f contact inhibited cells (0 hr) exhibited a
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Figure 4.2. EpH4 cells undergo growth arrest in G1 in response to TGF-0, 
whereas EpRas and X-Tumour cells do not
(A ) FACS-DNA profiles of EpH4 cells, EpRas and X-tumour cells. Cells were synchronised in G1 by 
contact inhibition for 72 hrs. Cells were detached from the plates with 0.2% EDTA and replated in 
fresh medium and allowed to re-enter the cell cycle for 22 hrs, in the presence or absence of TGF-fJl 
(2 ng/ml). Cells were harvested and analysed by fluorescence-activated cell sorting (FACS), to 
determine the number of cells in G1, S and G2/M.
(B) Quantitations of the FACS profiles indicating percentage of cells in each phase of the cell cycle, 
G1 (black bar), S (blue bar) or G2/M (grey bar).
206
Chapter 4 EpH4 tumour model system
prominent GO G1 peak indicative o f a cell cycle arrest. Upon release in the presence o f 
TGF-p. the EpH4 cells remained in G1 and their entry into S-phase is inhibited (Figure 
4.2A. left), whereas the control, untreated cells progress through the cell cycle. In 
contrast. HpRas and X-tum our cells proceeded rapidly into S phase regardless o f the 
presence o f TGF-p (Figure 4.2B, middle and right). Upon release in the absence o f 
IG F-p , the number o f HpRas and X-tum our cells in G2/M  was far greater than HpH4 
cells, which is consistent w ith a faster doubling rate o f  both HpRas and X-tum our cells 
than HpH4 cells. I conclude from this experiment that TGF-(3 inhibits progression o f 
HpH4 cells into S-phase, whereas entry o f  EpRas and X-tum our in the presence o f 
TGF-(3 is not affected.
4.2.1.4 Response of EpRas cells on Plastic
As part o f  the characterisation o f this tumour model system. I set up an EM T assay for 
HpRas cells on a plastic substrate. EpRas cells proliferate at a very high rate and it was 
observed that contluent cells were refractory to TGF-(3-induced EM T (For discussion, 
see Chapter 7). As a result. EpRas cells were grown at a low  density and were 
trypsinised every 2-3 days to ensure subconfluent monolayers. In the absence o f TGF- 
l l  HpRas cells formed a polarised monolayer o f  cells. This was demonstrated by H- 
cadherin and and Zona Occludens 1 (ZO-1) staining, which allowed the visualisation o f 
tight and adherens junctions (Figure 4.3A, top panel). Upon prolonged TGF-p 
treatment. HpRas cells lost epithelial polarity, demonstrated by the disintegration and 
disassembly o f eell-cell junctions, as demonstrated by the downregulation and 
delocalisation o f H-cadherin and ZO-1 (Figure 4.3A. second row o f panels). 
Upregulation o f mesenchymal markers, such as V im entin, was also observed (Figure 
4.3B. upper panel). This was accompanied by a dramatic remodelling o f the actin 
cytoskeleton from cortical actin to actin stress fibers, a hallmark o f migratory, 
mesenchymal cells ( I hiery, J. P. et al., 2006) (Figure 4.4, upper panels). During HMT, 
an autocrine loop o f TGF-p is established and maintains the fibroblastoid phenotype o f 
converted HpRas cells (O ft, M. et al., 1996). To investigate whether a feedback loop 
had been established, nuclear accumulation o f  Smad2/3 was investigated. The samples 
were harvested 48 hrs after addition o f  TGF-p. In human keratinocytes, 
phosphorylation o f Smad2/3 is terminated approximately 12 hrs after TGF-P addition 
resulting in the redistribution o f  Smad2/3 to the cytoplasm (Inman, G. J. et al.. 2002c;
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Figure 4.3. Knockdown of ALK5 abolishes TGF-P-induced EMT
(A and B) EpRas cells were transfected at low density with siRNA against ALK5 or a non-targeting 
oligo. After overnight incubation, cells were replated 1:2 and grown in the presence or absence of 
TGF-pi (2 ng/ml). The medium was changed 1 d after seeding and then every other day. TGF-pl was 
added to the cells upon medium change. Three days after plating, the cells were trypsinised and re-plated 
at equivalent density to day 1. A second siRNA transfection was performed on day 4. One, Final replating 
of cells was carried out on day 7. Cells were grown for a total o f 9 days in the presence or absence of 
TGF-p 1 and then harvested 48 hrs after Final TGF-p addition. Cells were processed for immunofluores­
cence and examined by confocal laser scanning microscopy. Antibodies against E-cadherin and Zona 
Occludens 1 (ZO-1) were used to analyze adherens junctions or tight junctions, respectively (A). An 
anti-vimentin (Vim) antibody was also used to analyze mesenchymal marker expression (B) and nuclei 
were visualized with DAPI.
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Pierreux. C. H. et al.. 2000). In EpRas cells, however. Smad2/3 localisation was 
predominantly nuclear, 48 hours after TGF-P addition, suggesting that prolonged TGF- 
p addition resulted in the induction o f an autocrine loop, which produced high levels o f  
TGF-p. Taken together, these results show that a valid assay for HMT progression in 
FpRas cells has been established.
I, therefore, tested my HMT assay to see i f  these cells exhibited sim ilar 
characteristics to the 3-D gel HMT assay. TGF-P receptor type I (AEK.5) activ ity has 
been shown to be crucial for EM T progression in HpRas cells (O ft, M. et al.. 1998; 
O ft. M. et al.. 1996). As a positive control for inh ib ition o f HMT. siRNA 
oligonucleotides against A LK 5  were transfected into the EpRas cells prior to TG F-p 
induction. EM T progression requires long-term incubation w ith  TGF-p, hence a 
second siRNA transfection was performed to ensure continued knockdown o f the 
receptor. A fter 9 days o f TGF-P stimulation, the cells were examined by 
immunofluorescence. In contrast to the control cells, ce ll-ce ll junctions remained 
intact and the integrity o f epithelial polarity was maintained (Figure 4.3A. lower 
panels). Although a slight delocalisation o f E-cadherin was observed, this was 
probably due to an increase in AEK5 expression at day 7-9 as the siRNA 
oligonucleotides were gradually diluted out. V im entin expression was inhibited 
(fig u re  4.3B. lower panel) and the actin cytoskeleton remained virtua lly  unaltered 
( fig u re  4.4, lower panels). This firm ly  establishes the requirement for AEK.5 
expression at the onset o f  TGF-p stimulation for a complete EM T. Further ev idence o f 
re-expression o f AEK.5 at late stages o f the experiment was evident when localisation 
o f Smad2 3 was examined. Nuclear accumulation o f  Smad2/3 suggested that a low 
level o f  AEK.5 was expressed at the final stages o f these cells, which is likely due to 
the loss o f effect o f  the siRNA oligonucleotides ( f  igure 4.4, lower set o f  panels). This 
gradual re-expression o f low levels o f  AEK.5 protein promoted the production o f an 
autocrine loop but which was not sufficient for HMT progression.
l hese results show that by using a combination o f siRNA technology w ith an 
established HMT assay, components o f  the TGF-P pathway involved in HMT 
progression can be inv estigated.
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Figure 4.4. An autocrine loop of TGF-p secretion is set up during EMT
EpRas cells were transfected at low density with siRNA against ALK5 or a non-targeting oligo. After 
overnight incubation, cells were replated 1:2 and grown in the presence or absence of TGF-P 1 (2 
ng/ml). The medium was changed 1 d after seeding and then every other day. TGF-p 1 was added to 
the cells upon medium change. Three days after plating, the cells were trypsinised and re-plated at 
equivalent density to day 1. A second siRNA transfection was performed on day 4. One, Final replat­
ing o f cells was carried out on day 7. Cells were grown for a total o f 9 days in the presence or absence 
of TGF-p 1 and then harvested 48 hrs after final TGF-p 1 addition. Cells were processed for immuno­
fluorescence and examined by confocal laser scanning microscopy. Smad2/3 localisation was deter­
mined using anti-Smad2/3. Actin reorganization was visualized with Texas red-conjugated phalloi­
din, and nuclei were visualized with DAPI. Samples were processed from the same experiment as in 
Figure 4.3.
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4.2.1.5 Cell cycle status of EpRas cells undergoing EMT
As HMT has been described as a dedifferentiation event (Grunert, S. et al., 2003). it 
was important to determine whether the HpRas cells were proliferating during HMT 
progression. The K i-67 antigen is the prototypic cell cycle related nuclear protein, 
expressed in proliferating cells in G l.  S, G2 and M. but not in GO. K i67 expression 
increases as a cell progresses through the cell cycle, w ith  highest expression being seen 
in G 2 M  phase cells. Cells stained w ith  an antibody recognizing K i-67. revealed that 
all o f  the cells, which were undergoing HMT, were cycling (Figure 4.5. lower set o f  
panels). However, epithelial islands o f  control EpRas cells revealed an asynchronous 
cell population, including cells which have exited the cell cycle (Figure 4.5. top 
panels). The relevance o f this w ill be discussed in Chapter 7.
4.2.1.6 Application of the EpH4 system
Characterisation o f the HpH4 system was performed to establish a functional TGF-p 
pathway and its responses. It is clear from the results so far presented in this chapter 
that these cells possess an intact TGF-p pathway and e lic it biological responses as 
previously described (O ft. M. et al.. 1998; Oft. M. et al.. 1996). fu rthe r biological 
characterisation o f this system fo llows in later Chapters (Chapter 5 and 6). Therefore, 
the Hpl 14 system is a viable cell system to be used to investigate novel components o f 
the TGF-p pathway by a dual tag purification technique. The application o f this 
method using the HpH4 system w ill be discussed next.
4.2.2 Dual Tag purification
4.2.2.1 Design of Dual Tags
The main aim o f the purification project was to design a dual a ffin ity  tag for the Smad 
proteins, which would facilitate effic ient binding during two steps o f purification, and 
thereby result in a reproducible high yie ld o f  Smad associated proteins in the final 
eluate. The Protein A -IgG  binding domains proved to provide an excellent first step in 
conjunction w ith  TEV cleavage. Previous data has shown that the presence o f  Protein
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Figure 4.5. EpRas cells undergoing TGF-p-induced EMT are proliferating
Ki67 antigen is expressed in proliferating cells in G 1, S, G2, and M, but not in Gq. EpRas cells were 
plated out at low density and either grown in the presence or absence of TGF-p 1 (2 ng/ml). The 
medium was changed I d after seeding and then every other day. TGF-p 1 was added to the cells 
upon medium change. Three days after plating, the cells were trypsinised and re-plated at equivalent 
density to day 1. Cells were grown for a total o f 10 days, which required two trypsinisations, and 
then harvested 48 hrs after final TGF-pi addition. Cells were stained with an antibody recognizing 
the Ki67 antigen and examined by confocal laser scanning microscopy. Actin reorganization was 
visualized with Texas red-conjugated phalloidin, and nuclei were visualized with DAPI.
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A -a ffin ity /T A P  tag does not impair the functionality o f  the Smads in mediating 
transcriptional responses (Chapter 3). Three alternative a ffin ity  tags were chosen to 
replace the CBP o f the TAP-Tag ( f  igure 4.6). The introduction o f  a new. small a ffin ity  
tag was unlike ly to cause any further interference. The FLAG  and HA epitope-tags 
have been in use in the lab as N-term inal constructs o f  the Smads w ith  no adverse 
effects on the ab ility  o f the Smads to act as mediators o f  TGF-|3 signalling (Inman. G. 
J. et al., 2002a). These tags have proved to be useful tools in the analysis o f  Smad 
function. The His tag provided a strategy which did not involve the use o f an antibody 
for purification, and offered the possibility o f  a lower level o f background 
contamination. Other alterations included the introduction o f two spacers and a double 
TEV site. The first spacer is located between the TE V  sites and the new tag. and the 
second between the latter and the Smad o f  interest (Figure 4.6B). The spacers were 
added to reduce interference between the tag and the MH1 domain o f the Smads. to 
a llow  sufficient access o f the TEV protease to the cleavage sites and to optimise 
binding o f the new tag post cleavage. The introduction o f a second TEV site was to 
improve the efficiency o f cleavage and to reduce residual bait bound to the IgG beads. 
Thus, the redesign o f the a ffin ity  tag would, in theory, optimise progress through 
purification steps. The tagged proteins were assayed to determine which tag was most 
successful.
4.2.2.2 Trial Purifications using different combinations o f the Dual Affinity Tag
To determine the most efficient dual a ffin ity  tag combination, it was essential to test 
the binding capabilities o f the individual tags in the cell context that was to be used for 
the final purification, the EpH4 cells. Each o f the a ffin ity  tags was fused to Smad3 and 
constructs expressing these fusion proteins were transiently transfected into EpH4 
cells. Purification o f the dual tagged Smad3 was carried out under the three different 
conditions as described in Chapter 2. Samples were taken at each step to monitor the 
progress o f the dual tagged-Smad3 throughout the purification procedure for each case 
( f  igure 4.7A). There was variab ility  in the transfection efficiency due to differences in 
cell confluence during the transfection. As a result the level o f  input o f the tagged 
Smad3 was not equal. Nevertheless, a comparison o f the different tags was still 
possible. In each purification procedure, no trace o f  the dual-tagged Smad3 was
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MGGGVDNKFNKEQQNAFYEILHLPNLNEEQRNAFIQSLKDDPSQSANLLAEAKKLNDA
QAPKVDNKFNKEQQNAFYEILHLPNLNEEQRNAFIQSLKDDPSQSANLLAEAKKLNGA
QAPKGSDYDIPTTENLYFQGGGGGGGSDYDIPTTENLYFQGGGGGGGTMKDYKDDDK
AGGGGGGEF
Protein A/HA Tag
MGGGVDNKFNKEQQNAFYEILHLPNLNEEQRNAFIQSLKDDPSQSANLLAEAKKLNDA
QAPKVDNKFNKEQQNAFYEILHLPNLNEEQRNAFIQSLKDDPSQSANLLAEAKKLNGA
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Protein A/His Tag
MGGGVDNKFNKEQQNAFYEILHLPNLNEEQRNAFIQSLKDDPSQSANLLAEAKKLNDA
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Figure 4.6. Alternative Dual A ffin ity Tags
(A) Schematic representation of the N-terminal dual-affinity tagged Smad constructs.
(B) The amino-acid structure of three alternative N-terminal dual-affinity tags. The Protein A/FLAG tag 
consists of two tandem Protein A IgG-binding domains, two TEV cleavage sites, and one copy of the 
FLAG sequence. The Protein A/HA tag and Protein A/His also contain two tandem Protein A IgG- 
binding domains and two TEV cleavage sites, but have one copy of the HA sequence or six histidines in 
place of the FLAG tag, respectively.
(C) Overview of the Dual-affinity Tag purification strategy. A protein complex containing the Dual­
tagged protein is purified sequentially by two independent affinity steps. The immobilized protein is 
specifically eluted in the first instance by protease cleavage (TEV), and by peptide competition or 
imidazole in the second step.
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detected in any o f the IgG flowthrough samples, which confirmed efficient binding to 
the IgG beads. A ll dual-tagged Smad3 were successfully and completely cleaved by 
THY protease, released from the IgG beads, resulting in a high level o f input for the 
second step. The second purification step was the critical determinant in choosing the 
most successful tag. In each case, the THV eluate bound completely to the beads, and 
no flowthrough was detected. Follow ing successful elution, all three purifications 
revealed a very high yield o f bait protein.
In Chapter 3, it was clear that the presence o f contaminants in the final eluate 
could dramatically interfere w ith the identification o f  novel interacting proteins. In the 
case o f the H A-purifica tion step, beads conjugated w ith  anti-H A  antibody were 
prepared for the purification. However, leakage/spillover o f  excess anti-HA antibody 
resulted in high levels o f  IgG chains in the final eluates (Figure 4.7A. middle panel). 
This did not occur in the case o f the FLAG  purification where beads were supplied 
commercially. To further inspect the level o f contamination resulting from each 
purification procedure. I carried out silver stain analysis o f  the final eluates. When 
compared w ith the Protein A -FLA G  and Protein A -H A  eluates, the Protein A-FIis 
eluate contained a remarkably high level o f background (Figure 4.7B). This was 
highlighted by the large amount o f  THV protease present in the sample. The TEV 
protease supplied by Invitrogen contains six histidine residues to facilitate removal o f 
the THV protease after digestion w ith  the enzyme. In this case, however, the TEV 
protease which remained in the supernatant bound e ffic ien tly  to the N ickel beads and 
also eluted w ith the imidazole. Invitrogen was the only known supplier to provide a 
very clean and active TEV protease and hence, the use o f  the N ickel column was not 
possible. The low level o f  contamination in the FLA G  tag purification and the ready 
availability o f beads conjugated w ith  anti-FLAG  antibody, made this purification 
process an attractive choice (Figure 4.7B).
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Figure 4.7. A Comparison of Dual A ffin ity  Tag Purification Procedures
(A) EpH4 cells were transfected with the different Dual-tagged Smad3 constructs as indicated. Cells 
were induced with TG F-pi, harvested, and individual purification procedures were carried out. 
Samples taken at each stage of the purification were analysed by Western blotting using antibodies 
against Smad2/3.
(B) Silver-stained gels depicting proteins recovered following purification by the different procedures. 
The final eluate fractions of the purifications were pooled and concentrated and analysed by SDS- 
PAGE. The purification protocols for each procedure are given in Chapter 2.
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4.2.2.3 Transcriptional Activity of the Protein A-FLAG (Dual Tag) Smads
On the basis o f the trial purification experiments, the Protein A -FLA G  tag was 
selected as the preferred a ffin ity  tag to be used fo r identification o f novel Smad 
partners. This tag w ill be referred to as the Dual Tag (D T) fo r the rest o f the chapter. 
N-terminal Dual Tag constructs o f Smad2, and 4 were also cloned and all three 
constructs were tested fo r their ability to induce TGF-P-dependent transcriptional 
activation. Smad4-null M D A-M B468 cells were transfected w ith the Smad3- 
dependent reporters, (c-jun SBR)6-luciferase or the (C A G A )i: luciferase. In the 
absence o f Smad4, no luciferase activ ity is observed (Figure 4.8A and B). 
Overexpression o f FLAG-Smad4 increases the TGF-P-induced level o f transcription o f 
Smad3-dependent reporters. Co-transfection o f Smad4 w ith Dual-Tagged Smad3 (D T- 
Smad3) substantially increases both the basal activity and TGF-P-induced transcription 
o f (c-jun SBR)h and (C A G A )i: reporters. These results indicate that DT-Smad3 can 
initiate transcription in response to TGF-p. S im ilarly, the functional activity o f Dual- 
Tagged-Smad2 (DT-Smad2) and Dual-Tagged-Smad4 (DT-Smad4), was tested using 
the (AREVluciferase reporter in M D A -M B468 cells. Transcription from  the AR E 
requires the transcription factor, X F oxH la , fo r recruitment o f Smad2/4 complexes to 
the promoter element (Chen, X. et al., 1996; Howell, M. et al., 2002). In the absence o f 
Smad4, transfection o f X F oxH la  elicited a weak TGF-P induction via the ARE 
(Figure 4.8C). Transfection o f DT-Smad2 or DT-Smad4 increased the basal activ ity 
and substantially increased the TGF-p-induced level o f transcription. This data 
indicates that DT-Smad2 and DT-Smad4 constructs can integrate and form  functional 
complexes (ARF1) at known promoter elements (ARE) and initiate transcription in 
response to TGF-p.
4.2.2.4 Stable Cell lines expressing Dual Tagged-Smad3 and -Smad4
The aim o f the project was to find different Smad-interacting factors in EpH4 cells 
versus EpRas cells. To accomplish this, it was necessary to stably express the DT- 
Smads in both cell lines. To generate stable cell lines, I transfected the cells w ith 
plasmids expressing the Dual-Tagged-Smads and selected pools using antibiotics, as
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Figure 4.8. Dual tagged-Smad constructs can mediate TGF-(3-induced 
transcriptional activation
Smad4-null MDA-MB468 cells were transfected with the Smad3-dependent reporters, c-jun SBR6-Euc 
(A) or C A G A |2-huc (B) together with plasmids expressing FLAG-Smad4 either alone or with Dual 
lagged (DT) Smad3 as indicated.
(C) Smad4-null M DA-MB468 cells were transfected with the Smad2-dependent reporter, AREr Luc 
reporter gene, together with plasmids expressing X FoxH la /XFast-l alone or with DT-Smad2 or DT- 
Smad4 as indicated. TGF-(31 was added 8 h before assaying luciferase activity. Luciferase was quantitated 
relative to (3-galactosidase from the pEFLacZ internal control. The data are the means and standard devia­
tions of three independent experiments.
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described in Chapter 2. Successful stable expression o f Smad proteins had previously 
been accomplished using this technique (Schmierer, B. et al., 2005). Firstly, 1 
generated EpH4 and EpRas stable lines expressing either DT-Smad3 or DT-Smad4. 
Smad3 was used in this case because previous studies have implicated a role for 
Smad3 in both TGF-p-induced growth arrest (Ashcroft, G. S. et al., 1999; Datto, M. B. 
et al., 1999) and in the progression o f TGF-p-dependent EM T (Nicolas, F. J. et al., 
2003b; Zavadil, J. et al., 2004). By using Smad3 as bait, transcription factors involved 
in these processes were more like ly to be identified. Smad4 was also selected because 
it can form complexes w ith all known R-Smads and therefore, there is a higher 
potential to discover a wider array o f interactions (Zhang, Y. et al., 1997).
Due to the low expression o f the Smad proteins in transfected pools, single cell 
clones were picked to achieve a higher expression o f the DT-Smads. Four clones were 
isolated, which expressed the DT-Smads at levels at or above endogenous. These 
included EpH4 clones expressing DT-Smad3 (EpH4-DTS3) and DT-Smad4 (EpH4- 
DTS4) and also EpRas clones expressing DT-Smad3 (EpRas-DTS3) and DT-Smad4 
(EpRas-DTS4). Nuclear extracts o f the individual clones were analysed to test whether 
the DT-Smads accumulate in the nucleus upon TG F-p stimulation. Antibodies against 
the FLAG epitope and anti-rabbit IgGs, which recognises the IgG binding domains o f 
Protein A, were used to detect the DT-Smads (Figure 4.9A) and parental cell lines 
were used as a negative control. DT-Smad3 was detected in the nucleus, even in the 
absence o f TGF-p, however there was a slight increase in level after 1 hr o f TGF-P 
treatment (Figure 4.9A). DT-Smad4 was also localised in the nucleus in the uninduced 
state, as is the case fo r endogenous Smad4, and again nuclear accumulation occurred 
after TG F-p stimulation. From these results, I conclude that the DT-Smads accumulate 
in the nucleus upon TG F-p treatment in both EpH4 and EpRas cells.
During the process o f analysing the clones. I noticed that the levels ot D I-  
Smads fluctuated relative to endogenous Smads. A lthough, it is not uncommon to lose 
expression o f a stably expressed protein w ith  increasing passage number, this was not 
the case here. The expression level o f the Smad did not gradually decrease over time 
but was expressed at high, low and even undetectable levels at different times. The 
only obvious difference between experiments was the confluency o f the culture before 
lysis and/or the time o f  harv est after splitting the cells. To investigate whether either o f 
these factors could explain the variation observed, EpH4-DTS3 cells were grown to
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Figure 4.9. Characterisation of stable clones of dual tagged-Smads in EpH4 and 
EpRas cells
(A) Dual-Tag-Smad3 (DT-Smad3) and Dual-Tag-Smad4 (DT-Smad4) accumulate in the nucleus upon 
TGF-P stimulation. EpH4, EpRas parental cells and their DT-Smad3 and DT-Smad4 clones were 
treated with 2 ng/ml TGF-p 1 for 1 hr, and equal amounts of nuclear extract were analysed by Western 
blotting using antibodies against FLAG and rabbit IgG.
(B) Expression of DT-Smad3 is regulated by the confluency of the cells. EpH4-Dual-Tagged-Smad3 
(DTS3) cells were synchronized by high density, contact inhibition and released by trypsinisation for 
the times indicated. Cells were stimulated with TGF-p 1 for lhr prior to harvest. Whole-cell extracts 
were prepared and analysed by Western blotting using antibodies against Smad2 and Smad3.
(C) Expression of DT-Smad3 is also regulated at the level of the cell cycle. EpH4-DTS3 cells were 
synchronized by contact inhibition and released by trypsinisation for 20 hrs at different levels of 
confluency. A second set of cells was released for 20 hrs from a growing culture. Extracts were 
analysed by Western blotting using antibodies against Smad2/3.
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high density resulting in contact inhib ition, as previously performed during 
investigation o f their growth inhib itory response to TGF-(3. When these cells are 
contact inhibited, the cells accumulate in Cil/GO, producing a synchronised culture. 
A fter synchronisation, the FpH4-DTS3 cells were then released into the fresh media 
for different times up to 25 hr and the level o f  DT-Smad3 expression was examined. 
When compared to the endogenous level, used as a loading control in this experiment, 
it is clear that the expression o f DT-Smad3 is dramatically reduced when these cells 
are highly confluent (Figure 4.9B). Upon release into serum-containing media, DT- 
Smad3 expression is restored and a constant level is maintained for up to 20 hrs. It is 
clear from this experiment that negative regulation o f the expression o f DT-Smad3 
occurs in confluent cultures.
For future purifications using these stable clones, it was critical to express the 
bait protein at maximal levels. For this reason, it was essential to find out how the DT- 
Smad level is regulated in these cells. The next question to be answered was whether 
the expression o f the DT-Smad protein is affected by the confluency o f the culture or 
by the cell cycle status. To address this issue, I prepared two sets o f EpH4-DTS3 cells, 
where one was synchronised by contact inhib ition and the other was a proliferating 
culture. The synchronized culture was plated out at different d ilution ratios to produce 
cultures w ith varying confluency (Figure 4.9C). The dilution ratios o f 1:3, 1:6 and 1:12 
correspond to approximately 20, 50 and 1009F confluency. The proliferating culture 
was plated out at 509? confluency fo r comparsion. A ll cells were harvested 20 hrs after 
replating. The results were strik ingly clear. The difference in culture confluency did 
not affect the expression level o f DT-Smad3 (Figure 4.9C). However, the 
synchronization o f the cells was an important determinant o f expression because it is 
clear that an asynchronous culture expresses a very low level o f DT-Smad3. This 
demonstrated that the expression o f DT-Smad3 is governed by a specific point in the 
cell cycle and that the confluency o f the culture is not an important determinant. The 
mechanism o f how the expression levels o f the DT-Smads were regulated was not 
investigated, however it was speculated that it was due to promoter activity in these 
cells. The impact o f  this finding was great in terms o f accumulation o f cell mass, but 
modifications were included to account for this regulation. In all subsequent 
experiments using the DT-Smad3 and DT-Smad4 clones, cell cultures were 
sunchronised and released into serum for 20 hrs to to maximise the expression level o f
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the DT-Smads.
4.2.2.5 Functional Studies of Dual-tagged Smads: DT-Smad3 and DT-Smad4 
form compexes on DNA
Further characterisation o f the DT-Smads was required to ensure their functionality. 
Nuclear import in response to TGF-(3 was confirmed but the next aspect I needed to 
examine was whether the DT-Smads expressed stably in EpH4 and EpRas cells could 
bind DNA. To investigate the DN A-binding ab ility  o f DT-Smad3 and DT-Smad4, I 
used DN A pulldown assays w ith oligonucleotides containing the Smad binding region 
(SBR) in the 5' UTR o f the c-jun promoter (Inman, G. J. et al., 2002a). In a pattern 
identical to endogenous Smad3, phosphorylated DT-Smad3 binds to the c-jun SBR 
oligo and not to the control mutant oligonucleotide in both EpH4 and EpRas cell lines 
(Figure 4.10). DT-Smad4 binds to the c-jun SBR oligo in the uninduced state and w ith 
higher a ffin ity  in the induced state, as observed w ith endogenous Smad4. These results 
indicate that indeed DT-Smad3 and DT-Smad4 can bind D N A and form  complexes 
w ith endogenous partners on DN A in a TGF-(3 inducible manner.
4.2.2.6 Preliminary Purification Trials
The EpH4-DTS3 clone was used in prelim inary experiments to optimise conditions for 
the purification. The first small-scale purification procedure was carried out using 30 
150 c ir f  plates o f  mock and DT-Smad3 expressing EpH4 cells each. Silver stain 
analysis o f  the final eluates revealed a high level o f  bait-Smad3 in the eluate from 
EpH4-DTS3 cells whereas it was absent in the parental line (data not shown). From 
Chapter 3. it was ev ident that large amounts o f input were required to retrieve a level 
o f bait detectable by Coomassie stain. Coomassie staining was preferrable as it does 
not interfere w ith mass spectrometric analysis. Thus I conducted a large-scale 
experiment using 125 plates o f EpH4-DTS3 cells, equivalent to 90 mgs o f proteins. An 
equal amount o f  input o f  the parental EpII4  cells (mock) was used as a negative 
control. Samples were taken at each stage o f the mock and tria l purification to monitor 
the progress throughout the purification procedure. Analysis o f  the mock experiment 
revealed that equal levels o f  Smad protein were observed in the IgG flow
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Figure 4.10. DT-Smad3 and DT-Smad4 form complexes on DNA
(A and B) DT-Smad3 (A) and DT-Smad4 clones (B) of EpH4 and EpRas cells were synchronized by 
contact inhibition and released by trypsinisation for 20 hrs. Whole cell extracts were prepared from 
uninduced or TGF-(J-induced cells and incubated overnight with either c-jun SBR or mutant c-jun 
SBR oligo-conjugated beads as indicated. After washing, the beads were resuspended in SDS sample 
buffer and associated proteins were separated by SDS-PAGE and analysed by Western blotting using 
antibodies against phosphorylated-Smad3, Smad3 and Smad4. Ten percent protein input is also 
shown.
# Indicates the DT-Smad3 protein, which has been recognised by the a-rabbit secondary antibody via its IgG- 
binding domains.
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through compared w ith  input levels (data not shown). Using the EpH4-DTS3 cells, 
efficient binding o f DT-Smad3 to the IgG beads was observed, as no DT-Smad3 was 
detected in the IgG flow  through (Figure 4.11 A). A  small amount o f cleaved DT- 
Smad3 was still present on the IgG beads, but there was no sign o f any uncleaved 
Smad3, suggesting TFV  cleavage was also complete. The T FV  eluate bound entirely 
to the FLAG beads and was eluted successfully in fractions 1-4. In conclusion, the 
purification scheme was very efficient at each stage, resulting in substantial elution o f 
the bait Smad3 protein. When the blot was reprobed w ith  anti-Smad4 antibody, no 
Smad4 was detected unexpectedly, but P-Smad2 was found to associate w ith  Smad3 
(discussed in Chapter 6 and 7).
The elution fractions containing cleaved DT-Smad3. were pooled and 
concentrated using YM -10 columns and subsequently analysed by SDS-PAGE. It was 
evident that the cleaved Smad3 bait was detectable on a Coomassie-stained gel but it 
was still quite weak (Figure 4.1 IB ). Mass spectrometric analysis confirmed the 
identity o f  this band as Smad3. Other bands were excised and tested for identification 
but due to low protein level, no positive identifications were made.
From in itia l experiments using EpH4-DTS3, the dual-tag purification process 
gave promising results. However, because the DT-Smad3 is expressed at close to 
endogenous level, a very high level o f input is required. This is necessary to overcome 
protein loss during the two steps o f purification and to give strong detection o f the bait 
protein and interacting partners at the final stage o f the purification, the Coomasse- 
stained gel.
4.2.2.7 Further Scale up of the Purification Scheme
The next experiment carried out was scaled up nearly 4-fo ld, and 360 mgs o f protein 
extract from FpH4-DTS3 cells was applied to IgG columns. Due to the large scale o f 
the purification, it was not practical to run a mock purification in parallel. The test 
lysate alone produced a very large volume (600 mis). Due to the high level o f protein 
input, a large volume o f beads was required. It is recommended for large-scale 
purifications to use m ultiple columns w ith  lower bead volume as the use o f large 
column beds has been shown to increase background contamination (Puig. O. et al., 
2001). This theory was applied throughout the purification by employing m ultip le
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Figure 4.11. Preliminary Dual Tag Purification using DT-Smad3
(A) EpH4-DTS3 cells were synchronized and released into new media for 18-22hrs. Cells were stimu­
lated with TGF-p for 1 hr prior to harvest. 90mgs (xl25 15cm plates) EpH4-DTS3 and equivalent 
input of EpH4 parental cells (mock) was used for the purification. Samples were taken at each stage 
and analysed by Western blotting using an antibody against Smad2/3. The blot was then stripped and 
reprobed using antibodies against Smad4 and P-Smad2. The following proportions of samples were 
loaded: Input (1/10,000), IgG flow through (1/10,000), TEV eluate (1/167), FLAG flow through 
(1/167) IgG beads (1/6), FLAG beads (1/6), and final eluates (1/20).
(B) Coomassie-stained gels depicting proteins recovered following purification. Smad3 positive 
fractions and equivalent mock fractions were pooled and concentrated using YM-10 spin columns. 
Samples were then resuspended in SDS loading buffer and separated by SDS-PAGE and Coomassie 
stained. The Dual Tag purification protocol is given in Chapter 2. The numbers to the left show the 
positions of molecular size markers (kilodaltons). Smad3 bait was confirmed by mass spectrometry, 
which was conducted by U lf Heilman, Ludwig Institute for Cancer Research, Uppsala, Sweden.
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columns at each stage o f the purification. Due to the large volume o f  extract, the IgG 
binding step was carried out in batch format in 50 ml falcon tubes. Representative 
samples from individual tubes were taken to analyse the progress o f the purification 
(Figure 4.12A). It can be seen that the level o f  Smad3 is close to endogenous level, 
however after TEV eluate step, the bait protein is highly concentrated. Overall the 
purification o f the Smad3 bait was highly efficient. 10 elution fractions are shown 
here, however this is representative o f  the three separate elution profiles from three 
individual FLAG  columns. Each profile  was identical.
The purification profile  was extremely promising. A ll Smad3 positive fractions 
were pooled and concentrated by TC A precipitation. A fte r an additional alkylation step 
to prevent cysteine modifications from the polyacrylamide gel, the sample was loaded 
and Coomassie stained. Numerous bands were stained including a prominent band, 
which migrated at a position sim ilar to where the cleaved Smad3 protein was expected 
to run (Figure 4.12B). It was also clear that a very strong band was visible around the 
43 kD position. Actin , a 42 kD cytoskeletal protein, is a notorious source o f 
contamination due to its exceptionally high expression level in cells. In previous small- 
scale experiments, a 42 kD band had also appeared, however, at a much lower level. 
Using an anti-pan actin antibody the Western blot was reprobed to investigate the level 
o f  actin contamination (Figure 4.12A, lower panel). This confirmed that actin was 
present in the first couple o f  elution fractions. Despite the background level o f actin in 
the final eluate, th irty-five  bands were excised from the acrylamide gel and sent for 
identification by mass spectrometry. The identity o f the bait Smad3 protein was 
confirmed and indeed, the 43 kD band was identified as actin (Figure 4.12B). F -Actin  
forms complexes w ith  a plethora o f cytoskeletal proteins, many o f which were also 
identified in this sample. The proteins, which have been previously shown to interact 
w ith  actin are shown in bold (Figure 4.12B, right). An astonishing twenty-five out o f  
th irty -five  proteins were attributed to actin biology. This high percentage o f actin 
partners may reflect the higher level o f actin in the final eluate than Smad3.
Despite the presence o f m ultip le cytoskeletal proteins in the final eluate, a 
handful o f  new identifications were also made. Where possible, I tried to verify the 
interactions w ith  Smad3 under sim ilar conditions, for example activation-induced 
cytidine deaminase (A ID ). Unfortunately, I did not observe any interactions o f Smad3 
w ith  these proteins. Some o f  the identifications were obtained from  single polypeptide
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fragments which may have given inaccurate identifications. This could explain the 
inability  to co-precipitate Smad3 and the identified proteins.
4.2.2.8 High Salt versus Low Salt Lysis
Another concern relating to the previous purifications was the absence o f a positive 
control co-purify ing w ith the DT-Smad3 bait. In both purifications, Smad3 was 
identified by mass spectrotmetry but Smad4, the transcription partner o f Smad3, was 
not ( f  igure 4.1 IB , figu re  4.12B). Also, Smad4 was not observed in the final eluates o f 
the purification when analysed by Western blotting (Figure 4.1 !A ). The interaction o f 
Smad3 and Smad4 was to be used as a marker for specific interacting proteins co- 
purify ing  w ith  the DT-Smad3 bait. It was therefore essential to ensure detection o f 
this complex in the final eluate. As a result, the lysis conditions were investigated. Up 
to this point, cells were lysed in 400 m M  NaCl to m axim ally extract proteins from 
D N A (Marais. R. et al.. 1993). Lysates were then diluted w ith  a salt free d ilution buffer 
after the lysate was cleared by centrifugation to maintain physiological conditions. 
Therefore, i f  any complexes were disrupted during the lysis procedure, it was assumed 
that these would reform when the salt concentration was lowered. To examine whether 
the lysis conditions were disrupting the binding o f Smad3 w ith  Smad4, I compared a 
high salt buffer lysis w ith lysis using a buffer at physiological salt concentration. This 
was tested using the LpH4-DTS4 cell line in which DT-Smad4 is expressed at 2-3 fold 
level o f  endogenous Smad4. IgG binding and TEV proteolytic cleavage were carried 
out at either 120 or 150 mM. It is very clear from the Smad2/3 blot that a higher level 
o f Smad2 interacts w ith DT-Smad4. when the cells are lysed at 150 mM NaCl 
compared to 400 mM ( f  igure 4.13). It was also demonstrated here that lowering the 
salt concentration to 120 mM NaCl, did not enhance the stability o f  the Smad2/4 
complex, f  urther experiments incorporated these results to optimise the complex 
formation o f the Smads.
4.2.2.9 Reducing Background contamination
Actin  is one o f the most abundant proteins in the cell, and therefore it is not surprising 
that contamination arises in the final eluates o f  purified samples. Nevertheless, it was 
imperative to elim inate this background in order to isolate and identify Smad-
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Figure 4.13. Effect of lysis conditions on Smad-Smad interactions
High salt lysis interferes with Smad complex formation. EpH4-DTS4 cells were lysed in buffer with a 
salt concentration of either 150 mM (left panel) or 400 mM (right panel).The extracts were then 
adjusted to either 120 mM or 150 mM final salt concentration, as indicated and incubated with IgG 
beads for 2 hrs at 4 °C. After washing, the beads were incubated with TEV protease at 14 °C for an 
additional 2 hrs. Supernatants were then fractionated by SDS-PAGE and analysed by Western blotting 
using antibodies against Smad2/3 and Smad4. Cleaved DT-Smad4 migrates as a doublet. The slower 
migrating band is likely to contain one of the two TEV cleavage sites due to insufficient cleavage with 
TEV protease.
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interacting partners. A  series o f tria l experiments were carried out to reduce the level 
o f  actin throughout the purification procedure. The cytoskeletal components o f  the 
cell, including polymerised actin (F-actin). are routinely removed by centrifugation. 
On the basis o f  the interacting proteins identified (Figure 4.12). it was concluded that 
the form o f actin bound to the beads was like ly to be F-actin. Thus low  speed 
c la rify ing spins were replaced by higher speed, more stringent centrifugation steps, 
which substantially reduced the level o f  actin in the cell extract (Data not shown and 
f  igure 4.14). This was determined by Western blotting using an anti-pan-actin 
antibody for sensitive detection.
Another problem regarding actin contamination was the non-specific a ffin ity  o f 
actin for the surface o f the beads. An example o f this attraction can be seen in Figure 
4.12. where a high level o f actin is s till bound to the IgG and FLAG  beads. The non­
specific interaction o f actin and the surface o f the beads results in an inevitable 
spillover o f actin into the next stage. To exploit the non-specific binding o f actin and 
its interacting partners to the IgG beads, another bead step was introduced to drain 
excess actin from the lysate. A fter TEV cleavage, the TEV eluates were transferred to 
fresh IgG columns before the final a ffin ity  anti-FLAG  bead column. The bait protein, 
no longer bound to the IgG beads because the IgG binding domains o f protein A  had 
been cleaved. On the other hand, any actin still present bound the IgG beads 
preferentially, again reducing the total actin in the eluates (data not shown).
4.2.2.10 Purification of DT-Smad4
The next large-scale purification incorporated the new adjustments (4.2.2.8 and 
4.2.2.9) to optimise complex formation o f Smads and other interacting proteins and 
also to eliminate high background and contamination w ith cytoskeletal proteins. In this 
experiment, the EplI4-DTS4 cells were used as the test cells and EpII4 parental cells 
were used in a parallel mock experiment to establish the experimental background. As 
shown in f  igure 4.13, a strong interaction exists between DT-S4 and Smad2, which 
could be used as a marker for true co-purified partners. 500 mgs o f protein extract was 
used as starting material and samples were taken throughout the procedure to m onitor 
the process o f the purification. Each step exhibited relatively high efficiency, however 
there was incomplete TEV cleavage and a small proportion o f residual Smad4 found
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on each set o f  beads, resulting in a decrease in the final yield. Most importantly, 
however, the level o f  actin present at each stage was dramatically reduced. No trace o f 
actin was detected at the TEV eluate step, indicating that c la rify ing the extract by 
centrifugation was successful in pelleting abundant cytoskeletal proteins. P-Smad2 was 
used as a marker in this final purification. A  high proportion o f P-Smad2 was lost on 
the in itia l IgG binding step, presumably due to its interaction w ith  endogenous Smad3 
and Smad4 (Figure 4.14A, bottom panel). Nevertheless, P-Smad2 was bound to DT- 
Smad4 in the TEV eluate. Subsequently, most o f  the bound P-Smad2 was lost in the 
FLA G  How through and only a very low  level remained in the final fractions. This 
indicated that few Smad2-Smad2 complexes survived the purification and suggested a 
sim ilar case for other partners w ith  equal or lower a ffin ity  binding. Indeed, analysis o f  
the final eluates o f both the mock and test cells in a Coomassie gel confirmed this 
result. Apart from  a small number o f  background bands observed in both eluates, the 
only additional band detected in the test eluate corresponded to the cleaved bait 
(Figure 4.14B). No other proteins that could be detected at Coomassie stain level had 
been isolated. From previous experiments, I had learned that i f  no protein was 
detectable at Coomassie stain level, it was unlike ly that a positive identification could 
be obtained.
4.3 Discussion
4.3.1 Dual Tag-Purification
4.3.1.1 Purification of Smad proteins in Mammalian Cells
In this chapter, I described the development o f  a novel dual tag for purification o f 
Smad complexes. Rigorous optim isation o f the purification procedure using this tag 
was carried out to ensure a pure final product. However, although Smad protein was 
purified to a high degree, this procedure did not recover any co-purifying proteins. The 
lack o f interacting proteins in the final eluate could be attributed to the relatively low 
amount o f  Smad protein retrieved from mammalian cells. More importantly it seems 
that the unstable nature o f the Smad protein complexes formed, prevents the 
preserv ation o f these complexes through two purification steps.
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The use o f a two-step purification system for the isolation o f protein complexes under 
non-denaturing conditions was developed very effectively in yeast (Rigaut, G. et al.. 
1999). It produces a high degree o f purity o f  protein complexes w ithout the application 
o f stringent conditions. In this Chapter. I demonstrated that the use o f this method in 
mammalian cells retains many o f the attractive features observed in yeast. Here, both 
a ffin ity  tags, the Protein A and the FLAG  peptide, allowed efficient recovery o f 
proteins present at low concentration. Haeh step was very tolerant to buffer conditions, 
which enabled changes to be applied for the isolation o f the Smads.
The transfer o f  this method for use in higher organisms, howev er, has lagged 
considerably behind its application in yeast. Many o f the reasons for this have been 
encountered in this Chapter. The first obstacle was obtaining adequate cell mass. The 
use o f  yeast cells obviates this problem, as yeast can easily be grown in large quantities 
in suspension flasks. Howev er, when dealing w ith  an epithelial monolayer culture, the 
problem o f recovery became acute. This issue was tackled by stockpiling pellets o f  
cells. However, this was not the ideal solution because it was labour intensive and 
extremely time consuming. The amount o f  starting material for purification purposes 
was dependent on the expression level o f  the dual-tagged Smad and also by the yie ld 
o f recov ery. It was ev ident that the regulation o f expression o f  the dual-tagged Smads 
in the L*pi 14 and HpRas cells further exacerbated the problem o f high cell number 
accumulation. Unlike yeast cells where the tagged protein can be regulated under its 
natural promoter, the DT-Smad proteins were driven by a C M V  promoter. The net 
result o f  this was a cell cycle dependent expression system combined w ith  the 
dovvnregulation o f Smad expression upon contact inhib ition. Cell preparation was 
adapted to facilitate expression o f the DT-Smads, whereby cells were synchronised by 
contact inhib ition and replated for 20 hrs at 60-80% confluency. Using this method, 
expression o f DT-Smad3 and DT-Smad4 was close to that o f  endogenous. However, 
the use o f subconfluent plates w ith  low expression o f protein was also a lim iting  
factor. Some researchers have turned to HeLa cells for the isolation o f protein 
complexes because these can be grown in spinner Tasks. However non-adherent HeLa 
cells are unresponsive to TGF-p (data not shown). Another wav to overcome this 
problem o f yie ld was to use overexpressed proteins. However, it has proved d ifficu lt to 
generate a cell line expressing Smads at a high level. Indeed, all o f the DT-Smad2 and 
DT-Smad3 clones tested, expressed DT-Smads at a level close to endogenous. DT-
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Smad4 clones were less restricted in that the level o f  DT-Smad4 protein was 2-3 fold 
that o f endogenous. A  sim ilar observation was made in generating the TAP-Smad 
clones in HaCaT cells (Chapter 3) and has been attributed to a decreased growth 
advantage o f cells expressing high levels o f  Smad. Furthermore, a very high level o f  
overexpression is not ideal because this can induce its association w ith non-specific 
partners or nonnatural partners (heat shock proteins, proteasome) (Puig, O. et al., 
2001) resulting in many false positives.
Although the accumulation o f cell mass was a problem, it was overcome. The 
main obstacle encountered using this system was the lack o f co-purified partners in the 
final eluate (Figure 4.14). There are many reasons that may explain this phenomenon. 
Firstly, the presence o f the untagged endogenous Smads may compete for 
incorporation into m ultiprotein complexes. This is not the case in yeast because the 
high efficiency o f homologous recombination allows the tagged protein to replace the 
endogenous, which reduces competition for interacting partners. Furthermore, it has 
been observed in the H ill laboratory that endogenous Smads are preferentially 
phosphorylated by the type I receptor over exogenous Smads (data not shown). 
Consistent w ith this view. I showed that endogenous Smad3 and Smad4 can integrate 
much more effic iently into a complex on D N A than their tagged counterparts (Figure 
3.3 and Figure 4.10). Therefore, the competition o f endogenous Smads is heightened 
by their higher a ffin ity  for partner Smads and most probably other interacting proteins. 
Despite the high level o f input used to overcome such a problem, the purification 
scheme failed to co-purify interacting proteins.
Other researchers have attempted to circumvent this problem in mammalian 
cells by developing the iTAP strategy, whereby the TAP-approach is combined w ith  
suppression o f the corresponding endogenous protein by RN Ai (Forler, D. et al., 
2003). Depletion o f  the endogenous protein is implemented to make more partner 
subunits available for association w ith the target protein. This alternative strategy was 
reported to improve the number and level o f  partners recovered. In this vein, attempts 
were made to make a stable HpRas line, w ith  inducible siRNA targeted against the 
Smads. However, this strategy encountered new problems. For the inducible system to 
function effic iently, it is first necessary to create a cell line that expresses the Tet 
repressor. In the absence o f tetracycline, the tet repressor inhibits the siRNA 
expression, whereas addition o f tetracyclin inhibits the Tet repressor and therefore
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induces the expression o f the siRNA. However, due to the dovvnregulation o f proteins 
under exogenous promoter control at high confluencv o f the EpRas cells, the 
inducib ility  o f the system was lost.
The second setback was a problem common to all purification methods; the 
copurification o f ‘ contaminating’ proteins. In a large-scale analysis o f  protein 
complexes in yeast using the TAP system, (Gavin, A. C. et al., 2002) an experimental 
background was determined. The contaminating proteins were mainly abundant 
proteins such as cytoskeletal proteins, translation factors (particularly for RNA protein 
complexes) and molecular chaperones. A  sample o f such proteins was also identified 
in the purification o f Smad3 (Figure 4.12). It is often d ifficu lt to conclude whether 
these 'contaminants' represent true endogenous partners or artific ia l asscociations 
generated by cell lysis. However, due to the substantial level o f  actin in the final 
eluate. a level which exceeded the bait Smad3 protein, a pragmatic decision was made 
to elim inate most o f  the proteins identified. This conclusion was confirmed by the 
absence o f Smad4 as a co-purify ing partner. To overcome this problem, the 
purification system was adapted to reduce the number o f contaminating proteins. This 
was a necessary action as the abundance o f these proteins interfered w ith the analysis 
o f  true partners. Actin and its partners were pelleted e ffic ien tly during extensive 
centrifugation spins (Figure 4.14A). However, such purification steps can also reduce 
the availability o f interacting proteins, such that possible interacting proteins were also 
lost.
Throughout the optimisation o f the purification scheme, the Smad-Smad 
interaction was always a biochemical consideration. In experiments using EpH4- 
DTS3. the absence o f Smad4 as a co-purify ing partner indicated that the purification 
was too stringent, despite the use o f non-denturing, physiological conditions. The salt 
concentration was adjusted to facilitate this interaction. In the final experiment, 
however, only a very low level o f P-Smad2 was present in the final eluate and it was 
completely absent from the Coomassie gel (Figure 4.14). This suggested that partners 
o f Smad4 did not proceed to the final stage o f purification due to the weak nature o f 
their interactions (Figure 4.12A). Use o f a two-step purification has proved successful 
in identifying proteins interacting in stable complexes as well as more transiently 
interacting proteins (Puig, O. et al.. 2001). In subsequent experiments, co- 
im m unoprecipition o f Smad proteins has revealed that a salt concentration o f lOOmM
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allows a more robust and reproducible interaction (Ross, S. et al., 2006) (Chapter 6). In 
addition, it has been shown that Smad3/Smad4 complexes are stabilised on D N A  
(Sean Harkin, unpublished data). It may also be the case that interacting partners o f  the 
Smads are part o f  large and easily disrupted complexes. In conclusion, these results 
show that the weak binding affin ities between the Smads and presumably other 
partners, and hence the destabilisation o f complexes during purification, were major 
lim itations for the identification o f novel interacting proteins.
Taken together, the purification o f Smad protein complexes through a two-step 
purification is not viable. In addition to the use o f  two discrim inatory purifica tion 
steps, further measures were required to decrease the level o f  background 
contamination. The Smad proteins interact w ith  each other and presumably other 
proteins w ith relatively low affin ity , and therefore the weak specific interactions o f  the 
Smads are not sufficient to overcome non-specific interactions during the purifica tion 
process. This is in contrast to certain transcription factor complexes w ith  are stable at 
500 mM  NaCl and thus can be recovered to a high o f  purity  by means o f  stringent 
conditions. Unfortunately, this is not the case for Smad-protein interactions.
4.3.1.2 Optimisation strategies for Dual-Tag Purification of Smad complexes
Due to the low a ffin ity  interactions o f the Smads, a more tailored approach is required 
to identify partners o f the Smads. An example o f  this is underway in the H ill 
Laboratory. The purification o f the components o f  the Smad complex on the c-jun 
promoter is being investigated using a combination o f  im m unoprecipitation and D N A  
pulldown where biotinylated DNA is the second ‘ a ffin ity  hook' for the complex (Sean 
Harkin. data not shown). Here. HA-Smad3 is a ffin ity  purified in the presence o f 
biotinylated DNA that is subsequently captured on a neutravidin-m atrix. The protein 
content o f  the purified complex is separated by SD S-PAG L and analysed by mass 
spectrometry. I'his system is currently being optimised. A n  example o f this has already 
been applied to the purification o f the spliceosome using biotinylated RNA and 
prefractionation by gel filtra tion (Neubauer. G. et al.. 1998).
Another possibility to stabilise the Smad interactions is to introduce a 
crosslinking step. This would require further optim isation however and due to time
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lim itations, the project could not be taken any further. Another method that could be 
employed would be to use mutated versions o f the Smads that m ight stabilise 
interactions w ith partners. The interaction between TGF-(3 fam ily receptors and R- 
Smads is transient, but can be visualised using mutant Smads lacking the receptor 
phosphorylation region (Lo. R. S. et al., 1998). However because o f the search for 
novel, unknown interacting partners, an array o f mutated Smads would be required to 
test this technique. As a result, the purification would be lim ited to transient 
transfections. A  sim ilar approach using deleted mutants o f the Smads would also be 
feasible, which may unmask contact areas and thus create a stable interaction. Again, 
time lim itations prevented these routes being investigated.
4.3.1.3 Other applications of Dual Tag purification
Although interacting proteins cannot be purified through use o f the dual tag 
purification strategy, a large amount o f  Smad protein can be isolated to a high degree 
o f purity. Characterisation o f purified bait protein is then possible. This allows 
investigation o f post-translational modifications o f the Smads, including 
phosphorylation, acetylation and methylation etc. Employing a 2-D gel approach 
together w ith the dual tag purification would increase the sensitivity o f the assay. By 
this means, the effects o f growth factors, kinases, phosphatases and inhibitors may be 
explored. Indeed, the effect o f p38 M A P K  on purified M EF2A phosphorylation status 
in mammalian cells was characterised upon purification by tandem a ffin ity  purification 
(Cox, D. \1. et al.. 2003). Furthermore, the use o f this dual tag could also be applied to 
other proteins o f interest, which interact more strongly w ith their partners. The 
incorporation o f the Protein A  and the FLAG peptide, would allow efficient recovery 
o f proteins complexes present at low concentration. This may be especially applicable 
to proteins that are regulated by Calcium or Calmodulin dependent mechanisms, as it 
would provide an alternative tag to the Calmodulin Binding Protein (CBP).
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4.3.1.4 Other Alternative Tags
An alternative purification system, which is a modified version o f the TAP-scheme has 
been devised, which incorporates the biotin-streptavidin interaction as one o f the 
a ffin ity  purification steps (Drakas, R. et al., 2005). Instead o f  using the CBP as the 
second a ffin ity  tag, a biotinylation tag o f 15 amino acids that is specifically 
biotinylated by the B ir A  gene is inserted at the N-terminus. Coexpression o f the Bir A 
gene on a separate expression vector, catalyzes the covalent addition o f biotin to the s 
amino group o f the lysine side chain. It was shown that by specifically b iotinylating a 
protein in mammalian cells, the strong biotin-strepavidin interaction can be utilised to 
dramatically increase the quantity o f  protein complexes isolated. The system was 
developed to facilitate the isolation o f  proteins interacting w ith  IRS-1, which was not 
feasible through other two-step procedures due to the low yie ld o f bait protein. The 
strepa\ id in-b iotin  interation is among the strongest noncovalent interactions known 
w ith a 10 ' 1:' kd. However, one p itfa ll o f  this system is the use o f 0.1M glycine, which 
has a low  pH. for elution o f the final step. This system would be applicable to increase 
the level o f Smad protein that is purified however, it would not address the problem o f 
the low a ffin ity  complexes that are formed.
4.3.1.5 Alternative systems for the identification of Smad-interacting partners
Interestingly, comparison o f orthologous complexes purified from various sources has 
revealed that they share sim ilar subunits (Estevez, A. M. et al., 2001; Gavin, A. C. et 
al.. 2002). In one case, a yeast homologue o f a human target protein was purified using 
the TAP strategy and its partners were identified (Schmitt, C. et al , 1999). Database 
searches revealed the human homologues o f these partners that were shown to 
associate w ith the original human target. Thus an alternative strategy based on 
phylogenetic conservation could possibly be developed. A lthough TGF-(3 signalling is 
absent in yeast. Smad homologues function in C. elegans and Drosophila 
Melanogaster. Indeed, the application o f tandem a ffin ity  purification has also been 
adapted for isolation o f native protein complexes from C. elegans (Polanowska. J. et 
al.. 2004). Here large-scale production o f nematode transgenic lines are generated in
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BioFlo fermenters to produce 60 litres o f dense worm culture. The worms are then 
harvested by centrifuation in 30% sucrose to generate sufficient starting material for 
purification purposes. This approach was validated by purify ing components o f the C. 
elegans BRCA1/BARD1 (CeBcD) complex using a tagged Cebrc-1 protein 
(Polanowska, J. et al.. 2006). The Smad proteins are highly conserved across diverse 
metazoan phyla. W ork in C. elegans revealed three Smads that function in the TGF-(3 
superfamily pathway. By this method, interacting partners o f the C.elegans Sma 
proteins could be identified.
The use o f a tandem a ffin ity  purification method has also been established as 
an effective technique for the study o f the Drosophila proteome (Veraksa. A. et al.. 
2005). Here three o f the critical features o f the TAP method are introduced; the 
enzymatically cleavable tag-based a ffin ity  purification; the use o f the native promoter 
to drive expression o f the tagged protein and fina lly  the replacement o f the original 
protein by the tagged version by means o f mutant background. Through this technique 
interacting proteins o f Mud, Medea or dSmad2 could be investigated. Again, this 
procedure m ight reduce the problem o f mass accumulation, however, as the Smads are 
highly homologous, presumably the interactions would be o f  a sim ilar nature and 
therefore they may not survive the two-step purification. However, the background 
noise in these systems may be lower and thus allow for less stringent conditions.
4.3.1.6 Genetic Screens to identify novel Smad-interating partners
The protein purification strategy has proved non-productive in yielding novel 
transcription factor partners o f the Smad proteins. Aside from biochemical approaches, 
genetic based screens have also proved a popular tool in the search for novel partners. 
An expression system that is based on the detection o f protein-protein interaction in 
vivo would potentially overcome the problem o f  low  a ffin ity  Smad interactions 
(Stagljar, I.. 2003). The yeast-2-hybrid system (Y T H ) system is a genetic expression 
system which provides a means to rapidly screen for binary interactions between 
proteins in the nucleus o f a yeast cell. This approach has also been adapted to perform 
analysis in mammalian cells, which would make it applicable for use w ith Smad 
proteins.
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Other genetic strategies designed specifically to dissect interactions among 
mammalian cells include the Ras recruitment system (RRS) and fluorescence 
resonance energy transfer (FRET)/bioluminescence resonance energy transfer 
(BRET)-based assays. The ras recruitment System is based on the complementation o f 
a temperature-sensitive yeast cdc25 mutant, deficient in Ras activity. Ras function 
requires plasma membrane localisation and this can be achieved through the 
interaction between two hybrid proteins (Broder, Y. C. et al., 1998). The bait protein 
can be screened using a cD N A library in which all encoded protens are fused to a 
m yristoylation signal. Interactions are based on the survival o f the clones at the 
restrictive temperature. This system has also been modified to screen for cytoplasmic, 
phosphorylation-dependent interactions (Nateri. A. S. et al., 2004). The BRET assay is 
based on a transfer o f energy principle. Proteins o f interest can be genetically fused to 
the bioluminescent donor or fluorescent acceptor ( ‘ the BRET tags'). When the BRET- 
tagged proteins come into close proxim ity, an energy emission can be detected 
(Pfleger. K. D. et al.. 2006). The added advantage o f this technique is that it can be 
monitored in real time, using live cells.
4.3.1.7 Final Conclusion on the Dual Tag purification
Overall the dual purification procedure to find novel Smad-interacting proteins failed 
to yield any new candidates. Despite great efforts to optimise this technique, the fragile 
nature o f Smad interactions prevented the co-purification o f new components o f the 
TGF-fT In conclusion, the generic purification method was not applicable for use by 
the Smad proteins. A more tailored approach is required to purify  Smad partners. This 
may involve further optimisation o f the current system by use o f crosslinking or 
addition o f DNA, or an alternative genetic approach.
4.3.2 EpH4 Tumour Cell Model System
The EpH4 tumour model system comprises o f three cell lines, which represent the 
progression o f a tumour from a normal epithelial to an invasive spindle-like cells (O ft.
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M. et al.. 1998; Oft. M. et al.. 1996). EpH4 cells are mouse mammary epithelial cells, 
which are non-tumourigenic and respond to TGF-|3 by growth inhib ition and apoptosis. 
The parental EpH4 cells, which have been transformed w ith  oncogenic Ras (EpRas). 
form rapidly growing tumours in mice and have an altered response to TGF-(3. EpRas 
cells no longer growth arrest upon TGF-|3 stimulation but undergo an EM T, so that 
they acquire an elongated mesenchymal phenotype. These mesenchymal EpRas cells 
m im ic the phenotype o f the X-tum our cells, which have been recovered from tumours 
formed by injection o f EpRas cells into mice (Oft. M. et al.. 1998; Oft, M. et al.. 
1996).
In this Chapter, I demonstrated prelim inary work on the characterisation o f  this 
system. In my hands, the EpH4 cells exhibited a robust response to the growth 
inhib itory effects o f TGF-(3. EpFI4 cells, synchronised in G1/G0, were prevented from 
entry into S-phase in the presence o f TGF-p. The EpRas cells and X-tum our cells, 
however, are resistant to this effect. I have also developed an assay to investigate the 
contribution o f the TGF-(3 signalling pathway to EM T progression. EpRas cells are 
grown on a plastic substrate at low  density in the presence o f TGF-|3. A fte r 9-12 days 
w ith  intermittent trypsinisation. the cells are converted to a mesenchymal phenotype. 
Unlike the use o f 3-D gels, the cell morphology o f EpRas cells grown on plastic and 
undergoing EM T is more obvious and reproducible by visual inspection and EM T 
markers. This technique also allows easy manipulation o f cells for use w ith  siRNA 
oligonucleotides. This was validated by using siRNA oligonucleotides targeted against 
A LK 5 . which was shown to inh ib it the downregulation o f epithelial markers o f EMT.
The main question posed using this model system was whether the different 
biological responses elicited by EpH4 and EpRas cells are governed by the set o f 
transcription factors to which the Smads bind? To address this question, the Smad 
purification system was set up using this model system to identify new interacting 
transcription partners in the individual cell lines. Although the dual tag purification did 
not yie ld any novel candidates to be tested, the fundamental question still remains. 
W hy do I 'p i 14 cells growth arrest in response to TGF-(3, whereas EpRas cells undergo 
an EMT? I have demonstrated that the system is robust in its responses to TGF-(3, but 
this question needs to be addressed in a different way. Genetic and biochemical 
analysis o f  human tumours has revealed that tumour cells frequently downregulate
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components o f the TGF-p pathway (W akefield, L. M. et al.. 2002). By this means, the 
cells overcome the growth inhib itory effects o f  TGF-|3. In light o f  this evidence, I 
investigated the levels o f the TGF-P pathway components in this tumour model system 
as an alternative approach. By this means. I have uncovered new insights into the 
mechanism by which FpRas cells have adapted their response to TGF-p. The evidence 
for this w ill be discussed in Chapter 5.
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5 The role of Smad3 in tumour progression
5.1 Introduction
Cancer is a multistep process which results in the emergence o f  tumour cells that have 
escaped the normal control that governs cell proliferation. A t early stages o f 
tumourigenesis, TGF-(3 signalling is thought to act as a tumour suppressor, as a result 
o f  its ab ility  to arrest the growth o f epithelial cells (Akhurst. R. J. et al., 2001; 
Derynck. R. et al.. 2001). It is therefore not surprising that many tumour cells 
downregulate or acquire mutations o f components o f the TGF-(3 signalling pathway, 
resulting in a reduced response or complete abolitian o f the antiproliferative effects o f 
TGF-(3 (Levy. L. et al., 2006). Unlike the other components o f the TGF-(3 pathway, 
which are mutated in human tumours, such as receptors. Smad2 and Smad4. Smad3 
mutations have not been identified. This finding was very surprising as Smad3 has 
been demonstrated to be a critical mediator o f  the cytostatic response in response to 
TGF-|3. Smad3 deficient mice show accelerated wound healing due to increased re- 
epithelialization which can be attributed to impaired TGF-(3 growth inh ib ition o f 
keratinocytes and increased recruitment o f  fibroblasts and macrophages (Ashcroft. G. 
S. et al.. 1999). In addition, a variety o f primary cells from Smad3 null mice are 
partially resistant to the growth inhib itory effects o f  TGF- (3 (Datto, M. B. et al.. 1999; 
Yang. X. et al.. 1999). Indeed, Smad3 has been shown to suppress liver tumorigenesis 
by promoting apoptosis in tumor cells (Yang. Y. A. et al., 2006).
Accumulating evidence has now revealed that although Smad3 is not mutated 
in cancer. Smad3 seems to be inactivated or inhibited by epigenetic factors, resulting 
in loss or reduction o f its expression, f  or example. Smad3 expression in gastric cancer 
is dramatically reduced in a significant portion o f gastric tumours and gastric cancer 
cell lines (Han, S. U. et al., 2004). In addition, Smad3 levels decrease during 
carcinogenesis in some tissues such as the breast, where the nuclear Smad3 level is 
reduced in high grade breast cancers (Jeruss. J. S. et al., 2003). Interestingly, it has 
become evident that although there is a strong correlation between reduced expression 
o f Smad3 w ith  cancer progression, the complete loss o f Smad3 expression is more 
rare.
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In recent years it has been revealed that the role o f TGF-p in cancer 
progression is more complex than orig ina lly anticipated and that during late stages o f 
cancer progression, the activities o f TGF-p switch from a tumour suppressor to that o f 
a stimulator o f  tumour progression, invasion and metastasis (Wakefield, L. M. et al., 
2002). Interestingly, the role o f Smad3 in TGF-p mediated responses appears to m im ic 
the dual role o f TGF-P during tumourigenesis. In addition to its role in TGF-P-induced 
growth arrest, Smad3 also plays a role in the pro-metastatic activities o f TGF-p. 
Indeed, reduction o f Smad3 strongly suppresses lung metastases o f aggressive 
carcinoma cells (Tian. F. et al., 2003).
Furthermore, a critical role for Smad3 in EM T has been firm ly  established, as 
highlighted by the inability o f TGF-p to induce EM T in response to TGF-p in primary 
tubular epithelial cells derived from kidneys o f Smad3 knockout mice (Zavadil. J. et 
al.. 2005). Taken together, these results would suggest Smad3 is required for both the 
growth inhib itory and tumour promoting activities o f TGF-p and this may help to 
explain the frequent downregulation o f  Smad3 expression in human cancers and not a 
complete deletion o f its activity. In line w ith  this hypothesis. M D C K  cells undergoing 
EM T were found to downregulate Smad3 expression, concomitant w ith  a resistance o f 
these ceils to TGF-p-induced growth inhib ition (Nicolas, F. J. et al., 2003b).
Interestingly a sim ilar observation was discovered when investigating the 
biological responses to TGF-p in the EpH4 tumour cell model system. In the EpF14 
cells, the TGF-p cytostatic response is intact, but EpRas cells are resistant to the 
antiproliferative effects o f  TGF-p. W hile studying the levels o f  the components o f  the 
TGF-p pathways in the EpH4 tumour cell model system, I noticed a remarkable 
difference in the level o f Smad3 in EpRas cells compared w ith  the EpH4 parental cell 
line. In this Chapter. I describe the details o f  Smad3 downregulation and provide some 
insights into the mechanism by which this is regulated. In addition, I provide evidence 
to suggest that Smad3 levels are important in determining the specificity o f  the 
biological responses elicited in response to TGF-p.
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5.2 Results
5.2.1 Smad3 is downregulated in EpH4 derivatives
A major aim o f my project was to investigate the TGF-f3 pathway components in the 
EpH4 tumour model system. Firstly, I analysed the downstream effectors o f the TG F-fl 
pathway. In itia lly  I tested the whole cell levels o f Smad2, 3 and 4 in confluent cultures 
o f EpH4, EpRas and X-tumour cells. A striking difference was observed in the level o f 
Smad3 protein, whereas both Smad2 and Smad4 expression remained constant. In 
EpH4 cells, high levels o f Smad3 were detected in contrast to the low levels 
demonstrated in both the EpRas and the X-tum our cell lines (Figure 5.1). Analysis o f 
the TGF-f3 response in these cells revealed that both Smad2 and Smad3 are 
phosphorylated in all three cell lines. The P-Smad2 levels were much lower in EpH4 
cells compared to both EpRas and X-tumour cells (Figure 5.1, third panel). In this 
experiment the EpH4 cells were more densely packed than the derivative cell lines, 
and therefore it is like ly that the confluent EpH4 cells had lim ited access to TGF-(5 due 
to the inaccessibility o f the receptor, which resulted in low P-Smad2 levels. This may 
also explain why despite much higher Smad3 protein levels in EpH4 cells, only a 
slight difference in the level o f P-Smad3 was observed (Figure 5.1, fourth panel).
During subsequent investigations o f Smad expression, I repeatedly observed 
that the levels o f Smad3 fluctuated relative to Smad2 protein levels. The culture 
confluency and position in the cell cycle was variable between experiments and 1 
hypothesized that this could be a contributing factor to the differences observed in 
Smad3 expression levels. As a result I decided to take a systematic approach to analyse 
the levels o f Smad3 through the cell cycle (Figure 5.2). Cells were grown to high 
density fo r 3 days, after which they entered a state o f quiescence as measured by flow  
cytometry. A second set o f cells was released from  a quiescent state into the cell cycle 
for 24 hr. Analysis o f the Smad3 protein levels in these cells revealed that the 
expression pattern o f Smad3 is regulated and dependent on the position o f the cells in 
the cell cycle. This was most apparent in the EpF14 cells, where high levels o f  Smad3 
protein are detected when the cells are quiescent, but Smad3 expression drops 
dramatically in the proliferating cells (Figure 5.2A. top panel). This is also the case for
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Figure 5.1. Smad3 expression is downregulated in EpRas cells compared with 
EpH4 cells
EpH4 parental cells and EpRas and X-tumour derivatives were treated with 2 ng/ml TGF-p 1 for 1 hr. 
Whole cell extracts were prepared and equal amounts of protein were analyzed by Western blotting 
using antibodies against the Smad2, 3 and 4 and phosphorylated Smad2 (P-Smad2) and 
phosphorylated Smad3 (P-Smad3) and Grb2 as a loading control.
246
Chapter 5 The role o fSm acti in tumour progression
the EpRas cells, however, the levels o f  Smad3 in quiescent cells are still much lower 
than in EpH4 cells. Thus, two levels o f  regulation exist w ith in  this model system. 
Firstly. Smad3 levels are regulated dependent on the cell cycle status o f the cell and 
secondly. Smad3 levels are downregulated by a mechanism dependent on the 
continuous activation o f Ras.
1 then proceeded w ith a more in depth investigation o f the timecourse o f 
downregulation o f Smad3 protein from quiescence to the proliferative level. 
Expression o f Smad3 was examined in synchronous cultures o f EpH4 and EpRas cells 
at different times after release from quiescence as they progress to S-phase. Western 
blotting analysis revealed that Smad3 protein level was downregulated over time at a 
steady rate (Figure 5.2B). A  high level o f  Smad3 expression was observed in EpH4 
cells, however by 24 hrs after release, the Smad3 protein level was dramatically 
reduced. A  sim ilar profile was observed in EpRas cells, although the in itia l level o f 
Smad3 was lower, as previously observed (Figure 5.2B). Cells prepared in parallel 
were analysed by FACS to determine the cell cycle distribution at each time point. 
This revealed that in both cell types the drop in Smad3 expression does not correlate 
w ith entry into S-phase, but rather it appears to be determined by the time/distance 
from  quiescence. In EpH4 cells, there is a linear rate o f Smad3 downregulation, 
whereas S-phase entry occurs between 16-20 hrs (Figure 5.2B, graphs and data not 
shown). However in the EpRas cells, there appears to be a more stepwise drop in 
Smad3 levels but both cell lines exhibit maximal downregulation at the 24 hr timepoint 
(Figure 5.2B).
In conclusion. Smad3 protein level is high in quiescent cells but upon exit from 
GO. the Smad3 expression is dramatically reduced. In addition, the EpRas cells have a 
lower Smad3 protein level than EpH4 cells, in both the quiescent and proliferative 
state.
5.2.2 Timecourse of signalling and induction of Smad3-depndent 
genes
The regulation o f Smad3 protein levels provided an avenue to pursue regarding the 
prevailing question o f how EpRas cells overcome the growth inhib itory response to 
TGF-(3 and undergo an EM T. As discussed in the Chapter 1, Smad3 has been
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Figure 5.2. The expression pattern of Smad3 is regulated during the cell cycle, 
with a gradual decrease in Smad3 protein expression upon entry into S-phase
(A) Synchronized, quiescent EpH4 and EpRas cells were prepared by contact inhibition for 72 hrs. 
Actively cycling low confluency EpH4 and EpRas cells were prepared by synchronizing the cells 
by contact inhibition and then plating into fresh medium for 24 hrs. Cells were either unstimulated 
or treated with 2 ng/ml TGF-fJl for l hr as indicated. Whole cell extracts were prepared and equal 
amounts of protein were analyzed by Western blotting using antibodies against Smad2/3 and Smad4 
and phosphorylated Smad2 (P-Smad2) and Grb2 as a loading control.
(B) EpH4 and EpRas cells were synchronized by contact inhibition and then plated into fresh 
medium for the number of hours indicated. Cells were harvested and analysed by 
fluorescence-activated cell sorting (FACS), to determine the number of cells in G l (black bar), S 
(blue bar) or G2/M yellow bar) and by Western blotting, using antibodies against Smad3 and Grb2 
as a loading control. 248
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demonstrated to play a major role in both TGF-(3-induced growth inhib ition and EMT. 
Therefore, it was possible that the downregulation o f Smad3 expression in EpRas cells 
may contribute to the loss in TGF-|3 growth inh ib ition and the induction o f EMT. It 
was thus important to establish the significance o f the reduced Smad3 expression in 
EpH4 cells compared w ith EpRas cells. To investigate whether the low level o f  Smad3 
protein had any effect on the downstream signalling o f TGF-(3, a timecourse analysis 
o f TGF-(3 signalling was performed and the phosphorylation states o f Smad2 and 
Smad3 over time were examined. The P-Smad3 antibody used in these experiments 
has subsequently been found to also recognise P-Smadl (See Chapter 6), observed as a 
slower migrating band. From Western blotting analysis, it is ev ident that the levels o f 
P-Smad3 were much lower in EpRas cells compared w ith  EpF14 cells, i f  the loading 
controls Grb2 are considered (Figure 5.3). In contrast, the levels o f  P-Smad2 are 
approximately equal. In addition, the duration o f Smad3 signalling is slightly 
attenuated in the EpRas cells compared w ith the EpH4 cells. A t 6 hrs post TGF-(3 
stimulation, the level o f P-Smad3 in EpRas cells is barely detectable, whereas a strong 
signal is observed in EpFI4 cells, despite equal levels o f  total protein, as determined by 
Grb2 (Figure 5.3). The P-Smad2 level at late timepoints in EpRas cells, is also slightly 
more transient than in EpH4 cells when the total protein levels are compared. 
However, at earlier timepoints an equal level o f  Smad2 phosphorylation is achieved in 
EpRas cells compared w ith EpH4 cells (Figure 5.3. second panel).
It has previously been demonstrated that the duration o f TGF-(3-Smad 
signalling is a critical determinant o f  the specificity o f the TGF-(3 response (Nicolas. F. 
J. et al.. 2003a). Attenuation o f the TGF-(3 signalling pathway in pancreatic carcinoma 
cell lines resulted in an altered expression profile o f  TGF-(3-inducible genes (Nicolas, 
F. J. et al.. 2003a). As Smad3 signalling was found to be attenuated in EpRas cells, I 
investigated whether EpRas cells were still responsive to Smad3 signalling. To this 
end I tested the ability o f EpRas cells to induce expression o f a well characterized 
Smad3 dependent gene. Plasminogen Activator Inh ib ito r-1 (PAI-1) (Dennler, S. et al., 
1998; Wong, C. et al., 1999). In EpH4 cells. PAI-1 expression is induced at 4 hours 
post TGF-|3 stimulation and its intensity increases gradually until the 8 hr timepoint 
(Figure 5.3. third panel). Conversely, EpRas cells are unable to induce expression o f 
PAI-1. The inability o f EpRas cells to upregulate the Smad3-dependent gene in
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Figure 5.3. TGF-(3 fails to induce Smad3-dependent target genes in EpRas cells
EpH4 and EpRas cells were synchronized by contact inhibition and released into the cell cycle for 20 
hrs before stimulation with TGF-pl (2 ng/ml) for different time periods. Whole-cell extracts were 
prepared, and equal amounts of protein were analysed by Western blotting using an antibody against 
PAI-1 as a representatives of a Smad3-dependent TGF-p target gene, and against P-Smad3 and P- 
Smad2 to show the level of phosphorylated Smad over time. Grb2 serves as a loading control. The P- 
Smad3 antibody also detects P-Smadl (see Chapter 6).
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response to TGF-(3 correlates w ith  the low Smad3 protein level in these cells. 
However, in pancreatic carcinoma cell lines, the attenuated TGF-(3 pathway and 
altered gene responses correlated w ith  low levels o f  A L K 5  (Nicolas, F. J. et al.. 
2003a). To investigate whether the levels o f  ALK.5 may be responsible for the 
attenuated Smad3 signalling and the inab ility  o f  EpRas cells to induce PAI-1 and not 
the level o f Smad3, A LK 5 protein levels were investigated. The antibodies are 
relatively poor for the TGF-{3 receptors. Fortunately, the extracellular domain o f  the 
TGF-|3 type I receptor, ALK.5, is glycosylated (Massague, J.. 1998) and this property 
can be exploited to detect the specific receptor by Western blotting. The enzyme, 
PNGase F. hydrolyzes nearly all types o f N-glycan chains from glycoproteins and 
therefore upon treatment w ith  this enzyme, there is a shift in the A L K 5  band on SDS- 
PAGE due to the reduced molecular weight. In the absence o f PNGaseF A L K 5  runs as 
a smear because o f its variable glycosylation state, however treatment w ith  PNGaseF 
reduces ALK.5 to a single band, which is distinguishable from background bands as it 
is not present in the untreated samples. Comparison o f A L K 5  levels in EpH4 and 
EpRas cells in S-phase. revealed that there is no significant variation between EpFI4 
and EpRas A LK 5 levels in cycling cells, which is the cell cycle phase whereby PAI-1 
induction was investigated and actually ALK.5 levels in quiescent EpRas cells appears 
to be higher than in EpH4 cells (Figure 5.4). However, although it is conclusive that 
the receptor protein levels are not affected in cycling cells, this does not rule out the 
possibility that the activity o f  ALK.5 has been compromised.
In conclusion, it is evident that the TGF-(3-Smad3 signalling pathway in EpRas 
cells is attenuated in comparison w ith the parental EpH4 cell line. This has resulted in 
an impaired response to TGF-[3 induction o f Smad3 dependent genes.
5.2.3 Transcriptional regulation of Smad3 contributes to the 
increased level of Smad3 protein in EpH4 cells.
Although the decreased level o f  Smad3 in EpRas cells was shown to be biologically 
significant, it was as yet unclear how these cells regulated the Smad3 levels. The first 
approach to gain insight into the mechanism involved was to investigate the 
transcriptional regulation o f Smad3 expression. Smad3 m RNA levels were determined
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Figure 5.4 ALK5 expression is not donwregulated in EpRas cells
Synchronized, quiescent EpH4 and EpRas cells were prepared by contact inhibition for 72 hrs. 
Actively cycling low confluency EpH4 and EpRas cells were prepared by synchronizing the cells by 
contact inhibition and then plating into fresh medium for 24 hrs. Cells were either untreated or 
stimulated with 2 ng/ml TGF-(31 for 1 hr as indicated. For PNGaseF treated extracts, 30 pg of whole 
cell extracts from each sample was incubated with PNGase F (0.1 pi; specific activity 1800000 U/mg) 
for 1 hr at 37°C. Untreated and PNGaseF treated extracts were then analyzed by Western blotting 
using antibodies against ALK5 and Grb2 as a loading control.
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by quantitative RNase mapping, as described in Chapter 2 (Treisman, R., 1985). Total 
RNA vv as prepared from  both EpH4 and EpRas cells, in both the quiescent and cycling 
state. In this experiment, mouse Smad2 and Smad3 m RNA protected the RNA probe 
to generate a 230 and a 300 bp fragment, respectively. The y-actin protection produces 
a smaller fragement o f 65 bp fragment (Figure 5.5A). The quantitation o f RPA 
analysis revealed that Smad2 m RNA did not vary s ignificantly, from  quiescence to 
cycling cells, or between EpH4 and EpRas, which was expected from  the Smad2 
protein data (Figure 5.5B, graph on the left). In contrast, however, Smad3 mRNA 
levels varied substantially, w ith a 3 fo ld  decrease in Smad3 m RNA in cycling EpH4 
cells compared w ith cells in quiescence (Figure 5.5B, graph on right). The Smad3 
transcriptional profile was sim ilar in EpRas cells, however, there was an overall 
decrease o f 2-3 fo ld  in Smad3 m RNA in EpRas cells compared w ith  EpH4 cells. These 
results exhibited a sim ilar trend as the profiles o f the Smad3 protein level, but the 
differences in protein level were much more pronounced than a 3-fold decrease. 
Hence, the relatively small decrease in mRNA from  quiescence to cycling cells and 
equally from EpH4 to EpRas cells, was unlikely to account in fu ll fo r the much more 
dramatic alteration in Smad3 protein levels.
To conclude, transcriptional regulation o f Smad3 m RNA levels contributes in 
part to the control o f expression levels o f Smad3 observed during the cell cycle and 
also the overall decrease Smad3 observed in EpRas cells compared w ith EpH4 cells. 
However other mechanisms must play a role in the downregulation o f Smad3 in 
addition to transcriptional regulation.
5.2.4 Instability of Smad3
In view o f the transcriptional data, it was necessary to further investigate the 
mechanisms that could account for the significant decrease in Smad3 protein levels. 
The downregulation o f Smad3 observed in both cell types was concomitant w ith exit 
from  GO. A possible explanation fo r this was that in addition to decreased 
transcriptional activation o f Smad3 in cycling cells, the changes in cellular 
environment could affect the stability o f Smad3 protein. In order to investigate this 
hypothesis, I used a well characterized protein synthesis inhib itor, cycloheximide, to 
prevent translation o f newly synthesized Smad3 mRNA. By preventing new protein
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Figure 5.5. Smad3 mRNA levels are elevated in quiescent cells compared with 
cycling cells and also slightly higher levels of Smad3 mRNA are observed in 
FpH4 cells compared with EpRas cells
(A) Expression levels of Smad2 and Smad3 was detected by RNase protection. RNA was isolated 
from both cycling (C) and quiescent (Q) EpH4 and EpRas cells. 20 pg of total RNA were analysed by 
RNase protection with probes for Smad2 and Smad3. The protected fragments (Smad2 or Smad3) are 
indicated, y-actin probe was used as a loading control. Data are representative of two independent 
experiments.
(B) Quantitation of RNAse protection by phosphorimaging analysis. The data are the means and 
standard deviations of two separate experiments relative to appropriate controls.
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synthesis, it is possible to determine the rate o f degradation o f the Smad3 pool under 
different conditions. Four conditions were tested: EpH4 cells and EpRas cells when 
cycling and quiescent. Cells were released from  quiescence by trypsinisation and 
replated for 15 hours before addition o f cycloheximide. Samples were taken at the 
equivalent times in the absence and presence o f cycloheximide and the Smad3 protein 
level examined (Figure 5.6). It is important to note that addition o f cycloheximide 
prevented further progression o f the cells through the cell cycle as determined by 
FACs analysis (data not shown) and therefore the stability o f  Smad3 could be assessed 
at these two positions in the cell cycle. In addition, the starting levels o f Smad3 vary 
between the four conditions, as has previously been shown in Figure 5.2. In the control 
cycloheximide untreated samples, the level o f Smad3 is relatively stable in each 
condition (Figure 5.6, left set o f panels). It is also evident that the Smad3 protein levels 
in cycloheximide treated samples o f quiescent EpH4 cells are extremely stable in the 
presence o f cycloheximde, suggesting that degradation o f Smad3 in these conditions is 
minimal (Figure 5.6, top right panel). The Smad3 protein level in the quiescent EpRas 
cells is relatively stable, but exhibits a slight degradation over time. A sim ilar trend can 
be observed fo r the cycling EpH4 cells (Figure 5.6, third set o f panels on the right). In 
contrast, Smad3 protein is extremely labile in the proliferating EpRas cells, w ith a half 
life  o f approximately 6 hrs. In addition to the differences in basal Smad3 levels, the 
most obvious difference in Smad3 stability is observed upon comparison o f  the 
quiescent EpH4 cells w ith the cycling EpRas cells. Furthermore, treatment w ith the 
proteasome inhib itor, MG 132, resulted in a decrease in the degradation o f Smad3 (data 
not shown), thus suggesting that the ubiquitin-proteasome pathway mediates 
degradation o f Smad3.
In conclusion, these results demonstrated that stability o f Smad3 in these cell 
lines appears to contribute to its downregulation during cell proliferation. It was 
observed that the most stable Smad3 protein exists in the quiescent state in EpH4 cells, 
whereas the most labile Smad3 protein occurs in cycling EpRas cells.
5.2.5 Regulation of Smad3 Stability
The realization that both the cell cycle state and Ras activity could have an 
impact on the stability o f Smad3 protein was intriguing. Previous studies have already 
implicated Ras activation through the ERK M APK pathway in alteration o f the activity
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Figure 5.6. Smad3 is less stable in cycling cells than when cells are quiescent
Synchronized, quiescent EpH4 and EpRas cells were prepared by contact inhibition for 72 hrs. 
Actively cycling, low confluency EpH4 and EpRas cells were prepared by synchronizing the cells by 
contact inhibition and subsequent release into fresh medium for 15 hrs. EpH4 were either untreated or 
treated with the protein synthesis inhibitor cyclohexamide (20 p.g/ml) for 3 to 24 hrs as indicated. 
Whole cell extracts were prepared and equal amounts of protein were analysed by Western blotting 
using antibodies against Smad3 and Grb2 as a loading control.
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o f Smad3. In this case, phosphorylation on consensus M A P K  sites by ERK1/2 in the 
linker o f Smad2 or Smad3 was proposed to inh ib it nuclear translocation and 
consequently reduce transcriptional activation (Kretzschmar, M. et al., 1999)(Figure 
5.7A). Although, this study was conducted in the EpI 14 system, by comparison o f 
HpH4 and EpRas cells lines, I have never encountered such inhib ition o f nuclear 
translocation. Interestingly, a study on the regulation o f Smad3 by cyclin dependent 
kinases (CDKs) was reported at the time o f these observations in this thesis. This study 
revealed that the linker o f Smad3 also contains phosphorylation sites for CDKs and 
that phosphorylation o f Smad3 by CD K4 and CDK2 inhibits its transcriptional activity 
and the antiproliferative function o f Smad3 (Matsuura, I. et al.. 2004)(Figure 5.7A). 
Taken together, these results showed that that both ERK and C D K activity decreases 
Smad3 transcriptional activity, however the mechanism by which this is achieved has 
not been fu lly  established. In theory, this inhib ition o f activity could be explained by a 
decrease in the stability o f Smad3 protein levels, as observed in EpRas cells, which 
would have high levels o f ERK and CDK2/4 activity. Previous work has shown that 
phosphorylation events can target proteins fo r degradation by E3 ubiquitin ligases 
(Cardozo. T. et al.. 2004). For example, components o f the SCF-ligase complex, the F- 
box proteins, recognize specific Ser/Thr phosphorylation consensus motifs on target 
proteins, which are then targeted for degradation by ubiquitination by the SCF-ligase. 
By this means, the levels o f crucial components o f fundamental cellular functions are 
regulated, including cell cycle components such as the cyclins, CD KIs and c-myc. 
Therefore, I set out to test whether the phosphorylation o f Smad3 by ERK and CDKs 
could target it fo r degradation in the EpH4 system. As the Smad3 phosphorylating 
activity o f CDKs had been demonstrated in human keratinocyte cell line, HaCaTs 
(Matsuura. I. et al.. 2004), it was first essential to determine whether Smad3 was also a 
physiological target for CDK2 and CD K4 in EpH4 and EpRas cells. Specific 
antibodies against the phosphorylation sites on Smad3 were generated by Fang Liu and 
were kindly donated upon request (Matsuura, I. et al., 2004). EpH4 and EpRas cells 
were released into serum for 24 hrs and analysed by Western blotting with a specific 
phosphopeptide antibody against a Smad3 ERK phosphorylation site (S207) and with 
an antibody against a CDK2/4 phosphorylation site (T178) (Matsuura, I. et al., 2004) 
(Figure 5.7A). Treatment o f TGF-(3 fo r 1 hr revealed that these phosphorylation sites 
are rapidly induced by TGF-(3 (Figure 5.7B). Next, I needed to test the cell cycle
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Figure 5.7. Smad3 is phosphorylated at CDK and Erk phosphorylation sites in EpH4 and EpRas cells
(A) Schematic diagram of Smad3 structure, indicating the sites of phosphorylation by ERK and CDK2/4.
(B) Smad3 is phosphorylated at the T178 and T207 sites in the linker. Both T178 and S207 phosphorylation events are rapidly induced by TGF-(3. Synchronized, cycling EpH4 
and EpRas cells were either untreated or stimulated with TGF-P for 1 hr. Whole cell extracts were fractionated by SDS-PAGE and analysed by Western blotting using 
phosphopeptide antibodies against T178 and T207 of Smad3.
(C) Endogenous Smad3 is phosphorylated in a cell cycle-dependent manner. EpH4 and EpRas cells were synchronized by contact inhibition and then released into fresh medium. 
Cells were collected at different time points to analyse the phosphorylation status at each of the sites by Western blotting with the corresponding phosphopeptide antibody. Note 
that the pT178 antibody also recognises the same site in Smad2.
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dependency o f these phosphorylation events in the absence of TGF-(3. The 
phosphorylation status o f Smad3 was examined in synchronous cultures o f EpH4 and 
EpRas cells at different times after release from quiescence as the cells progressed 
through the cell cycle and revealed that the phosphorylation o f  Smad3 at these sites 
oscillates in a cell-cycle-dependent manner. As shown in Figure 5.7C, phosphorylation 
o f Smad3 at the T207 residue is maximal early in G l,  which is consistent w ith a serum 
induction response of ERK 1/2 activity (Matsuura. I. et al., 2004). It is important to 
note that the level phosphorylation o f Smad3 on T207 is almost equal to that in the 
EpH4 cells, despite reduced Smad3 levels. This is like ly  due to the constitutive 
activation o f ERK 1/2 by H-Ras in these cells. The phosphorylation o f T 178 on Smad3 
(and also Smad2) was high at the G l/S  phase boundary but exhibited a more prolonged 
activity through the rest o f the cell cycle. Importantly, the activ ity profiles o f the 
kinase phosphorylation o f Smad3 correlated with the pattern o f Smad3 degradation 
(Figure 5.7C, top panel). This correlation suggests that the phosphorylation o f Smad3 
may function as a trigger fo r its degradation and thus decrease the stability o f Smad3 
when these kinases are active.
To conclude, I have confirmed that the phosphorylation o f Smad3 at the linker 
phosphorylation sites occurs in a cell-cycle dependent manner in EpH4 and EpRas 
cells. The phosphorylation events correlate w ith the cell cycle dependent activ ity o f 
ERK and CDK2/4. whereby serum induction causes a peak o f  ERK activ ity early in 
G l and CDK2/4 activity is high at G l/S  phase junction but persists throughout the 
early stages o f cell cycle entry. In addition, the phosphorylation o f Smad3 at these 
linker sites occurs concomitantly w ith the observed increase in Smad3 instability and it 
is thus possible that these phosphorylation events target Smad3 fo r degradation.
5.2.5.1 Smad3 Mutants
The combined activities o f ERK and C D K activation appeared to correlate w ith  the 
gradual decline o f Smad3 observed and suggested that the phosphorylation o f the 
linker sites might contribute to the decreased stability o f  Smad3 in cycling EpI 14 and 
EpRas cells. To determine the effect o f  these phosphorylation events on Smad3 
stability, a set o f  Smad3 mutant constructs were generated by M ike Howell in the 
Developmental Signalling Laboratory, which included different combinations o f  S-to-
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A  mutations o f the ERK and CD K phosphorylation sites (Figure 5.8A). By this means, 
I could test whether the degradation o f  Smad3 in EpRas cells could be stabilised by 
inh ib ition o f Smad3 ERK or CD K phosphorylation. F irstly, I needed to test whether 
these mutant plasmids expressing Smad3 were s till responsive to TGF-|3. EpRas cells 
were transiently transfected w ith each o f the plasmids expressing the mutant Smad3 
and fo llow ing immunoprecipitation and Western b lotting analysis, the C-terminal 
phosphorylation status was examined. For each o f the mutants tested, the proteins were 
e ffic iently phosphorylated fo llow ing TGF-(3 stimulation (Figure 5.8B).
1 then proceeded to test the effect o f  these mutants on the stability o f  the 
expressed Smad3 protein compared w ith  w ild  type Smad3 protein. Transient 
transfections were carried out in EpRas cells, as Smad3 protein was the most labile in 
these cells. These cells were synchronised by contact inh ib ition  and released into 
serum containing media to a llow  them to reenter the cell cycle. The cells were either 
untreated or treated w ith  cycloheximide for 18 hrs to test for the stability o f  the Smad3 
mutants compared to w ild  type. In both EpH4 and EpRas cells the w ild  type FLA G - 
Smad3 protein was e ffic iently degraded in the presence o f cyclohexim ide (Figure 5.9. 
cx-FLAG panel). The Smad3 blot serves as an internal control in this experiment, 
because it demonstrates the stability o f  endogenous Smad3, which can vary dependent 
on cell cycle position and culture confluency. The transfection efficiency for the EpH4 
cells is relatively weak and thus the contribution o f FLAG-Smad3 to the total Smad3 
level is generally quite low. In most o f the mutants tested, there seemed to be no 
obvious increased stability compared to the w ild  type. However, cells expressing 
Smad3 mutants no 4. 5 and 13, did exhibit some resistance to degradation, which was 
observed prim arily in EpH4 cells ( f  igure 5.9, right). The endogenous Smad3 levels in 
each case were also more stable, suggesting that the culture conditions were 
compromised in these cases. The Smad3 mutant no 13 appeared to be more stable in 
both cell lines and to further investigate its stability, stable cell lines expressing this 
mutant were generated. However, when these stable cell lines were investigated, no 
effect in stability o f  the mutant was detected (data not shown). These results suggested 
that phosphorylation o f these sites is not involved in targeting Smad3 for degradation. 
Nevertheless, further investigation is required to determine fu lly  the significance o f 
these phosphorylation events w ith respect to Smad3 activity.
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Figure 5.8. The Smad3 mutants are efficiently phosphory lated at the C-terminus
(A) A list of thirteen Smad3 mutants. CDK and ERK phosphorylation sites were mutated to alanine, in 
various combinations as shown.
(B) EpRas cells were transfected with plasmids expressing wild type FLAG-Smad3 (wt) or each of the 
FLAG-tagged mutant Smad3s (mt) as indicated. After 48 hrs incubation, cells were either untreated or 
stimulated with TGF-pi for 1 hr before lysis. Whole cell extracts were prepared and immuoprecipi- 
tated with beads conjugated with anti-FLAG antibody. The immunoprecipation reactions (IPs) were 
analysed by Western blotting with antibodies against P-Smad3.
Mutant constructs were kindly provided by Mike Howell.
261
w t m t4 m t5 m t6 m t7 m t8 m t9 m tl 0 m tl 1 m tl 2 m tl 3
Cycloheximide + - + - + .  + - + + .  +
(18hrs)
FLAG-Smad3 -           _ W
'  <D  O
u-FLAG
■ 2  
aFLAG-Smad3 -  
Smad3
a-Smad3
w t m t4 m t5 m t6 m t7 m t8 m t9 m tl 0 m tl 1 m tl 2 m tl 3
Cycloheximide + - + - + - + - + .  + - + -  + - + - + - + -  +
(18hrs)
FLAG-Smad3 -
FLAG-Smad3 =  
Smad3 ™
a-Smad3
Figure 5.9. Mutant Smad3 proteins exhibit the same stability as wild-type Smad3
EpH4 and EpRas cells were transfected with empty vector, or plasmids expressing wild type (wt) FLAG-Smad3 or each of the 
mutant (mt) Smad3s as indicated. After contact inhibition (48 hrs incubation), cells were released and replated 1:2 for 15 hrs. Cells 
were then either untreated or treated with the protein synthesis inhibitor, cyclohexamide (20 p,g/ml), for 18hrs to visualise Smad3 
degradation. Whole cell extracts were prepared and analysed by Western blotting with antibodies against Smad3 and FLAG. FLAG- 
Smad3 is observed in the Smad3 blot, where it is detected as a band running with slightly lower mobility compared to endogenous 
Smad3 (see arrows).
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5.2.6 Inhibition of ERK activity
The primary difference between the HpH4 and EpRas cells was the activation o f Ras 
and therefore it was highly like ly that the downstream mediators o f Ras were 
responsible, either directly or indirectly, for the regulation o f  Smad3 levels either by 
affecting transcription, upregulating degradation or by alternative means. Three well 
characterised pathways propagate the Ras signal, namely the Raf-ERK M AP kinase 
pathway. P13 Kinase pathway and Ral GTPase activation (Downward. J.. 1998). 
A lthough ERK activity had been indirectly tested by investigation o f  the mutants. I 
wanted to test whether inh ib iting ERK activ ity could revert the Smad3 level in EpRas 
cells to that o f  EpH4 cells. For this purpose. I used a M EK1/2 inh ib itor. U0126. which 
specifically abolishes ERK 12 activ ity. Again it was necessary to synchronise the cells 
by contact inh ib ition and allow them to enter the cell cycle. It could then be tested 
whether the high level o f Smad3 degradation in cycling EpRas cells could be 
prevented by inh ib iting ERK activity. As ERK activation is required for the regulation 
o f cells through G l-S  phase transition, it is like ly that upon addition o f  U0126, cell 
cycle progression was halted, thus preventing a further decrease in Smad3 levels. For 
comparison, quiescent EpRas cells were also treated w ith  U0126, again to test whether 
the Smad3 level could be restored. However, contrary to the expected result, inh ib ition 
o f HRK activ ity actually destabilised the Smad3 protein slightly (Figure 5.10). The 
increased instability o f  Smad3 observed was like ly  to be an indirect result o f  Ras 
transformtaion. This suggested that the R af-M H K-ER K pathway downstream o f  Ras 
was not involved in directing the downregulation o f Smad3 level. The two other 
effectors pathways downstream o f  Ras have not yet been investigated but may provide 
potential routes o f  investigation for the future.
5.2.7 The Role of Smad3 in EpRas cells
5.2.7.1 Generation of Smad3 Clones in EpRas cells
Although the mechanism by which EpRas cells had downregulated their Smad3 level 
not become apparent, the loss o f  P A I- l expression in response to TGF-(3 clearly
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Figure 5.10. M EK activity is not involved in the destabilisation of Smad3
Smad3 protein levels are lower in the presence of U0126. EpRas cells were synchronized by contact 
inhibition and then released into fresh medium for 15 hrs. Cells were then treated with or without 
the MEK inhibitor, U0126 (25 pM), for 6, 12 or 24 hrs. Quiescent cells were also treated with the 
inhibitor for 24 hrs for comparison. Whole cell extracts were prepared and analysed by Western 
blotting using antibodies against phosphorylated ERK 1/2 (P-ERK1 and P-ERK2), Smad2/3.
* indicates a non-specific band recognised by the antibody.
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showed that the low level o f Smad3 in EpRas cells could significantly alter its 
responses to TGF-J3. To determine whether the Smad3-dependent responses o f TGF-|3 
could be restored upon Smad3 re-expression or i f  these changes in responses were 
irreversible, I generated stable cell lines expressing FFAG-Smad3 in FpRas cells. Two 
Smad3 clones, FpRas Smad3 clonel (S3 C l)  and clone 2 (S3 C2), which exhibited 
different levels o f  Smad3 expression, were selected for use in biological assays, 
f  unctional analysis o f these clones established that the stably expressed FFAG-Smad3 
was responsive to TGF-|3. Immunoprecipitation o f FFAG-Smad3 in these clones 
followed by immunoblotting revealed FFAG-Smad3 was phosphorylated at its C- 
terminal serine residues after stimulation w ith TGF-|3 (Figure 5.11 A). The difference 
in FFAG-Smad3 expression can also be seen here, w ith  a much higher expression o f 
FFAG-Smad3 in C lonel and a lower level in Clone2. Next, the transcriptional activ ity 
o f  the FFAG-Smad3 expressing clones was compared to the parental EpRas cell line 
using a Smad3-dependent reporter. C A G A i2 -luciferase. Clones expressing FFAG- 
Smad3 exhibited both an increase in the basal signalling and slight increase in the 
induction o f CAG Ai:-luciferase activity relative to EpRas cells (Figure 5.1 IB ). 
Despite large standard deviations w ith in  triplicate experiments, there is a trend o f 
increased luciferase activity in FpRas Smad3-expressing clones. Unexpectedly, FpRas 
S3 Clone2 gave a marginally higher activity compared w ith  EpRas S3 C lone l. despite 
the lower level o f Smad3 present. Further investigation into the levels o f  Smad3 in 
these clones, demonstrated that expression o f FFAG-Smad3 exhibits a cell cycle 
dependent regulation as previously observed in the DT-Smad FpRas cell lines (Figure 
5.12B). Here the expression o f FFAG-Smad3 in quiescent cell clones is very low, 
however upon release into the cell cycle for 14 hrs. FFAG-Smad3 expression is 
upregulated. This is more pronounced for the FpRas C lone l, which exhibits a higher 
expression o f FFAG-Smad3. The expression o f  FFAG-Smad3 in these two clones, 
however is transient and after 18 hrs after release from quiescence, the expression o f 
FFAG-Smad3 protein is lost.
In conclusion, these results indicate that the FFAG-Smad3 expressed in the 
FpRas clones is phosphorylated in response to TGF-(3 and can induce expression o f a 
Smad3-dependent reporter. The short-lived expression o f  FFAG-Smad3 in these 
clones accounts for the variable and low  induction o f expression from this promoter.
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Figure 5.11. Functional analysis of the EpRas Smad3 clones
(A ) FLAG-Smad3 is efficiently phosphorylated at the C-terminal in response to TGF-p. EpRas parental 
cell line, EpRas S3 C l and EpRas S3 C2 cells were synchronized by contact inhibition and released for 
15 hrs. Cells were either untreated or stimulated with TGF-P 1 for 1 hr before lysis. Whole cell extracts 
were prepared and immunoprecipitated with beads conjugated with anti-FLAG antibody. The immuno- 
precipates (IPs) were analysed by Western blotting with antibodies against P-Smad3. 20% input is 
shown on the left as a control.
(B) Smad3 transcriptional activity is amplified in EpRas Smad3 clones. EpRas parental cell line and the 
two FLAG-Smad3 clones (EpRas S3 C l and EpRas S3 C2) were transfected with the Smad3-dependent 
reporter (CAGA)12-Luc. Following contact inhibition (48h incubation), cells were released into fresh 
medium for 12 hrs before TGF-p addition for 8 h. Luciferase activity was assayed and quantitated 
relative to p-galactosidase from the pEFLacZ internal control. The data are the means and standard 
deviations of three independent experiments.
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5.2.7.2 Expression of Smad3 in EpRas cells restores the antiproliferative 
activity of TGF-/3
The significance o f the low level and attenuated Smad3 signalling in EpRas cells was 
established by the inability o f EpRas cells to upregulate Smad3-target genes, such as 
PAI-1 (Figure 5.3). It was conceivable that the low  Smad3 expression level in EpRas 
cells could also account for its inability  to respond to the antiproliferative effects o f 
TGF-(3. This hypothesis was supported by the observation that Smad3 downregulation 
in M DCKs during Raf-induced EM T correlated w ith  a loss o f  TGF-(3-induced growth 
arrest (Nicolas. F. J. et al.. 2003b). Re-expression o f Smad3 in these cells restored the 
growth inhib itory action o f TGF-p. To investigate whether a sim ilar situation 
occurred/existed in EpRas cells, the stably expressing FLAG-Smad3 clones were 
tested for their ab ility  to respond to the antiproliferative effects o f  TGF-p. The EpH4 
cells. EpRas cells and its two clonal derivatives, EpRas S3 C l and EpRas S3 C2 cells, 
were synchronized by contact inh ib ition and released into serum in the absence and 
presence o f TGF-P for 16, 18 or 20 hrs. Samples were collected and analysed by 
FACS to determine the cell cycle distribution o f the cells at each timepoint. A fte r 18 
hrs post release from quiescence, the EpH4 cells entered S-phase in the absence o f 
TGF-P but as expected the cells remained in G l upon treatment o f  TG F-p (Figure 
5.12A. top row). S im ilarly at the 18 hr and 20hr timepoints, where a higher proportion 
o f EpH4 cells had progressed into S-phase in the absence o f TGF-p, this entry was 
again inhibited when TGF-P was present (Figure 5.12A, top row, on the right). In 
contrast the EpRas cells, which exhibit a higher proliferation rate, had entered S-phase 
after 16 hours regardless o f the presence o f TGF-P (Figure 5.12A, second row, left). A t 
this early timepoint, the EpRas cells were slightly sensitized to TGF-p, however at 
subsequent timepoints (18 and 20 hr), this sensitivity to TGF-P was lost and the EpRas 
cells progressed equally well through the cell cycle in the absence or presence o f TGF- 
p. Interestingly, the DN A profiles o f the EpRas Smad3-expressing clones more closely 
matched those o f the EpH4 cells. For the EpRas FLAG-Smad3 Clone 1, the percentage 
o f cells in S-phase was reduced compared to the EpRas cells at 16 hr post release, 
which is indicative o f their slower proliferative rate (Figure 5.12A, third row, left). In
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addition, the entry o f these cells into S-phase was inhibited in the presence o f TGF-p. 
This is even more evident at the 18 hr timepoint, where a substantial reduction in the 
number o f cells in S-phase and increase in the G l population is observed in the 
presence o f TGF-p (Figure 5.12A, third row, middle). This antiproliferative effect o f 
TGF-p persists after 20 hrs o f release from growth arrest, demonstrated by a higher 
population in G l and a lower number o f cells in G2. compared w ith  the uninduced 
sample. Samples were taken in parallel to determine the level o f  Smad3 in FpRas cells 
and the two Smad3 clones. The Smad3 protein levels o f  FpRas FFAG-Smad3 Clone 1 
depicted in Figure 5.12B reveal that high Smad3 levels persist for 16 hrs post release 
and are slightly lowered thereafter, but remain above endogenous levels o f  FpRas 
cells. Thus the increased Smad3 levels correlate w ith  the ab ility  o f  these cells to 
respond to the antiproliferative effects o f  TGF-p. The second FFAG-Smad3 
expressing clone has a lower level o f  Smad3 expression and as a result, the effect o f 
the growth inhib itory action o f TGF-P is slightly less prounounced (Figure 5.12A and 
B). A fter 16 hrs and 18 hrs o f release from quiescence, entry o f  EpRas FFAG-Smad3 
Clone2 is inhibited in the presence o f TGF-p. A t the 20 hr timepoint, the inh ib itory 
effect o f  TGF-p has abated, which correlates w ith the lower Smad3 expression level at 
this late timepoint. In conclusion, these data show that the level o f  Smad3 correlates 
w ith the ability o f  the FpRas cells to respond to the TGF-p-induced growth inh ib ition 
in a dose dependent manner.
5.2.7.3 TGF-fJ signalling requirements for EpH4 growth inhibition
The observation that the short-lived expression o f Smad3 in FpRas FFAG-Smad3 
Clone 2. resulted in a less effective TGF-p-induced growth inh ib ition was reminiscent 
o f  experiments conducted in HaCaT cells. Here, it was shown that continuous TGF-P- 
Smad signalling for 12-14 hrs was required for effic ient growth inhibition(N icolas, F. 
J. et al.. 2003a). In these experiments, the signalling requirements for TGF-p-induced 
growth arrest in HaCaT cells was determined by a rtific ia lly  attenuating the TGF-p- 
Smad signalling pathway and then investigating whether this then led to loss o f TGF- 
p-induced growth arrest. To test the duration o f  Smad3 dependent signalling required 
for TGF-p-induced growth inh ib ition in EpH4 cells, I conducted a sim ilar experiment.
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The TGF-p signalling pathway was therefore terminated at different times after TGF-P 
stimulation, and the effect o f  this on the ab ility  o f  TGF-P to prevent entry into the cell 
cycle was investigated. Termination o f the signal was achieved by treatment w ith  the 
A LK 5  inhibitor. SB-431542. It has previously been demonstrated that the SB-431542 
inh ib itor is a potent and selective inh ib itor o f  A LK 4 , A L K 5  and A L K 7  and acts almost 
immediately to inhib it receptor kinase activity, thus preventing Smad2 and Smad3 
phosphorylation (Inman, G. J. et al., 2002b). As shown in Figure 5.13, continuous 
stimulation o f FpH4 cells w ith TGF-p resulted in inh ib ition o f S-phase entry, indicated 
by the high number o f cells still in G l. Treatment o f  the cells w ith  SB-431542 at the 
same time as TGF-P inhibited the effect o f  TGF-p, as expected (Figure 5.13). 
A llow ing  TGF-p signalling for 4. 8 or 12 hrs was not sufficient to inh ib it S-phase 
entry, however, receptor signalling for 16 hr was sufficient to inh ib it cell cycle entry 
(Figure 5.13). This demonstrates that continuous Smad signalling for between 12 and 
16 hr is required for the antiproliferative effect o f  TGF-p and that attenuated Smad 
signalling in these cells would confer resistance to these effects. Interestingly, the 
short-lived expression o f Smad3 in EpRas Smad3-expressing Clone2 results in a 
partial growth inhib itory response. Taken together, this suggests that high levels o f 
Smad3 signalling for 12-16 hours is required for TGF-p-induced growth inh ib ition  in 
EpH4 or EpRas cells.
5.2.7.4 Effect of Smad3 stable expression on TGF-(3~induced EMT
Strong evidence exists for an essential role for Smad3 in EM T, however the levels o f 
Smad3 required for this response have not been investigated (Sato, M. et al., 2003; 
Zavadil. J. et al.. 2004). Smad3 levels in M D C K  are gradually downregulated during 
Raf-induced EM T and re-expression o f Smad3 in M D C K  cells that have undergone an 
EM T did not reverse the EM T as these cells s till maintained a mesenchymal phenotype 
(Nicolas. F. J. et al., 2003b). It was important to determine whether the increased 
Smad3 levels could interfere w ith the progression o f  EpRas cells through EM T. The 
clones were assayed for their ab ility  to undergo an EM T in response to TGF-p by the 
assay described in Chapter 4. The EpRas parental line and its two clonal derivatives 
were plated out at low density on plastic and stimulated w ith  TGF-P over the course o f
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Figure 5.13. Continuous TGF-P signaling for 12-16 h is required for TGF-p- 
induced growth arrest in EpH4 cells
The ALK5 inhibitor, SB-431542, inhibits activation of Smad2/3 and their translocation to the 
nucleus when added simultaneously with TGF-p. EpH4 were synchronized by contact inhibition and 
then plated into fresh medium. EpH4 cells were either untreated or treated with 2 ng/ml TGF-p 1, 
then treated with 10 pM SB-431542 at the same time as TGF-p 1 (0 time point), or at the times shown 
after TGF-p addition. After 22 h, cells were harvested and analysed by FACS to determine the 
number of cells in G l (black bar), S (blue bar) or G2/M (yellow bar).
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10 days. It is noteworthy that the expression o f  Smad3 in the clonal lines exhibits 
variab ility  in a cell cycle dependent manner, however, the culture confluency o f  these 
cells was kept sparse to promote cell pro liferation and cells were replated into fresh 
media every two to three day to promote Smad3 expression. Overall it can be assumed 
that a relatively high level o f Smad3 was expressed in these clones throughout the 
EM T assay. To investigate TGF-p-induced EM T in the parental lines and the clones, 
immunostaining o f epithelial and mesenchymal marker proteins was performed. The 
immunostaining pattern o f all three lines showed that in unstimulated cells, the 
adherens junction protein E-cadherin and the tight junction component ZO-1 are 
localized to intercellular junctions (Figure 5.14). Analysis o f  ZO-1 staining in TGF-|3- 
induced EpRas cells revealed a marked delocalisation and downregulation o f  tight 
junctions. In addition. E-cadherin staining showed a complete abolitian o f  this junction  
component, revealing a loss in epithelial polarity, indicative o f  EM T. S im ila rly  the two 
EpRas FLAG-Smad3 expressing clones revealed an identical phenotype, w ith  loss o f 
E-cadherin and downregulation o f  ZO-1, suggesting that Smad3 expression in these 
cells does not interfere w ith  the progression o f EM T. In addition, cells were also 
stained w ith phalloidin to visualise actin organisation w ith in  the cell. In the absence o f 
TGF-|T cortical actin can be seen at the cell periphery in all three cell lines (Figure 
5.15). However, in the presence o f TGF-p the actin organisaton has undergone a 
dramatic remodelling resulting in actin stress fibers, typical o f  m igratory, 
mesenchymal cells (Thiery. J. P. et al.. 2006). These cells were also stained w ith  an 
antibody recognising Smad2 and Smad3. What is quite clear from these images, is the 
higher level o f nuclear Smad2/3 in both EpRas Smad3 clones compared w ith  EpRas 
cells ( figu re  5.15. left panel). This suggests that basal TGF-|3 signalling in these cells 
results in a higher level o f nuclear Smad3. However, this does not affect the epithelial 
integrity o f these Smad3 expressing cells.
In conclusion these results establish that Smad3 does not interfere w ith 
progression o f TGF-p induced EM T in EpRas cells. In addition, although Smad3 
levels are sufficient for TGF-P-induced EM T, higher levels o f  Smad3 do not inh ib it it 
as shown by the dramatic decrease in epithelial markers and remodelling o f the actin 
cytokeleton in Smad3 expressing cells.
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Figure 5.14. Stable expression of Smad3 does not inhibit TGF-P-induced E M T in 
EpRas cells
Downregulation of E-cadherin and ZO-1 occurs in EpRas cells and EpRas Smad3 clones. EpRas, EpRas 
S3 C l and EpRas S3 C2 cells were plated out at low density and either grown in the presence or absence 
of TGF-p (2 ng/ml). The medium was changed 1 d after seeding and then every other day. TGF-pwas 
added to the cells upon medium change. Three days after plating, the cells were trypsinised and re-plated 
at equivalent density to day 1. Cells were grown for a total of 10 days, which required two trypsinisa- 
tions, and then harvested 48 hrs after final TGF-{5 addition. Cells were processed for immunofluores­
cence using an anti-E-cadherin antibody, to analyze adherens junctions or an anti-Zona Occludens 1 
(ZO-1) antibody, to analyze tight junctions. Nuclei were visualized with DAPI.
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Figure 5.15. EpRas Smad3 clones exhibit higher level of nuclear Smad3 in the 
uninduced state.
EpRas, EpRas S3 C l and EpRas S3 C2 cells were treated as in Figure 5.14. Cells were then processed 
for immunofluorescence using antibodies against Smad2/3 . Actin reorganization was visualized with 
Texas red-conjugated phalloidin, and nuclei were visualized with DAPI. Note images are taken from the 
same experiment as analysed in Figure 5.14.
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5.3 Discussion
Smad3 plays an essential role in mediating the responses o f TGF-|3 and has been 
implicated in both its antiproliferative and pro-invasive effects. Both o f these 
biological responses induced by TGF-(3 are functional in the FpH4 tumour cell model 
system. EpH4 mammary epithelial cells, are non-tumourigenic and undergo growth 
inhib ition and apoptosis in response to TGF-(3. However, although the Ras- 
transformed EpFI4 (EpRas) cells still exhibit an epithelial phenotype, these EpRas cells 
undergo EM T and invasive growth in the presence o f TGF-[3 (O ft. M. et al., 
1996)(present work). To dissect the molecular mechanisms governing these distinct 
biological responses. I began by investigating the levels o f  the TGF-P signalling 
pathway components in these cells. Data presented in this chapter revealed that the 
most significant difference observed between these cell lines was the expression level 
o f  Smad3 protein, whereby Smad3 was dramatically downregulated in EpRas cells 
compared w ith  EpH4 cells. In addition. Smad3 expression levels is regulated in a cell- 
cycle dependent manner. I also present evidence to demonstrate that Smad3 protein 
levels could function as a determinant o f the specificity o f  the TGF-|3 response in this 
tumour model system.
In stark contrast to Smad2 and Smad4. there is no evidence to date that Smad3 
is mutated in cancer (Levy. L. et al., 2006). On the other hand, accumulating evidence 
has revealed that Smad3 expression is more like ly controlled by epigenetic 
mechanisms, such as loss or reduction o f its expression. Indeed, it was recently shown 
that two out o f  nine gastric cancer cell lines are deficient in Smad3 protein level that 
have lost some TGF-(3 responsiveness, w ith concomitant lowr m RNA levels (Han, S. U. 
et al., 2004). However, the mechanisms controlling the epigenetic factors responsible 
for Smad3 loss o f expression have not yet been uncovered. In this chapter, 
investigations were carried out to determine the downregulation o f Smad3 expression 
in the EpH4 tumour cell model system and additionally, the significance o f Smad3 in 
this system was determined.
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5.3.1 Mechanisms of Smad3 Downregulation
I have established that w ith in  the EpH4 system two levels o f  regulation are in place to 
determine expression o f Smad3 protein. A t one level, Smad3 expression is regulated 
by the cell cycle in both EpH4 and EpRas cells and results in a maximal level o f 
Smad3 expression in quiescent cells and a gradual decrease o f  Smad3 upon entry into 
the cell cycle. A  second level appears to overlay the cell cycle regulation o f Smad3, 
whereby EpRas cells exhibit a much reduced expression o f  Smad3 protein compared 
w ith  EpEI4 cells, and this is possibly the result o f  the constitutive activation o f 
oncogenic Ras. One question that has arisen from this study is whether these two 
levels o f Smad3 expression are regulated by sim ilar mechanims or do the EpRas cells 
exhibit an exaggeration o f the cell cycle dependency? One reason to suggest that the 
mechanisms are the same is that activation o f Ras activ ity appears to be a common 
factor (see below).
5.3.1.1 Transcriptional Regulation
M y results reveal that two mechanisms play a role in contro lling the expression o f 
Smad3. The first o f  these is the transcriptional regulation o f Smad3. On average a 
threefold decrease in Smad3 m RNA was observed from  quiescent to cycling cells in 
both cell types, and additionally an approximate two fo ld  reduction in the levels o f  
Smad3 m RNA was observed in EpRas cells compared w ith  EpH4 cells (Figure 5.5). 
Consistent w ith  the protein expression, the highest level o f  Smad3 m R N A was 
observed in quiescent EpH4 cells, whereas the lowest level was observed in EpRas 
cycling cells (Figure 5.2 and Figure 5.5). This seems to suggest that a fluctuation in 
Smad3 transcripts affects both levels o f Smad3 expression and supports a role for 
transcriptional regulation in the cell cycle dependent- and Ras induced- Smad3 
expression. The transcriptional fluctuation during the cell cycle is by no means a novel 
phenomenon, as this has been recorded for hundreds o f genes in human fibroblasts 
(Cho, R. J. et al., 2001). Furthermore, it has been revealed through studies in model 
organisms that one in every five genes may be subject to cell cycle regulated 
transcription (Breeden, L. L.. 2003). How this regulation is achieved, however, is
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much less well understood. To date, no inform ation on regulatory elements located in 
the Smad3 promoter exists. However, in depth promoter analysis o f  upstream 
sequences o f  the Smad3 gene is required to identify cell cycle-dependent regulatory 
elements. The prelim inary work performed on Smad3 transcriptional regulation does 
not distinguish at which phase o f the cell cycle Smad3 is regulated. It w ill be important 
to gain a valid transcriptional profile  for Smad3 across the cell cycle. This could be 
achieved by taking a high number o f samples per cell cycle and m ultiple 
measurements at each time point. Transcriptional regulation o f genes often associates 
w ith  the function o f the gene product in that particular phase o f  the cell cycle and this 
future analysis may reveal additional functions o f Smad3 in cell cycle control.
5.3.1.2 Stability
The second mechanism by which Smad3 expression is regulated is through alterations 
in the rate o f degradation o f Smad3 protein. The maximal difference in stability o f 
Smad3 protein is observed when comparing quiescent EpH4 cells to cycling EpRas 
cells, which is again consistent w ith  the protein levels o f  Smad3. The observation that 
both the instability o f Smad3 in addition to decreased transcriptional regulation o f 
Smad3 is more exaggerated in the EpRas cells, lends support to the idea that Smad3 
protein level in EpRas cells is regulated in a sim ilar manner to the cell-cycle dependent 
regulation observed in EpH4 cells. However, the two contributing mechanisms are 
more pronounced in EpRas cells, which is mostly like ly  due to the increased Ras 
activity. The effect o f Ras activity on Smad3 in EpRas cells can be monitored by the 
phosphorylation o f E R K l/2  phosphorylation sites in the linker region o f Smad3. The 
level o f Ras activity peaks early in G1 in the cell cycle, in response to growth factors. 
This is evident in Figure 5.7C, where phosphory lation at T203 in both EpH4 and 
EpRas cells is maximal upon release into the cell cycle. Moreover, the level o f  Smad3 
phosphorylation on this residue in EpRas cells is much higher than in EpH4 cells, 
relative to Smad3 protein levels. The existence o f this Smad3 phosphorvlated state in 
EpRas cells persists throughout S-phase, despite the undetectable Smad3 level w ith  the 
Smad2/3 antibody. This is a measure o f constitutive Ras activation though E R K l/2  
activity in these cells.
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As Ras and CD K activity correlated w ith  the tim ing o f Smad3 degradation, it 
was reasonable to propose that the phosphorylation o f  Smad3 by these kinases was a 
trigger to target Smad3 for ubiquitin-mediated degradation. For example, the F-box 
proteins, Fbw l and Fbw7, have been proposed to recognize phosphorylation m otifs on 
target proteins generated by GSK-3(3. This results in SCF-ligase-mediated degradation 
o f target proteins including Myc, jun  and cyclin E (Cardozo, T. et al., 2004; Wei, W. et 
al., 2005). Furthermore the activity o f GSK-3(3 is regulated by Ras through the PI3 
Kinase pathway, which contributes to the cell-cycle dependency o f these proteins 
(Cardozo, T. et al., 2004). In spite o f  these sim ilarities, in itia l investigations have not 
supported a role for E R K l/2  and C D K activity in the increased instability o f  Smad3 in 
EpH4 and EpRas cells. Smad3 mutants lacking these phosphorylation sites did not 
appear to protect these proteins from  degradation in cycling EpRas cells (Figure 5.9). 
In addition, the phosphorylation o f the linker sites o f Smad3 by E R K l/2  and CDKs in 
human keratinocytes did not lead to Smad3 degradation in these cells (Matsuura, I. et 
al., 2004). However, this could also be explained by expression o f a cell-type specific 
ubiquitin ligase complex, which is not present in keratinocytes.
Activated Ras propagates downstream signals through activation o f three well 
known pathways including the Raf- M EK-ER K pathway, P I3 Kinase pathway and the 
Ral pathway (Downward, J.. 1998). As the E R K l/2  activity has been ruled out, further 
investigation into the other effector pathways is required to determine the mechanism 
o f Smad3 degradation. EpH4 derivative cell lines have also been generated using two 
well characterized Ras mutants, which selectively signal along the ERK M A P K  
pathway, S35-V12-Ras (S35-Ras), or the PI3K pathway, C40-V12-Ras (C40-Ras), 
due to specific amino acid changes in the effector loop o f the Ras protein (Downward, 
J., 1998). These cell lines have now been acquired and I w ill investigate the Smad3 
levels in each line, which w ill hopefully shed some light on the pathway involved in 
Smad3 degradation. The PI3 Kinase pathway is also a like ly candidate for this role as 
it has been previously implicated in abrogating Smad3 signalling in TGF-|3-induced 
apoptosis (Conerv, A. R. et al., 2004; Remy, I. et al., 2004; Yang, Y. A. et al., 2006). 
Hence, it is possible that in EpRas cells, the PI3 Kinase pathway could act to lower 
Smad3 levels, which would desensitise these cells to an apoptotic response upon TGF- 
(3 stimulation. Recent studies have demonstrated a direct physical interaction between 
A k t and Smad3 in some epithelial and hematopoietic cell lines (Conery, A. R. et al..
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2004; Remy, I. et al.. 2004). It has been proposed that through binding o f Smad3, A k t 
acts to sequester it at the plasma membrane, thus preventing nuclear accumulation and 
transcriptional activity and ultimately, protection from TGF-(3 induced apoptosis. 
Therefore a balance between A kt activ ity and Smad3 level are thought to determine 
the sensitivity o f  a cell to TGF-(3-induced apoptosis. Furthermore, a recent publication 
has revealed that Smad3 protein has been found to protect hepatocarcinoma cells from 
TGF-p-induced apoptosis by repressing the anti-apoptotic regulator, Bcl-2 (Yang, Y. 
A. et al., 2006). Consistently, studies in EpRas cells and in EpH4 cell lines expressing 
Ras mutants, P13Kinase was also found to protect these cells from  TGF-(3-induced 
apoptosis (Janda. E. et al.. 2002). Future work w ill focus on investigating the role o f 
PI3 Kinase pathway in regulating Smad3 stability.
To date, evidence already exists for the degradation o f basal Smad3. Two 
mechanisms have been proposed, invo lv ing the S k p l— C ull-F -box-pro te in  (SCF) and 
U-box E3 ligases. The F-box protein. Fbw l ((3TrCPl), has been shown to weakly 
interact w ith  Smad3. however the RING-containing component Rbx/Rocl o f  the SCF- 
Fbw l complex binds to Smad3. which then targets it for degradation (Fukuchi, M . et 
al.. 2001). In addition, an independent study demonstrated an interaction o f Smad3 
w ith  another F-box protein. (3TrCP2 (Ray. D. et al.. 2005). However, it is unclear 
whether these interactions between Smad3 and R bxl or the F-box proteins are 
b io log ica lly significant as the determinants o f specificity in both cases have not been 
demonstrated. CHIP (Carboxy o f Hsc70 interating protein), a newly recognized E3 
ubiquitin ligase. has also been implicated in the basal level o f  Smad3 through a 
ubiquitin-dependent degradation pathway (X in , H. et al., 2005). However, the 
specificity o f  this degradation is questionable as Smads 1, 2 and 4 were also found to 
bind directly to CHIP (L i. L. et al.. 2004).
As ubiquitin-mediated proteolysis is integral to the TGF-|3 signaling pathway, 
w ith  an important role in Smad3 signalling, it is important to determine the E3 
ubiquitin ligases that function in this pathway. To this end a screen for ubiquitin 
modifiers in the TGF-f3-Smad3 pathway is being carried out in the Developmental 
Signalling Laboratory. By em ploying a siRNA library for ubiquitin ligases w ith  a 
Smad3 dependent readout, it is hoped that the ubiquitin  m odifiers involved in Smad3 
regulation w ill be identified.
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5.3.1.3 Other mechanism for regulation of Smad3 expression
One final route o f investigation is the regulation o f Smad3 stability by m icroRNAs 
(m iRNAs). m iRNAs are small, non-coding RNAs that modulate the expression o f 
target mRNA. Many o f the m iRNAs that have been studied, act to reduce steady state 
protein levels for the targeted gene(s) w ithout impacting the corresponding levels o f 
m RNA (Olsen, P. H. et al., 1999). Although the mechanism by which m iRNAs reduce 
protein level is not fu lly  understood, it has been proposed that translational elongation, 
termination or protein stability are like ly to be influenced by m iR N A  (Hutvagner, G. et 
al., 2002; Olsen, P. H. et al., 1999). Many m iRNAs are known to be up- or 
downregulated in a variety o f cancers, suggesting a role for m iRNAs in tumorigenesis 
(Lee. Y. S. et al.. 2006). Hence it is possible that through activation o f Ras. a m iR N A  
targeting Smad3 is upregulated and hence decreases the level o f  Smad3 protein by 
translational inhibition.
5.3.1.4 Smad3 versus Smad2
It is important to account for the selective degradation o f  Smad3 over the h igh ly 
homologous (98% sequence identity) Smad2. The linker region is the most divergent 
sequence among Smads and is an ideal region for selective regulation o f Smad3. In 
addition, the configuration o f phosphorylation sites in the linker region o f Smad2 and 
Smad3 are slightly different. The Smad2 linker contains one PXTP (Thr-220) fo llowed 
by three XXSP sequences (Ser-245. Ser-250, Ser-255), whereas Smad3 contains two 
classical M APK sites (Ser-203. Ser-207) and two XXSP sites (Kretzschmar. M. et al.. 
1999). As demonstrated, these sequences can serve as phosphorylation sites for 
proline-directed protein kinases including ERK. I f  these phosphorylation sites were 
involved in regulating Smad3 stability by kinases other than ERK or CDK, it is like ly  
that the intervening sequences could determine the specificity o f  a binding site fo r a 
ubiquitin ligase. Regulation o f Smad3 at the transcriptional or translational level would 
alleviate this problem o f specificity as there is much greater variation at the level o f  the 
promoters o f these genes.
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5.3.2 Smad3 downregulation and the implications for cancer 
progression
5.3.2.1 Gro wth Inhibition
From my work it has been revealed that a m inimum  threshold level o f Smad3 
expression is required for the growth inhib itory responses o f  TGF-J3. In the EpRas 
cells, the decrease is Smad3 levels is sufficient to abrogate the responsiveness o f  these 
cells to TGF-(3-mediated growth inhibition. Furthermore, ectopic expression o f  Smad3 
in these cells sensitises them to this response in a dose dependent manner (Figure 
5.12). This is consistent w ith  work in other cell systems. A  gradual down-regulation o f 
Smad3 during the process o f Raf-induced EM T in M D C K  cells results in a 
concomitant resistance to the antiproliferative effects o f  TGF-(3 (Nicolas, F. J. et al.. 
2003b). Responsiveness is restored upon re-expression o f Smad3 to previous levels o f  
expression. In addition, introduction o f Smad3 into Smad3 deficient gastric cancer cell 
lines restores TGF-|3-mediated p i 5 and p21 induction as w ell as growth inhib ition. 
Moreover, these Smad3 expressing cells showed dramatically reduced tum ourigenicitv 
in vivo, providing strong evidence that Smad3 has an important tumour suppressive 
function in the early stages o f gastric carcinogenesis (Han, S. U. et al., 2004). Taken 
together, these results suggest that Smad3 plays a critical role in the control o f  cell 
proliferation by TGF-|3 and that lowering the level o f  Smad3 in these cells 
compromises their antiproliferative response to TGF-|3.
5.3.2.2 EMT
In contrast to the effects on growth arrest, the levels o f  Smad3 do not appear to be 
critical for the progression o f TGF-(3-mediated EMT. Expression o f  Smad3 in EpRas 
clones did not interfere w ith the progression o f I3MT. S im ilar results were found in 
M D C K cells where re-introducing Smad3 did not revert the mesenchymal phenotype 
induced by TGF-(3 (Nicolas, F. J. et al.. 2003b). However this may be cell-type specific 
as introduction o f Smad3 into Smad3 deficient gastric cell lines revealed that these 
Smad3 expressing cells showed dramatically reduced tumourigenicitv, which was 
accompanied by re-expression o f E-cadherin (Han, S. U. et al., 2004).
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To conclude, the work presented in this chapter reveals that the activ ity o f 
Smad3 mimics the dual role o f  TGF-(3 in tumourigenesis. By its manipulation through 
a complex integration o f signals, the level o f  Smad3, and therefore its activ ity is 
altered. The high level o f Smad3 is attributed to the antipro liferative effects o f  TGF-(3, 
whereas a lower, less critical level performs the m igratory and invasive properties 
associated w ith  TGF-(3.
282
Chapter 6 Sm adI phosphorylation in response to TGF-/3
6 SmadI phosphorylation in response to TGF-|3
6.1 Introduction
As explained in Chapter l.  the myriad o f  responses elicited by TGF-(3 highlights the 
requirement for tight regulation o f the downstream signalling pathway. Regulation can 
be achieved through numerous strategies to achieve specificity o f  the response. As 
discussed in Chapter 5. alteration o f the expression levels o f  the Smad proteins is one 
example o f  the how the TGF-(3 pathway is modulated to determine alternative 
responses. The diversity o f  gene targets o f TGF-P, however, is thought to arise from 
the D N A binding cofactors, to which the Smad complexes bind (Massague, J. et al.. 
2005). Current models o f  TGF-p action envision that activated Smad proteins move 
into the nucleus, recruit transcriptional coactivators and associate w ith  a host o f  D N A  
binding cofactors, generating a range o f discrete and distinct transcriptional 
complexes, each w ith high a ffin ity  and specificity toward a particular gene or set o f 
genes. The work presented in this Chapter suggests a novel mode o f activation in 
response to TGF-p, which may result in an even broader range o f  gene targets.
To date, two main branches exist w ith in the superfamily, defined by the Smads 
that are phosphorvlated in response to ligand binding. Smads 2 and 3 are 
phosphorylated by the TGF-P and A ctiv in  class o f ligand receptors, and Smads 1, 5, 
and 8 signal from the BMP and GDF class o f ligand receptors. The two classes o f  R- 
Smads initiate distinct transcriptional programs specific to the signal to which they 
respond (Graff, J. M. et al., 1996). The first evidence to suggest that there was overlap 
o f the two branches was observed specifically in endothelial cells (Goumans, M. J. et 
al., 2002). In this cell context, TGF-P also signals through a heteromeric receptor 
complex consisting o f TpR II, A LK 5  and A LK 1. The activation o f both ALK.1 and 
A LK 5  in these cells results in the phosphorylation o f Smad2 and Smad3 as well as 
SmadI and Smad5. Furthermore, signalling via the A L K 1 -A L K 5  receptor complex 
was shown to mediate a BM P-like response, demonstrated by induction o f  a BMP 
specific reporter. Thus, it was proposed that TGF-p stim ulation results in the activation
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o f both classes o f  Smad proteins, e lic iting BM P-like  and TGF-(3 like responses 
(Goumans. M. J. et al., 2003b; Goumans. M. J. et al., 2002).
During my investigation o f  the signalling pathways downstream o f TGF-(3 in 
EpFI4 and EpRas cells. I made another striking observation. In addition to the 
prototypic Smad2 and Smad3 phosphorylation, SmadI was also phosphorvlated in 
response to TGF-(3 in these cells. In this Chapter, I have investigated SmadI signalling 
in more detail and analysed the role o f phosphorvlated SmadI in EpFI4 and EpRas 
cells. As a result, I discovered a new branch o f  signalling in epithelial cells, whereby 
SmadI can form complexes w ith  Smads 2 and 3, which are like ly  to regulate a unique 
set transcriptional gene targets.
6.2 Results
6.2.1 Sm adI and Smad5 are phosphorylated by TGF-p
W hile investigating the levels and the phosphorylation states o f Smad3 (Chapter 5), an 
unusual observation was made. When synchronous cultures o f EpFI4 and EpRas cells 
were prepared and analysed by Western blotting using an antibody against the 
phosphorylated form  o f Smad3 (anti-P-Smad3 antibody), two bands o f equal intensity 
appeared in the lanes where cells have been stimulated w ith  TGF-|3 (Figure 6.1, third 
panel). Interestingly, the upper, slower m igrating band was only observed in cycling 
cells and not in quiescent cells, yet the lower band was observed under both 
conditions. The lower band migrates at the position where Smad3 is expected to run, 
but the higher band migrates at a position sim ilar to Smad2. The increase in intensity 
o f the upper band upon TGF-|3 treatment was an indication that it was a direct target o f 
TGF-|3 signalling. In view o f this, there was a high possibility that the P-Smad 
antibodies could cross-react w ith other Smads as the phospho-antobodies are raised 
against the peptide containing either the phosphorylation m o tif SSpMSp for Smad2 or 
SSpVSp for SmadI, Sniad3 and Smad5. Smad2 was elim inated as a candidate because 
its pattern o f phosphorylation did not match that o f the upper band. Further 
investigation suggested the possibility that the P-Smad3 antibody could cross-react 
w ith the phosphorylated form  o f Sm adl. This was not surprising as the C-term inal
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Figure 6.1. SmadI is phosphorylated in response to TGF-P
Synchronized, quiescent EpH4 and EpRas cells were prepared by contact inhibition for 72 hrs. 
Actively cycling, low confluency EpH4 and EpRas cells were prepared by synchronizing the cells 
by contact inhibition and then plating into fresh medium for 24 hrs. Cells were either uninduced 
or induced with 2 ng/ml TGF-p 1 for 1 hr as indicated. Whole cell extracts were prepared and 
equal amounts of protein were analysed by Western blotting using antibodies against Smad2/3, 
phosphorylated SmadI (P-Smadl), P-Smad2, P-Smad3 and Grb2 as a loading control.
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phosphorylation sites o f SmadI and Smad3 are identical (SSVS) (Shi, Y. et al., 2003). 
Probing w ith an antibody specific fo r phosphorylated SmadI, 5 and 8, revealed a 
pattern sim ilar to the upper band in the P-Smad3 blot (Figure 6.1, Compare 3rd and 4Ih 
panel).
To confirm  the specificity o f the phospho-specific Smad antibodies (anti-P- 
Smad antibodies), I used extracts o f HaCaT cells stably expressing enhanced Green 
Fluorescent Protein (EGFP)-Smad2 and GFP-Smad3 as controls (Schmierer, B. et al., 
2005) (Figure 6.2A). The EGFP-tagged-Smad migrates suffic iently slower on SDS- 
PAGF to allow a separation from  the endogenous Smads. Neither the anti-P- 
Smad 1/5/8, nor the anti-P-Smad3 antibody recognized the phosphorylated form  o f 
EGFP-Smad2 in contrast to the anti-P-Smad2 antibody (Figure 6.2A, Compare panel 2 
w ith panels 3 and 4). It is clear that the anti-P-Smad3 antibody only recognized 
phosphorylated forms o f endogenous and EGFP-tagged Smad3 and not Smad2. A faint 
band ran slightly higher than the endogenous P-Smad3, which may reflect a weak 
ph osphorylation o f SmadI in these cells (Figure 6.2, P-Smad3 panel, TGF-p-induced 
lanes). Since, P-Smad 1/5/8 cross-reactivity with either P-Smad2 or P-Smad3 has been 
eliminated from  the results o f this experiment. 1 conclude that SmadI, 5 or 8 is 
phosphorylated upon TGF-p stimulation in EpH4and EpRas cells.
To determine which o f the BMP-Smads, SmadI, 5 or 8 were phosphorylated in 
response to TGF-|3, I made use o f small interfering RNA (siR N A) oligonucleotides 
against the individual R-Smads (Figure 6.2B, top panel). EpH4 and EpRas cells are 
also responsive to BMP treatment and BMP induction was used as a positive control 
for P-Smad 1 events in this experiment. In cells transfected w ith non-targeting 
oligonucleotide, it is clear that upon BMP treatment, Smad 1/5/8 is phosphorylated to 
the same extent as stimulation w ith TGF-|3 (Figure 6.2B, top panel, non-targeting oligo 
lanes). However, when cells have been depleted o f SmadI, both the TGF-|3 and the 
BMP inductions o f Smad phosphorylation were abrogated. (Figure 6.2B, top panel, 
SmadI siRNA panels). This clearly showed the SmadI was the primary target fo r these 
activations. Knockdown o f Smad5 also slightly reduced the Smad phosphorylation 
observed using the anti-P-Smad 1/5/8 antibody but transfection w ith siRNA against 
SmadS had no effect (Figure 6.2B, top panel, right). In addition, no differences were 
observed using siRNA oligonucleotides against Smad2 and Smad3, as expected. This
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suggests that the anti-P-Smadl antibody recognises phosphorylated forms o f SmadI 
and Smad5 that comigrates in EpH4 cells and P-Smad 1 appears to be the major 
species.
The TGF-|3 activation o f Smad3 is easily detectable w ith  the anti-P-Smad3 
antibody and was reduced when Smad3 was knocked down in these cells (Figure 6.2B, 
anti-P-Smad3 panel). Interestingly, in SmadS depleted cells, a decrease in the intensity 
o f both bands recognized by the anti-P-Smad3 antibody was observed (Figure 6.2B, 
second panel, Smad5 siRNA lanes). Previous work has shown that Smad5 undergoes a 
m obility shift upon phosphorylation and consequently Smad5 can migrate as a doublet 
(Goumans. M. J. et al., 2002). This may explain the decrease in phosphorylation o f  two 
distinct bands in cells transfected w ith  siRNA oligonucleotides against Smad5. Indeed, 
phosphorylation o f Smad5 was also observed in response to BMP and is characterized 
by a discrete band underneath P-Smad 1 when probed w ith  either the anti-P-Smad 1/5/8 
or anti-P-Smad3 antibodies (Figure 6.10). This data revealed that the P-Smad3 
antibody not only recognizes P-Smad3, but also P-Smad 1 and 5 and w ill be referred to 
as the P-Smad 1/3/5 antibody for the rest o f the Chapter.
To conclude. TGF-(3 induced phosphorylation o f  SmadI and to a lesser extent, 
Smad5 in both cell types. The TGF-(3-induced Smad 1/5 phosphorylation attained a 
level comparable with Smad3 phosphorylation, and to the same extent as the BMP 
induction o f these Smads in EpF14 and EpRas cells.
6.2.2 Cell cycle regulation of phosphorylation of S m a d I/5
Phosphorylation o f SmadI and Smad5 in response to TGF-(3 was observed only in 
proliferating cells (Figure 6.1). This was not the result o f a decrease in the expression 
o f SmadI, which stayed constant in cycling versus quiescent cells (Figure 6.3). 
Phosphorylation o f Smad2 and 3 is reduced substantially in quiescent cells, but was 
not absent (Figure 6.1). This was like ly due to the inaccessibility o f TGF-(3 to A LK 5  
because o f high cell density. The absence o f TGF-fTinduced Smad 1/5 phosphorylation 
in contact inhibited cells may reflect the result o f sub-optimal levels o f ALK.5 achieved 
by high confluency or the exit o f the cells from  the cell cycle. In an attempt to better 
understand whether the phosphorylation o f Smad 1/5 was under the direct regulation o f
288
Cycling cells Quiescent cells
Ep H4  E p R a s  E p H 4  E p R a s
TGF-p + - + + +
SmadI — — - -----------
a-Smad1
Grb2 —-----------  -
a-Grb2
Figure 6.3. SmadI expression is level thoughout the cell cycle.
Synchronized, quiescent EpH4 and EpRas cells were prepared by contact inhibition for 72 hrs. 
Actively cycling, low confluency EpH4 and EpRas cells were prepared by synchronizing the cells 
by contact inhibition and then plating into fresh medium for 24 hrs. Cells were either uninduced 
or induced with 2 ng/ml TGF-pi for 1 hr as indicated. Whole cell extracts were prepared and 
equal amounts of protein were analysed by Western blotting using antibodies against Smad 1 and 
Grb2 as a loading control.
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cell cycle components or whether it was affected by a decrease in the availability o f 
A LK 5,1  tested the effect o f cell cycle status on the ability  o f the cells to phosphorylate 
Smad 1/5 in response to TGF-p. Contact inhibited EpH4 cells were released into fresh 
media fo r up to 40 hrs and treated w ith TGF-p, 1 hr prior to harvest. Neither P-Smad2 
nor P-Smad 1/5 was detected in response to TGF-p in quiescent cells, presumably due 
to high density (Figure 6.4, Compare top and middle panels, 0 timepoint). 
Phosphorylation o f both Smad 1/5 and Smad2 was observed at 5 hrs after release. P- 
Smad2 levels stayed relatively constant over the 40 hr release, taking into 
consideration the Grb2 levels (Figure 6.4, middle panel). This was in sharp contrast to 
the activation o f SmadI, where maximal phosphorylation was not attained until 15-20 
hrs. The most obvious difference in the intensity o f P-Smad 1/5 was observed between 
5 hrs and 15 hrs, whereas the P-Smad2 levels were equal at both timepoints (Figure 
6.4, top panel).
Cell cycle analysis has revealed that the GO-S phase interval o f EpH4 cells 
under these conditions is ~ 18 hr (Figure 5.2, Figure 6.4 and data not shown), yet 
significant detection o f  P-Smadl/5 in response to TG F-p was observed at around 15 
hrs. This was not the case for phosphorylation o f Smad2. This suggests that maximal 
phosphorylation o f Smadl/5 preceded entry into S-phase w ith  a time lag o f  about 15 
hrs after exit from growth arrest. The absence o f phosphorylation o f  Smadl/5 during 
quiescence and early G1 suggests the downregulation or deactivation o f  critica l 
components for this receptor/Smad pathway. The time lag before maximal 
phosphorylation o f  Smadl/5 may reflect the requirement o f  synthesis or activation o f 
key components for this pathway. On the other hand, the expression levels o f  SmadI 
and A LK 5 did not alter ffom  cycling to quiescent cells (Figure 5.4 and Figure 6.3) and 
also the activity o f  A LK 5 was not compromised in early G l,  as shown by 
phosphorylation o f  Smad2 (Figure 6.4).
From these results, I conclude the requirement o f  additional components for 
high levels o f  phosphorylation o f Smadl/5. The expression o f  these components, for 
example specific TGF-p receptors, is like ly  to be dependent on cell cycle status and 
thus, gives rise to variation in the level o f  Smadl/5 phosphorylation.
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Figure 6.4. Phosphorylation of Smadl/5 is regulated at the level of the cell cycle, 
where Smadl/5 can only be phosphorylated in cycling cells and not in quiescent 
cells.
EpH4 were synchronized by contact inhibition and then plated into fresh medium for the number o f hours 
indicated. Cells were either uninduced or induced with 2 ng/ml TGF-J51 for 45 min prior to harvest and then 
analysed by Western blotting, using antibodies against P-Smad 1, P-Smad2 and Grb2 as a loading control. 
Cells were also analysed by FACS to determine the number of cells in G1 (black bar), S (blue bar) or G2/M  
(yellow bar).
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6.2.3 ALK5 kinase activity is required for TGF-p-induced 
phosphorylation of Sm adI 15
Peter ten D ijke 's group showed that in endothelial cells the kinase activity o f  A L K 5  is 
required for ALK1 -dependent phosphorylation o f Sm adl/5 (Goumans, M. J. et al., 
2003b). To investigate whether ALK.5 activity was involved in the TGF-(3-induction o f 
P-Smad 1 in the HpH4 system, I made use o f a selective and well characterised A L K 5  
inhibitor, SB-431542 (Inman. G. J. et al.. 2002b). Pretreatment o f  TpH4 cells w ith  the 
inhib itor completely abolished TGF-|3-induced Smadl/5 phosphorylation, which 
clearly demonstrated a requirement for A LK 5  activity in this activation event (Figure 
6.5A, top two panels). As expected, phosphorylation o f Smad3 was also inhibited. For 
comparison. I tested the effect o f  the A LK 5 inhib itor on the BM P-induction o f  P- 
Smadl/5 (Figure 6.5B). SB-431542 has been shown to be a potent inhibitor o f A LK 4, 
A LK 5 and ALK7, which are all proposed to mediate phosphorylation o f Smad2 and 
Smad3 and not SmadI or Smad5 (Inman, G. J. et al., 2002b). In accordance w ith  
previous studies, BMP-induced phosphorylation o f Smadl/5 was unaffected by 
treatment with the inhibitor (Inman. G. J. et al., 2002b). I also examined the nature o f 
the BMP response, to see whether the BMP-induced P-Smad 1/5 also exhibited sim ilar 
cell cycle regulation. A  high level o f  basal BM P-Sm adl signalling was evident in 
cycling cells but was no longer observed in quiescent cells (Figure 6.5B, top panel). 
The lack o f basal BMP signalling in quiescent cells may reflect the low accessibility o f  
secreted BMP ligand to cell surface receptors in these densely packed cells. BMP 
induction o f P-Smad 1/5 was strong in cycling cells and weaker in quiescent cells but 
was still present, in a sim ilar fashion to P-Smad2 (Figure 6.5B, second panel). 
S im ilarly, the reduced level o f P-Smad 1/5 in quiescent cells was indicative o f low 
accessibility o f receptors. However, the ability  o f these cells to induce Sm adl/5 in 
response to BMP under these conditions, suggests that the components o f the BMP 
signalling receptor complex are functional in quiescent cells, which is sharp contrast to 
TGF-(3-dependent Smadl/5 signalling .
Taken together, these results suggest that a separate receptor complex is 
involved in the BMP and TGF-(3-dependent Smadl/5 phosphorylation.
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Figure 6.5. ALK5 kinase activity is required for the phosphorylation of Smadl/5 
by TGF-p
(A) Inhibition of ALK5 activity by SB-431542 abolishes TGF-p-induced Smadl/5 phosphorylation. 
EpH4 cells were synchronized by contact inhibition and then plated into fresh medium for 20 hrs. Cells 
were either untreated or treated with SB-431542 (10 |±M) 15 min prior to stimulation w ithTG F-pi for 
1 hr. Whole cell extracts were prepared and equal amounts of protein were analysed by Western 
blotting using antibodies against Smad2/3, phosphorylated Smad 1/3 (P-Smad 1/3), P-Smad 1/5/8.
(B) SB-431542 does not inhibit Smad 1/5/8 phosphorylation by BMP-2. Synchronized, quiescent EpH4 
and EpRas cells were prepared by contact inhibition for 72 hrs. Actively cycling, low confluency EpH4 
and EpRas cells were prepared by synchronizing the cells by contact inhibition and then plating into 
fresh medium for 20 hrs. Cells were either untreated or treated with SB-431542 (10 pM) 15 min prior 
to stimulation with TGF-pl or BMP2 for 1 hr as indicated. Whole cell extracts were prepared and equal 
amounts of protein were analyzed by Western blotting using antibodies against P-Smad 1/5/8, P-Smad2 
and Grb2 as a loading control.
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6.2.4 Determination of Type I receptors involved in Sm ad1/5 
phosphorylation
The results from the A LK 5  inh ib itor im ply a role for A L K 5  kinase activ ity in the 
phosphorylation o f Smadl/5. However, it is highly un like ly that A L K 5  alone is 
sufficient for phosphorylation o f Smadl/5. Previous studies show that the specificity 
o f ALK.5 allows binding and phosphorylation o f Smad2 and 3, but not SmadI or 5 
(Chen, Y. G. et al., 1998). This is achieved through specific interactions w ith  the L45 
loop o f A LK 5  and the L3 loop o f Smad2 and Smad3 (Chen, Y. G. et al., 1998). So 
although it is clear that A LK 5  is required for Smadl/5 phosphorylation, based on 
previous investigations it is not sufficient. Indeed, the results presented in the Chapter 
so far have implicated the requirement o f an additional receptor component fo r this 
pathway. The accumulating data have provided some specifications to the regulation o f  
the receptor kinase responsible for the phosphorylation o f Smadl/5 in response to 
TGF-P; the type I receptor can bind and phosphorvlate Sm adl/5; it is downregulated 
upon exit from quiescence but is resynthesised or activated when cells begin to 
proliferate; it works in cooperation w ith A LK 5, and is dependent on the receptor 
kinase activity o f A LK 5, possibly for activation through direct phosphorylation and/or 
recruitment into the TGF-p receptor complex.
W ith these specifications in mind, I sought to identify the additional 
component o f the functional receptor complex. Firstly, I analysed the expression o f  all 
seven TGF-p superfamily type I receptors (A LK s l -7) by RT-PCR to determine the 
repertoire o f receptors expressed in both EpH4 and EpRas cells (Figure 6.6). Both cell 
lines express ALK3 and ALK5 mRNA. This correlates w ith  their ab ility  to transduce 
signals via BMP and TGF-p, respectively. They also express equivalent levels o f 
ALK4 mRNA, which would suggest that they are responsive to Activ in . However, 
AEK.4 has the same specificity for Smads as AEK.5 and has not been shown to 
phosphorvlate Smadl/5. ALK.6, is not expressed, which implies that AEK3 alone is 
responsible for the BMP signalling in these cells. T his is consistent w ith  the restricted 
ALK.6 expression profile in that it is only found in brain and lung (ten D ijke, P. et al.,
1994b). A L K l is not present in EpFl4 cells, however, EpRas cells express detectable 
levels of ALKl  m RNA in cycling cells and this is upregulated in quiescent cells
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Figure 6.6. Expression of TGF-P type I  receptors
The expression of genes encoding the ALK receptors was analysed by reverse-transcription 
polymerase chain reaction (RT-PCR). RNA was isolated from EpH4 and EpRas cells, both cycling and 
quiescent cells, and RT-PCR was performed using primers specific for ALKs 1-7 and Grb2 as a 
control. The amplified product is indicated on the top of the panel. Expression of ALKs 2-5 is observed 
in both cell lines under the two conditions. A LK l expression is observed in EpRas cells only. The 
expression pattern of the receptors in both cycling and quiescent cells is identical in the individual cell 
lines.
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(Figure 6.6). EpH4 and EpRas cells both have an equal ab ility  to phosphorvlate SmadI 
when proliferating, despite the absence o f  A L K l in EpH4 cells. Thus, the ab ility  o f 
both the EpEI4 and EpRas cells to induce phosphorylation o f  Smadl/5 is probably not 
due to the expression o f A L K l in these cells. This is in contrast to what has been 
observed in endothelial cells, where expression o f  A L K l is high (Goumans, M. J. et 
al., 2002). EpH4 and EpRas cells, however, express high levels o f  A L K 2 . which is 
highly homologous to A L K l (Figure 6.6). A L K l and A L K 2  are classified into a 
specific subgroup o f type I receptors that interact w ith  the T(3RII but phosphorylate 
Smadl/5 instead o f  Smad2/3 (Chen, Y. G. et al., 1999). Furthermore, the h ighly 
homologous A L K l has been shown to form complexes w ith  A L K 5 , and so it is 
possible that A L K 2  behaves sim ilarly. Thus. A LK 2  is a possible candidate for the 
hetero-dimer complex o f type I receptors involved in the phosphorylation o f  Sm adl/5 
in EpH4 and EpRas cells.
I f  downregulation o f the receptor kinase is responsible for the cell cycle 
regulation o f the TGF-p-induced P-Smadl/5, a change in the pattern o f expression o f 
these type I receptors between cycling and quiescent cells m ight give an indication o f 
the receptor involved. Unfortunately, apart from an overall decrease in expression 
levels, no obvious decrease in the m RNA levels o f an individual receptor was observed 
in quiescent cells (Figure 6.6). The expression pattern o f the receptors in cycling EpH4 
cells is identical to the pattern in quiescent cells, as is also the case for EpRas cells.
Next, I wanted to confirm  the contribution o f the individual receptors to the 
Smadl/5 induction in response to TGF-(3. This was achieved by depletion o f  the 
individual receptors in EpH4 cells by siRNA and by assaying for phosphorylated 
Smadl/5 in response to TGF-|3 and to BMP (Figure 6.7A). When antibodies permitted, 
knockdown o f siRNA was verified (data not shown). A L K l,  2 and 6 s iR NA 
oligonucleotides had no effect on the ability  o f  Smadl/5 to be phosphorylated in 
response to either TGF-[3 or BMP or on the basal level o f  P-Smad 1/5 (Figure 6.7A). 
This result disagreed w ith the idea o f A LK 2  as a possible candidate for the receptor 
kinase responsible for Smadl/5 phosphorylation. Depletion o f AEK2 could not be 
verified, however, by analysis o f protein knockdown due to lack o f specific antibodies. 
To overcome this hurdle, more attempts were made to ensure knockdown o f  A L K 2  by 
use o f oligonucleotides from another supplier. Regardless o f  this, sim ilar results were
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Figure 6.7. ALK5 is required for TGF-p-induced Smadl/5 phosphorylation, 
whereas ALK3 is responsible for basal and BMP induced Smadl/5 phosphorylation
(A) A L K l, ALK2, ALK3 and ALK6 are not involved in TGF-p-induced Smadl/5 phosphorylation. Low- 
density EpH4 cells were transfected with siRNA oligos against the ALKs or a non-targeting oligo. After 
48 hrs of incubation, cells were trypsinised and plated out into fresh medium for 20 hrs. Cells were either 
uninduced or stimulated with TGF-p 1 or BMP2 for 45 min as indicated. Whole cell extracts were 
prepared, fractionated by SDS-PAGE and analysed by Western blotting using antibodies against P- 
Smad 1/5/8, P-Smad2 and Grb2 as a control for protein loading.
(B) TpRII is also required for TGF-p-induced Smadl/5 phosphorylation. Low-density EpRas cells were 
transfected with siRNA oligos against the ALK3, ALK5 and TpRII or a non-targeting oligo. Cells were 
harvested as in (A) and analysed by Western blotting using antibodies against P-Smad 1/5/8 and Grb2 as a 
loading control.
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obtained, arguing against a role for A L K 2  in TFG-P-mediated Sm adl/5 
phosphorylation.
Knockdown o f A LK 3  reproducibly and completely abolished basal and BM P- 
induced Smadl/5 phosphorylation, whereas the TGF-(3 response was unchanged 
(Figure 6.7A, compare knockdown o f A LK 3 and A LK 6). This result is consistent w ith  
the m RNA expression data, which shows that A LK 3  is the only BM P type 1 receptor 
expressed in both cell types (Figure 6.6). Knockdown o f A L K 5  abrogated the TGF-(3- 
induced phosphorylation o f Smadl/5, which confirmed the results obtained using the 
A LK 5  inhibitor. As a positive control, phosphorylation o f Smad2 was also abolished 
in A LK 5  depleted cells.
For successful signal transduction, TGF-P 1 binds directly to the type II 
receptor and the complex is stabilized by interactions w ith  the type I receptor. For 
completion. I wanted to establish whether the TGF-|3 type II receptor (T pR II) was also 
involved in the activation o f Smadl/5 in response to TGF-p. Depletion o f  the T pR II by 
siRNA revealed that the type II receptor is also required for the TGF-p-induced 
phosphorylation o f Smadl/5 and not the BMP response (Figure 6.7B).
To conclude. I have shown that TpR II and A LK 5  are required for the TGF-p 
induced activation o f Smadl/5 in EpH4 cells. Depletion o f other type I receptors, 
including A LK 2  did not impair the activation o f Smadl/5 in response to TGF-p. 
However, as A LK 5  alone is unable to phosphorylate BMP-Smads (Chen. Y. G. et al.. 
1998), it is unlikely that it is the sole component o f the TGF-P-Smadl/5 signalling 
complex. Therefore. I hypothesise the involvement o f  an additional receptor kinase. In 
addition, ALK 3 is required for the basal level and BMP-induction o f P-Smadl/5.
6.2.5 High Doses of TGF-p are required for phosphorylation of 
S m ad l/5
Next, I went on to further analyse the possibility o f  a heteromeric type I receptor 
complex containing A LK 5  w ith another type I receptor and this complex being 
responsible for TGF-p-induced P-Smadl/5. I tested this hypothesis biochem ically, by 
investigating the induction o f phosphorylated Smadl/5 and comparing it w ith  the
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induction o f phosphorylated Smad3. Firstly, I examined the effect o f  d ifferent doses on 
TGF-p-induced Smad3 versus Smadl/5 phosphorylation in both EpH4 and EpRas cells 
(Figure 6.8A). TGF-P induced considerable Smad3 phosphorylation at 0.2 ng/m l and 
reached a maximum at 1.6 ng/ml, which remained at this level at all higher doses o f 
TGF-p in both cell types. The requirement for high concentrations o f  TGF-P 1 was 
made more apparent when the basal BMP signalling was reduced by s iRNA 
knockdown o f A LK 3  (Figure 6.8B, right hand side). Flere, phosphorylation o f  Smad3 
is observed even at 0.1 ng/ml, whereas Smadl/5 is only induced when stimulated w ith  
a dose o f 1.6 ng/m l or higher. The requirement o f an 8-10 fo ld  higher concentration o f 
ligand has also been shown for ALK1 phosphorylation o f  Smadl compared w ith  
phosphorylation o f Smad2 via A LK 5  in response to TGF-P in primary endothelial cells 
(Goumans, M. J. et al.. 2002). The difference in dose response in this latter case was 
attributed to the different affin ities o f ALK1 and A LK 5  for TGF-p ligand (Goumans, 
M. J. et al.. 2002; ten D ijke. P. et al.. 1994a).
I also compared the dose responses o f TG F-p i w ith  TGF-P3, whose activities 
have been shown to exhibit different physiological responses in vivo (Brunet, C. L. et 
al.. 1995). The dose response profile  o f  TGF-P3 was sim ilar to the TG F-p i pro file  in 
that Smadl/5 required a higher concentration o f this isoform for maximal 
phosphorylation. However, differences were also observed, in that TGF-p3 
phosphorylated both Smadl/5 and Smad3 at lower concentrations than TGF-P 1 
(Figure 6.9). This difference may reflect a higher binding a ffin ity  o f TGF-P3 to both 
homomeric and heteromeric type I complexes and may have significant consequences 
in vivo.
From these results, I conclude that the activation o f Smadl/5 requires higher 
concentrations o f ligand than is required for phosphorylation o f  Smad3. This has been 
shown for two o f the TGF-p isoforms, TG F-p i and TGF-P3. This suggests that the 
phosphorylation o f Smadl/5 in response to TGF-p is dependent on a lower a ffin ity  
receptor complex than phosphorylation o f Smad3. Moreover, this evidence supports 
the hypothesis whereby a lower a ffin ity  ALK5/type I heteromeric receptor complex 
activates Smadl/5 whereas the A LK 5  homomeric complex induces Smad2/3 activation 
in response to TGF-p.
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Figure 6.8. High doses of ligand are required for TGF-|3-induced Smadl/5/8 
phosphorylation
(A) EpH4 and EpRas cells were synchronized by contact inhibition and then plated into fresh medium 
for 20 hrs. Cells were stimulated with increasing concentrations of TGF-p 1 for 1 hr at 37°C before 
lysis. Whole cell extracts were prepared and equal amounts of protein were analyzed by Western 
blotting using antibodies against P-Smad 1/3/5.
(B) Reduction of ALK3 basal Smadl/5 phosphorylation accentuates the high dose requirement of 
TGF-p 1. SiRNA oligos against ALK.3 or a non-targeting oligo were transfected into low density EpH4 
cells. After 48 hrs of incubation, cells were trypsinised and plated out into fresh medium for 20 hrs. 
Cells were stimulated with increasing concentrations of TGF-pi for 1 hr at 37°C as indicated. Whole 
cell extracts were prepared and analysed by Western blotting using antibodies against P-Smad 1/5/8, 
P-Smadl/3/5 and Grb2 as a loading control. The blot probed with a-P-Smadl/3/5 antibodywas 
stripped and reprobed with a-P-Smad 1/5/8 antibody.
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Figure 6.9. TG F-pi and TGF-p3 have different profiles of Smadl/5 
phosphorylation.
TGF-(S3 can induce Smadl/5 phosphorylation at much lower concentrations of ligand than TGF-pi. 
EpH4 cells were synchronized by contact inhibition and then plated into fresh medium for 20 hrs. 
Cells were stimulated with increasing concentrations of either TGF-p 1 or TGF-P3 for 1 hr as 
indicated. Whole cell extracts were prepared and equal amounts of protein were analysed by Western 
blotting using antibodies against P-Smad 1/3/5.
301
Chapter b Sm adl phosphorylation in response to TGF-ft
6.2.6 Phosphorylation of S m ad l/5  in response to TGF-p is transient
It has been previously shown that ALK1-dependent Sm adl/5 phosphorylation and 
ALK5-dependent Smad2/3 activation in endothelial cells exhibit differences in the 
kinetics o f Smad phosphorylation. To investigate whether the different receptor 
signalling complexes in the EpH4 and EpRas cells exhibited sim ilar differences, I 
determined the kinetics o f TGF-p-induced Smadl/5 versus Smad3 phosphorylation 
(Figure 6.10A). A fter 15 min o f continuous TGF-P stimulation, Smadl/5 and Smad3 
are effic iently phosphorylated and the levels o f  P-Sm adl/5 and P-Smad3 peak at 
approximately 30 min after TGF-P stimulation. P-Smad3 declined after 4 hr but did 
not decrease to zero even after 8 hr. Note that the lower band o f the anti-P-Smad3/5 
blot comprises mainly o f P-Smad3 (Figure 6.2). These results are consistent w ith  the 
duration o f signalling observed in the human keratinocyte cell line FlaCaT (Inman, G. 
J. et al., 2002c). In contrast, however, TGF-P-induced Smadl/5 phosphorylation is 
dramatically reduced by 2 hr and absent 4 hr after stimulation, as determined by the anti- 
P-Smad 1/5/8 antibody, which does not recognize any P-Smad3. The same behaviour is 
observed for the upper band o f the P-Smad 1/3/5 blot, which comprises P-Smadl/5. 
Conversely, BMP-induced Smadl/5 remained phosphorylated after 8 hr o f ligand 
stimulation (Figure 6 .10B). The disparity in signalling duration o f  the individual Smad 
pathways strongly suggests the existence o f a receptor kinase in addition to A L K 5 , 
which may be d ifferentia lly regulated and exhibits distinct properties.
To further analyse the mechanism underlying the transient P-Smadl/5 
phosphorylation, I treated the cells w ith  the protein synthesis inh ib itor, cycloheximide. 
Valdomarsdottir and colleagues previously investigated the temporal activation o f the 
ALK1-induced Smadl/5 phosphorylation in endothelial cells and discovered it was 
affected by de novo protein synthesis (Valdim arsdottir, G. et al., 2006). Indeed, 
compared to control EpH4 cells, the TGF-P-induced Smadl/5 phosphorylation in 
cyclohexamide-treated cells was more sustained and lasted at least 8 h (Figure 6.11 A). 
These results suggest that TGF-p-induced Smadl/5 signalling is attenuated by newly 
synthesized proteins, whereby the activity o f  the receptor kinase responsible fo r the 
phosphorylation is compromised.
In BMP-treated cells a different scenario is evident. In cells not treated with 
cycloheximide, there is a slow tra iling o f f  o f  the P-Smadl/5 signal after 2 hr o f
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Figure 6.10. TGF-p-induced Smadl/5 phosphorylation occurs transiently
(A) TGF-p-induced Smadl/5 phosphorylation is transient and absent 4 h after stimulation. EpH4 and 
EpRas cells were synchronized by contact inhibition and released into the cell cycle for 20 hrs before 
stimulation with TGF-p 1 (2 ng/ml) for different time periods. Whole cell lysates were fractionated by 
SDS-PAGE and analysed by Western blotting with antibodies against P-Smad 1/3/5, P-Smad 1/5/8 and 
Grb2 as a control for protein loading.To note, this is the same experiment that was used for Figure 5.3
(B) BMP-induced Smadl/5 phosphorylation is stable for at least 8 hrs. Synchronized, cycling EpH4 
and EpRas cells were stimulated with BMP2 (40 ng/ml) for different time periods at 37°C before lysis. 
Whole cell extracts were prepared and analysed by Western blotting as in (A). The blots probed with 
a-P-Smad 1/5/8 antibody in (A) and (B) were stripped and reprobed with a-P-Smad 1/3/5 antibody.
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continuous stimulation (Figure 6.1 IB ). This is like ly  due to a combination o f 
degradation and resynthesis o f  components o f  the pathway (possibly both receptors 
and Smads) (Inman. G. J. et al.. 2002c). In the presence o f the protein synthesis 
inhibitor, cycloheximide, the level o f  P-Smad 1 is elevated and the subsequent 
disappearance o f P-Smadl/5 occurs more abruptly after 2 hr o f  continuous TGF-P 
stimulation. It is clear from these results that the negative regulation o f the TGF-p- and 
BMP-induced Smadl/5 phosphorylation is different.
To conclude, these results show that the TGF-p-induced P-Smadl/5 is 
distinguishable from P-Smad3. Here, the kinetics o f  TGF-p-induced Smadl/5 
phosphorylation is much more transient than the TGF-P-induced Smad3. This strongly 
implies that the properties o f receptor kinase responsible for Sm adl/5 activation are 
distinct from ALK5-dependent activation o f Smad2/3. In addition, phosphorylation o f 
Smadl/5 by A LK 3 in response to BMP. displays distinct properties from  TG F-p- 
induced P-Smadl/5. Taken together, this stongly implies that the receptor complex 
involved in phosphorylation o f Smadl/5 in response to TG F-p is distinct from  the 
ALK5-dependent Smad2/3 activation upon TGF-p stimulation and the A L K 3 - 
dependent phosphorylation o f Smadl/5 in response to BMP.
6.2.7 Distinct downstream targets of BM P- and TGF-p-induced  
Sm adl
Cell cycle dependence, receptor requirement and kinetics o f  activation in response to 
ligand have revealed obvious differences in the regulation o f  BM P- and TGF-P- 
induced P-Smadl/5. I wanted to investigate further the extent to which these responses 
varied, in the hope that this may shed some ligh t on the orig in  o f  the TGF-p-induced 
Smadl/5 phosphorylation. First, I assayed the transcriptional response o f TG F-p- and 
BMP-induced HpH4 and FpRas cells using a BM P-specific transcriptional reporter, the 
(BRF)-luc. The BRF-luc consists o f  two repeats o f  a BMP response element (BRF) 
from the Id l promoter, and is used as a transcriptional readout for BM P-Sm adl/5 
signalling (Korchynskyi. O. et al., 2002). In endothelial cells, stimulation w ith  TGF-P 
induced weak BRE-luc activ ity (~3 fo ld) and therefore, activation o f ALK 1 in
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Figure 6.11. TG F-p- and BMP-induced Smadl/5 phosphorylation is regulated 
by de novo protein synthesis
(A) TGF-P-induced Smadl/5 phosphorylation is more sustained in the absence of protein synthesis. 
Synchronized, cycling EpH4 were either untreated or treated with the protein synthesis inhibitor, 
cyclohexamide (20 ng/ml), 15 minutes before they were stimulated with TGF-p 1 (2 ng/ml) for 
different time periods, as indicated. Whole cell lysates were fractionated by SDS-PAGE and 
analysed by Western blotting with antibodies against P-Smad 1/5/8 and Grb2 as a control for protein 
loading.
(B) Sustained BMP-induced Smadl/5 phosphorylation requires de novo protein synthesis. Synchro­
nized, cycling EpH4 were either untreated or treated with the protein synthesis inhibitor, cyclohex­
amide (20 p-g/ml), 15 minutes before they were stimulated with BMP2 (40 ng/ml) for different time 
periods at 37°C before lysis. Whole cell extracts were prepared and analysed by Western blotting as 
in (A).
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response to TGF-(3 in these cells was proposed to activate a BM P-like response 
(Goumans. M. J. et al.. 2003b; Goumans, M. J. et al., 2002). As a positive control, I 
stimulated EpH4, EpRas cells also the myoblast cell line, C2C12, w ith  BMP2, which 
strongly induced transcription o f  the BRE-luc in all three cell lines (Figure 6.12A). 
TGF-|3 has been shown to be as potent as BM P in stimulating phosphorylation o f 
Smadl/5 in EpFI4 and EpRas cells (Figure 6.2) and therefore, is like ly  to e lic it an 
equal transcriptional response to a Smadl/5-dependent reporter. However, TGF-|3 
failed to induce the transcription o f  the BRE-luciferase promoter (Figure 6.12A). In 
contrast TGF-(3 readily induced transcription o f  the Smad3-dependent reporter, 
(C A G A )i:-luc  in both EpFI4 and EpRas cells (Figure 6.12B). Thus, TGF-(3-induced 
phosphorylated Smadl/5 cannot initiate transcription o f BMP target genes.
6.2.8 The Existence of Mixed Smad Complexes
The inability  o f TGF-|3 to induce a BMP responsive, Smadl/5-dependent reporter 
raised many questions. From previous studies it has been shown that BMP stim ulation 
results in the phosphorylation o f the BMP R-Smads, Sm adl, Smad5 or Smad8, which 
then form complexes w ith  Smad4 and accumulate in the nucleus (ten D ijke. P. et al., 
2003). BMP R-Smad-Smad4 complexes then engage in specific D N A  binding and 
recruitment o f  transcription cofactors to regulate transcription. I f  Sm adl/5 do not form  
complexes w ith  Smad4 in response to TGF-|3, this m ight explain the failure to induce 
BMP-responsive elements. To investigate i f  Smadl can s till form  complexes w ith  
Smad4 in these cells. I analysed the ab ility  o f  Smadl to form  complexes w ith  other 
Smads in response to TGF-(3 and BMP2. EpH4 whole cell extracts were used to 
immunopreeipitate endogenous Smads using antibodies specific to Smadsl, 2, 3 and 4. 
As previously reported, Smad2 and Smad3 co-precipitated Smad4 in response to TGF- 
(3 specifically and not BMP2 (Figure 6.13A, compare lanes 11 and 14 w ith  lanes 12 
and 15). Smad4 could interact w ith  P-Smad2 and P-Smad 1, in response to TGF-|3 and 
BMP2, respectively (Figure 6.13A, lanes 17 and 18). This interaction was weak in 
both cases. Interestingly, Smadl co-immunoprecipitated Smad4 only after stimulation 
w ith BMP, and not TGF-(3 (Figure 6.13A , compare lanes 8 and 9). Also Smad2, and
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Figure 6.12. BMP-induced Smadl/5 phosphorylation induces transcription 
from a BMP-responsive element, wheras TGF-p-induced Smadl/5 phosphoryla­
tion fails to activate transcription from this promoter
BMP-induced BRE-luc transcriptional activation in EpH4 and EpRas cells is comparable with the 
BMP-response of the myoblast cell line, C2C12. TGF-p-induced Smadl/5 phosphorylation has no 
transcriptional activity from this Smadl-dependent reporter. C2C12, EpH4 and EpRas cells were 
transfected with the BRE-luciferase reporter. After overnight incubation, the cells were replated into 
fresh medium for 16 hrs before induction with TGF-p for 8 hrs. Luciferase activity was assayed and 
quantitated relative to p-galactosidase from the pEFLacZ internal control. The data are the means and 
standard deviations of three independent experiments.
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Figure 6.13. Smadl forms complexes with 
Smad2 and Smad3 after stimulation with 
TGF-P, and with Smad4 after stimulation 
with BMP
(A) EpH4 cells were synchronized by contact inhibi­
tion and then plated into fresh medium for 20 hrs. 
Cells were either untreated or stimulated with either 
TGF-p 1 (2 ng/ml) or BMP2 (40 ng/ml) for 45 min 
before lysis. Whole cell extracts were prepared and 
equal amounts of protein were immuoprecipitated 
with antibodies against Smadsl, 2, 3 and 4. The 
immunoprecipates (IPs) were analysed by Western 
blotting with antibodies against Smad2/3, Smad4 and 
P-Smadl/5/8. As a control, 20% inputs are also 
shown on the left of the panel. The blot probed with 
a-P-Smad 1/5/8 antibody was stripped and reprobed 
with a-Smad2/3 antibody.
(B) Smadl immunoprecipitates Smad2 after TGF-P 
induction. EpH4 cells were prepared as in (A). Equal 
amounts of whole cell extract were immuoprecipi­
tated with antibodies against Smadl and analysed by 
Western blotting with antibodies against Smad2/3 and 
P-Smadl/5/8. As a control, 10% inputs are also 
shown, the asterisk indicates an aspecific band recog­
nised by the antibody.
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Smad3 to a lesser extent, clearly co-precipitated P-Smadl/5 upon TGF-p treatment but 
not in response to BMP2 (Figure 6.13A, compare lanes 11 and 14 w ith  lanes 12 and 
15. In a separate, reciprocal experiment, an antibody against endogenous Smadl co­
precipitated endogenous Smad2 in a TGF-|3 dependent manner (Figure 6.13B, lane 8). 
In addition, mixed complexes o f  Smad2 and Smad3 were observed upon TGF-p 
induction (Figure 6.13B. lane 14).
These data clearly reveal that stimulation o f  EpH4 and EpRas cells w ith  TGF-P 
results in the formation o f novel Smad complexes. These results provide strong 
evidence that the ability o f  TGF-P to induce P-Smad 1 and P-Smad2/3 simultaneously 
has a functional consequence in that it produces mixed complexes o f  BMP R-Smads 
and TGF-p R-Smads.
6.3 Discussion
6.3.1 An alternative type I receptor signalling complex in EpH4 
cells
The current model o f TGF-P signalling suggests that TG F-p binds to the type II 
receptor complexes, which subsequently recruits and activates the type I receptor, 
resulting in the phosphorylation o f  Smad2 and Smad3 (Massague, J. et al., 2006). 
A LK 5  is the predominant type I receptor mediating downstream effects upon TGF-p 
binding in most cell types. Data shown here, however, challenges the previous dogma 
regarding receptor complexes and signal transduction schemes. I propose a novel 
paradigm for TGF-p signalling in mammary epithelial cells, in which the same ligand 
can activate two different classes o f Smad through a heteromeric type I receptor 
complex, comprising o f A LK 5  and as yet, an unidentified receptor kinase. This dual 
activation results in the formation o f novel heteromeric complexes containing R- 
Smads from two distinct Smad pathways. These ‘ m ixed' complexes fa il to induce 
transcription from defined promoter elements, but most like ly  induce transcription of a 
unique set o f genes.
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Figure 6.14 Two pathways signal downstream of TGF-p in EpH4 and EpRas cells
Schematic illustration of the signalling events downstream of TGF-P binding in mouse 
mammary epithelial cells. See text for discussion. For simplicity, Smad complexes are 
portrayed as dimers.
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A  model is shown in Figure 6.14 to depict the dual signalling pathways. The essence 
ot the model is that TGF-P signals via two distinct receptor complexes to activate two 
classes o f Smads. The prototypic Smad2/3 response is s till intact but superimposed on 
this is a more complex response, invo lv ing the form ation o f  a new set o f  mixed 
complexes w ith  alternative targets. The main assumption o f  the model is the 
involvement o f  an additional type I receptor kinase to initiate Sm adl/5 
phosphorylation. Several lines o f  evidence support this argument. The data presented 
in this Chapter confirms that the rapid and direct TGF-p-induced Sm adl/5 activation is 
critica lly  dependent on A LK 5. It requires not only the expression o f A L K 5  but also its 
kinase activity (Figure 6.5 and Figure 6.7). Previous work has shown that the substrate 
specificity o f  type I receptors, including A L K 5 , is tigh tly  restricted (Chen, Y. G. et al., 
1998; Chen. Y. G. et al.. 1999). The interaction and subsequent activation requires a 
complimentary pairing o f the L45 loop in the kinase domain o f  the type I receptor and 
the L3 loop in the C-terminal M H 2 domain o f  the Smad. Im portantly, the L45 loop 
sequence o f A LK 5  is compatible w ith  the L3 loop configuration o f  Smads 2 and 3, but 
not Smads 1 or 5 (Chen. Y. G. et al., 1998). This line o f  reasoning argues that A L K 5  
alone cannot activate Sm adl/5 and therefore, gives rise to the possibility that an 
alternative type I receptor complex is required for the activation o f  Sm adl/5.
In line w ith  this argument, A L K 5  has previously been shown to cooperate w ith  
another type I receptor. A L K 1 , to induce phosphorylation o f  Sm adl/5 (Goumans, M. J. 
et al., 2003a). Goumans et al. showed that in endothelial cells, A L K 5  can recruit 
ALK1 to form a heteromeric type I complex which can then induce phosphorylation o f 
Smadl/5 in a TGF-P dependent manner. In this study they showed that TG F-p binding 
results in the complex formation o f  a heterodimer o f  A LK 1  and A L K 5 , together w ith  a 
TpR II homodimer, and that Sm adl/5 phosphorylation requires active kinase domains 
o f all three receptor types.
The evidence revealed in this Chapter supports the role o f  an alternative 
receptor kinase in the TGF-P-induced Sm adl/5 phosphorylation. The first piece o f  data 
that alluded to the possibility o f  an additional signalling component, was the 
observation that quiescent cells are unable to induce Sm adl/5 phosphorylation in 
response to TG F-p but Smad2 is activated in response to TGF-P in quiescent cells 
(Figure 6.1). This immediately suggested that the activ ity o f  the receptor responsible 
for this phosphorylation event was compromised in quiescent cells. This may be due to
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downregulation o f the receptor or an inactive form  o f  the receptor under these 
conditions. This observation does not appear to be explained through the regulation o f 
A LK 5  in this case as both protein levels and activ ity  o f  A L K 5  do not alter between 
cycling and quiescent cells. m R N A levels o f  A L K 5  were not dramatically reduced in 
quiescent cells (Figure 6.6), and as shown in Chapter 5, the level o f  A L K 5  protein does 
not alter significantly between cycling cells and quiescence. In support o f this 
argument, I showed the requirement o f  10 to 15 hrs post release from  growth arrest to 
restore optimal activation o f Sm adl/5. whereas Smad2 phosphorylation is restored 
immediately. This distinction highlights the requirement for an additional component 
for Smadl/5 phosphorylation. The time lag may reflect the time taken for new protein 
synthesis and accumulation o f receptor or possibly a co-receptor as the cells re-enter 
the cell cycle.
Type I receptors bind w ith  different affin ities to their ligands. The apparent 
a ffin ity  o f TGF-p for A L K 5  was found to be higher than for ALK 1 (ten D ijke , P. et al., 
1994a). As a result, the heterodimeric A L K 1 /A L K 5  type I complex exhibited 
differential dose responses to TGF-P than A L K 5  homodimers (Goumans, M . J. et al., 
2002). Consistent w ith the hypothesis that A LK 5  heterodimers also signal via Sm adl/5 
in EpH4 cells, about a ten-fold higher concentration o f  ligand was required for 
Sm adl/5 phosphorylation compared w ith  the ALK5-induced Smad3 phosphorylation 
(Figure 6.8). This suggests that TG F-p also has a lower a ffin ity  for the receptor kinase 
involved in Sm adl/5 phosphorylation than for A LK 5. It is possible that this difference 
in a ffin ity  may function to regulate the balance o f the two pathways downstream o f 
TGF-P in vivo.
The duration o f  the TGF-P signal is dependent on the life tim e o f  active 
receptor as Smads continuously cycle between the nucleus and the cytoplasm, enabling 
them to sense receptor activ ity (Inman. G. J. et al., 2002c). Negative regulation is 
exerted on type I receptors to extinguish the signal via dephosphorylation, inactivation 
and/or degradation o f the receptors (Hbisawa, T. et al., 2001; Kavsak, P. et al., 2000; 
Shi, W. et al., 2004; Valdimarsdottir, G. et al., 2006). Here I show a clear distinction 
between the regulation o f A L K 5  kinase activ ity and that o f  the heteromeric complex 
responsible for P-Smadl/5 by direct comparison o f  signal duration. Whereas, P-Smad3 
is still present at 8 hrs after TGF-P stimulation, P-Smadl/5 is much more transient and 
is completely absent after 4 hrs o f  induction (Figure 6.10). Once again, these
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differences in the Smad2/3 and the Smadl/5 pathway downstream o f  TGF-P suggest 
the existence o f an alternative A L K 5  containing receptor complex. It is also important 
to note that the duration o f the BMP-induced P-Sm adl/5 has a completely distinct 
profile from the P-Smadl/5 phosphorylation in response to TGF-(3. This is consistent 
w ith the data that suggests A LK 3  is responsible fo r BMP-induced P-Smadl/5, whereas 
an A LK 5 heteromeric receptor complex mediates phosphorylation o f  Sm adl/5 in 
response to TGF-p.
The ALK1-induced phosphorylation o f Sm adl/5 in endothelial cells was also 
observed to be short lived, which was later shown to be due to dephosphorylation and 
inactivation o f ALK1 by PPIa. which required de novo protein synthesis 
(Valdimarsdottir, G. et al., 2006). In EpH4 cells, a s im ilar result was observed, in that 
when protein synthesis was inhibited. P-Smadl/5 levels were sustained until at least 8 
hrs after stimulation w ith TGF-|3 (Figure 6.11). However, previous studies on the 
duration o f  Smad2 signalling in HaCats shows that the disappearance o f  P-Smad2 
occurs more abruptly in the presence o f cyclohexim ide, approximately 2 hr after 
continuous TGF-P stimulation (Inman, G. J. et al., 2002c). This is sim ilar to the 
observed effect on BMP-induced Smadl/5 phosphorylation in the presence o f 
cycloheximide. The effect o f prolonged TGF-p-induced Sm adl/5 phosphorylation 
when protein synthesis is blocked suggests that the receptor kinase is regulated 
negatively, independently o f  A L K 5  but dependent on protein synthesis, s im ilar to 
A LK 1. Perhaps a sim ilar mechanism exists for the term ination o f  the Sm adl/5 signal 
in epithelial cells. Taken together, these results give strength to the argument o f  a 
heteromeric type I receptor complex, responsible fo r the phosphorylation o f  Sm adl/5 
in response to TGF-p.
A lthough ALK1 was not expressed in EpH4 and EpRas cells, A L K 2  was an 
attractive candidate for the kinase involved in Smadl phosphorylation. ALK 1 and 
A LK 2  can be classified into a specific subgroup o f type I receptors that interact w ith  
the TpR II and/or activin type II receptors, but phosphorylate Smadl and 5 instead o f 
Smad2 and 3 (Chen, Y. G. et al., 1999; Macias-Silva, M. et al., 1998). The data using 
siRNA oligonucleotides against A L K 2  did not support this idea (Figure 6.7A). 
However, the lack o f good antibodies to A L K 2  interfered w ith  assessing the depletion
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o f A L K 2  from the cells and I cannot entirely rule out this possibility. Future work w ill 
focus on testing this idea, and looking for other candidates (Chapter 7).
6.3.2 Bifurcation of the TGF-p response
Several parallels have been made between the TGF-[3-induced Sm adl/5 
phosphorylation in endothelial cells and epithelial cells. However, when investigating 
the TGF-(3 signalling responses in EpH4 and EpRas cells, an important distinction was 
made when compared to the responses in endothelial cells. This difference was 
characterised by the lack o f BRE-luciferase activ ity upon TGF-p stim ulation (Figure 
6 .i2 ). Equal levels o f Smadl/5 phosphorylation were obtained upon either TG F-p or 
BMP stimulation, however, the transcriptional readout from  the different ligands was 
far from sim iliar. One could argue that this may be due to the transient nature o f  TGF- 
P-induced P-Smadl/5. However, previous work has shown that continuous TGF-p 
signalling for 1-2 hrs is sufficient for a significant and measurable induction in the 
transcriptional readout, whereas 2-4 hrs is required for maximal transcriptional activ ity 
(Inman. G. J. et al., 2002c). A  more convincing argument to explain these results is the 
evidence o f mixed Smad complexes. Upon TGF-P treatment, Smadl is phosphorylated 
and forms complexes w ith  Smad2 and 3 (Figure 6.13). Hence, the inab ility  o f  TGF-|3- 
induced P-Smadl/5 to initiate transcription o f  the BRE-luc is like ly  due to the fact that 
it is not in a complex w ith  Smad4 and therefore cannot bind to the D N A  elements in a 
sim ilar fashion to P-Smadl/5-Smad4 complexes formed upon BM P signalling.
This result is in sharp contrast to the response observed in endothelial cells, 
where Smadl/5 phosphorylation resulted in an increase in BRE-luciferase activity. 
This has been interpreted as a B M P-like  response, whereby Sm adl/5 forms complexes 
w ith  Smad4 to in itiate transcription o f  BRE-responsive elements. Flowever, s im ilarly 
to my work, evidence for the formation mixed complexes was also detected in 
endothelial cells. Goumans and colleagues have observed that ALK1 activity 
antagonises the A L K 5  activ ity as measured by (C AG A)i:-luciferase, and therefore 
they have speculated that these complexes could only be inhib itory. They suggest that 
the interactions w ith  d ifferent Smads may interfere w ith  specific D N A  binding and/or 
recruitment o f  cofactors (Goumans. M . J. et al., 2003b; Goumans, M. J. et al., 2002).
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In contrast to this proposed inh ib itory role for m ixed complexes, I found that 
knockdown o f Smadl, 5 and 8 did not s ignificantly affect the transcriptional activation 
o f  the (CAG A)i:-luciferase promoter (data not shown). Furthermore, the 
transcriptional responses o f  downstream targets o f  TGF-|3 supported this view. TGF-P 
signals through A LK 5  via Smad3/4 complexes to induce transcription o f PAI-1. 
Despite the presence o f P-Smadl/5 signalling, PAI-1 is e ffic ien tly  upregulated in 
EpH4 cells (Figure 5.3). Taken together, this evidence suggests that these complexes 
are not inhib itory. However, the activ ity o f  the mixed complexes cannot be measured 
because the D N A  element to which they bind has not yet been determined.
The model in Figure 6.14 also challenges the established role o f  Smad4 as a 
common Smad partner and suggests that Smad4 is in fact dispensable for some TGF-(3 
responses. Recent evidence supports this idea and proposes TGF-|3-induced regulation 
o f a subset o f  genes in a Smad4-independent manner (Levy, L. et al., 2005). 
Interestingly, the knockdown o f  Smad4 results in a loss o f  the tumour-suppressor 
functions o f TGF-(3. for example growth arrest, but it has no effect on the tumour- 
promoting function o f TGF-(3. Smad4 is not required fo r EM T in that study and the 
data suggest that loss o f Smad4 may predispose a cell to the tumour promoting 
activities o f TGF-p. resulting in a more aggressive phenotype. This is consistent w ith  
the fact that Smad4 expression is frequently lost or decreased in pancreatic and colon 
cancer. Further investigation o f the role o f  m ixed complexes in regulating TGF-p 
responsive Smad4 independent genes is required.
The work presented in this Chapter has uncovered a novel mechanism by 
which specificity o f  the signalling pathway downstream o f  TGF-P can be achieved. A  
new level o f  complexity is added to the pathway, whereby the ligand can induce 
different responses depending on the nature o f  the activated receptor complex. In 
addition, the TGF-P pathway is bifurcated as both classes o f  R-Smads are employed, 
each exhibiting different dose requirements and kinetics. Through this action alone, 
critical determinants o f specificity have been met. Yet, this investigation has yielded 
now many more questions. Does cooperation exist between the two signalling 
pathways? Is the main function o f  P-Sm adl/5 to upregulate cofactors required for the 
transcription o f a defined gene set? One could imagine that the transient Smadl/5 
signalling could then feed into the Smad2/3 pathway by upregulating transcription
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factors which then mediate a specific transcription programme. The presence o f 
alternative 'm ixed ' Smad complexes also raises many questions. Do they have the 
same a ffin ity  for previously characterised response elements? (Chapter 7) What are the 
downstream targets? It w ill also be important to establish the role o f P-Sm adl/5 in 
mediating TGF-P-induced growth arrest and EM T. However, the identification o f  the 
receptor required for phosphorylation o f Sm adl/5 in response to TGF-P is needed to 
determine this role (Chapter 7).
In conclusion, TGF-P signalling via both Sm adl/5 and Smad2/3 allows 
regulation o f a wide spectrum o f  genes, which may reflect its plethora o f biological 
responses. Much work is required to establish the role o f  P-Smadl/5 signalling in the 
TGF-p pathway.
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7 Discussion
TGF-p plays a complex, biphasic role in the progression o f  cancer. In the early stages 
o f tumourigenesis, TGF-P acts as a tumor suppressor through its ab ility  to inh ib it 
proliferation in epithelial cells from which the m ajority o f  human tumors are derived. 
However, pro-metastatic effects o f  TGF-P occur in later stages o f carcinogenesis, thus 
implicating TGF-P as a tumour promoter (Akhurst, R. J. et al., 2001; W akefield, L. M. 
et al., 2002). It has frequently been found that tumor cells become resistant to TGF-p- 
induced growth inhib ition, however remain responsive to the tumour promoting 
activities o f the cytokine. The EpH4/EpRas system developed in Hartmut Beug’ s 
laboratory provided the means to investigate the dual activities o f TGF-p observed in 
tumourigenesis in a model cell culture system. The cell lines in the EpH4 system 
represent the stages o f tumourigenesis. whereby a normal epithelial cell develops into 
an invasive spindle-like cell. The EpH4 cells are mammary epithelial cells which 
exhibit sensitivity to the antiproliferative effects o f  TGF-P, whereas the EpRas cells 
are resistant to growth inhib ition but remain responsive to the pro-metastatic responses 
o f  TGF-p (Oft, M. et al.. 1998; Oft. M. et al., 1996). The EpRas cells undergo an EM T 
upon stimulation w ith TGF-p. which involves epithelial plasticity changes towards a 
migratory, fibroblastoid phenotype. This transition to an invasive, mesenchymal 
phenotype during EM T is a hallmark o f carcinoma progression and metastasis (Thiery, 
J. P., 2002). The main aim o f my thesis project was to investigate the mechanisms that 
determine the outcome o f the TGF-P response, whether it is growth inh ib ition  or a 
dramatic morphological alteration. To this end, this thesis represents an in-depth study 
o f the determinants o f specificity governing the different b iological responses o f TGF- 
P in this model system.
7.1 Regulation of TGF-p-Smad signalling in the EpH4 system
During the characterisation o f these cells, a common overriding theme in Smad 
regulation was the effect o f  the cell cycle. Both the phosphorylation o f Smadl and 
protein expression level o f  Smad3 are cell cycle regulated. So in essence, the position
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o f the cells in the cell cycle sets the scene for the outcome o f  the response to TGF-(3 in 
this model system. In quiescent cells, a high level o f  Smad3 is achieved, whereas the 
phosphorylation o f Smadl is inhib ited (Figure 7.1). H igh Smad3 levels correlates w ith  
the ab ility  o f  TGF-|3 to induce growth inh ib ition upon exit from  quiescence. The 
abolition o f Smadl phosphorylation upon cell cycle exit into a quiescent state suggests 
that responses through activated Smadl are restricted to the proliferative state (Chapter 
6). Conversely, in cycling cells Smad3 levels are low  and these cells can now strongly 
phosphorylate Smadl in response to TGF-P (see below).
7.1.1 The relevance of Smad3 levels in EpRas cells
The low  Smad3 level observed is consistent w ith  data from  both tumour samples and 
tumour cell lines. In addition, a downregulation o f Smad3 has been observed during 
progression o f  EM T concomitant w ith  a loss in growth inh ib ition, suggesting that this 
low  Smad3 is sufficient to promote transdifferentiation, but not growth arrest. M y data 
together w ith  other observations point to a model whereby the high levels o f  Smad3 
protect cells from tumour progression by inducing growth arrest and apoptosis, 
whereas these responses in cells expressing lower levels are compromised (Figure 7 .1). 
In this model, the low  levels o f  Smad3 would be sufficient to induce and maintain the 
invasive phenotype observed in cells undergoing E M T or metastasis. The epigenetic 
mechanisms governing the loss o f Smad3 expression have to date not been uncovered. 
From my work it seems that m ultip le modes o f  action could affect the level o f  Smad3 
in the cell, including transcriptional regulation and protein stability. Downregulation o f 
Smad3 in M D C K  cells was attributed to m ethylation due to the slow tim ing o f  this 
event. Indeed, the Smad3 promoter has CpG islands, which could be targeted by 
methylation. Other mechanisms could also act to downregulate Smad3. for example 
the activity o f  m icroRNAs.
7.1.2 The role of Sm adl in Endothelial Cells
The phosphorylation o f Smadl upon stim ulation o f TGF-|3 in these cells represents a 
major novel finding. Up until now, TG F-p induction o f  P-Smad 1 has only been
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Figure 7.1. Cell cycle control of TGF-P signalling in EpH4 and EpRas cells
Schematic model for the regulation of the components of the TGF-P pathway in mouse mammary epithelial cells. For 
discussion, see text. Smad complexes are displayed as dimers for simplicity.
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documented specifically in endothelial cells (ECs) (Goumans, M. J. et al., 2003b; 
Goumans, M. J. et al., 2002) and in some breast carcinoma cell lines (Inman, G. 
personal communication). The mechanism underlying this observation in endothelial 
cells has been thoroughly investigated (Goumans, M. J. et al., 2003b; Goumans, M. J. 
et al., 2002). TGF-|3 has been shown to activate two distinct type I receptors in 
endothelial cells; namely ALK5-dependent Smad2/3 phosphorylation and Smadl/5 
phosphorylation by ALK1 activity (Goumans, M. J. et al., 2003b; Goumans, M. J. et 
al., 2002). Endoglin, an accessory receptor expressed at high levels in endothelial cells 
(ECs). is also required to promote the TGF-|3/ALK1 signalling (Lebrin, F. et al., 2004). 
In contrast to my work, the phosphorylation o f Smadl in ECs has been shown to 
weakly stimulate transcription from the BMP-responsive reporter, the BRE-luc, 
although the activity is much weaker than when induced w ith  a constitutively activated 
ALK1 receptor (Goumans. M. J. et al., 2003b; Goumans, M. J. et al., 2002). As a 
result, the phosphorylation o f Smadl by TGF-(3 has been interpreted as TGF-f3 
inducing a BMP response, resulting in the formation o f  Smad 1/4 complexes. In 
addition. ALK1 activity has been shown to antagonise TGF-[3-Smad2/3 signalling, as 
demonstrated by decreased (CAG A)i:-luciferase activ ity upon expression o f A LK 1 in 
ECs (Goumans, M. J. et al., 2003b). Co-expression o f  Smad5 potentiated the ALK1 
inhib itory effect, whereas Smad3 rescued this antagonism (Goumans, M. J. et al., 
2003b). From these data, it was concluded that ALK 1 directly antagonizes 
ALK5/Smad2/3 signalling and this antagonism is exerted at the Smad level. M ixed 
Smad complexes containing BMP R-Smads and TGF-|3 R-Smads were also observed 
in ECs and thus it was proposed that A LK 1 inhib its A L K 5  activ ity through 
sequestration o f Smad2/3 into complexes w ith  Sm adl/5, which interfere w ith  the 
specific binding and/or recruitment to D N A  (Goumans, M. J. et al., 2003b). In light o f 
my findings, an alternative model could also explain the data observed. It is possible 
that the expression o f ALK1 in ECs increases the ratio o f  A L K 1 /A L K 5  complexes 
over A LK 5 complexes and consequently the activation o f  downstream signalling is 
affected by altering the ratio o f conventional Smad2/4 and Smad3/4 complexes relative 
to the mixed Smad 1/2 and Smad 1/3 complexes. Peter ten D ijke 's  group has proposed 
that these mixed complexes are inh ib itory because they do not induce C A G A i2 -luc or 
BRE-luc activity. However it is more like ly that these complexes are active at distinct 
but as yet unidentified promoter sites, recruiting new factors and perform ing new
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tricks. My work is currently focusing on identifying the targets of these mixed 
complexes.
7.1.3 The role o f mixed complexes in EpH4 and EpRas cells
My results suggest that similar to ECs, TGF-P signals via two receptor complexes in 
EpH4 and EpRas cells, which results in activation of BMP-type R- Smads and TGF-P 
R-Smads (Figure 7.2). ALK1 expression is highly specific to endothelail cells and 
therefore it is not involved in the activation of Smadl in this system. The simultaneous 
activation of ALK5 and an alternative receptor, results in the formation of ‘mixed’ 
complexes containing both TGF-P and BMP-type R-Smads. However, in contrast to 
TGF-p signalling in ECs, there is no BMP-like response observed in EpH4 or EpRas 
cells. The biological relevance of these mixed Smad complexes has yet to be 
elucidated, however it is envisioned that these Smad complexes behave very
differently to the conventional complexes defined by different DNA specificity and 
recruitment of a specific set of transcription factors. Strong evidence for endogenous 
complexes of both Smad 1/2 and Smad 1/3 has been demonstrated, however, the exact 
stoichiometry and combinations of the mixed Smad complexes have not been 
determined The presence of Smad4 in these complexes has not been shown, however, 
this possibility cannot be excluded, particularly regarding the weak binding of Smadl 
with Smad4 complex and the poor quality of the antibody. In the case of Smadl 
replacing a Smad2 monomer, Smadl would confer DNA binding ability and this is 
likely to confer some functional differences between Smad2/4 and Smad 1/2 
complexes. However it is likely that Smadl could replace Smad4 in a Smad2/4 
homotrimer and this alone is likely to direct these complexes to alternative DNA site,
such as GC rich sequences as opposed to an SBE.
Furthermore, these mixed complexes are likely to recruit either novel
transcription factors or unique combinations compared with a conventional BMP or 
TGF-P response. In the case of Smad 1/4 complexes, Drosophila and mammalian 
Schnurri has been proposed to act as a scaffolding protein for the recruitment of 
transcriptional coactivators and corepressors (Yao, L. C. et al., 2006). The promoter 
elements which recruit Schnurri are highly conserved, with a GC-rich binding site for
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Mad/Smadl and an SBE, GTCTG site for Medea/Smad4 separated by a spacer o f  5 bp 
(Pyrowolakis. G. et al., 2004; Yao, L. C. et al., 2006). Replacement o f  either Smadl or 
Smad4 w ith  a TGF-(3 specific R-Smad is un like ly to bind to these conserved sites w ith  
this specific spacing thus preventing docking o f  Schnurri and recruitment o f 
transcriptional mediators. Transcription factors recruited during the TGF-f3 response 
also interact w ith  the TGF-(3 R-Smads in a specific manner. The well characterised 
Smad-transcription factor complex, ARF, is composed o f  Smad2, Smad4 and XFoxH- 
1 which binds to an activin-responsive element (AR E) in response to Nodal, A c tiv in  or 
TGF-(3. Binding o f FoxH l is mediated via a Smad-interacting m o tif (S IM ) also present 
in M ix  transcription factors and an FoxH l m o tif (FM ) uniquely present in FoxFll 
(Randall. R. A. et al., 2002; Randall, R. A. et al., 2004). By investigating the binding 
sites for the SIM  and FM m otifs in Smad2 it has been proposed that a F oxH l 
monomer can interact w ith both subunits o f  Smad2 in a Smad2-Smad4 heterotrimer. 
Smad3. but not Smadl. can bind to the S IM  m otif, whereas both Smadl and Smad3 
fail to bind the FM motif, providing clear evidence that replacement o f  a Smad2 
subunit in a Smad2/4 heterotrimer. would completely abolish its interaction w ith  its 
transcriptional partner, FoxH l. These data provide evidence that the mixed complexes 
are distinct entities w ith unique D N A  binding specificities and most like ly  recruit 
alternative transcription factors.
As mentioned above, the phosphorylation o f  Smadl coincides w ith  a low  level 
o f  Smad3. In co-immunoprecipitation experiments, Smadl was found to be 
predominantly complexed to Smad2, w ith  a much lower proportion in complex w ith  
Smad3. This raises the question as to whether the downregulation o f Smad3 influences 
the specific ratio o f  Smadl/2 complexes and Sm adl/3 complexes. In addition to the 
mixed classes o f Smad complexes, there is also evidence to suggest that TGF-(3 can 
induce Smad2/3 complexes. Therefore, the com petition between Smadl and Smad3 for 
Smad2 binding would be reduced when Smad3 levels are lowered. Further work is 
required to establish the stochiometry o f  these m ixed complexes, their reletive 
abundance and biological effects.
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7.1.4 Receptor regulation during the cell cycle
It has been established that the Smad3 downregulation upon entry into the cell cycle is 
mediated through a combination o f protein stability and transcriptional regulation. 
However, the mechanism by which Smadl is activated specifically in proliferating 
cells, has not yet been established. Data in Chapter 6 indicates the requirement o f  an 
alternative receptor that is either inactive or downregulated in quiescent cells. The 
main piece o f evidence which points to this is the observed delay in Smadl activation 
upon release from quiescence, which suggests the requirement o f  protein synthesis or 
activation o f a latent form o f the receptor for maximal phosphorylation o f Smadl 
(Chapter 6). Cell cycle mediated downregulation could be achieved either by 
transcriptional repression or increased protein degradation in the quiescent state, 
whereas activation o f the receptor may be dependent on the activ ity o f  a cell cycle 
regulated protein. Unfortunately, this receptor has not yet been identified. A LK 1 is 
prim arily expressed in ECs so is not a candidate in this case. However, A L K 2  is a 
highly related receptor w ith  sim ilar signalling specificities and is expressed EpH4 
cells. As A L K l has been demonstrated to form  heteromeric complexes w ith  A L K 5 , it 
was reasonable to propose that A L K 2  may also function in this manner. However, 
in itia l evidence has not supported this hypothesis, and knockdown o f  this receptor does 
not impair phosphorylation o f Smadl. In addition, A L K 2  transcripts did not vary 
significantly between the proliferative and quiescent state. However, it is possible that 
downregulation o f the receptor is mediated at the translational or posttranslational 
level. A L K 4  is also expressed in these cells but its specificity is identical to A L K 5 , in 
that it phosphorylates Smad2 and Smad3 only (Chen, Y. G. et al., 1998). The specific 
interaction between the L45 loop o f the receptor and L3 loop in the R-Smads does not 
allow  crossover o f  activation and therefore A L K 4  or indeed A L K 5 , cannot mediate the 
phosphorylation o f Smadl. A L K 3 , on the other hand, e ffic ien tly  phosphorylates 
Smadl/5. but this receptor mediates BM P signals only, as was convincingly 
demonstrated in Chapter 6. W ork is now underway to uncover the receptor responsible 
for this signalling event, including a search for an as yet unidentified A LK .
Alternatively, it is equally possible that a co-receptor essential for Smadl 
phosphorylation could be downregulated during quiescence. Endoglin, an accessory 
TGF-P receptor has been shown to be absolutely required for Smadl phosphorylation
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in ECs (Lebrin, F. et al., 2004). A  co-receptor may function s im ilarly in EpH4 cells, 
and potentially it could be targeted for cell cycle regulated degradation during 
quiescence. Betaglycan has been shown to facilitate the binding o f TGF-(3 isoforms to 
its type II receptor, and is absolutely required for e ffic ient TGF-(32 binding (Lopez- 
Casillas. F. et al.. 1993). These results reveal that co-receptors are required for 
facilitating the binding o f low  a ffin ity  interactions. It has also been shown that the 
receptor responsible for Smadl activation in EpFI4 and EpRas cells has a lower 
a ffin ity  for TGF-(31 and 3 than A L K 5  (Chapter 6). Thus it is like ly  that a co-receptor is 
required for efficient binding in this instance. It is also clear that high levels o f  A L K 5  
are required for the activation o f Smadl in response to TGF-|3. Incomplete depletion o f 
A LK 5  completely abolishes phosphorylation o f  Sm adl, whereas Smad2 and Smad3 
phosphorylation is only partially affected (data not shown). It is possible that A L K 5  
preferentially forms homomeric complexes to signal via Smad2 and Smad3, whereas 
excess A LK 5  allows the lower a ffin ity  complex formation w ith  the alternative A L K .
7.1.5 The relevance of S m ad l/5  activation in proliferating cells
The inhib ition o f Smadl/5 activation in quiescent cells is in triguing. Whereas 
the downregulation o f Smad3 upon entry is compatible w ith  its role in mediating a 
cytostatic response, the relevance for Smadl phosphorylation only in cycling cells is a 
mystery. It is noteworthy that there appears to be a reciprocal relationship regarding 
the regulation o f Smad3 and the proposed regulation o f  the receptor required for 
Smadl phosphorylation. In short, when Smad3 expression is repressed, activ ity o f  the 
receptor is upregulated. What is the significance o f  this? Are these processes coupled? 
The answers to these questions have not been established but this observation 
prompted investigation into whether high Smad3 levels exerted an inh ib itory effect on 
the phosphorylation o f Smadl. However, there is no apparent difference in P-smadl 
levels between F!pl 14 and EpRas, despite a significant variation in Smad3 levels, when 
the proliferation rate o f EpRas cells is taken into consideration. In addition, stable 
expression o f high levels o f  Smad3 in the EpRas Smad3 clone 1, did not compromise 
phosphorylation o f  Smadl in response to TGF-|3 (data not shown).
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An important question remains, what is the relevance o f  P-Smadl activation in 
proliferating cells? A  role for Smadl in antiproliferative effects o f  TGF-|3 is unlikely, 
as high levels o f  P-Smadl are not present until 15 hours after release from  quiescence 
and it was shown that 12-16 hours o f signalling is required to prevent entry o f  EpH4 
cells into the cell cycle (Chapter 6). This led us to ask whether it is involved in the 
other response o f TGF-(3, such as EM T. In my attempts to study TG F-p induced EM T 
in EpRas cells, it was continuously observed that the EM T induced by TGF-|3 is more 
pronounced in subconfluent cells, where confluent cultures are more refractory to 
morphological changes induced by TGF-(3. This has also been observed in tubular 
epithelial cells, where cell cultures at lower density exhibited more dramatic epithelial 
plasticity than higher density cultures (Strutz, F. et al., 2002). Evidence from  K i67 
staining shows cells undergoing EM T and those that have reached E M T are 
proliferating. These results indicate that the ab ility  o f  EpRas cells to undergo E M T 
correlates w ith  their capacity to induce P-Smadl. Numerous studies have im plicated 
TGF-|3 type R-Smads and not BMP specific R-Smads as playing a role in EM T, 
however this has been shown through the expression o f  either type o f  R-Smad alone 
(Valcourt. U. et al., 2005). In the EpH4 model system, both types o f  R-Smads are 
activated by TGF-(3 in the presence o f each other, and can form  heteromeric complexes 
which are like ly to mediate different signalling responses.
Further support for a role for Smadl/5 in EM T comes from  the findings that 
A LK 2 . which specifically phosphorylates Smadl, 5 and 8, can mediate EM T. A  role 
for ALK.2 has also been implicated in MIS-induced E M T o f  coelomic epithelium  
during M ullerian duct regression. It was recently revealed that s iR NA knockdown o f 
A LK 2  resulted in inhib ition o f coelomic EM T and M ullerian duct regression in organ 
culture (Zhan, Y. et al., 2006). Inh ib ition o f Smad5 m im icked this response, however 
knockdown o f Smad8 accelerated the response. These data support a role fo r BM P- 
Smad activation in the progression o f EM T. Furthermore, A L K 2  has been shown to be 
sufficient to mediate EM T in endocardial chick cells (Desgrosellier, J. S. et al., 2005). 
In addition, A LK 2  has been proposed to mediate EM T in response to TGF-(3 in 
cultured mammary epithelial cells (M iettinen, P. J. et al., 1994). However, efforts to 
confirm  this observation have been unsuccessful (Piek, E. et al., 1999; Valcourt, U. et 
al., 2005). In studies using overexpressed constitutively active (ca) A L K  receptors in 
N M uM G  cells, it was concluded that only A L K 5  can mediate E M T (Valcourt, U. et
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al., 2005). In light o f  the data presented in this thesis, these results are by no means 
complete. These experiments were conducted by overexpressing caALKs ind iv idua lly  
which may not recapitulate the in vivo conditions (Valcourt, U. et al., 2005). The 
phosphorylation o f Smadl/5 in EpH4/EpRas cells requires not only the expression, but 
also the kinase activity o f  A LK 5 . Therefore, by overexpressing a constitutively active 
form o f this unidentified receptor, the response would not be replicated. So to take into 
account signalling through heteromeric type I receptor complexes, combinations o f 
caALKs need to be investigated and could prove critica l for the investigation o f the 
mediators o f the response.
Again, parallels can be drawn from  the TGF-(3 signalling in endothelial cell and 
the EpH4 system. In ECs, ALK1 is thought to induce cell pro life ra tion and A L K 5  
signalling has been implicated in the differentiation phase. I have proposed a sim ilar 
model for TGF-(3 signalling in the EpH4 system, whereby canonical A L K 5  signalling 
predominantly mediates the antiproliferative effects o f  TGF-[3, whereas the 
phosphorylation o f Smadl/5 promotes cell-cycle progression and EM T (Figure 7.1). 
The regulation o f the alternative receptor signalling is achieved at the level o f  the cell 
cycle, through the upregulation o f a receptor/co-receptor and the downregulation o f 
Smad3. This model proposes that in cycling cells, TGF-(3 signalling activates both the 
canonical and alternative signalling pathways in EpH4 and EpRas cells, and in the case 
o f  EpRas cells both pathways cooperate to promote the progression o f  EM T. In 
quiescent cells, however, Smad2/3 signalling is dominant and can lead to the growth 
inh ib itory effect o f  TGF-(3 upon stimulation o f ligand in EpH4 cells.
7.1.6 BMP signalling in the EpH4 cell system
During development. TGF-(3 superfamily members are all working in concert. The 
ultimate result o f  this is a fine tuned response. In the case o f  the EpII4 cell system, 
TGF-P responses have a background o f basal BMP signalling. Depletion o f  A L K 3  in 
both EpH4 and EpRas cells substantially reduced basal P-Smadl levels, suggesting 
that this receptor mediates the BMP response in these cells (Chapter 6). Three type I 
receptors have been found to mediate signals via BMP2 or BMP4, namely A L K 2 , 
A LK 3  and A L K 6  (Macias-Silva, M. et al., 1998). A L K 6  expression is tigh tly  restricted
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and is only found in brain and lung, and as such is not expressed in EpH4 cells, as 
confirmed by RT-PCR (ten D ijke, P. et al., 1994b). A L K 2  knockdown by s iR NA did 
not affect induction o f P-Smadl by BMP, whereas depletion o f  A L K 3  completely 
abolished the phosphorylation o f  Smadl in response to BMP2/4 (Chapter 6). 
Therefore, A LK 3 alone mediates the BMP response in EpH4 and EpRas cells.
As Smadl and 5 are common components to both the TGF-|3 and BMP 
pathways, it is possible that the two pathways are integrated by some means. Goumans 
et al., showed that knockdown o f ALK1 potentiated the Smad2/3 response o f  TGF-(3 
as measured by an increase in C A G A i2 -luciferase activ ity  (Goumans, M. J. et al., 
2003b; Goumans. M. J. et al., 2002). In the EpFI4 cells, an antagonistic effect on 
Smad2/3 signalling could not be investigated because, w ithout the identification o f  the 
receptor, it is impossible to selectively knockdown the non-canonical signalling 
pathway. However, knockdown o f  A LK 3 revealed that the basal BM P signalling is 
largely antagonistic to canonical Smad2/3 signalling, as measured using C A G A 12- 
luciferase (data not shown). This cannot be explained by simple competition, because 
addition o f excess Smad4 does not relieve this antagonism and suggests that this 
antagonism may act at the level o f  the receptors. In addition, prelim inary data suggests 
that knocking down A LK 3 sensitises EpRas cells to TGF-(3-induced EM T. Abrogation 
o f  BMP signalling liberates both Smadl and Smad4 from  complexes which could 
potentially complex w ith  Smad2 and Smad3 to e lic it cellular responses. The release o f 
both o f these components may contribute to TGF-|3-induced EM T. Conversely, BMP 
signalling has been implicated in developmental EM T such as neural crest formation. 
However, the level o f  BMP signal is crucial to theses events, such that high levels o f  
BMP signalling in the ectoderm and low levels in the neural plate, inh ib it neural crest 
formation (Tucker, R. P., 2004). Moreover, BMP is thought to play a more important 
role in the specification o f the neural crest cells, whereas its role in maintaining the 
invasive and migratory phenotype associated w ith  these cells is under debate 
(Barembaum, M. et al., 2005). An increasing number o f  studies report an antagonistic 
effect o f BMP in EMT, which is consistent w ith  my observations. BMPs have been 
shown to revert mesechymal cells produced by the activ ity o f  TGF-(3s to epithelial 
cells (M ET). BMP7 has been shown to reverse TGF-(3-induced EM T in a mouse model 
o f  renal in jury (Zeisberg, M. et al., 2003b). An esophageal cell line was induced w ith
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TGF-|3, which resulted in morphological changes and molecular changes sim ilar to 
EMT. These changes could be reversed by addition o f  BM P7 or s iRNA w ith  Smad4 
(Rees, J. R. et al., 2006). Consistently, BMP-7 has been identified as a key regulator 
during M ET in kidney ontogenesis (Dudley, A. T. et al., 1995). The mechanism 
underlying this inhib ition has not been established. Elowever, i f  the phosphorylation o f 
Smadl in response to TGF-(3 is required for EM T, then BM P signalling could act to 
sequester P-Smadl away from Smad2 and Smad3 to form  canonical complexes w ith  
Smad4 and therefore inh ib it EM T (Figure 7.2).
7.2 Future Perspectives
Many questions have been raised by this work and require further investigation. 
Downregulation o f Smad3 has been observed in some human cancers and my work 
further supports a role for Smad3 as tumour suppressor. A  systematic analysis o f 
expression levels o f  Smad3 in relation to Ras activ ity in human cancers would give an 
indication o f the prevalence o f  this event. Given my identification o f  the im port o f  
Smad3 levels, it was possible to make another correlation. It has been repeatedly 
observed that low  Smad3 protein levels correlate w ith  the ab ility  o f  cells to be 
transformed by oncogenic Ras. In two cases, both M D C K  cells and EpRas cells, 
transformation w ith  oncogenic ra f or ras, respectively, was concomitant w ith  a 
downregulation o f Smad3. Many epithelial cell lines, fo r example, the human 
keratinocyte FlaCat cell line, however, which have high levels o f  Smad3, senesce in 
response to these agents, which could possibly be attributed to their inab ility  to 
downregulate Smad3. Transformation o f  primary cells by ras requires either a 
cooperating oncogene or the inactivation o f  tumor suppressors such as p53 or p i 6 
(Serrano. M. et al., 1997). Inactivation o f  either p53 or p i 6 overcomes ra.v-induced 
senescence in rodent cells, whereas E l A  achieves a sim ilar effect in human cells 
(Serrano, M. et al., 1997). I would also like to propose that overcoming ras induced 
senescence may be achieved by inactivation or downregulation o f  the tumour 
suppressor Smad3. This is supported by data that revealed that defects in TG F-p 
signalling can overcome ras-induced senescence in mouse kertinocytes (Tremain, R. et 
al., 2000). This resistance is associated w ith  low  expression o f  p l5 in k4b  and p!6 ink4a,
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constitutive Rb phosphorylation and high levels o f  cdk4 and cdk2 kinase activ ity 
(Tremain, R. et al., 2000). Furthermore, it is also possible that the differential 
sensitivity between human and rodent cells to downregulate Smad3 levels may 
contribute to the well-known d ifficu lty  in establishing and transforming human cell 
lines in culture. Using a HaCat cell line w ith  constitutive expression o f  shRNA against 
Smad3, I hope to test whether these cells can at least proliferate in the presence o f 
oncogenic Ras. Prelim inary evidence suggests that this may be the case. Follow ing on 
from this, I hope to investigate a possible link  between the deownregulation Smad3 
and TERT expression. Telomerase reverse transcriptase (TER T) is required to regulate 
the structures o f chromosomal ends (telomeres) for continuous cell d iv is ion during 
embryonic development, stem cell renewal and proliferation, and cancer cell 
immortalization. Recent work has revealed that Smad3 binds to the TERT gene 
promoter to repress gene expression (L i, H. et al., 2006). Furthermore it has been 
shown that autocrine TGF-{3 signaling in human cancer cells, suppresses telomerase 
activity by repression o f TERT (Yang, H. et al., 2001). It would be interesting to 
determine whether Smad3 downregulation increases the basal expression level o f 
TERT and contributes to the cancer cell immortalisation. Furthermore, I would like to 
investigate the mechanism governing the downregulation o f  Smad3 in the 
EpH4/EpRas model system and test whether this is a general mechanism during 
tumour progression.
The phosphorylation o f  Smadl in response to TGF-|3 also requires further 
investigation. The main question I would like to address is which receptor is 
responsible for this phosphorylation event. We know that A L K 5  is required, however, 
previous work from the literature suggests that it, alone, is not sufficient. I would like 
to identify the receptor using a two-pronged approach, through more rigorous analysis 
o f the characterised A LK s and bioinform atic investigation for novel A LK s. Additional 
investigations o f co-receptors o f the pathway by siRNA depletion o f  these proteins in 
EpH4 cells w ill also be pursued. Once the receptor and/or co-receptor has been 
identified, gene targets o f the new Smadl complexes may be explored and the 
biological role o f  phosphorylated-Smadl may be addressed. Moreover, this study, 
together w ith  the work from Peter Ten D ijke 's  laboratory, has opened up a new realm 
o f  investigation. It is not known whether only A LK 5  can form  a heteromeric type I
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receptor complex or whether this may also apply to A L K 4  and A LK 7 . Can these 
receptors also engage in recruiment o f  A L K 1 , A L K  2 or an as yet unidentified A L K  
and mediate phosphorylation o f  Smadl/5 in respsonse to A c tiv in  and Nodal? This 
question may easily be addressed in EpH4 cells, which also express A L K 4 , but not 
ALK 7. It would be interesting to investigate whether these are responsive to A ctiv in , 
and i f  so, what are the downstream targets o f  this ligand stimulation? This may provide 
an alternative route to assess the contribution o f receptors to the phosphorylation o f 
Smadl in this system. Another question is whether A L K l- l ik e  type I receptors can also 
form heteromeric receptor complexes w ith  A L K 3  and A L K 6  and thereby modulate the 
pattern o f activation o f Smadsl, 5 and 8? This investigation has the potential to 
uncover an added level o f  complexity which would a llow  a fine-tuning o f  the 
transcriptional response downstream o f the TGF-|3 superfamily. U ltim ately, it is hoped 
that these investigations w ill lead to a better understanding o f the dual role o f  TGF-|3 
signalling in Cancer.
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Appendix I
List of Constructs:
Construct Details of 
Construct
Construction Details
pcD N A 3N -S m ad2 ProteinA-CBP Smad2 
fusion used for 
expression in stable 
lines
Cloned by PCR w ith  using 
C H I 123 and CHRSRF2 pFTX5 
Xmad2A3’U TR  as a template. 
PCR product cut w ith  EcoRI/Sel 
and ligated into pcD N A3N  cut 
w ith  EcoRI/Xbal.
pcD N A 3N -S m ad3 ProteinA-CBP Smad2 
fusion used in stable 
lines
EFplink myc hSmad3 
EcoRI/Xbal fragment ligated into 
pcDNA3N EcoRI/Xbal
p-Zom e-Sm ad 2 ProteinA-CBP Smad2 
fusion used for 
retroviral infection
Cloned by PCR w ith  using 
C H I 123 and C H 1225  pFTX5 
Xmad2A3’U TR  as a template. 
PCR product cut w ith  EcoRI and 
ligated into p -Z om e-l-N  cut w ith  
EcoRI.
p-Zom e-Sm ad 3 ProteinA-CBP Smad3 
fusion used for 
retroviral infection
Cloned by PCR w ith  
C H I 123(T7) and C H I2 2 6  using 
EFplink myc hSmad3 as a 
template. PCR product cut w ith  
EcoRI and ligated into p-Zome- 
1-N cut w ith  EcoRI.
p-Zom e-Sm ad 4 ProteinA-CBP Smad4 
fusion used for 
retroviral infection
Cloned by PCR w ith  CH74 and 
C H I 144  using pFTX5 HS dpc4 
as a template. PCR product cut 
w ith  EcoRI and ligated into p- 
Z om e-l-N  cut w ith  EcoRI.
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p c D N A 3 N H is 2 ProteinA-H is Tag L inker created using C H I604 and 
C H I605 and inserted into 
pcD NA3N cut w ith  EcoRI and 
BamHI.
p cD N A 3 N H is 2 -
Smad3
ProteinA-H is Smad3 
fusion used for 
expression in stable 
lines
L inker created using C H I604 and 
C H 1605 and inserted into 
pcDNA3N-Smad3 cut w ith  
EcoRI and BamHI.
p c D N A 3 N H A 2 ProteinA-HA Tag L inker created using using 
CH 1619 and CH1620 and 
inserted into pcD NA3N cut w ith  
EcoRI and BamHI.
p c D N A 3 N H A 2 -
Smad3
Prote inA-HA Smad3 
fusion used for 
expression in stable 
lines
L inker created using C H I619 and 
C H I620 and inserted into 
pcDNA3N-Smad3 cut w ith  
EcoRI and BamHI.
p cD N A 3 N F L A G 2 Prote inA-FLAG  Tag Linker created using C H I602 and 
C H I603 and inserted into 
pcD NA3N cut w ith  EcoRI and 
BamHI.
p cD N A 3 N F L A G 2 -
Smad2
ProteinA-FLAG  
Smad2 fusion used for 
expression in stable 
lines
p-Zome Smad2 EcoRI fragment 
was ligated into 
p c D N A 3 N F L A G 2  EcoRI.
pcD N A 3 N F L A G 2 -
Smad3
ProteinA-FLAG  
Smad3 fusion used for 
expression in stable 
lines
Linker created using C H I602 and 
C H I603 and inserted into 
pcDNA3N-Smad3cut w ith  EcoRI 
and BamHI.
pcD N  A 3 N F L  A G 2- 
Smad4
Prote inA-FLAG  
Smad4 fusion used for 
expression in stable 
lines
p-Zome Smad4 EcoRI fragment
was ligated into
p c D N  A 3 N F L  A G 2 EcoRI.
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Appendix II
List of Oligonucleotides:
ID Description Oligonucleotide Sequence
CH1123 XSmad2Forward aacatcatgcactggacagg
CHRSRF2 XSmad2 Reverse cctggagggaggtggggtc
CH1225 XSmad2 ECORI reverse Gccgaattcttaggacatgcttgagcagc
c g a a t t c t t a g g a c a tg c t tg a g c a
CH243 P-Globin/HSmad3 Forward tgcttacatttgcttctg
CH1142 HSmad3 ECORI REV gccgaattcctaagacacactggaaca
CH74 T7 PRIM ER tgcttacatttgcttctg
CH1144 HSmad4 ECORI REV ecceaattcctaetctaaaeetteteeetc
ID Description Oligonucleotide Sequence
C H I 602 p cD N A 3 N - 
Flag fo r
g g g a g a t c t g a t t a t g a t a t t c c a a c t a c t g a g a a t t t g t a t t t
tc a g g g tg g a g g tg g a g g tg g a g g ta c c a tg a a g g a c ta c a a g g
C H I 603 p cD N A 3 N - 
F lag re v
c c c g a a t t c a c c t c c a c c tc c a c c tc c g g c c t t g t c a tc g tc g t
c c t t g t a g t c c t t c a t g g t a c c t c c a c c t c c a c c t c c a c c c tg
C H I 604 p cD N A 3 N - 
H is fo r
g g g a g a t c t g a t t a t g a t a t t c c a a c t a c t g a g a a t t t g t a t t t
t c a g g g tg g a g g tg g a g g tg g a g g ta c c a tg c a tc a tc
C H I 605 p cD N A 3 N - 
H is re v
c c c g a a t t c a c c tc c a c c tc c a c c tc c a tg a tg a tg a tg a tg a t
g c a tg g ta c c tc c a c c tc c a c c tc c a c c c tg a a a a ta c
Chl619 p cD N A 3 N - 
H A  fo r
G g g g g ta c c a tg a a g ta c c c t ta c g a tg tg c c c g a t ta c
g c c c c c g g tg g a g g tg g a g g tg g a g a a ttc g g g
CH I 620 p cD N A 3 N - 
H A  re v
C c c g a a t tc tc c a c c tc c a c c tc c a c c g g g g g c g ta a tc g g g
c a c a tc g ta a g g g ta c t t c a tg g ta c c c c c
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Oligonuclotides used in RT-PCR:
ID Description Oligonucleotide Sequence
CH2030 ALK1F1 gcagtgttgcattgcagacc
CH2031 A LK1 R1 gcactctctcatcatctgg
CH2036 A L K 2  F2 gacagcactctagcggaactac
CH2037 A L K 2 R 2 gactgccaggcccaaatctgc
CH2319 A L K 3 F I gccacctccacacagaaatt
CH2320 A LK 3 R1 ttacatcctgggattcaacc
CH2324 A L K 4F 1 ctcctccttcttcccccttg
CH2325 A L K 4  R1 ctccatgtccaacctctggc
Ch2330 A L K 5  F I cctttcatttcagagggcac
CH2331 A LK 5  R1 ccacttgctgtggacagagc
CH2334 A L K 6  F2 caccaagcgctatatgcctc
Ch2335 A L K 6 R 2 ctctcttccaggaaagtctg
CH2336 A L K 7  F I catctattcggtggggctgg
CH2337 A L K 7  R1 cgggaaggaaagctgtgagc
CH2637 Grb2 gatcaacatccgtgtccagg
CH2638 Grb2 aacatcatgcactggacagg
Bold letters indicate bases that have been used to introduce a whole or partial 
restriction site for cloning purposes.
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